{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Miniscule sample of production code (training pipeline)\n",
    "---\n",
    "This notebook is mainly used as a sandbox and to visualize results of code fragments before adding them to the production pipeline"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<br>\n",
    "<hr>\n",
    "<br>"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<a id='toc'></a>\n",
    "### Table of Contents\n",
    "[1. Create Dataframe from USPTO bulk data](#section-1)<br>\n",
    "[2. Text Segmentation for Description Section](#section-2)<br>\n",
    "[3. Append information about Chemical Structures in the patents](#section-3)<br>\n",
    "[4. Extract chemical names from text](#section-4)<br>\n",
    "[5. Text Preprocessing & Tokenization](#section-5)<br>\n",
    "[6. Train word/document embeddings model](#section-6)<br>\n",
    "[7. Train LSTM using document embeddings](#section-7)<br>\n",
    "<br>\n",
    "<hr>"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<a id='section-1'></a>\n",
    "### - Create Dataframe from USPTO bulk data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Load dependencies\n",
    "import xml.etree.ElementTree as ET\n",
    "import xmltodict\n",
    "import pandas as pd\n",
    "import glob"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id</th>\n",
       "      <th>invention_title</th>\n",
       "      <th>abstract</th>\n",
       "      <th>claims</th>\n",
       "      <th>description</th>\n",
       "      <th>drawings_description</th>\n",
       "      <th>drawings_file_paths</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>20190151472</td>\n",
       "      <td>LIVER-SPECIFIC CONSTRUCTS, FACTOR VIII EXPRESS...</td>\n",
       "      <td>Described herein are constructs used for liver...</td>\n",
       "      <td>1-10. (canceled)  11. A method of providing a...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS The pr...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...</td>\n",
       "      <td>[US20190151472A1-20190523-D00001.TIF, US201901...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>20190135863</td>\n",
       "      <td>RETRO-INVERSO PEPTIDE INHIBITORS OF CELL MIGRA...</td>\n",
       "      <td>The present invention discloses retro-inverso ...</td>\n",
       "      <td>1. A compound of formula (I):   X1-(D)-Arg-X2...</td>\n",
       "      <td>The present invention concerns retro-inverso p...</td>\n",
       "      <td>DESCRIPTION OF THE FIGURES FIG. 1 High degree ...</td>\n",
       "      <td>[US20190135863A1-20190509-D00001.TIF, US201901...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>20190133992</td>\n",
       "      <td>CANNABINOID COMPOSITION HAVING AN OPTIMIZED FA...</td>\n",
       "      <td>A composition of matter for enhancing delivery...</td>\n",
       "      <td>1. A cannabinoid composition comprising: at l...</td>\n",
       "      <td>FIELD OF THE INVENTION The present invention r...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...</td>\n",
       "      <td>[US20190133992A1-20190509-D00001.TIF, US201901...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>20190136261</td>\n",
       "      <td>GENETIC MODIFICATION OF CYTOKINE INDUCIBLE SH2...</td>\n",
       "      <td>The present disclosure is in the field of geno...</td>\n",
       "      <td>1. A genetically modified cell comprising a g...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS The pr...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 shows...</td>\n",
       "      <td>[US20190136261A1-20190509-D00001.TIF, US201901...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>20190161536</td>\n",
       "      <td>ANTI-AP2 ANTIBODIES AND ANTIGEN BINDING AGENTS...</td>\n",
       "      <td>This invention is in the area of improved anti...</td>\n",
       "      <td>1. A method of attenuating an aP2-mediated di...</td>\n",
       "      <td>RELATED APPLICATIONS This application is a con...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1-8 ar...</td>\n",
       "      <td>[US20190161536A1-20190530-D00001.TIF, US201901...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>20190202865</td>\n",
       "      <td>TARGETING DIMERIZATION OF BAX TO MODULATE BAX ...</td>\n",
       "      <td>Methods are provided for identifying an agent ...</td>\n",
       "      <td>1-19. (canceled)  20. A method of inhibiting ...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS This a...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1A-1D. ...</td>\n",
       "      <td>[US20190202865A1-20190704-D00001.TIF, US201902...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>20190201532</td>\n",
       "      <td>SENSITIZATION OF BACTERIAL CELLS TO QUINOLONE ...</td>\n",
       "      <td>Provided herein are pharmaceutical composition...</td>\n",
       "      <td>1. A pharmaceutical composition comprising a ...</td>\n",
       "      <td>RELATED APPLICATION The present application cl...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1F....</td>\n",
       "      <td>[US20190201532A1-20190704-D00001.TIF, US201902...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>20190201444</td>\n",
       "      <td>GLYCOENGINEERING OF E-SELECTIN LIGANDS</td>\n",
       "      <td>The present invention provides methods of enfo...</td>\n",
       "      <td>1. A method of enforcing expression of an E-s...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS The pr...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1A-FIG....</td>\n",
       "      <td>[US20190201444A1-20190704-D00000.TIF, US201902...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>20190177429</td>\n",
       "      <td>Anti-HER2 Antibodies and Immunoconjugates</td>\n",
       "      <td>The invention provides anti-HER2 antibodies an...</td>\n",
       "      <td>1. An isolated antibody that binds to HER2, w...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS The pr...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE FIGURES FIG. 1 shows ...</td>\n",
       "      <td>[US20190177429A1-20190613-D00001.TIF, US201901...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>20190184190</td>\n",
       "      <td>PHOSPHOR-CONTAINING DRUG ACTIVATOR ACTIVATABLE...</td>\n",
       "      <td>A phosphor-containing drug activator activatab...</td>\n",
       "      <td>1. A phosphor-containing drug activator activ...</td>\n",
       "      <td>CROSS REFERENCE TO RELATED APPLICATIONS This a...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE FIGURES A more comple...</td>\n",
       "      <td>[US20190184190A1-20190620-D00000.TIF, US201901...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>20190192693</td>\n",
       "      <td>METHODS AND VECTORS FOR TREATING CNS DISORDERS</td>\n",
       "      <td>Methods and uses of treating a disease in a ma...</td>\n",
       "      <td>1. A method of delivering a therapeutic prote...</td>\n",
       "      <td>RELATED APPLICATIONS This application claims p...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE FIGURES A more comple...</td>\n",
       "      <td>[US20190184190A1-20190620-D00000.TIF, US201901...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>20190159474</td>\n",
       "      <td>AMELIORATIVE EFFECTS OF A WHOLE COFFEE FRUIT E...</td>\n",
       "      <td>The invention provides a method of extracting ...</td>\n",
       "      <td>1. A method of producing a whole coffee fruit...</td>\n",
       "      <td>FIELD OF THE INVENTION The invention provides ...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A and...</td>\n",
       "      <td>[US20190159474A1-20190530-D00000.TIF, US201901...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>20190125691</td>\n",
       "      <td>ENCAPSULATION-FREE CONTROLLED PROTEIN RELEASE ...</td>\n",
       "      <td>The present disclosure provides a delivery sys...</td>\n",
       "      <td>1. A biocompatible polymer composite comprise...</td>\n",
       "      <td>FIELD The present disclosure relates to a bioc...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS Embodiments ...</td>\n",
       "      <td>[US20190125691A1-20190502-D00000.TIF, US201901...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>20190169260</td>\n",
       "      <td>Human Leukocyte Antigen Restricted Gamma Delta...</td>\n",
       "      <td>Disclosed herein are compositions and methods ...</td>\n",
       "      <td>1. A composition comprising a polypeptide con...</td>\n",
       "      <td>SEQUENCE LISTING The instant application conta...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS The novel fe...</td>\n",
       "      <td>[US20190169260A1-20190606-D00001.TIF, US201901...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>20190194282</td>\n",
       "      <td>CHIMERIC PROTEINS FOR TARGETING dsRNA</td>\n",
       "      <td>Described herein are recombinant chimeric prot...</td>\n",
       "      <td>1. A chimeric recombinant protein comprising:...</td>\n",
       "      <td>CROSS REFERENCE TO RELATED APPLICATIONS Benefi...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1D:...</td>\n",
       "      <td>[US20190194282A1-20190627-D00000.TIF, US201901...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>20190127440</td>\n",
       "      <td>NOVEL TSLP INHIBITORS</td>\n",
       "      <td>The present invention relates to monomeric fus...</td>\n",
       "      <td>1. A monomeric fusion protein comprising: a f...</td>\n",
       "      <td>FIELD OF THE INVENTION The present invention r...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE FIGURES FIG. 1 shows ...</td>\n",
       "      <td>[US20190127440A1-20190502-D00001.TIF, US201901...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>20190177383</td>\n",
       "      <td>NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR...</td>\n",
       "      <td>The present invention relates to peptides, pro...</td>\n",
       "      <td>1. A method of treating a patient who has can...</td>\n",
       "      <td>CROSS REFERENCE TO RELATED APPLICATIONS This a...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS The patent o...</td>\n",
       "      <td>[US20190177383A1-20190613-D00001.TIF, US201901...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>20190194689</td>\n",
       "      <td>CNS TARGETING AAV VECTORS AND METHODS OF USE T...</td>\n",
       "      <td>The invention in some aspects relates to recom...</td>\n",
       "      <td>1-55. (canceled)  56. A method for delivering...</td>\n",
       "      <td>RELATED APPLICATIONS This application is a con...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1B ...</td>\n",
       "      <td>[US20190194689A1-20190627-D00001.TIF, US201901...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>20190144517</td>\n",
       "      <td>PROTEIN FOR NEUTRALIZING PROGRAMMED NECROCYTOS...</td>\n",
       "      <td>Provided is polypeptide which derives from wil...</td>\n",
       "      <td>1. A polypeptide that inhibits cell necrosis,...</td>\n",
       "      <td>TECHNICAL FIELD The present invention relates ...</td>\n",
       "      <td>DESCRIPTION OF DRAWINGS FIG. 1 shows the scree...</td>\n",
       "      <td>[US20190144517A1-20190516-D00001.TIF, US201901...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>20190177709</td>\n",
       "      <td>REGULATION OF GENE EXPRESSION USING ENGINEERED...</td>\n",
       "      <td>The present disclosure is in the field of geno...</td>\n",
       "      <td>1. A zinc finger nuclease (ZFN) comprising le...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS This a...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A and...</td>\n",
       "      <td>[US20190177709A1-20190613-D00000.TIF, US201901...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>20190169583</td>\n",
       "      <td>STEP-Derived Peptide for Brain Injury Treatment</td>\n",
       "      <td>A novel peptide sequence that is a modified de...</td>\n",
       "      <td>1. An isolated peptide comprising a kinase in...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS The fo...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...</td>\n",
       "      <td>[US20190169583A1-20190606-D00001.TIF, US201901...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "             id                                    invention_title  \\\n",
       "0   20190151472  LIVER-SPECIFIC CONSTRUCTS, FACTOR VIII EXPRESS...   \n",
       "1   20190135863  RETRO-INVERSO PEPTIDE INHIBITORS OF CELL MIGRA...   \n",
       "2   20190133992  CANNABINOID COMPOSITION HAVING AN OPTIMIZED FA...   \n",
       "3   20190136261  GENETIC MODIFICATION OF CYTOKINE INDUCIBLE SH2...   \n",
       "4   20190161536  ANTI-AP2 ANTIBODIES AND ANTIGEN BINDING AGENTS...   \n",
       "5   20190202865  TARGETING DIMERIZATION OF BAX TO MODULATE BAX ...   \n",
       "6   20190201532  SENSITIZATION OF BACTERIAL CELLS TO QUINOLONE ...   \n",
       "7   20190201444             GLYCOENGINEERING OF E-SELECTIN LIGANDS   \n",
       "8   20190177429          Anti-HER2 Antibodies and Immunoconjugates   \n",
       "9   20190184190  PHOSPHOR-CONTAINING DRUG ACTIVATOR ACTIVATABLE...   \n",
       "10  20190192693     METHODS AND VECTORS FOR TREATING CNS DISORDERS   \n",
       "11  20190159474  AMELIORATIVE EFFECTS OF A WHOLE COFFEE FRUIT E...   \n",
       "12  20190125691  ENCAPSULATION-FREE CONTROLLED PROTEIN RELEASE ...   \n",
       "13  20190169260  Human Leukocyte Antigen Restricted Gamma Delta...   \n",
       "14  20190194282              CHIMERIC PROTEINS FOR TARGETING dsRNA   \n",
       "15  20190127440                              NOVEL TSLP INHIBITORS   \n",
       "16  20190177383  NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR...   \n",
       "17  20190194689  CNS TARGETING AAV VECTORS AND METHODS OF USE T...   \n",
       "18  20190144517  PROTEIN FOR NEUTRALIZING PROGRAMMED NECROCYTOS...   \n",
       "19  20190177709  REGULATION OF GENE EXPRESSION USING ENGINEERED...   \n",
       "20  20190169583    STEP-Derived Peptide for Brain Injury Treatment   \n",
       "\n",
       "                                             abstract  \\\n",
       "0   Described herein are constructs used for liver...   \n",
       "1   The present invention discloses retro-inverso ...   \n",
       "2   A composition of matter for enhancing delivery...   \n",
       "3   The present disclosure is in the field of geno...   \n",
       "4   This invention is in the area of improved anti...   \n",
       "5   Methods are provided for identifying an agent ...   \n",
       "6   Provided herein are pharmaceutical composition...   \n",
       "7   The present invention provides methods of enfo...   \n",
       "8   The invention provides anti-HER2 antibodies an...   \n",
       "9   A phosphor-containing drug activator activatab...   \n",
       "10  Methods and uses of treating a disease in a ma...   \n",
       "11  The invention provides a method of extracting ...   \n",
       "12  The present disclosure provides a delivery sys...   \n",
       "13  Disclosed herein are compositions and methods ...   \n",
       "14  Described herein are recombinant chimeric prot...   \n",
       "15  The present invention relates to monomeric fus...   \n",
       "16  The present invention relates to peptides, pro...   \n",
       "17  The invention in some aspects relates to recom...   \n",
       "18  Provided is polypeptide which derives from wil...   \n",
       "19  The present disclosure is in the field of geno...   \n",
       "20  A novel peptide sequence that is a modified de...   \n",
       "\n",
       "                                               claims  \\\n",
       "0    1-10. (canceled)  11. A method of providing a...   \n",
       "1    1. A compound of formula (I):   X1-(D)-Arg-X2...   \n",
       "2    1. A cannabinoid composition comprising: at l...   \n",
       "3    1. A genetically modified cell comprising a g...   \n",
       "4    1. A method of attenuating an aP2-mediated di...   \n",
       "5    1-19. (canceled)  20. A method of inhibiting ...   \n",
       "6    1. A pharmaceutical composition comprising a ...   \n",
       "7    1. A method of enforcing expression of an E-s...   \n",
       "8    1. An isolated antibody that binds to HER2, w...   \n",
       "9    1. A phosphor-containing drug activator activ...   \n",
       "10   1. A method of delivering a therapeutic prote...   \n",
       "11   1. A method of producing a whole coffee fruit...   \n",
       "12   1. A biocompatible polymer composite comprise...   \n",
       "13   1. A composition comprising a polypeptide con...   \n",
       "14   1. A chimeric recombinant protein comprising:...   \n",
       "15   1. A monomeric fusion protein comprising: a f...   \n",
       "16   1. A method of treating a patient who has can...   \n",
       "17   1-55. (canceled)  56. A method for delivering...   \n",
       "18   1. A polypeptide that inhibits cell necrosis,...   \n",
       "19   1. A zinc finger nuclease (ZFN) comprising le...   \n",
       "20   1. An isolated peptide comprising a kinase in...   \n",
       "\n",
       "                                          description  \\\n",
       "0   CROSS-REFERENCE TO RELATED APPLICATIONS The pr...   \n",
       "1   The present invention concerns retro-inverso p...   \n",
       "2   FIELD OF THE INVENTION The present invention r...   \n",
       "3   CROSS-REFERENCE TO RELATED APPLICATIONS The pr...   \n",
       "4   RELATED APPLICATIONS This application is a con...   \n",
       "5   CROSS-REFERENCE TO RELATED APPLICATIONS This a...   \n",
       "6   RELATED APPLICATION The present application cl...   \n",
       "7   CROSS-REFERENCE TO RELATED APPLICATIONS The pr...   \n",
       "8   CROSS-REFERENCE TO RELATED APPLICATIONS The pr...   \n",
       "9   CROSS REFERENCE TO RELATED APPLICATIONS This a...   \n",
       "10  RELATED APPLICATIONS This application claims p...   \n",
       "11  FIELD OF THE INVENTION The invention provides ...   \n",
       "12  FIELD The present disclosure relates to a bioc...   \n",
       "13  SEQUENCE LISTING The instant application conta...   \n",
       "14  CROSS REFERENCE TO RELATED APPLICATIONS Benefi...   \n",
       "15  FIELD OF THE INVENTION The present invention r...   \n",
       "16  CROSS REFERENCE TO RELATED APPLICATIONS This a...   \n",
       "17  RELATED APPLICATIONS This application is a con...   \n",
       "18  TECHNICAL FIELD The present invention relates ...   \n",
       "19  CROSS-REFERENCE TO RELATED APPLICATIONS This a...   \n",
       "20  CROSS-REFERENCE TO RELATED APPLICATIONS The fo...   \n",
       "\n",
       "                                 drawings_description  \\\n",
       "0   BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...   \n",
       "1   DESCRIPTION OF THE FIGURES FIG. 1 High degree ...   \n",
       "2   BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...   \n",
       "3   BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 shows...   \n",
       "4   BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1-8 ar...   \n",
       "5   BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1A-1D. ...   \n",
       "6   BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1F....   \n",
       "7   BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1A-FIG....   \n",
       "8   BRIEF DESCRIPTION OF THE FIGURES FIG. 1 shows ...   \n",
       "9   BRIEF DESCRIPTION OF THE FIGURES A more comple...   \n",
       "10  BRIEF DESCRIPTION OF THE FIGURES A more comple...   \n",
       "11  BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A and...   \n",
       "12  BRIEF DESCRIPTION OF THE DRAWINGS Embodiments ...   \n",
       "13  BRIEF DESCRIPTION OF THE DRAWINGS The novel fe...   \n",
       "14  BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1D:...   \n",
       "15  BRIEF DESCRIPTION OF THE FIGURES FIG. 1 shows ...   \n",
       "16  BRIEF DESCRIPTION OF THE DRAWINGS The patent o...   \n",
       "17  BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1B ...   \n",
       "18  DESCRIPTION OF DRAWINGS FIG. 1 shows the scree...   \n",
       "19  BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A and...   \n",
       "20  BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...   \n",
       "\n",
       "                                  drawings_file_paths  \n",
       "0   [US20190151472A1-20190523-D00001.TIF, US201901...  \n",
       "1   [US20190135863A1-20190509-D00001.TIF, US201901...  \n",
       "2   [US20190133992A1-20190509-D00001.TIF, US201901...  \n",
       "3   [US20190136261A1-20190509-D00001.TIF, US201901...  \n",
       "4   [US20190161536A1-20190530-D00001.TIF, US201901...  \n",
       "5   [US20190202865A1-20190704-D00001.TIF, US201902...  \n",
       "6   [US20190201532A1-20190704-D00001.TIF, US201902...  \n",
       "7   [US20190201444A1-20190704-D00000.TIF, US201902...  \n",
       "8   [US20190177429A1-20190613-D00001.TIF, US201901...  \n",
       "9   [US20190184190A1-20190620-D00000.TIF, US201901...  \n",
       "10  [US20190184190A1-20190620-D00000.TIF, US201901...  \n",
       "11  [US20190159474A1-20190530-D00000.TIF, US201901...  \n",
       "12  [US20190125691A1-20190502-D00000.TIF, US201901...  \n",
       "13  [US20190169260A1-20190606-D00001.TIF, US201901...  \n",
       "14  [US20190194282A1-20190627-D00000.TIF, US201901...  \n",
       "15  [US20190127440A1-20190502-D00001.TIF, US201901...  \n",
       "16  [US20190177383A1-20190613-D00001.TIF, US201901...  \n",
       "17  [US20190194689A1-20190627-D00001.TIF, US201901...  \n",
       "18  [US20190144517A1-20190516-D00001.TIF, US201901...  \n",
       "19  [US20190177709A1-20190613-D00000.TIF, US201901...  \n",
       "20  [US20190169583A1-20190606-D00001.TIF, US201901...  "
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Define the pandas dataframe\n",
    "cols = ['id', 'invention_title', 'abstract', 'claims', 'description', 'drawings_description', 'drawings_file_paths']\n",
    "patents_df = pd.DataFrame(columns=cols)\n",
    "\n",
    "# File counter\n",
    "m = 0\n",
    "\n",
    "# Loop through all folders and grab xml files\n",
    "for folder in glob.glob('../Dataset/*'):\n",
    "    \n",
    "    # Select only main xml file (folder[11:35]) and ignore supplementary ones\n",
    "    # that have different name pattern\n",
    "    for _file in glob.glob(folder + '/' + folder[11:35] + '.XML'):\n",
    "        \n",
    "        # Taking a subgroup of only 20 files for experimentation purposes\n",
    "        if m <= 20:\n",
    "            # Parse xml tree\n",
    "            tree = ET.parse(_file)\n",
    "            root = tree.getroot()\n",
    "\n",
    "            # Placeholder for text content\n",
    "            abstract_text = ''\n",
    "            claims_text = ''\n",
    "            description_text = ''\n",
    "            drawings_description_text = ''\n",
    "            drawings_file_paths = []\n",
    "\n",
    "            # Traverse XML tree and extract data we need\n",
    "            if (root[0].tag == 'us-bibliographic-data-application'):\n",
    "\n",
    "                # Extract document number as id\n",
    "                _id = root[0].find('publication-reference').find('document-id').find('doc-number').text\n",
    "                \n",
    "                # Extract invention title\n",
    "                invention_title = root[0].find('invention-title').text\n",
    "                \n",
    "                # Extract abstract\n",
    "                abstract = root.find('abstract')\n",
    "                \n",
    "                # Extract claims\n",
    "                claims = root.find('claims')\n",
    "                \n",
    "                # Extract all description\n",
    "                description = root.find('description')\n",
    "                \n",
    "                # Extract drawings description (if present)\n",
    "                if root.find('drawings') != None:\n",
    "                    drawings_description = root.find('description').find('description-of-drawings')\n",
    "                    \n",
    "                # Extract drawings paths (if present)\n",
    "                if root.find('drawings') != None:\n",
    "                    drawings = root.find('drawings')\n",
    "\n",
    "                # Store all paragraphs in the abstract section\n",
    "                for child in abstract:\n",
    "                    if (child.text != None):\n",
    "                        abstract_text += child.text + '\\n'\n",
    "\n",
    "                # Store all paragraphs in the claims section\n",
    "                for child in claims:\n",
    "                    claims_text += ''.join(child.itertext()).replace('\\n', ' ')\n",
    "                    \n",
    "                # Store all paragraphs in the description section\n",
    "                for child in description:\n",
    "                    description_text += ''.join(child.itertext()) + ' '\n",
    "                    \n",
    "                # Store all paragraphs in the drawings description section\n",
    "                if drawings_description:\n",
    "                    for child in drawings_description:\n",
    "                        drawings_description_text += ''.join(child.itertext()) + ' '\n",
    "                        \n",
    "                # Store all drawings file paths\n",
    "                if drawings:\n",
    "                    for child in drawings:\n",
    "                        drawings_file_paths.append(child[0].get('file'))\n",
    "\n",
    "                # Write extracted content to dataframe\n",
    "                patents_df = patents_df.append(pd.Series([_id, invention_title, abstract_text, claims_text, \\\n",
    "                                                          description_text, drawings_description_text, \\\n",
    "                                                         drawings_file_paths], index=cols), ignore_index=True)\n",
    "                \n",
    "        # Process only 20 files and break out of the loop\n",
    "        else:\n",
    "            break\n",
    "    \n",
    "        # File counter increment\n",
    "        m += 1\n",
    "    \n",
    "# Show dataframe    \n",
    "patents_df"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<hr>\n",
    "<br>\n",
    "\n",
    "<a id='section-2'></a>\n",
    "\n",
    "### - Text Segmentation for Description Section"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Load dependencies\n",
    "import pandas as pd\n",
    "import re"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "def find_inbetween_text(text, sub1, sub2):\n",
    "    \"\"\"\n",
    "    This function accepts a piece of text and extracts what's\n",
    "    between any two given strings after finding their positions\n",
    "    \"\"\"\n",
    "    \n",
    "    # Get positions for the two strings\n",
    "    pos1 = sub1\n",
    "    pos2 = sub2\n",
    "    \n",
    "    if pos1 > pos2 and pos2 > 0:\n",
    "        return text[pos2:pos1]\n",
    "    elif pos2 > pos1 and pos1 > 0:\n",
    "        return text[pos1:pos2]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Gene therapy can be used to genetically engineer a cell to have one or more inactivated genes and/or to cause that cell to express a product not previously being produced in that cell (e.g., via transgene insertion and/or via correction of an endogenous sequence). Examples of uses of transgene insertion include the insertion of one or more genes encoding one or more novel therapeutic proteins, insertion of a coding sequence encoding a protein that is lacking in the cell or in the individual, insertion of a wild type gene in a cell containing a mutated gene sequence, and/or insertion of a sequence that encodes a structural nucleic acid such as a microRNA or siRNA. Examples of useful applications of ‘correction’ of an endogenous gene sequence include alterations of disease-associated gene mutations, alterations in sequences encoding splice sites, alterations in regulatory sequences and/or targeted alterations of sequences encoding structural characteristics of a protein. Hepatic gene transfer provides an effective means of delivering transgenes to a subject for treatment and/or prevention of various disorders, including hemophilias and lysosomal storage disorders. See, e.g., U.S. Pat. No. 9,150,847 and U.S. Publication Nos. 20130177983 and 20140017212. Vectors specific for liver-directed gene therapy have also been described. See, e.g., WO 2014064277; WO 2009130208; EP 2451474B1, Chuah et al., (2014)Molecular Therapy, 22, 1605-1613; and Nair et al. (2014) Blood 123:3195-3199. These vectors can include the wild-type mouse minute virus (MVM) intron sequence. See, e.g., Haut and Pintel (1998) J. Virol. 72:1834-1843; Haut and Pintel (1998) Virol. 258:84-94. In whole mammals, there are complex mechanisms that can regulate either the activation or the suppression of the cellular members of the immune system. For example, dendritic cells (DCs) have been established as central players in the balance between immune activation versus immune tolerance. They are the most potent antigen presenting cells in the immune system and specifically capture and present antigens to naïve T cells. Immature DCs interact with potential antigens through specific receptors such as Toll-like receptors where the antigen is brought into the cell by micropinocytosis. The antigen is then broken up into smaller peptides that are presented to T cells by the major histocompatibility complexes. In addition, mature DCs secrete inflammatory mediators such as IL-1β, IL-12, IL-6 and TNF which further serve to activate the T cells. On the other side, DCs also play a role in tolerizing the body to some antigens in order to maintain central and peripheral tolerance. Tolerogenic DCs (tolDC) have low amounts of co-stimulatory signals on the cell surfaces and have a reduced expression of the inflammatory mediators described above. However, these tolDCs express large amounts of anti-inflammatory cytokines like IL-10 and when these cells interact with naïve T cells, the T cells are driven to become anergic/regulatory T cells (CD8+ Tregs). In fact, it has been shown that this process is enhanced upon repeated stimulation of T cells with these immature/tolerogenic DCs. Several factors have also been identified that work in concert with tolDCs to induce different types of Tregs. For example, naïve T cells co-exposed with tolDCs and HGF, VIP peptide, TSLP or Vitamin D3 leads to the induction of CD4+CD25+Foxp3+ Tregs, co-exposure with TGF-β or IL-10 leads to Trl T regs and co-exposure with corticosteroids, rapamycin, retinoic acid can lead to CD4+/CD8+ Tregs (Raker et al (2015) Front Immunol 6: art 569 and Osorio et al (2015) Front Immunol 6: art 535). Hemophilias such as Hemophilia A and Hemophilia B, are genetic disorders of the blood-clotting system, characterized by bleeding into joints and soft tissues, and by excessive bleeding into any site experiencing trauma or undergoing surgery. Hemophilia A is clinically indistinguishable from Hemophilia B, but factor VIII (FVIII or F8) is deficient or absent in Hemophilia A while factor IX (FIX or F.IX) is deficient or absent in patients with Hemophilia B. The F8 gene encodes a plasma glycoprotein that circulates in association with von Wilebrand's factor in its inactive form. Upon surface injury, the intrinsic clotting cascade initiates and FVIII is released from the complex and is activated. The activated form works with Factor IX to activate Factor X to become the activated Xa, eventually leading to change of fibrinogen to fibrin and clot induction. See, Levinson et al. (1990) Genomics 7(1):1-11. 40-50% of Hemophilia A patients have a chromosomal inversion involving F8 intron 22 (also known as IVS22). The inversion is caused by an intra-chromosomal recombination event between a 9.6 kb sequence within the intron 22 of the F8 gene and one of the two closely related inversely orientated sequences located about 300 kb distal to the F8 gene, resulting in an inversion of exons 1 to 22 with respect to exons 23 to 26. See, Textbook of Hemophilia, Lee et al. (eds) 2005, Blackwell Publishing. Other hemophilia A patients have defects in F8 including active site mutations, and nonsense and missense mutations. Clinically, Hemophilia A patients are evaluated and stratified depending on how often a patient has a bleeding episode, and how long those episodes last. Both of these characteristics are directly dependent on the amount of FVIII protein in a patient's blood. Patients with severe hemophilia typically have less than 1% of the normal blood level of FVIII, experience bleeding following injury and often spontaneous bleeding into their joints. Moderate patients have 1-5% of the normal FVIII level while mild patients have 6% or more of normal FVIII and have bleeding episodes only after serious injury, trauma or surgery (Kulkarni et al (2009) Haemophilia 15:1281-90). Patients with Hemophilia A are treated with replacement FVIII protein derived either from human plasma or produced recombinantly where the frequency of treatment is based upon bleeding patterns and severity of the hemophilia. Patients with severe Hemophilia A receive prophylaxtic treatment on a regular basis to prevent bleeds from occurring while less severe patients can receive treatment only as needed following injury. Gene therapy for patients with Hemophilia A or B, involving the introduction of plasmid and other vectors (e.g., AAV) encoding a functional FVIII or F.IX proteins have been described. (See, e.g., U.S. Pat. Nos. 6,936,243; 7,238,346 and 6,200,560; Shi et al. (2007)J Thromb Haemost. (2):352-61; Lee et al. (2004) Pharm. Res. 7:1229-1232; Graham et al. (2008) Genet Vaccines Ther. 3:6-9; Manno et al. (2003) Blood 101(8): 2963-72; Manno et al. (2006) Nature Medicine 12(3): 342-7; Nathwani et al. (2011)Mol Ther 19(5): 876-85; Nathwani et al. (2011); N Engl J Med. 365(25): 2357-65 and McIntosh et al. (2013) Blood 121(17):3335-44). However, in these protocols, the formation of inhibitory anti-factor VIII or IX (anti-FVIII or anti-F.IX) antibodies, and antibodies against the delivery vehicle remains a major complication of FVIII and F.IX replacement-based treatment for hemophilia. See, e.g., Scott & Lozier (2012) Br J Haematol. 156(3):295-302. However, there remains a need for liver-specific polynucleotides (expression constructs and transcription modules) that drive expression of one or more transgenes (including transgenes encoding one or more proteins lacking in a hemophilia) in liver cells at high levels. \n"
     ]
    }
   ],
   "source": [
    "# Try an example on first document description\n",
    "# extract the background section text\n",
    "boundary1 = re.search('([A-Z])*BACKGROUND(([A-Z])*(\\s))*', patents_df['description'][0], re.MULTILINE)\n",
    "boundary2 = re.search('([A-Z])*SUMMARY(([A-Z])*(\\s))*', patents_df['description'][0], re.MULTILINE)\n",
    "\n",
    "print(find_inbetween_text(patents_df['description'][0], boundary1.end(), boundary2.start()))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Formulations of bioactive compounds have been developed for human and animal consumption and therapeutic use since the beginning of recorded history. Since ancient times flowers and herbs were gathered and consumed therapeutically, often brewed into tea and cooked in food or compressed into a poultice and applied to the skin to treat wounds, pain and other maladies. Animals also self-medicate by eating plants. Transmucosal and transdermal methodologies often have an advantage over orally deliverable formulations because the human digestive tract can reduce the efficacy and bioavailability of any particular remedy. In particular, first pass metabolism may modify the therapeutic components of orally deliverable bioactive compounds. Additionally stomach acids can inhibit the effectiveness of oral delivery. Presently, whole-plant botanical mixtures, extracts, decoctions, distillations, essential oils and other various forms have been developed for treating various ailments. Some of these include synthetic and isolated components as well as whole plant extracts. Transdermal patches are commonly used to deliver compounds through the skin. Oral medications are sometimes specially formulated to absorb directly through the oral mucosa and the oral dermal tissue. Nasal sprays are also formulated to achieve rapid absorption and transmucosal delivery into the bloodstream. Various other delivery modalities have been developed to improve delivery of bioactive compounds. Transmucosal and transdermal formulations have widely varying pharmacokinetics upon administration depending on the route, manner and system of delivery. Oromucosal and sublingual delivery work well for various bioactive compounds because the digestive tract is bypassed. With the resurgence of botanical therapeutics in recent years, the vast breadth and depth of therapeutic effects afforded by herbal and traditional systems of medicine and therapies has made the art and science of botanical pharmacokinetics of significant importance. Human skin includes the epidermis, dermis and subcutis. The epidermis includes the stratum corneum. The stratum corneum is the outer layer of skin that protects the body. It is composed primarily of layers of dead, flattened keratinocytes surrounded by a phospholipid matrix. This can be visualized as brick and mortar wall and functions to provide a barrier to microbial parasites as well as environmental toxins. The stratum corneum also presents a significant barrier to the delivery of transdermal drugs, vitamins, minerals, nutraceuticals and pharmaceuticals. The stratum corneum varies in thickness in various parts of the body. In some regions a mucosal layer covers the skin, such as in the nasal, oral and other bodily cavities. It is commonly intended that bioactive compounds applied to the epidermis of the skin reach the blood vessels of the dermis, entering into general circulation. There are two major transdermal pathways. One is the intercellular route, which includes the movement of topically applied product around the cells of the stratum corneum via a phospholipid matrix that surrounds the cells. This is a tortuous path, so there are challenges to optimizing the speed of delivery and efficacy of bioactive compounds. The other pathway is the transcellular pathway, which includes substances directly passing through the cytoplasm of the dead keratinocytes of the stratum corneum, as well as the phospholipids matrix surrounding the cells. This is a more direct pathway yet there are still challenges to optimizing delivery and efficacy of bioactive compounds. Human mucosa includes outer epithelial layers, superficially keratinized or nonkeratinized, above a basal lamina that separates them from a deeper lamina propria whose papillary layer and capillary plexus contain the blood vessels bioactive compounds are often intended to diffuse into across the superficial mucosa, entering general circulation. There exists the challenge to penetrate the mucus membranes. Often the mucus membrane is relatively thin, so that the transcellular pathway and the intercellular pathway are more easily navigated when bioactive compounds are delivered transmucosally. This is especially true when an excipient having heightened transmucosal and transdermal diffusion and functionality is formulated with a bioactive compound. Oleic acid is a common pharmaceutical excipient that is widely used for long-term stabilization, solid formation bulking, and for the therapeutic enhancement of active ingredients including serving as an emulsion agent in topical pharmaceutical formulations and a solubility enhancer for gastrointestinal tract delivery. What is desired is a formulation including bioactive compounds and a non-toxic excipient carrier that improves rate and efficiency of absorption, bioavailability and efficacy of the bioactive compounds. What is also desired is a formulation having an extended shelf life. \n"
     ]
    }
   ],
   "source": [
    "background_boundary_start = 0\n",
    "background_boundary_end = 0\n",
    "invention_col = []\n",
    "\n",
    "for index, row in patents_df.iterrows():\n",
    "    background_boundary_start = re.search('([A-Z])*BACKGROUND(([A-Z])*(\\s))*', \\\n",
    "                                          str(row['description']), re.MULTILINE)\n",
    "    background_boundary_end = re.search('([A-Z])*SUMMARY(([A-Z])*(\\s))*', \\\n",
    "                                        str(row['description']), re.MULTILINE)\n",
    "    \n",
    "    if background_boundary_start and background_boundary_end:\n",
    "        invention_col.append(find_inbetween_text(str(row['description']), background_boundary_start.end(), \\\n",
    "                                             background_boundary_end.start()))\n",
    "    else:\n",
    "        invention_col.append(' ')\n",
    "        \n",
    "print(invention_col[2])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>invention_background</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Gene therapy can be used to genetically engine...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Formulations of bioactive compounds have been ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Cells communicate with each other either by di...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Human adipocyte lipid-binding protein (aP2) be...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Throughout this application various publicatio...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Antibiotics are the main tools to treat infect...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Mesenchymal stem cells (MSCs) hold much promis...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Breast cancer is a highly significant cause of...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>Field of Invention The invention relates to me...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>Coffee fruits are mainly produced in Africa an...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>Controlled protein release is a key strategy t...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>Cancer has a major impact on society across th...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>Prostate cancer is the second most commonly di...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>Thymic stromal lymphopoietin (TSLP) is an inte...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>Ovarian Cancer With an estimated 239 000 new c...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>Gene therapy has been investigated for deliver...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>Tumor necrosis factor α (TNF) is a multifuncti...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>When one considers that genome sequencing effo...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                 invention_background\n",
       "0   Gene therapy can be used to genetically engine...\n",
       "1                                                    \n",
       "2   Formulations of bioactive compounds have been ...\n",
       "3   Cells communicate with each other either by di...\n",
       "4   Human adipocyte lipid-binding protein (aP2) be...\n",
       "5   Throughout this application various publicatio...\n",
       "6   Antibiotics are the main tools to treat infect...\n",
       "7   Mesenchymal stem cells (MSCs) hold much promis...\n",
       "8   Breast cancer is a highly significant cause of...\n",
       "9   Field of Invention The invention relates to me...\n",
       "10                                                   \n",
       "11  Coffee fruits are mainly produced in Africa an...\n",
       "12  Controlled protein release is a key strategy t...\n",
       "13  Cancer has a major impact on society across th...\n",
       "14  Prostate cancer is the second most commonly di...\n",
       "15  Thymic stromal lymphopoietin (TSLP) is an inte...\n",
       "16  Ovarian Cancer With an estimated 239 000 new c...\n",
       "17  Gene therapy has been investigated for deliver...\n",
       "18  Tumor necrosis factor α (TNF) is a multifuncti...\n",
       "19  When one considers that genome sequencing effo...\n",
       "20                                                   "
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "inventions_df = pd.DataFrame({'invention_background': invention_col})\n",
    "inventions_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id</th>\n",
       "      <th>invention_title</th>\n",
       "      <th>abstract</th>\n",
       "      <th>claims</th>\n",
       "      <th>description</th>\n",
       "      <th>drawings_description</th>\n",
       "      <th>drawings_file_paths</th>\n",
       "      <th>invention_background</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>20190151472</td>\n",
       "      <td>LIVER-SPECIFIC CONSTRUCTS, FACTOR VIII EXPRESS...</td>\n",
       "      <td>Described herein are constructs used for liver...</td>\n",
       "      <td>1-10. (canceled)  11. A method of providing a...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS The pr...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...</td>\n",
       "      <td>[US20190151472A1-20190523-D00001.TIF, US201901...</td>\n",
       "      <td>Gene therapy can be used to genetically engine...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>20190135863</td>\n",
       "      <td>RETRO-INVERSO PEPTIDE INHIBITORS OF CELL MIGRA...</td>\n",
       "      <td>The present invention discloses retro-inverso ...</td>\n",
       "      <td>1. A compound of formula (I):   X1-(D)-Arg-X2...</td>\n",
       "      <td>The present invention concerns retro-inverso p...</td>\n",
       "      <td>DESCRIPTION OF THE FIGURES FIG. 1 High degree ...</td>\n",
       "      <td>[US20190135863A1-20190509-D00001.TIF, US201901...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>20190133992</td>\n",
       "      <td>CANNABINOID COMPOSITION HAVING AN OPTIMIZED FA...</td>\n",
       "      <td>A composition of matter for enhancing delivery...</td>\n",
       "      <td>1. A cannabinoid composition comprising: at l...</td>\n",
       "      <td>FIELD OF THE INVENTION The present invention r...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...</td>\n",
       "      <td>[US20190133992A1-20190509-D00001.TIF, US201901...</td>\n",
       "      <td>Formulations of bioactive compounds have been ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>20190136261</td>\n",
       "      <td>GENETIC MODIFICATION OF CYTOKINE INDUCIBLE SH2...</td>\n",
       "      <td>The present disclosure is in the field of geno...</td>\n",
       "      <td>1. A genetically modified cell comprising a g...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS The pr...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 shows...</td>\n",
       "      <td>[US20190136261A1-20190509-D00001.TIF, US201901...</td>\n",
       "      <td>Cells communicate with each other either by di...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>20190161536</td>\n",
       "      <td>ANTI-AP2 ANTIBODIES AND ANTIGEN BINDING AGENTS...</td>\n",
       "      <td>This invention is in the area of improved anti...</td>\n",
       "      <td>1. A method of attenuating an aP2-mediated di...</td>\n",
       "      <td>RELATED APPLICATIONS This application is a con...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1-8 ar...</td>\n",
       "      <td>[US20190161536A1-20190530-D00001.TIF, US201901...</td>\n",
       "      <td>Human adipocyte lipid-binding protein (aP2) be...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>20190202865</td>\n",
       "      <td>TARGETING DIMERIZATION OF BAX TO MODULATE BAX ...</td>\n",
       "      <td>Methods are provided for identifying an agent ...</td>\n",
       "      <td>1-19. (canceled)  20. A method of inhibiting ...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS This a...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1A-1D. ...</td>\n",
       "      <td>[US20190202865A1-20190704-D00001.TIF, US201902...</td>\n",
       "      <td>Throughout this application various publicatio...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>20190201532</td>\n",
       "      <td>SENSITIZATION OF BACTERIAL CELLS TO QUINOLONE ...</td>\n",
       "      <td>Provided herein are pharmaceutical composition...</td>\n",
       "      <td>1. A pharmaceutical composition comprising a ...</td>\n",
       "      <td>RELATED APPLICATION The present application cl...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1F....</td>\n",
       "      <td>[US20190201532A1-20190704-D00001.TIF, US201902...</td>\n",
       "      <td>Antibiotics are the main tools to treat infect...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>20190201444</td>\n",
       "      <td>GLYCOENGINEERING OF E-SELECTIN LIGANDS</td>\n",
       "      <td>The present invention provides methods of enfo...</td>\n",
       "      <td>1. A method of enforcing expression of an E-s...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS The pr...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1A-FIG....</td>\n",
       "      <td>[US20190201444A1-20190704-D00000.TIF, US201902...</td>\n",
       "      <td>Mesenchymal stem cells (MSCs) hold much promis...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>20190177429</td>\n",
       "      <td>Anti-HER2 Antibodies and Immunoconjugates</td>\n",
       "      <td>The invention provides anti-HER2 antibodies an...</td>\n",
       "      <td>1. An isolated antibody that binds to HER2, w...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS The pr...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE FIGURES FIG. 1 shows ...</td>\n",
       "      <td>[US20190177429A1-20190613-D00001.TIF, US201901...</td>\n",
       "      <td>Breast cancer is a highly significant cause of...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>20190184190</td>\n",
       "      <td>PHOSPHOR-CONTAINING DRUG ACTIVATOR ACTIVATABLE...</td>\n",
       "      <td>A phosphor-containing drug activator activatab...</td>\n",
       "      <td>1. A phosphor-containing drug activator activ...</td>\n",
       "      <td>CROSS REFERENCE TO RELATED APPLICATIONS This a...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE FIGURES A more comple...</td>\n",
       "      <td>[US20190184190A1-20190620-D00000.TIF, US201901...</td>\n",
       "      <td>Field of Invention The invention relates to me...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>20190192693</td>\n",
       "      <td>METHODS AND VECTORS FOR TREATING CNS DISORDERS</td>\n",
       "      <td>Methods and uses of treating a disease in a ma...</td>\n",
       "      <td>1. A method of delivering a therapeutic prote...</td>\n",
       "      <td>RELATED APPLICATIONS This application claims p...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE FIGURES A more comple...</td>\n",
       "      <td>[US20190184190A1-20190620-D00000.TIF, US201901...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>20190159474</td>\n",
       "      <td>AMELIORATIVE EFFECTS OF A WHOLE COFFEE FRUIT E...</td>\n",
       "      <td>The invention provides a method of extracting ...</td>\n",
       "      <td>1. A method of producing a whole coffee fruit...</td>\n",
       "      <td>FIELD OF THE INVENTION The invention provides ...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A and...</td>\n",
       "      <td>[US20190159474A1-20190530-D00000.TIF, US201901...</td>\n",
       "      <td>Coffee fruits are mainly produced in Africa an...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>20190125691</td>\n",
       "      <td>ENCAPSULATION-FREE CONTROLLED PROTEIN RELEASE ...</td>\n",
       "      <td>The present disclosure provides a delivery sys...</td>\n",
       "      <td>1. A biocompatible polymer composite comprise...</td>\n",
       "      <td>FIELD The present disclosure relates to a bioc...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS Embodiments ...</td>\n",
       "      <td>[US20190125691A1-20190502-D00000.TIF, US201901...</td>\n",
       "      <td>Controlled protein release is a key strategy t...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>20190169260</td>\n",
       "      <td>Human Leukocyte Antigen Restricted Gamma Delta...</td>\n",
       "      <td>Disclosed herein are compositions and methods ...</td>\n",
       "      <td>1. A composition comprising a polypeptide con...</td>\n",
       "      <td>SEQUENCE LISTING The instant application conta...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS The novel fe...</td>\n",
       "      <td>[US20190169260A1-20190606-D00001.TIF, US201901...</td>\n",
       "      <td>Cancer has a major impact on society across th...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>20190194282</td>\n",
       "      <td>CHIMERIC PROTEINS FOR TARGETING dsRNA</td>\n",
       "      <td>Described herein are recombinant chimeric prot...</td>\n",
       "      <td>1. A chimeric recombinant protein comprising:...</td>\n",
       "      <td>CROSS REFERENCE TO RELATED APPLICATIONS Benefi...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1D:...</td>\n",
       "      <td>[US20190194282A1-20190627-D00000.TIF, US201901...</td>\n",
       "      <td>Prostate cancer is the second most commonly di...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>20190127440</td>\n",
       "      <td>NOVEL TSLP INHIBITORS</td>\n",
       "      <td>The present invention relates to monomeric fus...</td>\n",
       "      <td>1. A monomeric fusion protein comprising: a f...</td>\n",
       "      <td>FIELD OF THE INVENTION The present invention r...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE FIGURES FIG. 1 shows ...</td>\n",
       "      <td>[US20190127440A1-20190502-D00001.TIF, US201901...</td>\n",
       "      <td>Thymic stromal lymphopoietin (TSLP) is an inte...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>20190177383</td>\n",
       "      <td>NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR...</td>\n",
       "      <td>The present invention relates to peptides, pro...</td>\n",
       "      <td>1. A method of treating a patient who has can...</td>\n",
       "      <td>CROSS REFERENCE TO RELATED APPLICATIONS This a...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS The patent o...</td>\n",
       "      <td>[US20190177383A1-20190613-D00001.TIF, US201901...</td>\n",
       "      <td>Ovarian Cancer With an estimated 239 000 new c...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>20190194689</td>\n",
       "      <td>CNS TARGETING AAV VECTORS AND METHODS OF USE T...</td>\n",
       "      <td>The invention in some aspects relates to recom...</td>\n",
       "      <td>1-55. (canceled)  56. A method for delivering...</td>\n",
       "      <td>RELATED APPLICATIONS This application is a con...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1B ...</td>\n",
       "      <td>[US20190194689A1-20190627-D00001.TIF, US201901...</td>\n",
       "      <td>Gene therapy has been investigated for deliver...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>20190144517</td>\n",
       "      <td>PROTEIN FOR NEUTRALIZING PROGRAMMED NECROCYTOS...</td>\n",
       "      <td>Provided is polypeptide which derives from wil...</td>\n",
       "      <td>1. A polypeptide that inhibits cell necrosis,...</td>\n",
       "      <td>TECHNICAL FIELD The present invention relates ...</td>\n",
       "      <td>DESCRIPTION OF DRAWINGS FIG. 1 shows the scree...</td>\n",
       "      <td>[US20190144517A1-20190516-D00001.TIF, US201901...</td>\n",
       "      <td>Tumor necrosis factor α (TNF) is a multifuncti...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>20190177709</td>\n",
       "      <td>REGULATION OF GENE EXPRESSION USING ENGINEERED...</td>\n",
       "      <td>The present disclosure is in the field of geno...</td>\n",
       "      <td>1. A zinc finger nuclease (ZFN) comprising le...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS This a...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A and...</td>\n",
       "      <td>[US20190177709A1-20190613-D00000.TIF, US201901...</td>\n",
       "      <td>When one considers that genome sequencing effo...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>20190169583</td>\n",
       "      <td>STEP-Derived Peptide for Brain Injury Treatment</td>\n",
       "      <td>A novel peptide sequence that is a modified de...</td>\n",
       "      <td>1. An isolated peptide comprising a kinase in...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS The fo...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...</td>\n",
       "      <td>[US20190169583A1-20190606-D00001.TIF, US201901...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "             id                                    invention_title  \\\n",
       "0   20190151472  LIVER-SPECIFIC CONSTRUCTS, FACTOR VIII EXPRESS...   \n",
       "1   20190135863  RETRO-INVERSO PEPTIDE INHIBITORS OF CELL MIGRA...   \n",
       "2   20190133992  CANNABINOID COMPOSITION HAVING AN OPTIMIZED FA...   \n",
       "3   20190136261  GENETIC MODIFICATION OF CYTOKINE INDUCIBLE SH2...   \n",
       "4   20190161536  ANTI-AP2 ANTIBODIES AND ANTIGEN BINDING AGENTS...   \n",
       "5   20190202865  TARGETING DIMERIZATION OF BAX TO MODULATE BAX ...   \n",
       "6   20190201532  SENSITIZATION OF BACTERIAL CELLS TO QUINOLONE ...   \n",
       "7   20190201444             GLYCOENGINEERING OF E-SELECTIN LIGANDS   \n",
       "8   20190177429          Anti-HER2 Antibodies and Immunoconjugates   \n",
       "9   20190184190  PHOSPHOR-CONTAINING DRUG ACTIVATOR ACTIVATABLE...   \n",
       "10  20190192693     METHODS AND VECTORS FOR TREATING CNS DISORDERS   \n",
       "11  20190159474  AMELIORATIVE EFFECTS OF A WHOLE COFFEE FRUIT E...   \n",
       "12  20190125691  ENCAPSULATION-FREE CONTROLLED PROTEIN RELEASE ...   \n",
       "13  20190169260  Human Leukocyte Antigen Restricted Gamma Delta...   \n",
       "14  20190194282              CHIMERIC PROTEINS FOR TARGETING dsRNA   \n",
       "15  20190127440                              NOVEL TSLP INHIBITORS   \n",
       "16  20190177383  NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR...   \n",
       "17  20190194689  CNS TARGETING AAV VECTORS AND METHODS OF USE T...   \n",
       "18  20190144517  PROTEIN FOR NEUTRALIZING PROGRAMMED NECROCYTOS...   \n",
       "19  20190177709  REGULATION OF GENE EXPRESSION USING ENGINEERED...   \n",
       "20  20190169583    STEP-Derived Peptide for Brain Injury Treatment   \n",
       "\n",
       "                                             abstract  \\\n",
       "0   Described herein are constructs used for liver...   \n",
       "1   The present invention discloses retro-inverso ...   \n",
       "2   A composition of matter for enhancing delivery...   \n",
       "3   The present disclosure is in the field of geno...   \n",
       "4   This invention is in the area of improved anti...   \n",
       "5   Methods are provided for identifying an agent ...   \n",
       "6   Provided herein are pharmaceutical composition...   \n",
       "7   The present invention provides methods of enfo...   \n",
       "8   The invention provides anti-HER2 antibodies an...   \n",
       "9   A phosphor-containing drug activator activatab...   \n",
       "10  Methods and uses of treating a disease in a ma...   \n",
       "11  The invention provides a method of extracting ...   \n",
       "12  The present disclosure provides a delivery sys...   \n",
       "13  Disclosed herein are compositions and methods ...   \n",
       "14  Described herein are recombinant chimeric prot...   \n",
       "15  The present invention relates to monomeric fus...   \n",
       "16  The present invention relates to peptides, pro...   \n",
       "17  The invention in some aspects relates to recom...   \n",
       "18  Provided is polypeptide which derives from wil...   \n",
       "19  The present disclosure is in the field of geno...   \n",
       "20  A novel peptide sequence that is a modified de...   \n",
       "\n",
       "                                               claims  \\\n",
       "0    1-10. (canceled)  11. A method of providing a...   \n",
       "1    1. A compound of formula (I):   X1-(D)-Arg-X2...   \n",
       "2    1. A cannabinoid composition comprising: at l...   \n",
       "3    1. A genetically modified cell comprising a g...   \n",
       "4    1. A method of attenuating an aP2-mediated di...   \n",
       "5    1-19. (canceled)  20. A method of inhibiting ...   \n",
       "6    1. A pharmaceutical composition comprising a ...   \n",
       "7    1. A method of enforcing expression of an E-s...   \n",
       "8    1. An isolated antibody that binds to HER2, w...   \n",
       "9    1. A phosphor-containing drug activator activ...   \n",
       "10   1. A method of delivering a therapeutic prote...   \n",
       "11   1. A method of producing a whole coffee fruit...   \n",
       "12   1. A biocompatible polymer composite comprise...   \n",
       "13   1. A composition comprising a polypeptide con...   \n",
       "14   1. A chimeric recombinant protein comprising:...   \n",
       "15   1. A monomeric fusion protein comprising: a f...   \n",
       "16   1. A method of treating a patient who has can...   \n",
       "17   1-55. (canceled)  56. A method for delivering...   \n",
       "18   1. A polypeptide that inhibits cell necrosis,...   \n",
       "19   1. A zinc finger nuclease (ZFN) comprising le...   \n",
       "20   1. An isolated peptide comprising a kinase in...   \n",
       "\n",
       "                                          description  \\\n",
       "0   CROSS-REFERENCE TO RELATED APPLICATIONS The pr...   \n",
       "1   The present invention concerns retro-inverso p...   \n",
       "2   FIELD OF THE INVENTION The present invention r...   \n",
       "3   CROSS-REFERENCE TO RELATED APPLICATIONS The pr...   \n",
       "4   RELATED APPLICATIONS This application is a con...   \n",
       "5   CROSS-REFERENCE TO RELATED APPLICATIONS This a...   \n",
       "6   RELATED APPLICATION The present application cl...   \n",
       "7   CROSS-REFERENCE TO RELATED APPLICATIONS The pr...   \n",
       "8   CROSS-REFERENCE TO RELATED APPLICATIONS The pr...   \n",
       "9   CROSS REFERENCE TO RELATED APPLICATIONS This a...   \n",
       "10  RELATED APPLICATIONS This application claims p...   \n",
       "11  FIELD OF THE INVENTION The invention provides ...   \n",
       "12  FIELD The present disclosure relates to a bioc...   \n",
       "13  SEQUENCE LISTING The instant application conta...   \n",
       "14  CROSS REFERENCE TO RELATED APPLICATIONS Benefi...   \n",
       "15  FIELD OF THE INVENTION The present invention r...   \n",
       "16  CROSS REFERENCE TO RELATED APPLICATIONS This a...   \n",
       "17  RELATED APPLICATIONS This application is a con...   \n",
       "18  TECHNICAL FIELD The present invention relates ...   \n",
       "19  CROSS-REFERENCE TO RELATED APPLICATIONS This a...   \n",
       "20  CROSS-REFERENCE TO RELATED APPLICATIONS The fo...   \n",
       "\n",
       "                                 drawings_description  \\\n",
       "0   BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...   \n",
       "1   DESCRIPTION OF THE FIGURES FIG. 1 High degree ...   \n",
       "2   BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...   \n",
       "3   BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 shows...   \n",
       "4   BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1-8 ar...   \n",
       "5   BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1A-1D. ...   \n",
       "6   BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1F....   \n",
       "7   BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1A-FIG....   \n",
       "8   BRIEF DESCRIPTION OF THE FIGURES FIG. 1 shows ...   \n",
       "9   BRIEF DESCRIPTION OF THE FIGURES A more comple...   \n",
       "10  BRIEF DESCRIPTION OF THE FIGURES A more comple...   \n",
       "11  BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A and...   \n",
       "12  BRIEF DESCRIPTION OF THE DRAWINGS Embodiments ...   \n",
       "13  BRIEF DESCRIPTION OF THE DRAWINGS The novel fe...   \n",
       "14  BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1D:...   \n",
       "15  BRIEF DESCRIPTION OF THE FIGURES FIG. 1 shows ...   \n",
       "16  BRIEF DESCRIPTION OF THE DRAWINGS The patent o...   \n",
       "17  BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1B ...   \n",
       "18  DESCRIPTION OF DRAWINGS FIG. 1 shows the scree...   \n",
       "19  BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A and...   \n",
       "20  BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...   \n",
       "\n",
       "                                  drawings_file_paths  \\\n",
       "0   [US20190151472A1-20190523-D00001.TIF, US201901...   \n",
       "1   [US20190135863A1-20190509-D00001.TIF, US201901...   \n",
       "2   [US20190133992A1-20190509-D00001.TIF, US201901...   \n",
       "3   [US20190136261A1-20190509-D00001.TIF, US201901...   \n",
       "4   [US20190161536A1-20190530-D00001.TIF, US201901...   \n",
       "5   [US20190202865A1-20190704-D00001.TIF, US201902...   \n",
       "6   [US20190201532A1-20190704-D00001.TIF, US201902...   \n",
       "7   [US20190201444A1-20190704-D00000.TIF, US201902...   \n",
       "8   [US20190177429A1-20190613-D00001.TIF, US201901...   \n",
       "9   [US20190184190A1-20190620-D00000.TIF, US201901...   \n",
       "10  [US20190184190A1-20190620-D00000.TIF, US201901...   \n",
       "11  [US20190159474A1-20190530-D00000.TIF, US201901...   \n",
       "12  [US20190125691A1-20190502-D00000.TIF, US201901...   \n",
       "13  [US20190169260A1-20190606-D00001.TIF, US201901...   \n",
       "14  [US20190194282A1-20190627-D00000.TIF, US201901...   \n",
       "15  [US20190127440A1-20190502-D00001.TIF, US201901...   \n",
       "16  [US20190177383A1-20190613-D00001.TIF, US201901...   \n",
       "17  [US20190194689A1-20190627-D00001.TIF, US201901...   \n",
       "18  [US20190144517A1-20190516-D00001.TIF, US201901...   \n",
       "19  [US20190177709A1-20190613-D00000.TIF, US201901...   \n",
       "20  [US20190169583A1-20190606-D00001.TIF, US201901...   \n",
       "\n",
       "                                 invention_background  \n",
       "0   Gene therapy can be used to genetically engine...  \n",
       "1                                                      \n",
       "2   Formulations of bioactive compounds have been ...  \n",
       "3   Cells communicate with each other either by di...  \n",
       "4   Human adipocyte lipid-binding protein (aP2) be...  \n",
       "5   Throughout this application various publicatio...  \n",
       "6   Antibiotics are the main tools to treat infect...  \n",
       "7   Mesenchymal stem cells (MSCs) hold much promis...  \n",
       "8   Breast cancer is a highly significant cause of...  \n",
       "9   Field of Invention The invention relates to me...  \n",
       "10                                                     \n",
       "11  Coffee fruits are mainly produced in Africa an...  \n",
       "12  Controlled protein release is a key strategy t...  \n",
       "13  Cancer has a major impact on society across th...  \n",
       "14  Prostate cancer is the second most commonly di...  \n",
       "15  Thymic stromal lymphopoietin (TSLP) is an inte...  \n",
       "16  Ovarian Cancer With an estimated 239 000 new c...  \n",
       "17  Gene therapy has been investigated for deliver...  \n",
       "18  Tumor necrosis factor α (TNF) is a multifuncti...  \n",
       "19  When one considers that genome sequencing effo...  \n",
       "20                                                     "
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "patents_df2 = pd.concat([patents_df, inventions_df], axis=1)\n",
    "patents_df2"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "This application claims the benefit of U.S. Provisional Patent Application No. 62/005,013, filed on May 30, 2014, the contents of which are herein incorporated by reference \n"
     ]
    }
   ],
   "source": [
    "# Repeat process for cross-reference section\n",
    "ref_boundary_start = 0\n",
    "ref_boundary_end = 0\n",
    "ref_col = []\n",
    "\n",
    "for index, row in patents_df2.iterrows():\n",
    "    ref_boundary_start = re.search('CROSS-REFERENCE(([A-Z])*(\\s))*', \\\n",
    "                                          str(row['description']), re.MULTILINE)\n",
    "    ref_boundary_end = re.search('in their entirety', \\\n",
    "                                        str(row['description']), re.MULTILINE)\n",
    "    \n",
    "    if ref_boundary_start and ref_boundary_end:\n",
    "        ref_col.append(find_inbetween_text(str(row['description']), ref_boundary_start.end(), \\\n",
    "                                             ref_boundary_end.start()))\n",
    "    else:\n",
    "        ref_col.append(' ')\n",
    "        \n",
    "print(ref_col[5])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>cross_reference</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>The present application is a divisional of U.S...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>The present application claims the benefit of ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>This application claims the benefit of U.S. Pr...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>The present application is a divisional of U.S...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>This application is filed pursuant to 35 U.S.C...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                      cross_reference\n",
       "0   The present application is a divisional of U.S...\n",
       "1                                                    \n",
       "2                                                    \n",
       "3   The present application claims the benefit of ...\n",
       "4                                                    \n",
       "5   This application claims the benefit of U.S. Pr...\n",
       "6                                                    \n",
       "7                                                    \n",
       "8   The present application is a divisional of U.S...\n",
       "9                                                    \n",
       "10                                                   \n",
       "11                                                   \n",
       "12                                                   \n",
       "13                                                   \n",
       "14                                                   \n",
       "15                                                   \n",
       "16                                                   \n",
       "17                                                   \n",
       "18                                                   \n",
       "19  This application is filed pursuant to 35 U.S.C...\n",
       "20                                                   "
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ref_df = pd.DataFrame({'cross_reference': ref_col})\n",
    "ref_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id</th>\n",
       "      <th>invention_title</th>\n",
       "      <th>abstract</th>\n",
       "      <th>claims</th>\n",
       "      <th>description</th>\n",
       "      <th>drawings_description</th>\n",
       "      <th>drawings_file_paths</th>\n",
       "      <th>invention_background</th>\n",
       "      <th>cross_reference</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>20190151472</td>\n",
       "      <td>LIVER-SPECIFIC CONSTRUCTS, FACTOR VIII EXPRESS...</td>\n",
       "      <td>Described herein are constructs used for liver...</td>\n",
       "      <td>1-10. (canceled)  11. A method of providing a...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS The pr...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...</td>\n",
       "      <td>[US20190151472A1-20190523-D00001.TIF, US201901...</td>\n",
       "      <td>Gene therapy can be used to genetically engine...</td>\n",
       "      <td>The present application is a divisional of U.S...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>20190135863</td>\n",
       "      <td>RETRO-INVERSO PEPTIDE INHIBITORS OF CELL MIGRA...</td>\n",
       "      <td>The present invention discloses retro-inverso ...</td>\n",
       "      <td>1. A compound of formula (I):   X1-(D)-Arg-X2...</td>\n",
       "      <td>The present invention concerns retro-inverso p...</td>\n",
       "      <td>DESCRIPTION OF THE FIGURES FIG. 1 High degree ...</td>\n",
       "      <td>[US20190135863A1-20190509-D00001.TIF, US201901...</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>20190133992</td>\n",
       "      <td>CANNABINOID COMPOSITION HAVING AN OPTIMIZED FA...</td>\n",
       "      <td>A composition of matter for enhancing delivery...</td>\n",
       "      <td>1. A cannabinoid composition comprising: at l...</td>\n",
       "      <td>FIELD OF THE INVENTION The present invention r...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...</td>\n",
       "      <td>[US20190133992A1-20190509-D00001.TIF, US201901...</td>\n",
       "      <td>Formulations of bioactive compounds have been ...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>20190136261</td>\n",
       "      <td>GENETIC MODIFICATION OF CYTOKINE INDUCIBLE SH2...</td>\n",
       "      <td>The present disclosure is in the field of geno...</td>\n",
       "      <td>1. A genetically modified cell comprising a g...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS The pr...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 shows...</td>\n",
       "      <td>[US20190136261A1-20190509-D00001.TIF, US201901...</td>\n",
       "      <td>Cells communicate with each other either by di...</td>\n",
       "      <td>The present application claims the benefit of ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>20190161536</td>\n",
       "      <td>ANTI-AP2 ANTIBODIES AND ANTIGEN BINDING AGENTS...</td>\n",
       "      <td>This invention is in the area of improved anti...</td>\n",
       "      <td>1. A method of attenuating an aP2-mediated di...</td>\n",
       "      <td>RELATED APPLICATIONS This application is a con...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1-8 ar...</td>\n",
       "      <td>[US20190161536A1-20190530-D00001.TIF, US201901...</td>\n",
       "      <td>Human adipocyte lipid-binding protein (aP2) be...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>20190202865</td>\n",
       "      <td>TARGETING DIMERIZATION OF BAX TO MODULATE BAX ...</td>\n",
       "      <td>Methods are provided for identifying an agent ...</td>\n",
       "      <td>1-19. (canceled)  20. A method of inhibiting ...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS This a...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1A-1D. ...</td>\n",
       "      <td>[US20190202865A1-20190704-D00001.TIF, US201902...</td>\n",
       "      <td>Throughout this application various publicatio...</td>\n",
       "      <td>This application claims the benefit of U.S. Pr...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>20190201532</td>\n",
       "      <td>SENSITIZATION OF BACTERIAL CELLS TO QUINOLONE ...</td>\n",
       "      <td>Provided herein are pharmaceutical composition...</td>\n",
       "      <td>1. A pharmaceutical composition comprising a ...</td>\n",
       "      <td>RELATED APPLICATION The present application cl...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1F....</td>\n",
       "      <td>[US20190201532A1-20190704-D00001.TIF, US201902...</td>\n",
       "      <td>Antibiotics are the main tools to treat infect...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>20190201444</td>\n",
       "      <td>GLYCOENGINEERING OF E-SELECTIN LIGANDS</td>\n",
       "      <td>The present invention provides methods of enfo...</td>\n",
       "      <td>1. A method of enforcing expression of an E-s...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS The pr...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1A-FIG....</td>\n",
       "      <td>[US20190201444A1-20190704-D00000.TIF, US201902...</td>\n",
       "      <td>Mesenchymal stem cells (MSCs) hold much promis...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>20190177429</td>\n",
       "      <td>Anti-HER2 Antibodies and Immunoconjugates</td>\n",
       "      <td>The invention provides anti-HER2 antibodies an...</td>\n",
       "      <td>1. An isolated antibody that binds to HER2, w...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS The pr...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE FIGURES FIG. 1 shows ...</td>\n",
       "      <td>[US20190177429A1-20190613-D00001.TIF, US201901...</td>\n",
       "      <td>Breast cancer is a highly significant cause of...</td>\n",
       "      <td>The present application is a divisional of U.S...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>20190184190</td>\n",
       "      <td>PHOSPHOR-CONTAINING DRUG ACTIVATOR ACTIVATABLE...</td>\n",
       "      <td>A phosphor-containing drug activator activatab...</td>\n",
       "      <td>1. A phosphor-containing drug activator activ...</td>\n",
       "      <td>CROSS REFERENCE TO RELATED APPLICATIONS This a...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE FIGURES A more comple...</td>\n",
       "      <td>[US20190184190A1-20190620-D00000.TIF, US201901...</td>\n",
       "      <td>Field of Invention The invention relates to me...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>20190192693</td>\n",
       "      <td>METHODS AND VECTORS FOR TREATING CNS DISORDERS</td>\n",
       "      <td>Methods and uses of treating a disease in a ma...</td>\n",
       "      <td>1. A method of delivering a therapeutic prote...</td>\n",
       "      <td>RELATED APPLICATIONS This application claims p...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE FIGURES A more comple...</td>\n",
       "      <td>[US20190184190A1-20190620-D00000.TIF, US201901...</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>20190159474</td>\n",
       "      <td>AMELIORATIVE EFFECTS OF A WHOLE COFFEE FRUIT E...</td>\n",
       "      <td>The invention provides a method of extracting ...</td>\n",
       "      <td>1. A method of producing a whole coffee fruit...</td>\n",
       "      <td>FIELD OF THE INVENTION The invention provides ...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A and...</td>\n",
       "      <td>[US20190159474A1-20190530-D00000.TIF, US201901...</td>\n",
       "      <td>Coffee fruits are mainly produced in Africa an...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>20190125691</td>\n",
       "      <td>ENCAPSULATION-FREE CONTROLLED PROTEIN RELEASE ...</td>\n",
       "      <td>The present disclosure provides a delivery sys...</td>\n",
       "      <td>1. A biocompatible polymer composite comprise...</td>\n",
       "      <td>FIELD The present disclosure relates to a bioc...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS Embodiments ...</td>\n",
       "      <td>[US20190125691A1-20190502-D00000.TIF, US201901...</td>\n",
       "      <td>Controlled protein release is a key strategy t...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>20190169260</td>\n",
       "      <td>Human Leukocyte Antigen Restricted Gamma Delta...</td>\n",
       "      <td>Disclosed herein are compositions and methods ...</td>\n",
       "      <td>1. A composition comprising a polypeptide con...</td>\n",
       "      <td>SEQUENCE LISTING The instant application conta...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS The novel fe...</td>\n",
       "      <td>[US20190169260A1-20190606-D00001.TIF, US201901...</td>\n",
       "      <td>Cancer has a major impact on society across th...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>20190194282</td>\n",
       "      <td>CHIMERIC PROTEINS FOR TARGETING dsRNA</td>\n",
       "      <td>Described herein are recombinant chimeric prot...</td>\n",
       "      <td>1. A chimeric recombinant protein comprising:...</td>\n",
       "      <td>CROSS REFERENCE TO RELATED APPLICATIONS Benefi...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1D:...</td>\n",
       "      <td>[US20190194282A1-20190627-D00000.TIF, US201901...</td>\n",
       "      <td>Prostate cancer is the second most commonly di...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>20190127440</td>\n",
       "      <td>NOVEL TSLP INHIBITORS</td>\n",
       "      <td>The present invention relates to monomeric fus...</td>\n",
       "      <td>1. A monomeric fusion protein comprising: a f...</td>\n",
       "      <td>FIELD OF THE INVENTION The present invention r...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE FIGURES FIG. 1 shows ...</td>\n",
       "      <td>[US20190127440A1-20190502-D00001.TIF, US201901...</td>\n",
       "      <td>Thymic stromal lymphopoietin (TSLP) is an inte...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>20190177383</td>\n",
       "      <td>NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR...</td>\n",
       "      <td>The present invention relates to peptides, pro...</td>\n",
       "      <td>1. A method of treating a patient who has can...</td>\n",
       "      <td>CROSS REFERENCE TO RELATED APPLICATIONS This a...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS The patent o...</td>\n",
       "      <td>[US20190177383A1-20190613-D00001.TIF, US201901...</td>\n",
       "      <td>Ovarian Cancer With an estimated 239 000 new c...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>20190194689</td>\n",
       "      <td>CNS TARGETING AAV VECTORS AND METHODS OF USE T...</td>\n",
       "      <td>The invention in some aspects relates to recom...</td>\n",
       "      <td>1-55. (canceled)  56. A method for delivering...</td>\n",
       "      <td>RELATED APPLICATIONS This application is a con...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1B ...</td>\n",
       "      <td>[US20190194689A1-20190627-D00001.TIF, US201901...</td>\n",
       "      <td>Gene therapy has been investigated for deliver...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>20190144517</td>\n",
       "      <td>PROTEIN FOR NEUTRALIZING PROGRAMMED NECROCYTOS...</td>\n",
       "      <td>Provided is polypeptide which derives from wil...</td>\n",
       "      <td>1. A polypeptide that inhibits cell necrosis,...</td>\n",
       "      <td>TECHNICAL FIELD The present invention relates ...</td>\n",
       "      <td>DESCRIPTION OF DRAWINGS FIG. 1 shows the scree...</td>\n",
       "      <td>[US20190144517A1-20190516-D00001.TIF, US201901...</td>\n",
       "      <td>Tumor necrosis factor α (TNF) is a multifuncti...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>20190177709</td>\n",
       "      <td>REGULATION OF GENE EXPRESSION USING ENGINEERED...</td>\n",
       "      <td>The present disclosure is in the field of geno...</td>\n",
       "      <td>1. A zinc finger nuclease (ZFN) comprising le...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS This a...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A and...</td>\n",
       "      <td>[US20190177709A1-20190613-D00000.TIF, US201901...</td>\n",
       "      <td>When one considers that genome sequencing effo...</td>\n",
       "      <td>This application is filed pursuant to 35 U.S.C...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>20190169583</td>\n",
       "      <td>STEP-Derived Peptide for Brain Injury Treatment</td>\n",
       "      <td>A novel peptide sequence that is a modified de...</td>\n",
       "      <td>1. An isolated peptide comprising a kinase in...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS The fo...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...</td>\n",
       "      <td>[US20190169583A1-20190606-D00001.TIF, US201901...</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "             id                                    invention_title  \\\n",
       "0   20190151472  LIVER-SPECIFIC CONSTRUCTS, FACTOR VIII EXPRESS...   \n",
       "1   20190135863  RETRO-INVERSO PEPTIDE INHIBITORS OF CELL MIGRA...   \n",
       "2   20190133992  CANNABINOID COMPOSITION HAVING AN OPTIMIZED FA...   \n",
       "3   20190136261  GENETIC MODIFICATION OF CYTOKINE INDUCIBLE SH2...   \n",
       "4   20190161536  ANTI-AP2 ANTIBODIES AND ANTIGEN BINDING AGENTS...   \n",
       "5   20190202865  TARGETING DIMERIZATION OF BAX TO MODULATE BAX ...   \n",
       "6   20190201532  SENSITIZATION OF BACTERIAL CELLS TO QUINOLONE ...   \n",
       "7   20190201444             GLYCOENGINEERING OF E-SELECTIN LIGANDS   \n",
       "8   20190177429          Anti-HER2 Antibodies and Immunoconjugates   \n",
       "9   20190184190  PHOSPHOR-CONTAINING DRUG ACTIVATOR ACTIVATABLE...   \n",
       "10  20190192693     METHODS AND VECTORS FOR TREATING CNS DISORDERS   \n",
       "11  20190159474  AMELIORATIVE EFFECTS OF A WHOLE COFFEE FRUIT E...   \n",
       "12  20190125691  ENCAPSULATION-FREE CONTROLLED PROTEIN RELEASE ...   \n",
       "13  20190169260  Human Leukocyte Antigen Restricted Gamma Delta...   \n",
       "14  20190194282              CHIMERIC PROTEINS FOR TARGETING dsRNA   \n",
       "15  20190127440                              NOVEL TSLP INHIBITORS   \n",
       "16  20190177383  NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR...   \n",
       "17  20190194689  CNS TARGETING AAV VECTORS AND METHODS OF USE T...   \n",
       "18  20190144517  PROTEIN FOR NEUTRALIZING PROGRAMMED NECROCYTOS...   \n",
       "19  20190177709  REGULATION OF GENE EXPRESSION USING ENGINEERED...   \n",
       "20  20190169583    STEP-Derived Peptide for Brain Injury Treatment   \n",
       "\n",
       "                                             abstract  \\\n",
       "0   Described herein are constructs used for liver...   \n",
       "1   The present invention discloses retro-inverso ...   \n",
       "2   A composition of matter for enhancing delivery...   \n",
       "3   The present disclosure is in the field of geno...   \n",
       "4   This invention is in the area of improved anti...   \n",
       "5   Methods are provided for identifying an agent ...   \n",
       "6   Provided herein are pharmaceutical composition...   \n",
       "7   The present invention provides methods of enfo...   \n",
       "8   The invention provides anti-HER2 antibodies an...   \n",
       "9   A phosphor-containing drug activator activatab...   \n",
       "10  Methods and uses of treating a disease in a ma...   \n",
       "11  The invention provides a method of extracting ...   \n",
       "12  The present disclosure provides a delivery sys...   \n",
       "13  Disclosed herein are compositions and methods ...   \n",
       "14  Described herein are recombinant chimeric prot...   \n",
       "15  The present invention relates to monomeric fus...   \n",
       "16  The present invention relates to peptides, pro...   \n",
       "17  The invention in some aspects relates to recom...   \n",
       "18  Provided is polypeptide which derives from wil...   \n",
       "19  The present disclosure is in the field of geno...   \n",
       "20  A novel peptide sequence that is a modified de...   \n",
       "\n",
       "                                               claims  \\\n",
       "0    1-10. (canceled)  11. A method of providing a...   \n",
       "1    1. A compound of formula (I):   X1-(D)-Arg-X2...   \n",
       "2    1. A cannabinoid composition comprising: at l...   \n",
       "3    1. A genetically modified cell comprising a g...   \n",
       "4    1. A method of attenuating an aP2-mediated di...   \n",
       "5    1-19. (canceled)  20. A method of inhibiting ...   \n",
       "6    1. A pharmaceutical composition comprising a ...   \n",
       "7    1. A method of enforcing expression of an E-s...   \n",
       "8    1. An isolated antibody that binds to HER2, w...   \n",
       "9    1. A phosphor-containing drug activator activ...   \n",
       "10   1. A method of delivering a therapeutic prote...   \n",
       "11   1. A method of producing a whole coffee fruit...   \n",
       "12   1. A biocompatible polymer composite comprise...   \n",
       "13   1. A composition comprising a polypeptide con...   \n",
       "14   1. A chimeric recombinant protein comprising:...   \n",
       "15   1. A monomeric fusion protein comprising: a f...   \n",
       "16   1. A method of treating a patient who has can...   \n",
       "17   1-55. (canceled)  56. A method for delivering...   \n",
       "18   1. A polypeptide that inhibits cell necrosis,...   \n",
       "19   1. A zinc finger nuclease (ZFN) comprising le...   \n",
       "20   1. An isolated peptide comprising a kinase in...   \n",
       "\n",
       "                                          description  \\\n",
       "0   CROSS-REFERENCE TO RELATED APPLICATIONS The pr...   \n",
       "1   The present invention concerns retro-inverso p...   \n",
       "2   FIELD OF THE INVENTION The present invention r...   \n",
       "3   CROSS-REFERENCE TO RELATED APPLICATIONS The pr...   \n",
       "4   RELATED APPLICATIONS This application is a con...   \n",
       "5   CROSS-REFERENCE TO RELATED APPLICATIONS This a...   \n",
       "6   RELATED APPLICATION The present application cl...   \n",
       "7   CROSS-REFERENCE TO RELATED APPLICATIONS The pr...   \n",
       "8   CROSS-REFERENCE TO RELATED APPLICATIONS The pr...   \n",
       "9   CROSS REFERENCE TO RELATED APPLICATIONS This a...   \n",
       "10  RELATED APPLICATIONS This application claims p...   \n",
       "11  FIELD OF THE INVENTION The invention provides ...   \n",
       "12  FIELD The present disclosure relates to a bioc...   \n",
       "13  SEQUENCE LISTING The instant application conta...   \n",
       "14  CROSS REFERENCE TO RELATED APPLICATIONS Benefi...   \n",
       "15  FIELD OF THE INVENTION The present invention r...   \n",
       "16  CROSS REFERENCE TO RELATED APPLICATIONS This a...   \n",
       "17  RELATED APPLICATIONS This application is a con...   \n",
       "18  TECHNICAL FIELD The present invention relates ...   \n",
       "19  CROSS-REFERENCE TO RELATED APPLICATIONS This a...   \n",
       "20  CROSS-REFERENCE TO RELATED APPLICATIONS The fo...   \n",
       "\n",
       "                                 drawings_description  \\\n",
       "0   BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...   \n",
       "1   DESCRIPTION OF THE FIGURES FIG. 1 High degree ...   \n",
       "2   BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...   \n",
       "3   BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 shows...   \n",
       "4   BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1-8 ar...   \n",
       "5   BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1A-1D. ...   \n",
       "6   BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1F....   \n",
       "7   BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1A-FIG....   \n",
       "8   BRIEF DESCRIPTION OF THE FIGURES FIG. 1 shows ...   \n",
       "9   BRIEF DESCRIPTION OF THE FIGURES A more comple...   \n",
       "10  BRIEF DESCRIPTION OF THE FIGURES A more comple...   \n",
       "11  BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A and...   \n",
       "12  BRIEF DESCRIPTION OF THE DRAWINGS Embodiments ...   \n",
       "13  BRIEF DESCRIPTION OF THE DRAWINGS The novel fe...   \n",
       "14  BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1D:...   \n",
       "15  BRIEF DESCRIPTION OF THE FIGURES FIG. 1 shows ...   \n",
       "16  BRIEF DESCRIPTION OF THE DRAWINGS The patent o...   \n",
       "17  BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1B ...   \n",
       "18  DESCRIPTION OF DRAWINGS FIG. 1 shows the scree...   \n",
       "19  BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A and...   \n",
       "20  BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...   \n",
       "\n",
       "                                  drawings_file_paths  \\\n",
       "0   [US20190151472A1-20190523-D00001.TIF, US201901...   \n",
       "1   [US20190135863A1-20190509-D00001.TIF, US201901...   \n",
       "2   [US20190133992A1-20190509-D00001.TIF, US201901...   \n",
       "3   [US20190136261A1-20190509-D00001.TIF, US201901...   \n",
       "4   [US20190161536A1-20190530-D00001.TIF, US201901...   \n",
       "5   [US20190202865A1-20190704-D00001.TIF, US201902...   \n",
       "6   [US20190201532A1-20190704-D00001.TIF, US201902...   \n",
       "7   [US20190201444A1-20190704-D00000.TIF, US201902...   \n",
       "8   [US20190177429A1-20190613-D00001.TIF, US201901...   \n",
       "9   [US20190184190A1-20190620-D00000.TIF, US201901...   \n",
       "10  [US20190184190A1-20190620-D00000.TIF, US201901...   \n",
       "11  [US20190159474A1-20190530-D00000.TIF, US201901...   \n",
       "12  [US20190125691A1-20190502-D00000.TIF, US201901...   \n",
       "13  [US20190169260A1-20190606-D00001.TIF, US201901...   \n",
       "14  [US20190194282A1-20190627-D00000.TIF, US201901...   \n",
       "15  [US20190127440A1-20190502-D00001.TIF, US201901...   \n",
       "16  [US20190177383A1-20190613-D00001.TIF, US201901...   \n",
       "17  [US20190194689A1-20190627-D00001.TIF, US201901...   \n",
       "18  [US20190144517A1-20190516-D00001.TIF, US201901...   \n",
       "19  [US20190177709A1-20190613-D00000.TIF, US201901...   \n",
       "20  [US20190169583A1-20190606-D00001.TIF, US201901...   \n",
       "\n",
       "                                 invention_background  \\\n",
       "0   Gene therapy can be used to genetically engine...   \n",
       "1                                                       \n",
       "2   Formulations of bioactive compounds have been ...   \n",
       "3   Cells communicate with each other either by di...   \n",
       "4   Human adipocyte lipid-binding protein (aP2) be...   \n",
       "5   Throughout this application various publicatio...   \n",
       "6   Antibiotics are the main tools to treat infect...   \n",
       "7   Mesenchymal stem cells (MSCs) hold much promis...   \n",
       "8   Breast cancer is a highly significant cause of...   \n",
       "9   Field of Invention The invention relates to me...   \n",
       "10                                                      \n",
       "11  Coffee fruits are mainly produced in Africa an...   \n",
       "12  Controlled protein release is a key strategy t...   \n",
       "13  Cancer has a major impact on society across th...   \n",
       "14  Prostate cancer is the second most commonly di...   \n",
       "15  Thymic stromal lymphopoietin (TSLP) is an inte...   \n",
       "16  Ovarian Cancer With an estimated 239 000 new c...   \n",
       "17  Gene therapy has been investigated for deliver...   \n",
       "18  Tumor necrosis factor α (TNF) is a multifuncti...   \n",
       "19  When one considers that genome sequencing effo...   \n",
       "20                                                      \n",
       "\n",
       "                                      cross_reference  \n",
       "0   The present application is a divisional of U.S...  \n",
       "1                                                      \n",
       "2                                                      \n",
       "3   The present application claims the benefit of ...  \n",
       "4                                                      \n",
       "5   This application claims the benefit of U.S. Pr...  \n",
       "6                                                      \n",
       "7                                                      \n",
       "8   The present application is a divisional of U.S...  \n",
       "9                                                      \n",
       "10                                                     \n",
       "11                                                     \n",
       "12                                                     \n",
       "13                                                     \n",
       "14                                                     \n",
       "15                                                     \n",
       "16                                                     \n",
       "17                                                     \n",
       "18                                                     \n",
       "19  This application is filed pursuant to 35 U.S.C...  \n",
       "20                                                     "
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "patents_df3 = pd.concat([patents_df2, ref_df], axis=1)\n",
    "patents_df3"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The present invention includes a cannabinoid composition including a cannabinoid and an excipient including palmitoleic acid in a therapeutic ratio. The cannabinoid composition includes at least one cannabinoid. In a preferred embodiment, the excipient includes palmitoleic acid, oleic acid and palmitic acid. The ratio of palmitoleic acid to the at least one cannabinoid is between 1:19 to 1000:1. In another embodiment of the invention, the ratio of palmitic acid to the at least one cannabinoid is between 1:100 to 1000:1. In yet another embodiment of the invention, the ratio of the oleic acid to the at least one cannabinoid is between 1:100 to 1000:1. In another embodiment of the invention, the ratio of the palmitic acid and oleic acid combined, to the at least one cannabinoid, is between 1:50 to 2000:1. Some research indicates that oleic acid included in the excipient for oral delivery can increase the plasma concentration of bioactive compounds in vivo, as compared to an aqueous excipient. The combination of oleic acid, palmitic acid and palmitoleic acid has also been show to have superior sublingual and oral rates of delivery for cannabinoids. In an alternate embodiment, the cannabinoid composition is a whole plant extract of Cannabis having at least 60% total cannabinoid content. In another embodiment, the cannabinoid composition is an isolated cannabinoid. In a further embodiment of the invention, the cannabinoid composition is a mixture of isolated cannabinoids having a greater purity than the whole plant extract described in an embodiment of the invention. In yet another embodiment, the cannabinoid composition includes at least one essential oil selected from the group consisting of Anise, Basil, Bergamot, Cannabis, Cardamom, Chamomile, Cinnamon, Cocoa, Cypress, Eucalyptus, Fennel, Frankincense, Geranium, Ginger, Ginkgo Biloba, Gotu Kola, Grapefruit, Hemp, Jasmine, Lavender, Lavandin, Lemon, Lemon Verbena, Lemongrass, Lime, Marjoram, Neroli, Nutmeg, Orange, Oregano, Peppermint, Pepper, Pine, Ravintsara, Rose, Rosemary, Sage, Spearmint, Tea Tree, Thyme, Turmeric, Vanilla, Ylang Ylang, and any other therapeutic plant essential oils, and combinations thereof, including any of one or more of the monoterpenes, sequiterpenes and/or diterpenes, and/or their alcohols, and/or aldehydes and/or esters normally found in any therapeutic plant essential oil, and combinations thereof. In one embodiment, the cannabinoid composition includes at least 0.1% by weight of at least one cannabinoid derived from Cannabis sativa L. It can be appreciated that the cannabinoid can be synthetic, derived from yeast, or other plant material. The cannabinoid composition includes at least 5% by weight of palmitoleic acid. In another embodiment, the invention includes at least one additional fatty acid selected from the group consisting of oleic acid and palmitic acid. In an alternate embodiment the additional fatty acid is any omega-7 fatty acid having synergistic effects for cannabinoid delivery. In one embodiment of the invention the additional fatty acid is palmitic acid, and the ratio of palmitic acid to the at least one cannabinoid is between 1:100 to 1000:1. The invention further includes a delivery system. In one embodiment, the delivery system utilizes Transmucosal delivery. Preferably the cannabinoid composition is administered transmucosally in a manner selected from the group consisting of a dropper, spray, swab, lozenge, capsule, gelcap, paste, cream, gel, lotion, ointment, pouch, kitchen utensil, suppository or enema or other manner of transmucosal delivery. In another embodiment the delivery system includes Oral delivery administered in a manner selected from a dropper, spray, swab, lozenge, capsule, gelcap, emulsion, tincture, kitchen utensil, food, drink or other manner of oral delivery. In another embodiment the delivery system includes enteral delivery administered in a manner selected from rectal administration of any kind, gastric intubation of any kind, Oral delivery of any kind, or other manner of enteral delivery. In another embodiment the delivery system includes Transdermal delivery administered in a manner selected from a dropper, spray, swab, patch, paste, cream, gel, lotion or ointment or other manner of transdermal delivery. The cannabinoid composition consists of any oil or oil blend, whether of a) a single natural origin, b) two or more natural origins, c) one or more fractionated and/or isolated fatty acid(s) and/or glyceride(s), d) one or more synthetic fatty acid(s) and/or glyceride(s), or e) any combination of two or more of (a), (b), (c), or (d); that A) consists of 10% by weight or more of either one, or any mixture of both together, of Macadamia Nut Oil and/or Macadamia-Nut-Oil-simile, and/or B) consists of 10% by weight or more of either one, or any mixture of both together, of Sea Buckthorn Oil and/or Sea-Buckthorn-Oil-simile, and/or C) consists of 5% by weight or more of Palmitoleic Acid. The cannabinoid composition, in one embodiment, is whole plant Cannabis sativa extract derived from hemp, marijuana, or combinations thereof. Such extracts can be prepared using any of various extraction methods including methods that rely on CO2, ethanol, hydrocarbon, or combinations thereof. It can be appreciated that other method(s) or solvent(s) can be used for extraction with non-toxic methods preferable. In the case of the use of an ethanol extraction protocol the concentration of ethanol should be limited to 5000 parts-per-million at the highest, preferably to 50 parts-per-million or less, in the final extract to enable generally safe formulation of the extract with the particular fatty acids expressed herein. Cannabinoids include one or more of the following: Cannabidiol (CBD), Cannabidiolic Acid (CBDA), Cannabichromene (CBC), Tetrahydrocannabinol (THC), Tetrahydrocannabinolic Acid (THCA), Cannabigerol (CBG), Cannabidivarin (CBDV), Tetrahydrocannabivarin (THCV), or any other compound found exclusively or primarily in the Cannabis sativa L. plant, or any other compound that is a cannabinoid receptor (CB receptor) agonist, co-agonist, partial agonist, inverse agonist or antagonist in the human or animal organism. The sesquiterpene beta-caryophyllene is considered to be a cannabinoid. The cannabinoids can be derived from Cannabis sativa, other plants, manufactured synthetically or derived from animal sources, fungal sources, or combinations thereof. A cannabinoid is one of a class of diverse chemical compounds that acts on cannabinoid receptors in humans and other animals The most notable cannabinoid is the phytocannabinoid tetrahydrocannabinol (THC), which is a cannabinoid found in Cannabis sativa. Cannabidiol (CBD) is another major cannabinoid constituent of the plant. There are at least 113 different cannabinoids isolated from Cannabis, each exhibiting varied bioactive effects. Synthetic cannabinoids encompass a variety of distinct chemical classes: the classical cannabinoids structurally related to Tetrahydrocannabinol (THC), the non-classical cannabinoids (cannabimimetics) including the aminoalkylindoles, 1,5-diarylpyrazoles, quinolines, and arylsulfonamides, as well as eicosanoids related to endocannabinoids. THC as used herein includes both acid and non-acid forms of this molecule, including isomers thereof. Cannabidiol (CBD) is a major phytocannabinoid found in Cannabis sativa and other plants. The compositions described herein can be infused with one or more additional bioactive compounds, other than cannabinoids, including botanical essential oil, preparations, and formulations thereof. In another embodiment, the compositions do not include cannabinoids, but instead rely on various non-cannabinoid bioactive compounds, such as essential oils for example. Essential oils can be derived by steam-distillation, CO2 extraction or any other manner(s) from any one or more plants including, but not limited to, any species or subspecies of any of Anise, Basil, Bergamot, Cannabis, Cardamom, Chamomile, Cinnamon, Cocoa, Cypress, Eucalyptus, Fennel, Frankincense, Geranium, Ginger, Ginkgo Biloba, Gotu Kola, Grapefruit, Hemp, Jasmine, Lavender, Lavandin, Lemon, Lemon Verbena, Lemongrass, Lime, Marjoram, Neroli, Nutmeg, Orange, Oregano, Peppermint, Pepper, Pine, Ravintsara, Rose, Rosemary, Sage, Spearmint, Tea Tree, Thyme, Turmeric, Vanilla or Ylang Ylang. The Bioactive compound(s) can be one or more of monoterpenes, sequiterpenes and/or diterpenes, and/or their alcohols, and/or aldehydes and/or esters which include, but are not limited to, any of alpha-Bisabolol, alpha-Caryophyllene (also known as Humulene), beta-Caryophyllene, Fenchone, Isobutyl Angelate, Guaiol, Limonene, Linalool, Myrcene, Neral, Nerolidol, Ocimene, alpha-Pinene, beta-Pinene, Terpineol, or Terpinolene, be they a) naturally-present in a botanical extract, or b) an isolate, or c) a synthetic version thereof, or d) a complex or mixture of two or more of any of (a), (b) and/or (c). In various embodiments, the Bioactive compound includes at least one lipophilic pharmaceutical or nutraceutical compound, other than a cannabinoid. In a variation of the invention various lipophilic nutraceutical compounds including cannabinoids are utilized. In another embodiment, THC, CBD and combinations thereof are utilized as the lipophilic nutraceutical compounds. In various alternate embodiments, the bioactive compounds include one or more non-lipophilic pharmaceutical or nutraceutical compounds, other than cannabinoids. These non-lipophilic compounds are modified to become soluble in oil by chemical reactions, preferably non-toxic ones, by mixing with at least one lipophilic compound, by emulsification, or by any other process. It can be appreciated that the bioactive compound can be one or more of a nutritional supplement, vitamin, mineral, and any substance of established or intended macro- or micro-nutritive value to the human or animal organism, and combinations thereof. In a further embodiment of the invention, the composition described herein includes an aqueous adjuvant such as Aloe Vera, a micro-emulsifier, a nano-emulsifier, ethanol, water, a food, a drink, a substance that has received G.R.A.S. (Generally Recognized As Safe) status by the Food and Drug Administration of the United States of America, a nutrient, a dietary supplement, a nutritional supplement, a botanical extract, a synthetic compound, a natural compound, any combination of any of the previous in any form, or anything else whatsoever. The combination of excipient fatty acids and components yields a shelf life of up to three years. \n",
      "BRIEF \n"
     ]
    }
   ],
   "source": [
    "# Extract summary section\n",
    "summary_boundary_start = 0\n",
    "summary_boundary_end = 0\n",
    "summary_col = []\n",
    "\n",
    "for index, row in patents_df3.iterrows():\n",
    "    summary_boundary_start = re.search('([A-Z])*SUMMARY(([A-Z])*(\\s))*', \\\n",
    "                                          str(row['description']), re.MULTILINE)\n",
    "    summary_boundary_end = re.search('([A-Z])*DESCRIPTION(([A-Z])*(\\s))*', \\\n",
    "                                        str(row['description']), re.MULTILINE)\n",
    "    \n",
    "    if summary_boundary_start and summary_boundary_end:\n",
    "        summary_col.append(find_inbetween_text(str(row['description']), summary_boundary_start.end(), \\\n",
    "                                             summary_boundary_end.start()))\n",
    "    else:\n",
    "        summary_col.append(' ')\n",
    "        \n",
    "print(summary_col[2])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>summary</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>The present invention describes compositions a...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>The present invention includes a cannabinoid c...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>The present invention describes compositions a...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Anti-aP2 monoclonal antibodies and antigen bin...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>The present invention discloses assays for ide...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Density-dependent drug failure is a form of an...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Despite the promise of these methods, there ex...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>The invention provides anti-HER2 antibodies an...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>In one embodiment, the present invention provi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>In certain embodiments, the invention provides...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>It is found in the present invention that a wh...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>The present invention provides a biocompatible...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>There exists a pressing need for alternative a...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>Described herein is an improved approach to th...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>It is surprisingly shown herein that a monomer...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>In a first aspect of the present invention, th...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>Aspects of the invention, are based on the dis...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>It is an object of the present invention to pr...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>The present invention describes highly specifi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                              summary\n",
       "0   The present invention describes compositions a...\n",
       "1                                                    \n",
       "2   The present invention includes a cannabinoid c...\n",
       "3   The present invention describes compositions a...\n",
       "4   Anti-aP2 monoclonal antibodies and antigen bin...\n",
       "5   The present invention discloses assays for ide...\n",
       "6   Density-dependent drug failure is a form of an...\n",
       "7   Despite the promise of these methods, there ex...\n",
       "8   The invention provides anti-HER2 antibodies an...\n",
       "9   In one embodiment, the present invention provi...\n",
       "10  In certain embodiments, the invention provides...\n",
       "11  It is found in the present invention that a wh...\n",
       "12  The present invention provides a biocompatible...\n",
       "13  There exists a pressing need for alternative a...\n",
       "14  Described herein is an improved approach to th...\n",
       "15  It is surprisingly shown herein that a monomer...\n",
       "16  In a first aspect of the present invention, th...\n",
       "17  Aspects of the invention, are based on the dis...\n",
       "18  It is an object of the present invention to pr...\n",
       "19  The present invention describes highly specifi...\n",
       "20                                                   "
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "summary_df = pd.DataFrame({'summary': summary_col})\n",
    "summary_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id</th>\n",
       "      <th>invention_title</th>\n",
       "      <th>abstract</th>\n",
       "      <th>claims</th>\n",
       "      <th>description</th>\n",
       "      <th>drawings_description</th>\n",
       "      <th>drawings_file_paths</th>\n",
       "      <th>invention_background</th>\n",
       "      <th>cross_reference</th>\n",
       "      <th>summary</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>20190151472</td>\n",
       "      <td>LIVER-SPECIFIC CONSTRUCTS, FACTOR VIII EXPRESS...</td>\n",
       "      <td>Described herein are constructs used for liver...</td>\n",
       "      <td>1-10. (canceled)  11. A method of providing a...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS The pr...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...</td>\n",
       "      <td>[US20190151472A1-20190523-D00001.TIF, US201901...</td>\n",
       "      <td>Gene therapy can be used to genetically engine...</td>\n",
       "      <td>The present application is a divisional of U.S...</td>\n",
       "      <td>The present invention describes compositions a...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>20190135863</td>\n",
       "      <td>RETRO-INVERSO PEPTIDE INHIBITORS OF CELL MIGRA...</td>\n",
       "      <td>The present invention discloses retro-inverso ...</td>\n",
       "      <td>1. A compound of formula (I):   X1-(D)-Arg-X2...</td>\n",
       "      <td>The present invention concerns retro-inverso p...</td>\n",
       "      <td>DESCRIPTION OF THE FIGURES FIG. 1 High degree ...</td>\n",
       "      <td>[US20190135863A1-20190509-D00001.TIF, US201901...</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>20190133992</td>\n",
       "      <td>CANNABINOID COMPOSITION HAVING AN OPTIMIZED FA...</td>\n",
       "      <td>A composition of matter for enhancing delivery...</td>\n",
       "      <td>1. A cannabinoid composition comprising: at l...</td>\n",
       "      <td>FIELD OF THE INVENTION The present invention r...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...</td>\n",
       "      <td>[US20190133992A1-20190509-D00001.TIF, US201901...</td>\n",
       "      <td>Formulations of bioactive compounds have been ...</td>\n",
       "      <td></td>\n",
       "      <td>The present invention includes a cannabinoid c...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>20190136261</td>\n",
       "      <td>GENETIC MODIFICATION OF CYTOKINE INDUCIBLE SH2...</td>\n",
       "      <td>The present disclosure is in the field of geno...</td>\n",
       "      <td>1. A genetically modified cell comprising a g...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS The pr...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 shows...</td>\n",
       "      <td>[US20190136261A1-20190509-D00001.TIF, US201901...</td>\n",
       "      <td>Cells communicate with each other either by di...</td>\n",
       "      <td>The present application claims the benefit of ...</td>\n",
       "      <td>The present invention describes compositions a...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>20190161536</td>\n",
       "      <td>ANTI-AP2 ANTIBODIES AND ANTIGEN BINDING AGENTS...</td>\n",
       "      <td>This invention is in the area of improved anti...</td>\n",
       "      <td>1. A method of attenuating an aP2-mediated di...</td>\n",
       "      <td>RELATED APPLICATIONS This application is a con...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1-8 ar...</td>\n",
       "      <td>[US20190161536A1-20190530-D00001.TIF, US201901...</td>\n",
       "      <td>Human adipocyte lipid-binding protein (aP2) be...</td>\n",
       "      <td></td>\n",
       "      <td>Anti-aP2 monoclonal antibodies and antigen bin...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>20190202865</td>\n",
       "      <td>TARGETING DIMERIZATION OF BAX TO MODULATE BAX ...</td>\n",
       "      <td>Methods are provided for identifying an agent ...</td>\n",
       "      <td>1-19. (canceled)  20. A method of inhibiting ...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS This a...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1A-1D. ...</td>\n",
       "      <td>[US20190202865A1-20190704-D00001.TIF, US201902...</td>\n",
       "      <td>Throughout this application various publicatio...</td>\n",
       "      <td>This application claims the benefit of U.S. Pr...</td>\n",
       "      <td>The present invention discloses assays for ide...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>20190201532</td>\n",
       "      <td>SENSITIZATION OF BACTERIAL CELLS TO QUINOLONE ...</td>\n",
       "      <td>Provided herein are pharmaceutical composition...</td>\n",
       "      <td>1. A pharmaceutical composition comprising a ...</td>\n",
       "      <td>RELATED APPLICATION The present application cl...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1F....</td>\n",
       "      <td>[US20190201532A1-20190704-D00001.TIF, US201902...</td>\n",
       "      <td>Antibiotics are the main tools to treat infect...</td>\n",
       "      <td></td>\n",
       "      <td>Density-dependent drug failure is a form of an...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>20190201444</td>\n",
       "      <td>GLYCOENGINEERING OF E-SELECTIN LIGANDS</td>\n",
       "      <td>The present invention provides methods of enfo...</td>\n",
       "      <td>1. A method of enforcing expression of an E-s...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS The pr...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1A-FIG....</td>\n",
       "      <td>[US20190201444A1-20190704-D00000.TIF, US201902...</td>\n",
       "      <td>Mesenchymal stem cells (MSCs) hold much promis...</td>\n",
       "      <td></td>\n",
       "      <td>Despite the promise of these methods, there ex...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>20190177429</td>\n",
       "      <td>Anti-HER2 Antibodies and Immunoconjugates</td>\n",
       "      <td>The invention provides anti-HER2 antibodies an...</td>\n",
       "      <td>1. An isolated antibody that binds to HER2, w...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS The pr...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE FIGURES FIG. 1 shows ...</td>\n",
       "      <td>[US20190177429A1-20190613-D00001.TIF, US201901...</td>\n",
       "      <td>Breast cancer is a highly significant cause of...</td>\n",
       "      <td>The present application is a divisional of U.S...</td>\n",
       "      <td>The invention provides anti-HER2 antibodies an...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>20190184190</td>\n",
       "      <td>PHOSPHOR-CONTAINING DRUG ACTIVATOR ACTIVATABLE...</td>\n",
       "      <td>A phosphor-containing drug activator activatab...</td>\n",
       "      <td>1. A phosphor-containing drug activator activ...</td>\n",
       "      <td>CROSS REFERENCE TO RELATED APPLICATIONS This a...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE FIGURES A more comple...</td>\n",
       "      <td>[US20190184190A1-20190620-D00000.TIF, US201901...</td>\n",
       "      <td>Field of Invention The invention relates to me...</td>\n",
       "      <td></td>\n",
       "      <td>In one embodiment, the present invention provi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>20190192693</td>\n",
       "      <td>METHODS AND VECTORS FOR TREATING CNS DISORDERS</td>\n",
       "      <td>Methods and uses of treating a disease in a ma...</td>\n",
       "      <td>1. A method of delivering a therapeutic prote...</td>\n",
       "      <td>RELATED APPLICATIONS This application claims p...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE FIGURES A more comple...</td>\n",
       "      <td>[US20190184190A1-20190620-D00000.TIF, US201901...</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>In certain embodiments, the invention provides...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>20190159474</td>\n",
       "      <td>AMELIORATIVE EFFECTS OF A WHOLE COFFEE FRUIT E...</td>\n",
       "      <td>The invention provides a method of extracting ...</td>\n",
       "      <td>1. A method of producing a whole coffee fruit...</td>\n",
       "      <td>FIELD OF THE INVENTION The invention provides ...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A and...</td>\n",
       "      <td>[US20190159474A1-20190530-D00000.TIF, US201901...</td>\n",
       "      <td>Coffee fruits are mainly produced in Africa an...</td>\n",
       "      <td></td>\n",
       "      <td>It is found in the present invention that a wh...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>20190125691</td>\n",
       "      <td>ENCAPSULATION-FREE CONTROLLED PROTEIN RELEASE ...</td>\n",
       "      <td>The present disclosure provides a delivery sys...</td>\n",
       "      <td>1. A biocompatible polymer composite comprise...</td>\n",
       "      <td>FIELD The present disclosure relates to a bioc...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS Embodiments ...</td>\n",
       "      <td>[US20190125691A1-20190502-D00000.TIF, US201901...</td>\n",
       "      <td>Controlled protein release is a key strategy t...</td>\n",
       "      <td></td>\n",
       "      <td>The present invention provides a biocompatible...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>20190169260</td>\n",
       "      <td>Human Leukocyte Antigen Restricted Gamma Delta...</td>\n",
       "      <td>Disclosed herein are compositions and methods ...</td>\n",
       "      <td>1. A composition comprising a polypeptide con...</td>\n",
       "      <td>SEQUENCE LISTING The instant application conta...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS The novel fe...</td>\n",
       "      <td>[US20190169260A1-20190606-D00001.TIF, US201901...</td>\n",
       "      <td>Cancer has a major impact on society across th...</td>\n",
       "      <td></td>\n",
       "      <td>There exists a pressing need for alternative a...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>20190194282</td>\n",
       "      <td>CHIMERIC PROTEINS FOR TARGETING dsRNA</td>\n",
       "      <td>Described herein are recombinant chimeric prot...</td>\n",
       "      <td>1. A chimeric recombinant protein comprising:...</td>\n",
       "      <td>CROSS REFERENCE TO RELATED APPLICATIONS Benefi...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1D:...</td>\n",
       "      <td>[US20190194282A1-20190627-D00000.TIF, US201901...</td>\n",
       "      <td>Prostate cancer is the second most commonly di...</td>\n",
       "      <td></td>\n",
       "      <td>Described herein is an improved approach to th...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>20190127440</td>\n",
       "      <td>NOVEL TSLP INHIBITORS</td>\n",
       "      <td>The present invention relates to monomeric fus...</td>\n",
       "      <td>1. A monomeric fusion protein comprising: a f...</td>\n",
       "      <td>FIELD OF THE INVENTION The present invention r...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE FIGURES FIG. 1 shows ...</td>\n",
       "      <td>[US20190127440A1-20190502-D00001.TIF, US201901...</td>\n",
       "      <td>Thymic stromal lymphopoietin (TSLP) is an inte...</td>\n",
       "      <td></td>\n",
       "      <td>It is surprisingly shown herein that a monomer...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>20190177383</td>\n",
       "      <td>NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR...</td>\n",
       "      <td>The present invention relates to peptides, pro...</td>\n",
       "      <td>1. A method of treating a patient who has can...</td>\n",
       "      <td>CROSS REFERENCE TO RELATED APPLICATIONS This a...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS The patent o...</td>\n",
       "      <td>[US20190177383A1-20190613-D00001.TIF, US201901...</td>\n",
       "      <td>Ovarian Cancer With an estimated 239 000 new c...</td>\n",
       "      <td></td>\n",
       "      <td>In a first aspect of the present invention, th...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>20190194689</td>\n",
       "      <td>CNS TARGETING AAV VECTORS AND METHODS OF USE T...</td>\n",
       "      <td>The invention in some aspects relates to recom...</td>\n",
       "      <td>1-55. (canceled)  56. A method for delivering...</td>\n",
       "      <td>RELATED APPLICATIONS This application is a con...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1B ...</td>\n",
       "      <td>[US20190194689A1-20190627-D00001.TIF, US201901...</td>\n",
       "      <td>Gene therapy has been investigated for deliver...</td>\n",
       "      <td></td>\n",
       "      <td>Aspects of the invention, are based on the dis...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>20190144517</td>\n",
       "      <td>PROTEIN FOR NEUTRALIZING PROGRAMMED NECROCYTOS...</td>\n",
       "      <td>Provided is polypeptide which derives from wil...</td>\n",
       "      <td>1. A polypeptide that inhibits cell necrosis,...</td>\n",
       "      <td>TECHNICAL FIELD The present invention relates ...</td>\n",
       "      <td>DESCRIPTION OF DRAWINGS FIG. 1 shows the scree...</td>\n",
       "      <td>[US20190144517A1-20190516-D00001.TIF, US201901...</td>\n",
       "      <td>Tumor necrosis factor α (TNF) is a multifuncti...</td>\n",
       "      <td></td>\n",
       "      <td>It is an object of the present invention to pr...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>20190177709</td>\n",
       "      <td>REGULATION OF GENE EXPRESSION USING ENGINEERED...</td>\n",
       "      <td>The present disclosure is in the field of geno...</td>\n",
       "      <td>1. A zinc finger nuclease (ZFN) comprising le...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS This a...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A and...</td>\n",
       "      <td>[US20190177709A1-20190613-D00000.TIF, US201901...</td>\n",
       "      <td>When one considers that genome sequencing effo...</td>\n",
       "      <td>This application is filed pursuant to 35 U.S.C...</td>\n",
       "      <td>The present invention describes highly specifi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>20190169583</td>\n",
       "      <td>STEP-Derived Peptide for Brain Injury Treatment</td>\n",
       "      <td>A novel peptide sequence that is a modified de...</td>\n",
       "      <td>1. An isolated peptide comprising a kinase in...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS The fo...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...</td>\n",
       "      <td>[US20190169583A1-20190606-D00001.TIF, US201901...</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "             id                                    invention_title  \\\n",
       "0   20190151472  LIVER-SPECIFIC CONSTRUCTS, FACTOR VIII EXPRESS...   \n",
       "1   20190135863  RETRO-INVERSO PEPTIDE INHIBITORS OF CELL MIGRA...   \n",
       "2   20190133992  CANNABINOID COMPOSITION HAVING AN OPTIMIZED FA...   \n",
       "3   20190136261  GENETIC MODIFICATION OF CYTOKINE INDUCIBLE SH2...   \n",
       "4   20190161536  ANTI-AP2 ANTIBODIES AND ANTIGEN BINDING AGENTS...   \n",
       "5   20190202865  TARGETING DIMERIZATION OF BAX TO MODULATE BAX ...   \n",
       "6   20190201532  SENSITIZATION OF BACTERIAL CELLS TO QUINOLONE ...   \n",
       "7   20190201444             GLYCOENGINEERING OF E-SELECTIN LIGANDS   \n",
       "8   20190177429          Anti-HER2 Antibodies and Immunoconjugates   \n",
       "9   20190184190  PHOSPHOR-CONTAINING DRUG ACTIVATOR ACTIVATABLE...   \n",
       "10  20190192693     METHODS AND VECTORS FOR TREATING CNS DISORDERS   \n",
       "11  20190159474  AMELIORATIVE EFFECTS OF A WHOLE COFFEE FRUIT E...   \n",
       "12  20190125691  ENCAPSULATION-FREE CONTROLLED PROTEIN RELEASE ...   \n",
       "13  20190169260  Human Leukocyte Antigen Restricted Gamma Delta...   \n",
       "14  20190194282              CHIMERIC PROTEINS FOR TARGETING dsRNA   \n",
       "15  20190127440                              NOVEL TSLP INHIBITORS   \n",
       "16  20190177383  NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR...   \n",
       "17  20190194689  CNS TARGETING AAV VECTORS AND METHODS OF USE T...   \n",
       "18  20190144517  PROTEIN FOR NEUTRALIZING PROGRAMMED NECROCYTOS...   \n",
       "19  20190177709  REGULATION OF GENE EXPRESSION USING ENGINEERED...   \n",
       "20  20190169583    STEP-Derived Peptide for Brain Injury Treatment   \n",
       "\n",
       "                                             abstract  \\\n",
       "0   Described herein are constructs used for liver...   \n",
       "1   The present invention discloses retro-inverso ...   \n",
       "2   A composition of matter for enhancing delivery...   \n",
       "3   The present disclosure is in the field of geno...   \n",
       "4   This invention is in the area of improved anti...   \n",
       "5   Methods are provided for identifying an agent ...   \n",
       "6   Provided herein are pharmaceutical composition...   \n",
       "7   The present invention provides methods of enfo...   \n",
       "8   The invention provides anti-HER2 antibodies an...   \n",
       "9   A phosphor-containing drug activator activatab...   \n",
       "10  Methods and uses of treating a disease in a ma...   \n",
       "11  The invention provides a method of extracting ...   \n",
       "12  The present disclosure provides a delivery sys...   \n",
       "13  Disclosed herein are compositions and methods ...   \n",
       "14  Described herein are recombinant chimeric prot...   \n",
       "15  The present invention relates to monomeric fus...   \n",
       "16  The present invention relates to peptides, pro...   \n",
       "17  The invention in some aspects relates to recom...   \n",
       "18  Provided is polypeptide which derives from wil...   \n",
       "19  The present disclosure is in the field of geno...   \n",
       "20  A novel peptide sequence that is a modified de...   \n",
       "\n",
       "                                               claims  \\\n",
       "0    1-10. (canceled)  11. A method of providing a...   \n",
       "1    1. A compound of formula (I):   X1-(D)-Arg-X2...   \n",
       "2    1. A cannabinoid composition comprising: at l...   \n",
       "3    1. A genetically modified cell comprising a g...   \n",
       "4    1. A method of attenuating an aP2-mediated di...   \n",
       "5    1-19. (canceled)  20. A method of inhibiting ...   \n",
       "6    1. A pharmaceutical composition comprising a ...   \n",
       "7    1. A method of enforcing expression of an E-s...   \n",
       "8    1. An isolated antibody that binds to HER2, w...   \n",
       "9    1. A phosphor-containing drug activator activ...   \n",
       "10   1. A method of delivering a therapeutic prote...   \n",
       "11   1. A method of producing a whole coffee fruit...   \n",
       "12   1. A biocompatible polymer composite comprise...   \n",
       "13   1. A composition comprising a polypeptide con...   \n",
       "14   1. A chimeric recombinant protein comprising:...   \n",
       "15   1. A monomeric fusion protein comprising: a f...   \n",
       "16   1. A method of treating a patient who has can...   \n",
       "17   1-55. (canceled)  56. A method for delivering...   \n",
       "18   1. A polypeptide that inhibits cell necrosis,...   \n",
       "19   1. A zinc finger nuclease (ZFN) comprising le...   \n",
       "20   1. An isolated peptide comprising a kinase in...   \n",
       "\n",
       "                                          description  \\\n",
       "0   CROSS-REFERENCE TO RELATED APPLICATIONS The pr...   \n",
       "1   The present invention concerns retro-inverso p...   \n",
       "2   FIELD OF THE INVENTION The present invention r...   \n",
       "3   CROSS-REFERENCE TO RELATED APPLICATIONS The pr...   \n",
       "4   RELATED APPLICATIONS This application is a con...   \n",
       "5   CROSS-REFERENCE TO RELATED APPLICATIONS This a...   \n",
       "6   RELATED APPLICATION The present application cl...   \n",
       "7   CROSS-REFERENCE TO RELATED APPLICATIONS The pr...   \n",
       "8   CROSS-REFERENCE TO RELATED APPLICATIONS The pr...   \n",
       "9   CROSS REFERENCE TO RELATED APPLICATIONS This a...   \n",
       "10  RELATED APPLICATIONS This application claims p...   \n",
       "11  FIELD OF THE INVENTION The invention provides ...   \n",
       "12  FIELD The present disclosure relates to a bioc...   \n",
       "13  SEQUENCE LISTING The instant application conta...   \n",
       "14  CROSS REFERENCE TO RELATED APPLICATIONS Benefi...   \n",
       "15  FIELD OF THE INVENTION The present invention r...   \n",
       "16  CROSS REFERENCE TO RELATED APPLICATIONS This a...   \n",
       "17  RELATED APPLICATIONS This application is a con...   \n",
       "18  TECHNICAL FIELD The present invention relates ...   \n",
       "19  CROSS-REFERENCE TO RELATED APPLICATIONS This a...   \n",
       "20  CROSS-REFERENCE TO RELATED APPLICATIONS The fo...   \n",
       "\n",
       "                                 drawings_description  \\\n",
       "0   BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...   \n",
       "1   DESCRIPTION OF THE FIGURES FIG. 1 High degree ...   \n",
       "2   BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...   \n",
       "3   BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 shows...   \n",
       "4   BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1-8 ar...   \n",
       "5   BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1A-1D. ...   \n",
       "6   BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1F....   \n",
       "7   BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1A-FIG....   \n",
       "8   BRIEF DESCRIPTION OF THE FIGURES FIG. 1 shows ...   \n",
       "9   BRIEF DESCRIPTION OF THE FIGURES A more comple...   \n",
       "10  BRIEF DESCRIPTION OF THE FIGURES A more comple...   \n",
       "11  BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A and...   \n",
       "12  BRIEF DESCRIPTION OF THE DRAWINGS Embodiments ...   \n",
       "13  BRIEF DESCRIPTION OF THE DRAWINGS The novel fe...   \n",
       "14  BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1D:...   \n",
       "15  BRIEF DESCRIPTION OF THE FIGURES FIG. 1 shows ...   \n",
       "16  BRIEF DESCRIPTION OF THE DRAWINGS The patent o...   \n",
       "17  BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1B ...   \n",
       "18  DESCRIPTION OF DRAWINGS FIG. 1 shows the scree...   \n",
       "19  BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A and...   \n",
       "20  BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...   \n",
       "\n",
       "                                  drawings_file_paths  \\\n",
       "0   [US20190151472A1-20190523-D00001.TIF, US201901...   \n",
       "1   [US20190135863A1-20190509-D00001.TIF, US201901...   \n",
       "2   [US20190133992A1-20190509-D00001.TIF, US201901...   \n",
       "3   [US20190136261A1-20190509-D00001.TIF, US201901...   \n",
       "4   [US20190161536A1-20190530-D00001.TIF, US201901...   \n",
       "5   [US20190202865A1-20190704-D00001.TIF, US201902...   \n",
       "6   [US20190201532A1-20190704-D00001.TIF, US201902...   \n",
       "7   [US20190201444A1-20190704-D00000.TIF, US201902...   \n",
       "8   [US20190177429A1-20190613-D00001.TIF, US201901...   \n",
       "9   [US20190184190A1-20190620-D00000.TIF, US201901...   \n",
       "10  [US20190184190A1-20190620-D00000.TIF, US201901...   \n",
       "11  [US20190159474A1-20190530-D00000.TIF, US201901...   \n",
       "12  [US20190125691A1-20190502-D00000.TIF, US201901...   \n",
       "13  [US20190169260A1-20190606-D00001.TIF, US201901...   \n",
       "14  [US20190194282A1-20190627-D00000.TIF, US201901...   \n",
       "15  [US20190127440A1-20190502-D00001.TIF, US201901...   \n",
       "16  [US20190177383A1-20190613-D00001.TIF, US201901...   \n",
       "17  [US20190194689A1-20190627-D00001.TIF, US201901...   \n",
       "18  [US20190144517A1-20190516-D00001.TIF, US201901...   \n",
       "19  [US20190177709A1-20190613-D00000.TIF, US201901...   \n",
       "20  [US20190169583A1-20190606-D00001.TIF, US201901...   \n",
       "\n",
       "                                 invention_background  \\\n",
       "0   Gene therapy can be used to genetically engine...   \n",
       "1                                                       \n",
       "2   Formulations of bioactive compounds have been ...   \n",
       "3   Cells communicate with each other either by di...   \n",
       "4   Human adipocyte lipid-binding protein (aP2) be...   \n",
       "5   Throughout this application various publicatio...   \n",
       "6   Antibiotics are the main tools to treat infect...   \n",
       "7   Mesenchymal stem cells (MSCs) hold much promis...   \n",
       "8   Breast cancer is a highly significant cause of...   \n",
       "9   Field of Invention The invention relates to me...   \n",
       "10                                                      \n",
       "11  Coffee fruits are mainly produced in Africa an...   \n",
       "12  Controlled protein release is a key strategy t...   \n",
       "13  Cancer has a major impact on society across th...   \n",
       "14  Prostate cancer is the second most commonly di...   \n",
       "15  Thymic stromal lymphopoietin (TSLP) is an inte...   \n",
       "16  Ovarian Cancer With an estimated 239 000 new c...   \n",
       "17  Gene therapy has been investigated for deliver...   \n",
       "18  Tumor necrosis factor α (TNF) is a multifuncti...   \n",
       "19  When one considers that genome sequencing effo...   \n",
       "20                                                      \n",
       "\n",
       "                                      cross_reference  \\\n",
       "0   The present application is a divisional of U.S...   \n",
       "1                                                       \n",
       "2                                                       \n",
       "3   The present application claims the benefit of ...   \n",
       "4                                                       \n",
       "5   This application claims the benefit of U.S. Pr...   \n",
       "6                                                       \n",
       "7                                                       \n",
       "8   The present application is a divisional of U.S...   \n",
       "9                                                       \n",
       "10                                                      \n",
       "11                                                      \n",
       "12                                                      \n",
       "13                                                      \n",
       "14                                                      \n",
       "15                                                      \n",
       "16                                                      \n",
       "17                                                      \n",
       "18                                                      \n",
       "19  This application is filed pursuant to 35 U.S.C...   \n",
       "20                                                      \n",
       "\n",
       "                                              summary  \n",
       "0   The present invention describes compositions a...  \n",
       "1                                                      \n",
       "2   The present invention includes a cannabinoid c...  \n",
       "3   The present invention describes compositions a...  \n",
       "4   Anti-aP2 monoclonal antibodies and antigen bin...  \n",
       "5   The present invention discloses assays for ide...  \n",
       "6   Density-dependent drug failure is a form of an...  \n",
       "7   Despite the promise of these methods, there ex...  \n",
       "8   The invention provides anti-HER2 antibodies an...  \n",
       "9   In one embodiment, the present invention provi...  \n",
       "10  In certain embodiments, the invention provides...  \n",
       "11  It is found in the present invention that a wh...  \n",
       "12  The present invention provides a biocompatible...  \n",
       "13  There exists a pressing need for alternative a...  \n",
       "14  Described herein is an improved approach to th...  \n",
       "15  It is surprisingly shown herein that a monomer...  \n",
       "16  In a first aspect of the present invention, th...  \n",
       "17  Aspects of the invention, are based on the dis...  \n",
       "18  It is an object of the present invention to pr...  \n",
       "19  The present invention describes highly specifi...  \n",
       "20                                                     "
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "patents_df4 = pd.concat([patents_df3, summary_df], axis=1)\n",
    "patents_df4"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Disclosed herein are expression cassettes for expression of a transgene, particularly in liver cells. The constructs can be used to deliver any transgene(s) to liver cells, in vivo or in vitro and can be used for the treatment and/or prevention of any disease or disorder which can be ameliorated by the provision of one or more of the transgenes. Unlike currently used hepatic-targeted constructs, the constructs described herein include modified enhancer and/or intronic sequences and, in addition, express the transgene at high levels even without the use of an MVM intron. These constructs are also small, allowing for successful use with transgenes delivered by small vector systems such as AAV. The constructs described herein can be used to express hFVIII BDD in the liver of non-human primates. Depending on the initial dose of the AAV hF8 cDNA expression cassette, circulating plasma levels of hFVIII were upwards of 800% of normal circulating hFVIII. Following these initial high doses, many animals settled in to expression of 10-150% of normal levels for greater than eight weeks. In addition, some of the animals did not mount an anti-hFVIII antibody response upon challenge with injected hFVIII protein (Xyntha®), suggestive of the development of tolerance to the hFVIIII protein in these animals over the course of the experiment. General Practice of the methods, as well as preparation and use of the compositions disclosed herein employ, unless otherwise indicated, conventional techniques in molecular biology, biochemistry, chromatin structure and analysis, computational chemistry, cell culture, recombinant DNA and related fields as are within the skill of the art. These techniques are fully explained in the literature. See, for example, Sambrook et al. MOLECULAR CLONING: A LABORATORY MANUAL, Second edition, Cold Spring Harbor Laboratory Press, 1989 and Third edition, 2001; Ausubel et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, 1987 and periodic updates; the series METHODS IN ENZYMOLOGY, Academic Press, San Diego; Wolffe, CHROMATIN STRUCTURE AND FUNCTION, Third edition, Academic Press, San Diego, 1998; METHODS IN ENZYMOLOGY, Vol. 304, “Chromatin” (P.M. Wassarman and A. P. Wolffe, eds.), Academic Press, San Diego, 1999; and METHODS IN MOLECULAR BIOLOGY, Vol. 119, “Chromatin Protocols” (P.B. Becker, ed.) Humana Press, Totowa, 1999. Definitions The terms “nucleic acid,” “polynucleotide,” and “oligonucleotide” are used interchangeably and refer to a deoxyribonucleotide or ribonucleotide polymer, in linear or circular conformation, and in either single- or double-stranded form. For the purposes of the present disclosure, these terms are not to be construed as limiting with respect to the length of a polymer. The terms can encompass known analogues of natural nucleotides, as well as nucleotides that are modified in the base, sugar and/or phosphate moieties (e.g., phosphorothioate backbones). In general, an analogue of a particular nucleotide has the same base-pairing specificity; i.e., an analogue of A will base-pair with T. The terms “polypeptide,” “peptide” and “protein” are used interchangeably to refer to a polymer of amino acid residues. The term also applies to amino acid polymers in which one or more amino acids are chemical analogues or modified derivatives of a corresponding naturally-occurring amino acids. “Recombination” refers to a process of exchange of genetic information between two polynucleotides, including but not limited to, capture by non-homologous end joining (NHEJ) and homologous recombination. For the purposes of this disclosure, “homologous recombination (HR)” refers to the specialized form of such exchange that takes place, for example, during repair of double-strand breaks in cells via homology-directed repair mechanisms. In certain methods of the disclosure, one or more targeted nucleases as described herein create a double-stranded break (DSB) in the target sequence (e.g., cellular chromatin) at a predetermined site (e.g., albumin gene). The DSB mediates integration of a construct as described herein. Optionally, the construct has homology to the nucleotide sequence in the region of the break. The expression construct may be physically integrated or, alternatively, the expression cassette is used as a template for repair of the break via homologous recombination, resulting in the introduction of all or part of the nucleotide sequence as in the expression cassette into the cellular chromatin. Thus, a first sequence in cellular chromatin can be altered and, in certain embodiments, can be converted into a sequence present in an expression cassette. Thus, the use of the terms “replace” or “replacement” can be understood to represent replacement of one nucleotide sequence by another, (i.e., replacement of a sequence in the informational sense), and does not necessarily require physical or chemical replacement of one polynucleotide by another. In any of the methods described herein, the exogenous nucleotide sequence (the “expression construct” or “expression cassette” or “vector”) can contain sequences that are homologous, but not identical, to genomic sequences in the region of interest, thereby stimulating homologous recombination to insert a non-identical sequence in the region of interest. Thus, in certain embodiments, portions of the expression cassette sequence that are homologous to sequences in the region of interest exhibit between about 80 to 99% (or any integer therebetween) sequence identity to the genomic sequence that is replaced. In other embodiments, the homology between the expression cassette and genomic sequence is higher than 99%, for example if only 1 nucleotide differs as between the homology regions of the expression cassette and genomic sequences of over 100 contiguous base pairs. In certain cases, a non-homologous portion of the expression cassette can contain sequences not present in the region of interest, such that new sequences are introduced into the region of interest. In these instances, the non-homologous sequence is generally flanked by sequences of 50-1,000 base pairs (or any integral value therebetween) or any number of base pairs greater than 1,000, that are homologous or identical to sequences in the region of interest. The term “sequence” refers to a nucleotide sequence of any length, which can be DNA or RNA; can be linear, circular or branched and can be either single-stranded or double stranded. The term “transgene” refers to a nucleotide sequence that is inserted into a genome. A transgene can be of any length, for example between 2 and 100,000,000 nucleotides in length (or any integer value therebetween or thereabove), preferably between about 100 and 100,000 nucleotides in length (or any integer therebetween), more preferably between about 2000 and 20,000 nucleotides in length (or any value therebetween) and even more preferable, between about 5 and 15 kb (or any value therebetween). A “chromosome,” is a chromatin complex comprising all or a portion of the genome of a cell. The genome of a cell is often characterized by its karyotype, which is the collection of all the chromosomes that comprise the genome of the cell. The genome of a cell can comprise one or more chromosomes. An “episome” is a replicating nucleic acid, nucleoprotein complex or other structure comprising a nucleic acid that is not part of the chromosomal karyotype of a cell. Examples of episomes include plasmids and certain viral genomes. The liver specific constructs described herein may be epiosomally maintained or, alternatively, may be stably integrated into the cell. An “exogenous” molecule is a molecule that is not normally present in a cell, but can be introduced into a cell by one or more genetic, biochemical or other methods. “Normal presence in the cell” is determined with respect to the particular developmental stage and environmental conditions of the cell. Thus, for example, a molecule that is present only during embryonic development of muscle is an exogenous molecule with respect to an adult muscle cell. Similarly, a molecule induced by heat shock is an exogenous molecule with respect to a non-heat-shocked cell. An exogenous molecule can comprise, for example, a functioning version of a malfunctioning endogenous molecule or a malfunctioning version of a normally-functioning endogenous molecule. An exogenous molecule can be, among other things, a small molecule, such as is generated by a combinatorial chemistry process, or a macromolecule such as a protein, nucleic acid, carbohydrate, lipid, glycoprotein, lipoprotein, polysaccharide, any modified derivative of the above molecules, or any complex comprising one or more of the above molecules. Nucleic acids include DNA and RNA, can be single- or double-stranded; can be linear, branched or circular; and can be of any length. Nucleic acids include those capable of forming duplexes, as well as triplex-forming nucleic acids. See, for example, U.S. Pat. Nos. 5,176,996 and 5,422,251. Proteins include, but are not limited to, DNA-binding proteins, transcription factors, chromatin remodeling factors, methylated DNA binding proteins, polymerases, methylases, demethylases, acetylases, deacetylases, kinases, phosphatases, ligases, deubiquitinases, integrases, recombinases, ligases, topoisomerases, gyrases and helicases. An exogenous molecule can be the same type of molecule as an endogenous molecule, e.g., an exogenous protein or nucleic acid. For example, an exogenous nucleic acid can comprise an infecting viral genome, a plasmid or episome introduced into a cell, or a chromosome that is not normally present in the cell. Methods for the introduction of exogenous molecules into cells are known to those of skill in the art and include, but are not limited to, lipid-mediated transfer (i.e., liposomes, including neutral and cationic lipids), electroporation, direct injection, cell fusion, particle bombardment, calcium phosphate co-precipitation, DEAE-dextran-mediated transfer and viral vector-mediated transfer. An exogenous molecule can also be the same type of molecule as an endogenous molecule but derived from a different species than the cell is derived from. For example, a human nucleic acid sequence may be introduced into a cell line originally derived from a mouse or hamster. Methods for the introduction of exogenous molecules into plant cells are known to those of skill in the art and include, but are not limited to, protoplast transformation, silicon carbide (e.g., WHISKERS™) Agrobacterium-mediated transformation, lipid-mediated transfer (i.e., liposomes, including neutral and cationic lipids), electroporation, direct injection, cell fusion, particle bombardment (e.g., using a “gene gun”), calcium phosphate co-precipitation, DEAE-dextran-mediated transfer and viral vector-mediated transfer. By contrast, an “endogenous” molecule is one that is normally present in a particular cell at a particular developmental stage under particular environmental conditions. For example, an endogenous nucleic acid can comprise a chromosome, the genome of a mitochondrion, chloroplast or other organelle, or a naturally-occurring episomal nucleic acid. Additional endogenous molecules can include proteins, for example, transcription factors and enzymes. As used herein, the term “product of an exogenous nucleic acid” includes both polynucleotide and polypeptide products, for example, transcription products (polynucleotides such as RNA) and translation products (polypeptides). A “fusion” molecule is a molecule in which two or more subunit molecules are linked, preferably covalently. The subunit molecules can be the same chemical type of molecule, or can be different chemical types of molecules. Examples of fusion molecules include, but are not limited to, fusion proteins (for example, a fusion between a protein DNA-binding domain and a cleavage domain), fusions between a polynucleotide DNA-binding domain (e.g., sgRNA) operatively associated with a cleavage domain, and fusion nucleic acids (for example, a nucleic acid encoding the fusion protein). Expression of a fusion protein in a cell can result from delivery of the fusion protein to the cell or by delivery of a polynucleotide encoding the fusion protein to a cell, wherein the polynucleotide is transcribed, and the transcript is translated, to generate the fusion protein. Trans-splicing, polypeptide cleavage and polypeptide ligation can also be involved in expression of a protein in a cell. Methods for polynucleotide and polypeptide delivery to cells are presented elsewhere in this disclosure. A “gene,” for the purposes of the present disclosure, includes a DNA region encoding a gene product (see infra), as well as all DNA regions which regulate the production of the gene product, whether or not such regulatory sequences are adjacent to coding and/or transcribed sequences. Accordingly, a gene includes, but is not necessarily limited to, promoter sequences, terminators, translational regulatory sequences such as ribosome binding sites and internal ribosome entry sites, enhancers, silencers, insulators, boundary elements, replication origins, matrix attachment sites and locus control regions. “Gene expression” refers to the conversion of the information, contained in a gene, into a gene product. A gene product can be the direct transcriptional product of a gene (e.g., mRNA, tRNA, rRNA, antisense RNA, ribozyme, structural RNA or any other type of RNA) or a protein produced by translation of an mRNA. Gene products also include RNAs which are modified, by processes such as capping, polyadenylation, methylation, and editing, and proteins modified by, for example, methylation, acetylation, phosphorylation, ubiquitination, ADP-ribosylation, myristilation, and glycosylation. “Modulation” of gene expression refers to a change in the activity of a gene. Modulation of expression can include, but is not limited to, gene activation and gene repression. Genome editing (e.g., cleavage, alteration, inactivation, random mutation) can be used to modulate expression. Gene inactivation refers to any reduction in gene expression as compared to a cell that does not include a ZFP, TALE or CRISPR/Cas system as described herein. Thus, gene inactivation may be partial or complete. A “region of interest” is any region of cellular chromatin, such as, for example, a gene or a non-coding sequence within or adjacent to a gene, in which it is desirable to bind an exogenous molecule. Binding can be for the purposes of targeted DNA cleavage and/or targeted recombination. A region of interest can be present in a chromosome, an episome, an organellar genome (e.g., mitochondrial, chloroplast), or an infecting viral genome, for example. A region of interest can be within the coding region of a gene, within transcribed non-coding regions such as, for example, leader sequences, trailer sequences or introns, or within non-transcribed regions, either upstream or downstream of the coding region. A region of interest can be as small as a single nucleotide pair or up to 2,000 nucleotide pairs in length, or any integral value of nucleotide pairs. “Eukaryotic” cells include, but are not limited to, fungal cells (such as yeast), plant cells, animal cells, mammalian cells and human cells (e.g., T-cells), including stem cells (pluripotent and multipotent). The terms “operative linkage” and “operatively linked” (or “operably linked”) are used interchangeably with reference to a juxtaposition of two or more components (such as sequence elements), in which the components are arranged such that both components function normally and allow the possibility that at least one of the components can mediate a function that is exerted upon at least one of the other components. By way of illustration, a transcriptional regulatory sequence, such as a promoter, is operatively linked to a coding sequence if the transcriptional regulatory sequence controls the level of transcription of the coding sequence in response to the presence or absence of one or more transcriptional regulatory factors. A transcriptional regulatory sequence is generally operatively linked in cis with a coding sequence, but need not be directly adjacent to it. For example, an enhancer is a transcriptional regulatory sequence that is operatively linked to a coding sequence, even though they are not contiguous. A “functional fragment” of a protein, polypeptide or nucleic acid is a protein, polypeptide or nucleic acid whose sequence is not identical to the full-length protein, polypeptide or nucleic acid, yet retains the same function as the full-length protein, polypeptide or nucleic acid. A functional fragment can possess more, fewer, or the same number of residues as the corresponding native molecule, and/or can contain one or more amino acid or nucleotide substitutions. Methods for determining the function of a nucleic acid (e.g., coding function, ability to hybridize to another nucleic acid) are well-known in the art. Similarly, methods for determining protein function are well-known. For example, the B-domain deleted human Factor VIII is a functional fragment of the full-length Factor VIII protein. A polynucleotide “vector” or “construct” is capable of transferring gene sequences to target cells. Typically, “vector construct,” “expression vector,” “expression construct,” “expression cassette,” and “gene transfer vector,” mean any nucleic acid construct capable of directing the expression of a gene of interest and which can transfer gene sequences to target cells. Thus, the term includes cloning, and expression vehicles, as well as integrating vectors. The terms “subject” and “patient” are used interchangeably and refer to mammals such as human patients and non-human primates, as well as experimental animals such as rabbits, dogs, cats, rats, mice, and other animals. Accordingly, the term “subject” or “patient” as used herein means any mammalian patient or subject to which the expression cassettes of the invention can be administered. Subjects of the present invention include those with a disorder. Liver-Specific Expression Constructs Described herein are expression cassettes (constructs) for use in directing expression of a transgene in a liver cell, including in vivo following administration of the expression cassette(s) to the subject (e.g., hepatic delivery). The expression construct may be maintained episomally and drive expression of the transgene extrachromosomally or, alternatively, the expression construct may be integrated into the genome of a liver cell, for example by nuclease-mediated targeted integration. The polynucleotide expression construct comprises an enhancer sequence, a promoter sequence, and one or more transgenes. Optionally included are one or more of the following: an intronic sequence, a polyadenylation sequence and/or a signal peptide. Any enhancer sequence may be used in the expression constructs described herein. In certain embodiments, the enhancer is a wild-type or modified Serpin1 enhancer (Chuah et al., (2014) Molecular Therapy, 22, 1605-1613, Nair et al., (2014) Blood, 123, 3195-3199) In preferred embodiments, the Serpin1 enhancer comprises one or more mutations (e.g., point mutations) as compared to wild-type, for example a Serpin1 enhancer containing one or more nucleotide modifications as shown in FIG. 5, namely modifications of nucleotides at one or more of residues 1, 5, 14, 32 and/or 39 of the sequence shown in any of SEQ ID NOs:1-13. In certain embodiments, the Serpin1 enhancer comprises modifications at positions 1, 5, 14 and 32 (constructs designated CRMSBS1) of any of SEQ ID NOs:1-13 while in other embodiments, the Serpin1 enhancer comprises modification at positions 1, 14, 32 and 39 (constructs designated CRMSBS2) or any of SEQ ID NOs:1-13. Exemplary enhancer sequences are shown below: \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "CRMSBS1 (SEQ ID NO: 35):\n",
      "\n",
      "\n",
      "5′GGGGGAGGCTGCTGGTGAATATTAACCAAGATCAGCCCAGTTACCGGAG\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "\n",
      "GAGCAAACAGGGGCTAAGTTCAC\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "\n",
      "CRMSBS2 (SEQ ID NO: 36):\n",
      "\n",
      "\n",
      "5′GGGGGAGGCTGCTGGTGAATATTAACCAAGATCACCCCAGTTACCGGAG\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "\n",
      "GAGCAAACAGGGACTAAGTTCAC\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " Similarly, any promoter sequence can be used in the expression cassettes of the invention. In certain embodiments, the promoter is a constitutive promoter. In other embodiments, the promoter is an inducible or tissue specific promoter. In some embodiments, the promoter is a liver-specific promoter. In certain embodiments, the promoter is a transthyretin minimal promoter (TTRm) promoter. In other embodiments, the promoter is an alpha-1 anti-trypsin (hAAT) promoter. Any of the polynucleotides described herein may further optionally comprise an intronic sequence. In certain embodiments, the expression construct includes a truncated chimeric intron (T-chimeric intron) sequence, for example as shown in the bottom panels of FIGS. 6, 7, 19 and 20. The T-chimeric intron is a truncated version of the chimeric intron in pCI-neo (GenBank U47120). The chimeric intron in pCI-neo is the 5′ splice donor site from the human β-globin gene, and the branchpoint and 3′ acceptor site of an immunoglobulin gene heavy chain variable region. The T-chimeric intron contains a 45 bp deletion between the 5′ splice donor and the branchpoint. In yet other embodiments, the expression constructs include a mutated MVM intron sequence (e.g., one or more of the mutations shown in FIGS. 12, 13 and 14 (SEQ ID NOs:15-17). Alternatively, the expression constructs as described herein may lack an intronic sequence, for example as shown in the constructs depicted in the middle panels of FIGS. 6, 7, 19 and 20. An exemplary construct, with annotations including a Factor VIII transgene is shown below and it will be apparent that the F8 transgene can be replaced with any transgene and that the promoter and insulator sequences may be further modified as described herein: hF8 cDNA, no intron (complete sequence including promoter module, poly A and Ins, CRMSBS2 No intron) (SEQ ID NO:34): \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Name: CRMSBS2 No Intron\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "                   Module\n",
      "Residues\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "                   Ins 1\n",
      "  14-32\n",
      "\n",
      "\n",
      "                   CRMSBS2\n",
      "  33-104\n",
      "\n",
      "\n",
      "                   TTRm\n",
      " 117-339\n",
      "\n",
      "\n",
      "                   hF8 BDD\n",
      " 345-4718\n",
      "\n",
      "\n",
      "                   SPA51\n",
      "4725-4775\n",
      "\n",
      "\n",
      "                   Ins 3\n",
      "4776-4792\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "|        |         |         |         |         |\n",
      "\n",
      "\n",
      "GCGGCCTAAGCTTGGAACCATTGCCACCTTCAGGGGGAGGCTGCTGGTGA -   50\n",
      "\n",
      "\n",
      "ATATTAACCAAGATCACCCCAGTTACCGGAGGAGCAAACAGGGACTAAGT -  100\n",
      "\n",
      "\n",
      "TCACACGCGTGGTACCGTCTGTCTGCACATTTCGTAGAGCGAGTGTTCCG -  150\n",
      "\n",
      "\n",
      "ATACTCTAATCTCCCTAGGCAAGGTTCATATTTGTGTAGGTTACTTATTC -  200\n",
      "\n",
      "\n",
      "TCCTTTTGTTGACTAAGTCAATAATCAGAATCAGCAGGTTTGGAGTCAGC -  250\n",
      "\n",
      "\n",
      "TTGGCAGGGATCAGCAGCCTGGGTTGGAAGGAGGGGGTATAAAAGCCCCT -  300\n",
      "\n",
      "\n",
      "TCACCAGGAGAAGCCGTCACACAGATCCACAAGCTCCTGCTAGTATGCAG -  350\n",
      "\n",
      "\n",
      "ATCGAGCTCTCCACCTGCTTCTTTCTGTGCCTGTTGAGATTCTGCTTCAG -  400\n",
      "\n",
      "\n",
      "CGCCACCAGGAGATACTACCTGGGGGCTGTGGAGCTGAGCTGGGACTACA -  450\n",
      "\n",
      "\n",
      "TGCAGTCTGACCTGGGGGAGCTGCCTGTGGATGCCAGGTTCCCCCCCAGA -  500\n",
      "\n",
      "\n",
      "GTGCCCAAGAGCTTCCCCTTCAACACCTCTGTGGTGTACAAGAAGACCCT -  550\n",
      "\n",
      "\n",
      "GTTTGTGGAGTTCACTGACCACCTGTTCAACATTGCCAAGCCCAGGCCCC -  600\n",
      "\n",
      "\n",
      "CCTGGATGGGCCTGCTGGGCCCCACCATCCAGGCTGAGGTGTATGACACT -  650\n",
      "\n",
      "\n",
      "GTGGTGATCACCCTGAAGAACATGGCCAGCCACCCTGTGAGCCTGCATGC -  700\n",
      "\n",
      "\n",
      "TGTGGGGGTGAGCTACTGGAAGGCCTCTGAGGGGGCTGAGTATGATGACC -  750\n",
      "\n",
      "\n",
      "AGACCAGCCAGAGGGAGAAGGAGGATGACAAGGTGTTCCCTGGGGGCAGC -  800\n",
      "\n",
      "\n",
      "CACACCTATGTGTGGCAGGTGCTGAAGGAGAATGGCCCCATGGCCTCTGA -  850\n",
      "\n",
      "\n",
      "CCCCCTGTGCCTGACCTACAGCTACCTGAGCCATGTGGACCTGGTGAAGG -  900\n",
      "\n",
      "\n",
      "ACCTGAACTCTGGCCTGATTGGGGCCCTGCTGGTGTGCAGGGAGGGCAGC -  950\n",
      "\n",
      "\n",
      "CTGGCCAAGGAGAAGACCCAGACCCTGCACAAGTTCATCCTGCTGTTTGC - 1000\n",
      "\n",
      "\n",
      "TGTGTTTGATGAGGGCAAGAGCTGGCACTCTGAAACCAAGAACAGCCTGA - 1050\n",
      "\n",
      "\n",
      "TGCAGGACAGGGATGCTGCCTCTGCCAGGGCCTGGCCCAAGATGCACACT - 1100\n",
      "\n",
      "\n",
      "GTGAATGGCTATGTGAACAGGAGCCTGCCTGGCCTGATTGGCTGCCACAG - 1150\n",
      "\n",
      "\n",
      "GAAGTCTGTGTACTGGCATGTGATTGGCATGGGCACCACCCCTGAGGTGC - 1200\n",
      "\n",
      "\n",
      "ACAGCATCTTCCTGGAGGGCCACACCTTCCTGGTCAGGAACCACAGGCAG - 1250\n",
      "\n",
      "\n",
      "GCCAGCCTGGAGATCAGCCCCATCACCTTCCTGACTGCCCAGACCCTGCT - 1300\n",
      "\n",
      "\n",
      "GATGGACCTGGGCCAGTTCCTGCTGTTCTGCCACATCAGCAGCCACCAGC - 1350\n",
      "\n",
      "\n",
      "ATGATGGCATGGAGGCCTATGTGAAGGTGGACAGCTGCCCTGAGGAGCCC - 1400\n",
      "\n",
      "\n",
      "CAGCTGAGGATGAAGAACAATGAGGAGGCTGAGGACTATGATGATGACCT - 1450\n",
      "\n",
      "\n",
      "GACTGACTCTGAGATGGATGTGGTGAGGTTTGATGATGACAACAGCCCCA - 1500\n",
      "\n",
      "\n",
      "GCTTCATCCAGATCAGGTCTGTGGCCAAGAAGCACCCCAAGACCTGGGTG - 1550\n",
      "\n",
      "\n",
      "CACTACATTGCTGCTGAGGAGGAGGACTGGGACTATGCCCCCCTGGTGCT - 1600\n",
      "\n",
      "\n",
      "GGCCCCTGATGACAGGAGCTACAAGAGCCAGTACCTGAACAATGGCCCCC - 1650\n",
      "\n",
      "\n",
      "AGAGGATTGGCAGGAAGTACAAGAAGGTCAGGTTCATGGCCTACACTGAT - 1700\n",
      "\n",
      "\n",
      "GAAACCTTCAAGACCAGGGAGGCCATCCAGCATGAGTCTGGCATCCTGGG - 1750\n",
      "\n",
      "\n",
      "CCCCCTGCTGTATGGGGAGGTGGGGGACACCCTGCTGATCATCTTCAAGA - 1800\n",
      "\n",
      "\n",
      "ACCAGGCCAGCAGGCCCTACAACATCTACCCCCATGGCATCACTGATGTG - 1850\n",
      "\n",
      "\n",
      "AGGCCCCTGTACAGCAGGAGGCTGCCCAAGGGGGTGAAGCACCTGAAGGA - 1900\n",
      "\n",
      "\n",
      "CTTCCCCATCCTGCCTGGGGAGATCTTCAAGTACAAGTGGACTGTGACTG - 1950\n",
      "\n",
      "\n",
      "TGGAGGATGGCCCCACCAAGTCTGACCCCAGGTGCCTGACCAGATACTAC - 2000\n",
      "\n",
      "\n",
      "AGCAGCTTTGTGAACATGGAGAGGGACCTGGCCTCTGGCCTGATTGGCCC - 2050\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "\n",
      "1        10        20        30        40        50\n",
      "\n",
      "\n",
      "|        |         |         |         |         |\n",
      "\n",
      "\n",
      "CCTGCTGATCTGCTACAAGGAGTCTGTGGACCAGAGGGGCAACCAGATCA - 2100\n",
      "\n",
      "\n",
      "TGTCTGACAAGAGGAATGTGATCCTGTTCTCTGTGTTTGATGAGAACAGG - 2150\n",
      "\n",
      "\n",
      "AGCTGGTACCTGACTGAGAACATCCAGAGGTTCCTGCCCAACCCTGCTGG - 2200\n",
      "\n",
      "\n",
      "GGTGCAGCTGGAGGACCCTGAGTTCCAGGCCAGCAACATCATGCACAGCA - 2250\n",
      "\n",
      "\n",
      "TCAATGGCTATGTGTTTGACAGCCTGCAGCTGTCTGTGTGCCTGCATGAG - 2300\n",
      "\n",
      "\n",
      "GTGGCCTACTGGTACATCCTGAGCATTGGGGCCCAGACTGACTTCCTGTC - 2350\n",
      "\n",
      "\n",
      "TGTGTTCTTCTCTGGCTACACCTTCAAGCACAAGATGGTGTATGAGGACA - 2400\n",
      "\n",
      "\n",
      "CCCTGACCCTGTTCCCCTTCTCTGGGGAGACTGTGTTCATGAGCATGGAG - 2450\n",
      "\n",
      "\n",
      "AACCCTGGCCTGTGGATTCTGGGCTGCCACAACTCTGACTTCAGGAACAG - 2500\n",
      "\n",
      "\n",
      "GGGCATGACTGCCCTGCTGAAAGTCTCCAGCTGTGACAAGAACACTGGGG - 2550\n",
      "\n",
      "\n",
      "ACTACTATGAGGACAGCTATGAGGACATCTCTGCCTACCTGCTGAGCAAG - 2600\n",
      "\n",
      "\n",
      "AACAATGCCATTGAGCCCAGGAGCTTCAGCCAGAATCCACCCGTCCTTAA - 2650\n",
      "\n",
      "\n",
      "GCGCCATCAGCGCGAGATCACCAGGACCACCCTGCAGTCTGACCAGGAGG - 2700\n",
      "\n",
      "\n",
      "AGATTGACTATGATGACACCATCTCTGTGGAGATGAAGAAGGAGGACTTT - 2750\n",
      "\n",
      "\n",
      "GACATCTACGACGAGGACGAGAACCAGAGCCCCAGGAGCTTCCAGAAGAA - 2800\n",
      "\n",
      "\n",
      "GACCAGGCACTACTTCATTGCTGCTGTGGAGAGGCTGTGGGACTATGGCA - 2850\n",
      "\n",
      "\n",
      "TGAGCAGCAGCCCCCATGTGCTGAGGAACAGGGCCCAGTCTGGCTCTGTG - 2900\n",
      "\n",
      "\n",
      "CCCCAGTTCAAGAAGGTGGTGTTCCAGGAGTTCACTGATGGCAGCTTCAC - 2950\n",
      "\n",
      "\n",
      "CCAGCCCCTGTACAGAGGGGAGCTGAATGAGCACCTGGGCCTGCTGGGCC - 3000\n",
      "\n",
      "\n",
      "CCTACATCAGGGCTGAGGTGGAGGACAACATCATGGTGACCTTCAGGAAC - 3050\n",
      "\n",
      "\n",
      "CAGGCCAGCAGGCCCTACAGCTTCTACAGCAGCCTGATCAGCTATGAGGA - 3100\n",
      "\n",
      "\n",
      "GGACCAGAGGCAGGGGGCTGAGCCCAGGAAGAACTTTGTGAAGCCCAATG - 3150\n",
      "\n",
      "\n",
      "AAACCAAGACCTACTTCTGGAAGGTGCAGCACCACATGGCCCCCACCAAG - 3200\n",
      "\n",
      "\n",
      "GATGAGTTTGACTGCAAGGCCTGGGCCTACTTCTCTGATGTGGACCTGGA - 3250\n",
      "\n",
      "\n",
      "GAAGGATGTGCACTCTGGCCTGATTGGCCCCCTGCTGGTGTGCCACACCA - 3300\n",
      "\n",
      "\n",
      "ACACCCTGAACCCTGCCCATGGCAGGCAGGTGACTGTGCAGGAGTTTGCC - 3350\n",
      "\n",
      "\n",
      "CTGTTCTTCACCATCTTTGATGAAACCAAGAGCTGGTACTTCACTGAGAA - 3400\n",
      "\n",
      "\n",
      "CATGGAGAGGAACTGCAGGGCCCCCTGCAACATCCAGATGGAGGACCCCA - 3450\n",
      "\n",
      "\n",
      "CCTTCAAGGAGAACTACAGGTTCCATGCCATCAATGGCTACATCATGGAC - 3500\n",
      "\n",
      "\n",
      "ACCCTGCCTGGCCTGGTGATGGCCCAGGACCAGAGGATCAGGTGGTACCT - 3550\n",
      "\n",
      "\n",
      "GCTGAGCATGGGCAGCAATGAGAACATCCACAGCATCCACTTCTCTGGCC - 3600\n",
      "\n",
      "\n",
      "ATGTGTTCACTGTGAGGAAGAAGGAGGAGTACAAGATGGCCCTGTACAAC - 3650\n",
      "\n",
      "\n",
      "CTGTACCCTGGGGTGTTTGAGACTGTGGAGATGCTGCCCAGCAAGGCTGG - 3700\n",
      "\n",
      "\n",
      "CATCTGGAGGGTGGAGTGCCTGATTGGGGAGCACCTGCATGCTGGCATGA - 3750\n",
      "\n",
      "\n",
      "GCACCCTGTTCCTGGTGTACAGCAACAAGTGCCAGACCCCCCTGGGCATG - 3800\n",
      "\n",
      "\n",
      "GCCTCTGGCCACATCAGGGACTTCCAGATCACTGCCTCTGGCCAGTATGG - 3850\n",
      "\n",
      "\n",
      "CCAGTGGGCCCCCAAGCTGGCCAGGCTGCACTACTCTGGCAGCATCAATG - 3900\n",
      "\n",
      "\n",
      "CCTGGAGCACCAAGGAGCCCTTCAGCTGGATCAAGGTGGACCTGCTGGCC - 3950\n",
      "\n",
      "\n",
      "CCCATGATCATCCATGGCATCAAGACCCAGGGGGCCAGGCAGAAGTTCAG - 4000\n",
      "\n",
      "\n",
      "CAGCCTGTACATCAGCCAGTTCATCATCATGTACAGCCTGGATGGCAAGA - 4050\n",
      "\n",
      "\n",
      "AGTGGCAGACCTACAGGGGCAACAGCACTGGCACCCTGATGGTGTTCTTT - 4100\n",
      "\n",
      "\n",
      "GGCAATGTGGACAGCTCTGGCATCAAGCACAACATCTTCAACCCCCCCAT - 4150\n",
      "\n",
      "\n",
      "CATTGCCAGATACATCAGGCTGCACCCCACCCACTACAGCATCAGGAGCA - 4200\n",
      "\n",
      "\n",
      "CCCTGAGGATGGAGCTGATGGGCTGTGACCTGAACAGCTGCAGCATGCCC - 4250\n",
      "\n",
      "\n",
      "CTGGGCATGGAGAGCAAGGCCATCTCTGATGCCCAGATCACTGCCAGCAG - 4300\n",
      "\n",
      "\n",
      "CTACTTCACCAACATGTTTGCCACCTGGAGCCCCAGCAAGGCCAGGCTGC - 4350\n",
      "\n",
      "\n",
      "ATCTGCAGGGCAGGAGCAATGCCTGGAGGCCCCAGGTCAACAACCCCAAG - 4400\n",
      "\n",
      "\n",
      "GAGTGGCTGCAGGTGGACTTCCAGAAGACCATGAAGGTGACTGGGGTGAC - 4450\n",
      "\n",
      "\n",
      "CACCCAGGGGGTGAAGAGCCTGCTGACCAGCATGTATGTGAAGGAGTTCC - 4500\n",
      "\n",
      "\n",
      "TGATCAGCAGCAGCCAGGATGGCCACCAGTGGACCCTGTTCTTCCAGAAT - 4550\n",
      "\n",
      "\n",
      "GGCAAGGTGAAGGTGTTCCAGGGCAACCAGGACAGCTTCACCCCTGTGGT - 4600\n",
      "\n",
      "\n",
      "GAACAGCCTGGACCCCCCCCTGCTGACCAGATACCTGAGGATTCACCCCC - 4650\n",
      "\n",
      "\n",
      "AGAGCTGGGTGCACCAGATTGCCCTGAGGATGGAGGTGCTGGGCTGTGAG - 4700\n",
      "\n",
      "\n",
      "GCCCAGGACCTGTACTGAGGATCCAATAAAATATCTTTATTTTCATTACA - 4750\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "\n",
      "1        10        20        30        40        50\n",
      "\n",
      "\n",
      "|        |         |         |         |         |\n",
      "\n",
      "\n",
      "TCTGTGTGTTGGTTTTTTGTGTGTTTTCCTGTAACGATCGGGCTCGAGCG - 4800\n",
      "\n",
      "\n",
      "5′\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " Another exemplary construct, with annotations including a Factor VIII transgene is shown below and it will also be apparent that the F8 transgene can be replaced with any transgene and that the promoter and insulator sequences may be further modified as described herein: hF8 cDNA, including intron (complete sequence including promoter module, poly A and Ins, CRMSBS2 SBR Intron 3) (SEQ ID NO:37): \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Name: CRMSBS2 SBR Intron 3\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "                  Module\n",
      "Residues\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "                  Ins 1\n",
      "  14-32\n",
      "\n",
      "\n",
      "                  CRMSBS2\n",
      "  33-104\n",
      "\n",
      "\n",
      "                  TTRm\n",
      " 117-339\n",
      "\n",
      "\n",
      "                  SBR Intron 3\n",
      " 340-432\n",
      "\n",
      "\n",
      "                  hF8 BDD\n",
      " 438-4811\n",
      "\n",
      "\n",
      "                  SPA51\n",
      "4818-4868\n",
      "\n",
      "\n",
      "                  Ins 3\n",
      "4869-4885\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "1        10        20        30        40        50\n",
      "\n",
      "\n",
      "|        |         |         |         |         |\n",
      "\n",
      "\n",
      "GCGGCCTAAGCTTGGAACCATTGCCACCTTCAGGGGGAGGCTGCTGGTGA -   50\n",
      "\n",
      "\n",
      "ATATTAACCAAGATCACCCCAGTTACCGGAGGAGCAAACAGGGACTAAGT -  100\n",
      "\n",
      "\n",
      "TCACACGCGTGGTACCGTCTGTCTGCACATTTCGTAGAGCGAGTGTTCCG -  150\n",
      "\n",
      "\n",
      "ATACTCTAATCTCCCTAGGCAAGGTTCATATTTGTGTAGGTTACTTATTC -  200\n",
      "\n",
      "\n",
      "TCCTTTTGTTGACTAAGTCAATAATCAGAATCAGCAGGTTTGGAGTCAGC -  250\n",
      "\n",
      "\n",
      "TTGGCAGGGATCAGCAGCCTGGGTTGGAAGGAGGGGGTATAAAAGCCCCT -  300\n",
      "\n",
      "\n",
      "TCACCAGGAGAAGCCGTCACACAGATCCACAAGCTCCTGAAGAGGTAAGG -  350\n",
      "\n",
      "\n",
      "GTTTAAGTTATCGTTAGTTCGTGCACCATTAATGTTTAATTACCTGGAGC -  400\n",
      "\n",
      "\n",
      "ACCTGCCTGAAATCATTTTTTTTTCAGGTTGGCTAGTATGCAGATCGAGC -  450\n",
      "\n",
      "\n",
      "TCTCCACCTGCTTCTTTCTGTGCCTGTTGAGATTCTGCTTCAGCGCCACC -  500\n",
      "\n",
      "\n",
      "AGGAGATACTACCTGGGGGCTGTGGAGCTGAGCTGGGACTACATGCAGTC -  550\n",
      "\n",
      "\n",
      "TGACCTGGGGGAGCTGCCTGTGGATGCCAGGTTCCCCCCCAGAGTGCCCA -  600\n",
      "\n",
      "\n",
      "AGAGCTTCCCCTTCAACACCTCTGTGGTGTACAAGAAGACCCTGTTTGTG -  650\n",
      "\n",
      "\n",
      "GAGTTCACTGACCACCTGTTCAACATTGCCAAGCCCAGGCCCCCCTGGAT -  700\n",
      "\n",
      "\n",
      "GGGCCTGCTGGGCCCCACCATCCAGGCTGAGGTGTATGACACTGTGGTGA -  750\n",
      "\n",
      "\n",
      "TCACCCTGAAGAACATGGCCAGCCACCCTGTGAGCCTGCATGCTGTGGGG -  800\n",
      "\n",
      "\n",
      "GTGAGCTACTGGAAGGCCTCTGAGGGGGCTGAGTATGATGACCAGACCAG -  850\n",
      "\n",
      "\n",
      "CCAGAGGGAGAAGGAGGATGACAAGGTGTTCCCTGGGGGCAGCCACACCT -  900\n",
      "\n",
      "\n",
      "ATGTGTGGCAGGTGCTGAAGGAGAATGGCCCCATGGCCTCTGACCCCCTG -  950\n",
      "\n",
      "\n",
      "TGCCTGACCTACAGCTACCTGAGCCATGTGGACCTGGTGAAGGACCTGAA - 1000\n",
      "\n",
      "\n",
      "CTCTGGCCTGATTGGGGCCCTGCTGGTGTGCAGGGAGGGCAGCCTGGCCA - 1050\n",
      "\n",
      "\n",
      "AGGAGAAGACCCAGACCCTGCACAAGTTCATCCTGCTGTTTGCTGTGTTT - 1100\n",
      "\n",
      "\n",
      "GATGAGGGCAAGAGCTGGCACTCTGAAACCAAGAACAGCCTGATGCAGGA - 1150\n",
      "\n",
      "\n",
      "CAGGGATGCTGCCTCTGCCAGGGCCTGGCCCAAGATGCACACTGTGAATG - 1200\n",
      "\n",
      "\n",
      "GCTATGTGAACAGGAGCCTGCCTGGCCTGATTGGCTGCCACAGGAAGTCT - 1250\n",
      "\n",
      "\n",
      "GTGTACTGGCATGTGATTGGCATGGGCACCACCCCTGAGGTGCACAGCAT - 1300\n",
      "\n",
      "\n",
      "CTTCCTGGAGGGCCACACCTTCCTGGTCAGGAACCACAGGCAGGCCAGCC - 1350\n",
      "\n",
      "\n",
      "TGGAGATCAGCCCCATCACCTTCCTGACTGCCCAGACCCTGCTGATGGAC - 1400\n",
      "\n",
      "\n",
      "CTGGGCCAGTTCCTGCTGTTCTGCCACATCAGCAGCCACCAGCATGATGG - 1450\n",
      "\n",
      "\n",
      "CATGGAGGCCTATGTGAAGGTGGACAGCTGCCCTGAGGAGCCCCAGCTGA - 1500\n",
      "\n",
      "\n",
      "GGATGAAGAACAATGAGGAGGCTGAGGACTATGATGATGACCTGACTGAC - 1550\n",
      "\n",
      "\n",
      "TCTGAGATGGATGTGGTGAGGTTTGATGATGACAACAGCCCCAGCTTCAT - 1600\n",
      "\n",
      "\n",
      "CCAGATCAGGTCTGTGGCCAAGAAGCACCCCAAGACCTGGGTGCACTACA - 1650\n",
      "\n",
      "\n",
      "TTGCTGCTGAGGAGGAGGACTGGGACTATGCCCCCCTGGTGCTGGCCCCT - 1700\n",
      "\n",
      "\n",
      "GATGACAGGAGCTACAAGAGCCAGTACCTGAACAATGGCCCCCAGAGGAT - 1750\n",
      "\n",
      "\n",
      "TGGCAGGAAGTACAAGAAGGTCAGGTTCATGGCCTACACTGATGAAACCT - 1800\n",
      "\n",
      "\n",
      "TCAAGACCAGGGAGGCCATCCAGCATGAGTCTGGCATCCTGGGCCCCCTG - 1850\n",
      "\n",
      "\n",
      "CTGTATGGGGAGGTGGGGGACACCCTGCTGATCATCTTCAAGAACCAGGC - 1900\n",
      "\n",
      "\n",
      "CAGCAGGCCCTACAACATCTACCCCCATGGCATCACTGATGTGAGGCCCC - 1950\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "\n",
      "1        10        20        30        40        50\n",
      "\n",
      "\n",
      "|        |         |         |         |         |\n",
      "\n",
      "\n",
      "TGTACAGCAGGAGGCTGCCCAAGGGGGTGAAGCACCTGAAGGACTTCCCC - 2000\n",
      "\n",
      "\n",
      "ATCCTGCCTGGGGAGATCTTCAAGTACAAGTGGACTGTGACTGTGGAGGA - 2050\n",
      "\n",
      "\n",
      "TGGCCCCACCAAGTCTGACCCCAGGTGCCTGACCAGATACTACAGCAGCT - 2100\n",
      "\n",
      "\n",
      "TTGTGAACATGGAGAGGGACCTGGCCTCTGGCCTGATTGGCCCCCTGCTG - 2150\n",
      "\n",
      "\n",
      "ATCTGCTACAAGGAGTCTGTGGACCAGAGGGGCAACCAGATCATGTCTGA - 2200\n",
      "\n",
      "\n",
      "CAAGAGGAATGTGATCCTGTTCTCTGTGTTTGATGAGAACAGGAGCTGGT - 2250\n",
      "\n",
      "\n",
      "ACCTGACTGAGAACATCCAGAGGTTCCTGCCCAACCCTGCTGGGGTGCAG - 2300\n",
      "\n",
      "\n",
      "CTGGAGGACCCTGAGTTCCAGGCCAGCAACATCATGCACAGCATCAATGG - 2350\n",
      "\n",
      "\n",
      "CTATGTGTTTGACAGCCTGCAGCTGTCTGTGTGCCTGCATGAGGTGGCCT - 2400\n",
      "\n",
      "\n",
      "ACTGGTACATCCTGAGCATTGGGGCCCAGACTGACTTCCTGTCTGTGTTC - 2450\n",
      "\n",
      "\n",
      "TTCTCTGGCTACACCTTCAAGCACAAGATGGTGTATGAGGACACCCTGAC - 2500\n",
      "\n",
      "\n",
      "CCTGTTCCCCTTCTCTGGGGAGACTGTGTTCATGAGCATGGAGAACCCTG - 2550\n",
      "\n",
      "\n",
      "GCCTGTGGATTCTGGGCTGCCACAACTCTGACTTCAGGAACAGGGGCATG - 2600\n",
      "\n",
      "\n",
      "ACTGCCCTGCTGAAAGTCTCCAGCTGTGACAAGAACACTGGGGACTACTA - 2650\n",
      "\n",
      "\n",
      "TGAGGACAGCTATGAGGACATCTCTGCCTACCTGCTGAGCAAGAACAATG - 2700\n",
      "\n",
      "\n",
      "CCATTGAGCCCAGGAGCTTCAGCCAGAATCCACCCGTCCTTAAGCGCCAT - 2750\n",
      "\n",
      "\n",
      "CAGCGCGAGATCACCAGGACCACCCTGCAGTCTGACCAGGAGGAGATTGA - 2800\n",
      "\n",
      "\n",
      "CTATGATGACACCATCTCTGTGGAGATGAAGAAGGAGGACTTTGACATCT - 2850\n",
      "\n",
      "\n",
      "ACGACGAGGACGAGAACCAGAGCCCCAGGAGCTTCCAGAAGAAGACCAGG - 2900\n",
      "\n",
      "\n",
      "CACTACTTCATTGCTGCTGTGGAGAGGCTGTGGGACTATGGCATGAGCAG - 2950\n",
      "\n",
      "\n",
      "CAGCCCCCATGTGCTGAGGAACAGGGCCCAGTCTGGCTCTGTGCCCCAGT - 3000\n",
      "\n",
      "\n",
      "TCAAGAAGGTGGTGTTCCAGGAGTTCACTGATGGCAGCTTCACCCAGCCC - 3050\n",
      "\n",
      "\n",
      "CTGTACAGAGGGGAGCTGAATGAGCACCTGGGCCTGCTGGGCCCCTACAT - 3100\n",
      "\n",
      "\n",
      "CAGGGCTGAGGTGGAGGACAACATCATGGTGACCTTCAGGAACCAGGCCA - 3150\n",
      "\n",
      "\n",
      "GCAGGCCCTACAGCTTCTACAGCAGCCTGATCAGCTATGAGGAGGACCAG - 3200\n",
      "\n",
      "\n",
      "AGGCAGGGGGCTGAGCCCAGGAAGAACTTTGTGAAGCCCAATGAAACCAA - 3250\n",
      "\n",
      "\n",
      "GACCTACTTCTGGAAGGTGCAGCACCACATGGCCCCCACCAAGGATGAGT - 3300\n",
      "\n",
      "\n",
      "TTGACTGCAAGGCCTGGGCCTACTTCTCTGATGTGGACCTGGAGAAGGAT - 3350\n",
      "\n",
      "\n",
      "GTGCACTCTGGCCTGATTGGCCCCCTGCTGGTGTGCCACACCAACACCCT - 3400\n",
      "\n",
      "\n",
      "GAACCCTGCCCATGGCAGGCAGGTGACTGTGCAGGAGTTTGCCCTGTTCT - 3450\n",
      "\n",
      "\n",
      "TCACCATCTTTGATGAAACCAAGAGCTGGTACTTCACTGAGAACATGGAG - 3500\n",
      "\n",
      "\n",
      "AGGAACTGCAGGGCCCCCTGCAACATCCAGATGGAGGACCCCACCTTCAA - 3550\n",
      "\n",
      "\n",
      "GGAGAACTACAGGTTCCATGCCATCAATGGCTACATCATGGACACCCTGC - 3600\n",
      "\n",
      "\n",
      "CTGGCCTGGTGATGGCCCAGGACCAGAGGATCAGGTGGTACCTGCTGAGC - 3650\n",
      "\n",
      "\n",
      "ATGGGCAGCAATGAGAACATCCACAGCATCCACTTCTCTGGCCATGTGTT - 3700\n",
      "\n",
      "\n",
      "CACTGTGAGGAAGAAGGAGGAGTACAAGATGGCCCTGTACAACCTGTACC - 3750\n",
      "\n",
      "\n",
      "CTGGGGTGTTTGAGACTGTGGAGATGCTGCCCAGCAAGGCTGGCATCTGG - 3800\n",
      "\n",
      "\n",
      "AGGGTGGAGTGCCTGATTGGGGAGCACCTGCATGCTGGCATGAGCACCCT - 3850\n",
      "\n",
      "\n",
      "GTTCCTGGTGTACAGCAACAAGTGCCAGACCCCCCTGGGCATGGCCTCTG - 3900\n",
      "\n",
      "\n",
      "GCCACATCAGGGACTTCCAGATCACTGCCTCTGGCCAGTATGGCCAGTGG - 3950\n",
      "\n",
      "\n",
      "GCCCCCAAGCTGGCCAGGCTGCACTACTCTGGCAGCATCAATGCCTGGAG - 4000\n",
      "\n",
      "\n",
      "CACCAAGGAGCCCTTCAGCTGGATCAAGGTGGACCTGCTGGCCCCCATGA - 4050\n",
      "\n",
      "\n",
      "TCATCCATGGCATCAAGACCCAGGGGGCCAGGCAGAAGTTCAGCAGCCTG - 4100\n",
      "\n",
      "\n",
      "TACATCAGCCAGTTCATCATCATGTACAGCCTGGATGGCAAGAAGTGGCA - 4150\n",
      "\n",
      "\n",
      "GACCTACAGGGGCAACAGCACTGGCACCCTGATGGTGTTCTTTGGCAATG - 4200\n",
      "\n",
      "\n",
      "TGGACAGCTCTGGCATCAAGCACAACATCTTCAACCCCCCCATCATTGCC - 4250\n",
      "\n",
      "\n",
      "AGATACATCAGGCTGCACCCCACCCACTACAGCATCAGGAGCACCCTGAG - 4300\n",
      "\n",
      "\n",
      "GATGGAGCTGATGGGCTGTGACCTGAACAGCTGCAGCATGCCCCTGGGCA - 4350\n",
      "\n",
      "\n",
      "TGGAGAGCAAGGCCATCTCTGATGCCCAGATCACTGCCAGCAGCTACTTC - 4400\n",
      "\n",
      "\n",
      "ACCAACATGTTTGCCACCTGGAGCCCCAGCAAGGCCAGGCTGCATCTGCA - 4450\n",
      "\n",
      "\n",
      "GGGCAGGAGCAATGCCTGGAGGCCCCAGGTCAACAACCCCAAGGAGTGGC - 4500\n",
      "\n",
      "\n",
      "TGCAGGTGGACTTCCAGAAGACCATGAAGGTGACTGGGGTGACCACCCAG - 4550\n",
      "\n",
      "\n",
      "GGGGTGAAGAGCCTGCTGACCAGCATGTATGTGAAGGAGTTCCTGATCAG - 4600\n",
      "\n",
      "\n",
      "CAGCAGCCAGGATGGCCACCAGTGGACCCTGTTCTTCCAGAATGGCAAGG - 4650\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "\n",
      "1        10        20        30        40        50\n",
      "\n",
      "\n",
      "|        |         |         |         |         |\n",
      "\n",
      "\n",
      "TGAAGGTGTTCCAGGGCAACCAGGACAGCTTCACCCCTGTGGTGAACAGC - 4700\n",
      "\n",
      "\n",
      "CTGGACCCCCCCCTGCTGACCAGATACCTGAGGATTCACCCCCAGAGCTG - 4750\n",
      "\n",
      "\n",
      "GGTGCACCAGATTGCCCTGAGGATGGAGGTGCTGGGCTGTGAGGCCCAGG - 4800\n",
      "\n",
      "\n",
      "ACCTGTACTGAGGATCCAATAAAATATCTTTATTTTCATTACATCTGTGT - 4850\n",
      "\n",
      "\n",
      "GTTGGTTTTTTGTGTGTTTTCCTGTAACGATCGGGCTCGAGCGC\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " In preferred embodiments, the constructs described herein comprise insulator (spacer) sequences as shown in FIGS. 1, 2, 4, 6, 7, 10, 19, 20, and 25. Exemplary insulator sequences include Ins1: 5′ GGAACCATTGCCACCTTCA (SEQ ID NO:28); Ins2: 5′ CTATCCATTGCACTATGCT (SEQ ID NO:29); Ins3: 5′ TTTCCTGTAACGATCGGG (SEQ ID NO:30) and Ins4: 5′ TTGAATTCATAACTATCCCAA (SEQ ID NO:38). As will be apparent, any transgene can be used in the constructs described herein. Furthermore, the individual components (promoter, enhancer, insulator, transgene, etc.) of the constructs described herein may be mixed and matched in any combination. The constructs described herein may be contained within any viral or non-viral vector. The constructs may be maintained episomally or may be integrated into the genome of the cell (e.g., via nuclease-mediated targeted integration). Non-viral vectors include DNA or RNA plasmids, DNA MCs, naked nucleic acid, and nucleic acid complexed with a delivery vehicle such as a liposome, nanoparticle or poloxamer. Viral vectors that may be used to carry the expression cassettes described herein include, but are not limited to, retroviral, lentivirus, adenoviral, adeno-associated viral vectors, vaccinia and herpes simplex virus vectors. Integration in the host genome is possible with the retrovirus, lentivirus, and adeno-associated virus gene transfer methods, and as described herein may be facilitated by nuclease-mediated integration. In certain preferred embodiments, the constructs are included in an adeno-associated virus (“AAV”) vector or vector system that may be maintained episomally or integrated into the genome of a liver cell (e.g., via nuclease-mediated targeted integration). Construction of recombinant AAV vectors is in a number of publications, including U.S. Pat. No. 5,173,414; Tratschin et al., Mol. Cell. Biol. 5:3251-3260 (1985); Tratschin, et al., Mol. Cell. Biol. 4:2072-2081 (1984); Hermonat & Muzyczka, PNAS 81:6466-6470 (1984); and Samulski et al., J. Virol. 63:03822-3828 (1989). Thus, in certain embodiments, the expression construct is carried on an AAV construct and further comprises 5′ and 3′ ITRs flanking the expression constructs elements (e.g., enhancer, promoter, optional intron, transgene, etc.) as described herein. Optionally, spacer molecules are also included between one or more of the components of the expression construct, for example, between the 5′ ITR and the enhancer and/or between the polyadenylation signal and the 3′ ITR. The spacers may function as homology arms to facilitate recombination into a safe-harbor locus (e.g. albumin). In certain embodiments, the construct is a construct as shown in any of FIG. 1, 2, 4, 6, 7, 10, 18, 19, 20 or 25. In certain embodiments, the AAV vectors as described herein can be derived from any AAV. In certain embodiments, the AAV vector is derived from the defective and nonpathogenic parvovirus adeno-associated type 2 virus. All such vectors are derived from a plasmid that retains only the AAV 145 bp inverted terminal repeats flanking the transgene expression cassette. Efficient gene transfer and stable transgene delivery due to integration into the genomes of the transduced cell are key features for this vector system. (Wagner et al., Lancet 351:9117 1702-3 (1998), Kearns et al., Gene Ther. 9:748-55 (1996)). Other AAV serotypes, including AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9 and AAVrh.10 and any novel AAV serotype can also be used in accordance with the present invention. In some embodiments, chimeric AAV is used where the viral origins of the LTR sequences of the viral nucleic acid are heterologous to the viral origin of the capsid sequences. Non-limiting examples include chimeric virus with LTRs derived from AAV2 and capsids derived from AAV5, AAV6, AAV8 or AAV9 (i.e. AAV2/5, AAV2/6, AAV2/8 and AAV2/9, respectively). Retroviral vectors include those based upon murine leukemia virus (MuLV), gibbon ape leukemia virus (GaLV), Simian Immunodeficiency virus (SIV), human immunodeficiency virus (HIV), and combinations thereof (see, e.g., Buchscher et al., J. Virol. 66:2731-2739 (1992); Johann et al., J Virol. 66:1635-1640 (1992); Sommerfelt et al., Virol. 176:58-59 (1990); Wilson et al., J. Virol. 63:2374-2378 (1989); Miller et al., J. Virol. 65:2220-2224 (1991); PCT/US94/05700). The constructs described herein may also be incorporated into an adenoviral vector system. Adenoviral based vectors are capable of very high transduction efficiency in many cell types and do not require cell division. With such vectors, high titer and high levels of expression have been obtained. This vector can be produced in large quantities in a relatively simple system. pLASN and MFG-S are examples of retroviral vectors that have been used in clinical trials (Dunbar et al., Blood 85:3048-305 (1995); Kohn et al., Nat. Med. 1:1017-102 (1995); Malech et al., PNAS 94:22 12133-12138 (1997)). PA317/pLASN was the first therapeutic vector used in a gene therapy trial. (Blaese et al., Science 270:475-480 (1995)). Transduction efficiencies of 50% or greater have been observed for MFG-S packaged vectors. (Ellem et al., Immunol Immunother. 44(1):10-20 (1997); Dranoff et al., Hum. Gene Ther. 1:111-2 (1997). Replication-deficient recombinant adenoviral vectors (Ad) can also be used with the polynucleotides described herein. Most adenovirus vectors are engineered such that a transgene replaces the Ad E1a, E1b, and/or E3 genes; subsequently the replication defective vector is propagated in human 293 cells that supply deleted gene function in trans. Ad vectors can transduce multiple types of tissues in vivo, including nondividing, differentiated cells such as those found in liver, kidney and muscle. Conventional Ad vectors have a large carrying capacity. An example of the use of an Ad vector in a clinical trial involved polynucleotide therapy for antitumor immunization with intramuscular injection (Sterman et al., Hum. Gene Ther. 7:1083-9 (1998)). Additional examples of the use of adenovirus vectors for gene transfer in clinical trials include Rosenecker et al., Infection 24:1 5-10 (1996); Sterman et al., Hum. Gene Ther. 9:7 1083-1089 (1998); Welsh et al., Hum. Gene Ther. 2:205-18 (1995); Alvarez et al., Hum. Gene Ther. 5:597-613 (1997); Topf et al., Gene Ther. 5:507-513 (1998); Sterman et al., Hum. Gene Ther. 7:1083-1089 (1998). Packaging cells are used to form virus particles that are capable of infecting a host cell. Such cells include HEK293 and Sf9 cells, which can be used to package AAV and adenovirus, and ψ2 cells or PA317 cells, which package retrovirus. Viral vectors used in gene therapy are usually generated by a producer cell line that packages a nucleic acid vector into a viral particle. The vectors typically contain the minimal viral sequences required for packaging and subsequent integration into a host (if applicable), other viral sequences being replaced by an expression cassette encoding the protein to be expressed. The missing viral functions are supplied in trans by the packaging cell line. For example, AAV vectors used in gene therapy typically only possess inverted terminal repeat (ITR) sequences from the AAV genome which are required for packaging and integration into the host genome. Viral DNA is packaged in a cell line, which contains a helper plasmid encoding the other AAV genes, namely rep and cap, but lacking ITR sequences. The cell line is also infected with adenovirus as a helper. The helper virus promotes replication of the AAV vector and expression of AAV genes from the helper plasmid. The helper plasmid is not packaged in significant amounts due to a lack of ITR sequences. Contamination with adenovirus can be reduced by, e.g., heat treatment to which adenovirus is more sensitive than AAV. In some embodiments, AAV is produced using a baculovirus expression system. In many gene therapy applications, it is desirable that the gene therapy vector be delivered with a high degree of specificity to a particular tissue type. Accordingly, a viral vector can be modified to have specificity for a given cell type by expressing a ligand as a fusion protein with a viral coat protein on the outer surface of the virus. The ligand is chosen to have affinity for a receptor known to be present on the cell type of interest. For example, Han et al., Proc. Natl. Acad. Sci. USA 92:9747-9751 (1995), reported that Moloney murine leukemia virus can be modified to express human heregulin fused to gp70, and the recombinant virus infects certain human breast cancer cells expressing human epidermal growth factor receptor. This principle can be extended to other virus-target cell pairs, in which the target cell expresses a receptor and the virus expresses a fusion protein comprising a ligand for the cell-surface receptor. For example, filamentous phage can be engineered to display antibody fragments (e.g., FAB or Fv) having specific binding affinity for virtually any chosen cellular receptor. Although the above description applies primarily to viral vectors, the same principles can be applied to nonviral vectors. Such vectors can be engineered to contain specific uptake sequences which favor uptake by specific target cells. The polynucleotides described herein may include one or more non-natural bases and/or backbones. In particular, an expression cassette as described herein may include methylated cytosines to achieve a state of transcriptional quiescence in a region of interest. Furthermore, the expression constructs as described herein may also include additional transcriptional or translational regulatory or other sequences, for example, Kozak sequences, additional promoters, enhancers, insulators, internal ribosome entry sites, sequences encoding 2A peptides, furin cleavage sites and/or polyadenylation signals. Further, the control elements of the genes of interest can be operably linked to reporter genes to create chimeric genes (e.g., reporter expression cassettes). Transgenes The constructs described herein can be used for hepatic delivery of any transgene. Exemplary transgenes (also referred to as genes of interest and/or exogenous sequences) include, but are not limited to any polypeptide coding sequence (e.g., cDNAs), promoter sequences, enhancer sequences, epitope tags, marker genes, cleavage enzyme recognition sites and various types of expression constructs. Marker genes include, but are not limited to, sequences encoding proteins that mediate antibiotic resistance (e.g., ampicillin resistance, neomycin resistance, G418 resistance, puromycin resistance), sequences encoding colored or fluorescent or luminescent proteins (e.g., green fluorescent protein, enhanced green fluorescent protein, red fluorescent protein, luciferase), and proteins which mediate enhanced cell growth and/or gene amplification (e.g., dihydrofolate reductase). Epitope tags include, for example, one or more copies of FLAG, His, myc, Tap, HA or any detectable amino acid sequence. In a preferred embodiment, the transgene comprises a polynucleotide encoding any polypeptide of which expression in the cell is desired, including, but not limited to antibodies, antigens, enzymes, receptors (cell surface or nuclear), hormones, lymphokines, cytokines, reporter polypeptides, growth factors, and functional fragments of any of the above. The coding sequences may be, for example, cDNAs. In certain embodiments, the transgene(s) encodes functional versions of proteins lacking of deficient in any genetic disease, including but not limited to, lysosomal storage disorders (e.g., Gaucher's, Fabry's, Hunter's, Hurler's, Neimann-Pick's, etc.), metabolic disorders, and/or blood disorders such as hemophilias and hemoglobinopathies, etc. See, e.g., U.S. Publication No. 20140017212 and 20140093913; U.S. Pat. Nos. 9,255,250 and 9,175,280. For example, the transgene may comprise a sequence encoding a polypeptide that is lacking or non-functional in the subject having a genetic disease, including but not limited to any of the following genetic diseases: achondroplasia, achromatopsia, acid maltase deficiency, adenosine deaminase deficiency (OMIM No. 102700), adrenoleukodystrophy, aicardi syndrome, alpha-1 antitrypsin deficiency, alpha-thalassemia, androgen insensitivity syndrome, apert syndrome, arrhythmogenic right ventricular, dysplasia, ataxia telangictasia, barth syndrome, beta-thalassemia, blue rubber bleb nevus syndrome, canavan disease, chronic granulomatous diseases (CGD), cri du chat syndrome, cystic fibrosis, dercum's disease, ectodermal dysplasia, fanconi anemia, fibrodysplasiaossificans progressive, fragile X syndrome, galactosemis, Gaucher's disease, generalized gangliosidoses (e.g., GM1), hemochromatosis, the hemoglobin C mutation in the 6th codon of beta-globin (HbC), hemophilia, Huntington's disease, Hurler Syndrome, hypophosphatasia, Klinefleter syndrome, Krabbes Disease, Langer-Giedion Syndrome, leukocyte adhesion deficiency (LAD, OMIM No. 116920), leukodystrophy, long QT syndrome, Marfan syndrome, Moebius syndrome, mucopolysaccharidosis (MPS), nail patella syndrome, nephrogenic diabetes insipdius, neurofibromatosis, Neimann-Pick disease, osteogenesisimperfecta, porphyria, Prader-Willi syndrome, progeria, Proteus syndrome, retinoblastoma, Rett syndrome, Rubinstein-Taybi syndrome, Sanfilippo syndrome, severe combined immunodeficiency (SCID), Shwachman syndrome, sickle cell disease (sickle cell anemia), Smith-Magenis syndrome, Stickler syndrome, Tay-Sachs disease, Thrombocytopenia Absent Radius (TAR) syndrome, Treacher Collins syndrome, trisomy, tuberous sclerosis, Turner's syndrome, urea cycle disorder, von Hippel-Landau disease, Waardenburg syndrome, Williams syndrome, Wilson's disease, Wiskott-Aldrich syndrome, X-linked lymphoproliferative syndrome (XLP, OMIM No. 308240), acquired immunodeficiencies, lysosomal storage diseases (e.g., Gaucher's disease, GM1, Fabry disease and Tay-Sachs disease), mucopolysaccahidosis (e.g. Hunter's disease, Hurler's disease), hemoglobinopathies (e.g., sickle cell diseases, HbC, α-thalassemia, β-thalassemia) and hemophilias. Non-limiting examples of proteins (including functional fragments thereof such as truncated versions) that may be expressed as described herein include fibrinogen, prothrombin, tissue factor, Factor V, Factor VII, Factor VIII, Factor IX, Factor X, Factor XI, Factor XII (Hageman factor), Factor XIII (fibrin-stabilizing factor), von Willebrand factor, prekallikrein, high molecular weight kininogen (Fitzgerald factor), fibronectin, antithrombin III, heparin cofactor II, protein C, protein S, protein Z, protein Z-related protease inhibitor, plasminogen, alpha 2-antiplasmin, tissue plasminogen activator, urokinase, plasminogen activator inhibitor-1, plasminogen activator inhibitor-2, glucocerebrosidase (GBA), α-galactosidase A (GLA), iduronate sulfatase (IDS), iduronidase (IDUA), acid sphingomyelinase (SMPD1), MMAA, MMAB, MMACHC, MMADHC (C2orf25), MTRR, LMBRD1, MTR, propionyl-CoA carboxylase (PCC) (PCCA and/or PCCB subunits), a glucose-6-phosphate transporter (G6PT) protein or glucose-6-phosphatase (G6Pase), an LDL receptor (LDLR), ApoB, LDLRAP-1, a PCSK9, a mitochondrial protein such as NAGS (N-acetylglutamate synthetase), CPS1 (carbamoyl phosphate synthetase I), and OTC (ornithine transcarbamylase), ASS (argininosuccinic acid synthetase), ASL (argininosuccinase acid lyase) and/or ARG1 (arginase), and/or a solute carrier family 25 (SLC25A13, an aspartate/glutamate carrier) protein, a UGT1A1 or UDP glucuronsyltransferase polypeptide A1, a fumarylacetoacetate hydrolyase (FAH), an alanine-glyoxylate aminotransferase (AGXT) protein, a glyoxylate reductase/hydroxypyruvate reductase (GRHPR) protein, a transthyretin gene (TTR) protein, an ATP7B protein, a phenylalanine hydroxylase (PAH) protein, a lipoprotein lyase (LPL) protein, an engineered nuclease, an engineered transcription factor and/or a therapeutic single chain antibody. In certain embodiments, the transgene can comprise a marker gene (described above), allowing selection of cells that have undergone targeted integration, and a linked sequence encoding an additional functionality. Non-limiting examples of marker genes include GFP, drug selection marker(s) and the like. The constructs described herein may also be used for delivery of non-coding transgenes. Sequences encoding antisense RNAs, RNAi, shRNAs and micro RNAs (miRNAs) may also be used for targeted insertions. In certain embodiments, the transgene includes sequences (e.g., coding sequences, also referred to as transgenes) greater than 1 kb in length, for example between 2 and 200 kb, between 2 and 10 kb (or any value therebetween). The transgene may also include one or more nuclease target sites. When integrated (e.g., via nuclease-mediate integration), the transgene may be inserted into an endogenous gene such that all, some or none of the endogenous gene is expressed. Nucleases As noted above, the expression cassettes may be maintained episomally or may be integrated into the genome of the cell. Integration may be random. Preferably, integration of the transgene construct(s) is targeted following cleavage of the target gene by one or more nucleases (e.g., zinc finger nucleases (“ZFNs”), TALENs, TtAgo, CRISPR/Cas nuclease systems, and homing endonucleases) and the construct integrated by either homology directed repair (HDR) or by end capture during non-homologous end joining (NHEJ) driven processes. See, e.g., U.S. Pat. Nos. 9,255,250; 9,200,266; 9,045,763; 9,005,973; 9,150,847; 8,956,828; 8,945,868; 8,703,489; 8,586,526; 6,534,261; 6,599,692; 6,503,717; 6,689,558; 7,067,317; 7,262,054; 7,888,121; 7,972,854; 7,914,796; 7,951,925; 8,110,379; 8,409,861; U.S. Patent Publications 20030232410; 20050208489; 20050026157; 20050064474; 20060063231; 20080159996; 201000218264; 20120017290; 20110265198; 20130137104; 20130122591; 20130177983; 20130196373 and 20150056705, the disclosures of which are incorporated by reference in their entireties for all purposes. Any nuclease can be used for targeted integration of the transgene expression construct. In certain embodiments, the nuclease comprises a zinc finger nuclease (ZFN), which comprises a zinc finger DNA-binding domain and a cleavage (nuclease) domain. See, e.g., U.S. Pat. Nos. 9,255,250; 9,200,266; 9,045,763; 9,005,973; 9,150,847; 8,956,828; 8,945,868; 8,703,489; 8,586,526; 6,534,261; 6,599,692; 6,503,717; 6,689,558; 7,067,317; 7,262,054; 7,888,121; 7,972,854; 7,914,796; 7,951,925; 8,110,379; 8,409,861. In other embodiments, the nuclease comprises a TALEN, which comprises a TAL-effector DNA binding domain and a cleavage (nuclease) domain. See, e.g., U.S. Pat. No. 8,586,526 and U.S. Publication No. 20130196373. In still further embodiments, the nuclease comprises a CRISPR/Cas nuclease system, which includes a single guide RNA for recognition of the target site and one or more cleavage domains. See, e.g., U.S. Patent Publication No. 20150056705. In some embodiments, the CRISPR-Cpf1 system is used (see Fagerlund et al, (2015) Genom Bio 16:251). It is understood that the term “CRISPR/Cas” system refers to both CRISPR/Cas and CRISPR/Cfp1 systems. The cleavage domains of the nucleases may be wild-type or mutated, including non-naturally occurring (engineered) cleavage domains that form obligate heterodimers. See, e.g., U.S. Pat. Nos. 8,623,618; 7,888,121; 7,914,796; and 8,034,598 and U.S. Publication No. 20110201055. The nuclease(s) may make one or more double-stranded and/or single-stranded cuts in the target site. In certain embodiments, the nuclease comprises a catalytically inactive cleavage domain (e.g., FokI and/or Cas protein). See, e.g., U.S. Pat. Nos. 9,200,266; 8,703,489 and Guillinger et al. (2014) Nature Biotech. 32(6):577-582. The catalytically inactive cleavage domain may, in combination with a catalytically active domain act as a nickase to make a single-stranded cut. Therefore, two nickases can be used in combination to make a double-stranded cut in a specific region. Additional nickases are also known in the art, for example, McCaffery et al. (2016) Nucleic Acids Res. 44(2):ell. doi: 10.1093/nar/gkv878. Epub 2015 Oct. 19. In certain embodiments, the nuclease cleaves a safe harbor gene (e.g., CCR5, Rosa, albumin, AAVS1, etc. See, e.g., U.S. Pat. Nos. 7,888,121; 7,972,854; 7,914,796; 7,951,925; 8,110,379; 8,409,861; 8,586,526; U.S. Patent Publications 20030232410; 20050208489; 20050026157; 20060063231; 20080159996; 201000218264; 20120017290; 20110265198; 20130137104; 20130122591; 20130177983 and 20130177960. In preferred embodiments, the nuclease cleaves an endogenous albumin gene such that the expression cassette is integrated into the endogenous albumin locus of a liver cell. Albumin-specific nucleases are described, for example, in U.S. Pat. No. 9,150,847; and U.S. Publication Nos. 20130177983 and 20150056705. Delivery The constructs described herein (and/or nucleases) may be delivered in vivo or ex vivo by any suitable means into any cell type, preferably to the liver (hepatic delivery). Similarly, when used in combination with nucleases for targeted integration, the nucleases may be delivered in polynucleotide and/or protein form, for example using non-viral vector(s), viral vectors(s) and/or in RNA form, e.g., as mRNA. Methods of non-viral delivery of nucleic acids include electroporation, lipofection, microinjection, biolistics, virosomes, liposomes, immunoliposomes, other nanoparticle, polycation or lipid:nucleic acid conjugates, naked DNA, artificial virions, and agent-enhanced uptake of DNA. Sonoporation using, e.g., the Sonitron 2000 system (Rich-Mar) can also be used for delivery of nucleic acids. Additional exemplary nucleic acid delivery systems include those provided by AmaxaBiosystems (Cologne, Germany), Maxcyte, Inc. (Rockville, Md.), BTX Molecular Delivery Systems (Holliston, Mass.) and Copernicus Therapeutics Inc., (see for example U.S. Pat. No. 6,008,336). In preferred embodiments, the expression constructs are AAV vectors. The optional nucleases may be administered in mRNA form or using one or more viral vectors (AAV, Ad, etc.). Administration can be by any means in which the polynucleotides are delivered to the desired target cells. Both in vivo and ex vivo methods are contemplated. Intravenous injection to the portal vein is a preferred method of administration. Other in vivo administration modes include, for example, direct injection into the lobes of the liver or the biliary duct and intravenous injection distal to the liver, including through the hepatic artery, direct injection in to the liver parenchyma, injection via the hepatic artery, and/or retrograde injection through the biliary tree. Ex vivo modes of administration include transduction in vitro of resected hepatocytes or other cells of the liver, followed by infusion of the transduced, resected hepatocytes back into the portal vasculature, liver parenchyma or biliary tree of the human patient, see e.g., Grossman et al., (1994) Nature Genetics, 6:335-341. In systems involving delivery of more than one polynucleotides (e.g., construct as described herein and nuclease in polynucleotide form), the two or more polynucleotide(s) are delivered using one or more of the same and/or different vectors. For example, the nuclease in polynucleotide form may be delivered in mRNA form and the liver-specific constructs as described herein may be delivered via other modalities such as viral vectors (e.g., AAV), minicircle DNA, plasmid DNA, linear DNA, liposomes, nanoparticles and the like. Pharmaceutically acceptable carriers are determined in part by the particular composition being administered, as well as by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable formulations of pharmaceutical compositions available, as described below (see, e.g., Remington's Pharmaceutical Sciences, 17th ed., 1989). The effective amount of expression cassette (and optional nuclease(s), and/or modified cells) to be administered will vary from patient to patient. Accordingly, effective amounts are best determined by the physician administering the compositions (e.g., cells) and appropriate dosages can be determined readily by one of ordinary skill in the art. Analysis of the serum, plasma or other tissue levels of the therapeutic polypeptide and comparison to the initial level prior to administration can determine whether the amount being administered is too low, within the right range or too high. Suitable regimes for initial and subsequent administrations are also variable, but are typified by an initial administration followed by subsequent administrations if necessary. Subsequent administrations may be administered at variable intervals, ranging from daily to annually to every several years. One of skill in the art will appreciate that appropriate immunosuppressive techniques may be recommended to avoid inhibition or blockage of transduction by immunosuppression of the delivery vectors, see e.g., Vilquin et al., (1995) Human Gene Ther., 6:1391-1401. Formulations for both ex vivo and in vivo administrations include suspensions (e.g., of genetically modified cells, liposomes or nanoparticles) in liquid or emulsified liquids. The active ingredients often are mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients include, for example, water, saline, dextrose, glycerol, ethanol or the like, and combinations thereof. In addition, the composition may contain minor amounts of auxiliary substances, such as, wetting or emulsifying agents, pH buffering agents, stabilizing agents or other reagents that enhance the effectiveness of the pharmaceutical composition. Applications The methods and compositions disclosed herein are for providing therapies for any disease by provision of a transgene that expresses a product that is lacking or deficient in the disease or otherwise treats or prevents the disease. The cell may be modified in vivo or may be modified ex vivo and subsequently administered to a subject. Thus, the methods and compositions provide for the treatment and/or prevention of such genetic diseases. The following Examples include exemplary embodiments of the present disclosure in which the optionally used nuclease comprises a zinc finger nuclease (ZFN). It will be appreciated that this is for purposes of exemplification only and that other nucleases can be used, for example TALENs, CRISPR/Cas systems, homing endonucleases (meganucleases) with engineered DNA-binding domains and/or fusions of naturally occurring of engineered homing endonucleases (meganucleases) DNA-binding domains and heterologous cleavage domains and/or fusions of meganucleases and TALE proteins. In addition, it will be appreciated that expression constructs as described herein can be carried on other vectors (other than AAV) to produce the same results in the treatment and/or prevention of disorders caused by deficient protein production. Examples Example 1: Methods DNA Constructs The overall structure and approach followed for the development of exemplary constructs carrying the human Factor VIII cDNA is depicted in FIG. 1. The constructs include a liver-specific enhancer, liver-specific promoter, an optional intron, insulator sequences and a transgene (e.g., codon-optimized human Factor VIII B-domain deleted transgene), synthetic poly adenylation sequence, spacers and 5′/3′ inverted terminal repeats. All constructs were assembled using routine molecular biology cloning methods. As shown in FIG. 1, several steps were followed during the vector development. We initially examined the effect of the construct components on the viral yield obtained during manufacturing. The influence of the sequence of the insulator regions in the constructs was explored by using three difference potential insulator sequences, as shown: Ins 1: 5′ GGAACCATTGCCACCTTCA (SEQ ID NO:28), Ins2: 5′ CTATCCATTGCACTATGCT (SEQ ID NO:29), and Ins3: 5′ TTTCCTGTAACGATCGGG (SEQ ID NO:30). The insulator regions were then inserted into the transgene expression cassette where the insulator used between the 5′ ITR sequence and the beginning of the enhancer/promoter sequence was always Ins1. However, the at the 3′ end of the construct, either Ins2 or Ins3 sequences were linked to the SPA51 synthetic poly A sequence (5′ AATAAAATATCTTTATTTTCATTACATCTGTGTGTTGGTTTTTTGTGTGTT, SEQ ID NO:31) as follows: Ins2-SPA51: 5′ ATAAAATATCTTTATTTTCATTACATCTGTGTGTTGGTTTTTTGTGTGTTCTAT CCATTGCACTATGCT, SEQ ID NO:32, and Ins3-SPA51: 5′ AATAAAATATCTTTATTTTCATTACATCTGTGTGTTGGTTTTTTGTGTGTTTTC CTGTAACGATCGGG, SEQ ID NO:33. In some embodiments, Ins4 is linked to the SPA51. The Ins sequence variants were also used in expression constructs where the SerpE-TTRm-MVM promoter region was replaced with a hybrid liver promoter (HLP, McIntosh et al, ibid). These constructs are illustrated in FIG. 2. These constructs were then packaged into AAV2/6 particles using HEK293 cells where the yields are from 2 cell factories (Yuan et al., (2011) Hum Gene Ther., 22, 613-624, 2011).The yield (vector genomes) for the constructs containing the modified insulator sequences were found nearly three logs higher for the construct comprising the parent promoter region where the expression cassette was flanked by the Ins1 and Ins3 insulator regions at the 5′ and 3′ ends, respectively (FIG. 3). In addition, these insulator sequences were also inserted into the modified CRMSBS1 and CRMSBS2 constructs described below in step 2 (FIGS. 19 and 20), and tested for viral yield (FIG. 22). The data showed a 8-10 fold improvement in viral yield for the new construct as compared to the parent construct. In step 2, point mutations were introduced in the Serpin 1 enhancer to create the first two derivative vectors CRMSBS1 and CRMSBS2 (FIG. 4). These vectors differ in their enhancer sequences where point mutations were introduced as shown in FIG. 5. The specific changes made are the following: for CRMSBS1, denoted as 1, 2, 3, and 4 as depicted in FIG. 5 the following substitutions were made, respectively: 1=G to A, 2=C to G, 3=T to C and 4=G to A. Similarly, for CRMSBS2, positions 1, 3, 4 and 5 were modified as follows: 1=G to A, 3=T to C, 4=G to A and 5=C to T. In step 3, constructs were made to investigate the intron sequence in the vector. As shown in FIGS. 6 and 7, the intron sequences in the CRMSBS2 and CRMSBS2 vectors were modified by removing the MVM intron (“CRMSBS1 No intron”, FIG. 6, and “CRMSBS2 No intron”, FIG. 7). In another variant, a T-chimeric intron sequence was tested (“CRMSBS1 T-chimeric intron”, FIG. 6, and “CRMSBS2 T-chimeric intron”, FIG. 7). For step 4, changes were made to the MVM intron through the introduction of mutations aimed at the splice donor and acceptor sites. The maps of these vectors are shown in FIG. 10, where the altered introns are referred to as SBR Intron 1-3. The MVM intron has two potential donor sites and two potential acceptor sites of those donors (see FIG. 11 for an illustration). In FIG. 11, the two donor sites are denoted with D1 and D2, and their corresponding acceptor sites are shown as A1 and A2. The splice junctions made by the splice of D1-A1 and D2-A2 are shown above the gene as dotted lines. A partial sequence of the MVM intron is shown below the gene in FIG. 11 (SEQ ID NO:14) and the location (underlined) of the intronic enhancer sequence (IES) is indicated as well as the sites of the A1 and A2 acceptors (Haut and Pintel, (1998) J Virol, 72:1834-1843; Haut and Pintel, (1998) Virol J, 258:84-94). Three introns were constructed for testing, and these are illustrated in FIG. 10, and are denoted SBR Intron 1-3 (intron sequences shown in SEQ ID NOs:15-17). Activity of the expressed hFVIII delivered by AAV F8 cDNA was also evaluated in vitro. AAV2/6 F8 cDNA (CRMSBS2 SBR Intron 3) was added to HepG2 cells at doses of 4.8E+06, 2.4E+06, 1.2E+06 and 0.6E+06 vector genomes/mL per 1E+05 cells in a 24-well dish (denoted as time, t0 days). Supernatants were analyzed for secreted hFVIII levels by ELISA, and activity by the APTT clotting assay and the Chromogenic activity assay at seven days (t7) post-AAV2/6 virus addition (for methods, see below). Results (FIG. 21) demonstrated good correlation between secreted hFVIII levels and activity. Data shown are of n=6 biological replicates. Error bars represent the standard error of the mean of replicates. These constructs were then tested in vivo as described below. Quantitative PCR qRT-PCR (for Human Factor VIII mRNA Levels): Mouse tissue was lysed using FastPrep and Lysing Matrix D (MP Biomedicals, Santa Ana Calif.) per the manufacturer's instructions. RNA/DNA was isolated from mouse tissue using AllPrep DNA/RNA kit per the manufacturer's instructions (Qiagen, Carlsbad Calif.). Extracted RNA was then used to make cDNA using Quantitect cDNA synthesis kit (Qiagen, Carlsbad Calif.). Quantitative PCR was then carried out using SsoAdvanced Universal Probes Supermix (Biorad, Hercules Calif.) on the Biorad CFX 96 using labelled primer/probe assays from IDT (Coralville Iowa). The mouse GAPDH assay was Mm.PT.39a.1. For the specific detection of human Factor VIII mRNA the primer/probe assay was custom; Forward primer (GGAGATGAAGAAGGAGGACTTTG) (SEQ ID NO:18), probe (ACATCTACGACGAGGACGAGAACCA) (SEQ ID NO:19) and Reverse primer (TCCACAGCAGCAATGAAGTAG) (SEQ ID NO:20). Quantitative qRT-PCR (not absolute) was used with normalization to GAPDH for each sample, and final data analyses was reported as relative to one mouse sample which was set to 1.0. No template control and no reverse transcriptase controls were run with all samples and produced no detectable signal. qPCR (for Vector Genome, VG, Analyses): Mouse tissue was lysed using FastPrep and Lysing Matrix D (MP Biomedicals, Santa Ana Calif.) per the manufacturer's instructions. RNA/DNA was isolated from mouse tissue using AllPrep DNA/RNA kit per the manufacturer's instructions (Qiagen, Carlsbad Calif.). Extracted DNA was used for quantitative PCR with TaqMan Fast Universal PCR Master Mix, No AmpErase UNG (Applied Biosystems, Foster City, Calif.) on the AB 7300 real-time PCR system (Applied Biosystems, Foster City, Calif.). For the specific detection of human Factor VIII the primer/probe assay was custom; forward primer (CCTGGGCCAGTTCCTGCT) (SEQ ID NO:21), probe (TTCTGCCACATCAGCAGCCACCA) (SEQ ID NO:22) and reverse primer (GGCCTCCATGCCATCATG) (SEQ ID NO:23). No-template controls were run with all samples and produced no detectable signal. The qPCR DNA standard curve was generated from seven, serial 4-fold dilutions of a known amount of purified, linearized human Factor VIII plasmid. qPCR (for Targeted Integration by NHEJ Using HepG2 Cells)— DNA was isolated from human HepG2 cells using QIAamp DNA micro per the manufacturer's instructions (Qiagen, Carlsbad Calif.). Quantitative PCR was then carried out using SsoAdvanced Univesal Probes Supermix (Biorad, Hercules Calif.) on the Biorad CFX 96 using labelled primer/probe assays from IDT (Coralville Iowa). The human GAPDH assay was Hs.PT.39a.22214836. For the specific detection of targeted integration of human Factor VIII by NHEJ at the endogenous human albumin locus the primer/probe assay was custom; Forward primer (AGTGCAAAGTAACTTAGAGTGACT) (SEQ ID NO:24), probe (CCATCACTAGGGGTTCCTGCGGCCT) (SEQ ID NO:25) and Reverse primer (CCTGAAGGTGGCAATGGT) (SEQ ID NO:26). For the purposes of this study we used quantitative qPCR (not absolute) with normalization to GAPDH for each sample, and final data analyses reported as relative to one sample which was set to 1.0. No template control, no transcriptase control and no ZFN controls were run and produced no detectable signal. qPCR (for Targeted Integration by NHEJ and HDR from Mouse Tissues)— Mouse tissue was lysed using FastPrep and Lysing Matrix D (MP Biomedicals, Santa Ana Calif.) per the manufacturer's instructions. RNA/DNA was isolated from mouse tissue using AllPrep DNA/RNA kit per the manufacturer's instructions (Qiagen, Carlsbad Calif.). Quantitative PCR was then carried out using SsoAdvanced Universal Probes Supermix (Biorad, Hercules Calif.) on the Biorad CFX 96 using labelled primer/probe assays from IDT (Coralville Iowa). The mouse GAPDH assay was Mm.PT.39a. 1. For the specific detection of targeted integration of human Factor 8 cDNA by NHEJ at the endogenous mouse albumin locus the primer/probe assay was custom; Forward primer (GTGTAGCAGAGAGGAACCATT, SEQ ID NO:39), probe (CCATCACTAGGGGTTCCTGCGGCCT, SEQ ID NO:40) and Reverse primer (GTTAATATTCACCAGCAGCCT, SEQ ID NO:41). For the specific detection of targeted integration of ZFNs by NHEJ at the endogenous mouse albumin locus the primer/probe assay was custom; Forward primer (AGTGTAGCAGAGAGGAACCA, SEQ ID NO:42), probe (CCATCACTAGGGGTTCCTGCGGCCT, SEQ ID NO:43) and Reverse primer (CAGGGTGAGCCCAGAAAC, SEQ ID NO:44). For the specific detection of targeted integration of human Factor 8 by HDR at the endogenous mouse albumin locus the primer/probe assay was custom; Forward primer (AACTTTGAGTGTAGCAGAGAGG, SEQ ID NO:45), probe (TACCGGAGGAGCAAACAGGGACTA, SEQ ID NO:46) and Reverse primer (CTCTACGAAATGTGCAGACAGA, SEQ ID NO:47). For the purposes of this study we used quantitative qPCR (not absolute) with final data analyses reported as relative to one sample which was set to 1.0. No template control, no transcriptase control and no ZFN controls were run and produced no detectable signal. Indel (Insertions and Deletions)— Mouse tissue was lysed using FastPrep and Lysing Matrix D (MP Biomedicals, Santa Ana Calif.) per the manufacturer's instructions. RNA/DNA was isolated from mouse tissue using AllPrep DNA/RNA kit per the manufacturer's instructions (Qiagen, Carlsbad Calif.). Extracted DNA was used for PCR and deep sequencing to measure indels at the mouse albumin locus. Plasma— Blood was collected from all mice on Days 7, 14, 21 (non-terminal) and Day 28, or longer as noted (terminal) for the C57BL/6 studies. Blood was collected from all mice on Days 8, 14, 21, 28, 35 and 42 (non-terminal) for the Hemophilia A mouse studies. All blood was collected into tubes containing sodium citrate and processed to plasma. Non-terminal blood collections were collected via the submandibular vein or the retro-orbital sinus. Blood collections at the time of sacrifice were collected via cardiac puncture or vena cava. The plasma was separated and stored at −60 to −80° C. until use in the ELISA assay or Chromogenix Coamatic activity assay described below. Liver— For the C57BL/6 studies, mice were sacrificed at Day 28 and the liver, spleen, testes, brain, heart, lung and kidneys were collected and weighed. The left lateral lobe of the liver was separated and divided into 3 pieces and snap frozen in liquid nitrogen separately from the rest of the liver. The remaining liver lobes and other tissues (whole) were snap frozen in liquid nitrogen. Frozen specimens were stored at −60 to −80° C. until processing for RNA/DNA extraction. In Vitro Studies, HepG2 AAV F8 cDNA/ZFNs. Human HepG2 liver cells were maintained per manufacturer's guidelines (ATCC, Manassas Va.). On the day of the experiment, HepG2 cells were washed, trypsinized and counted. ZFNs used were to the human albumin intron locus, left SBS47171 and right SBS47898. ZFNs, together with the hF8 cDNA (CRMSBS2 No Intron) were delivered as AAV2/6, denoted as time zero. AAV2/6 ZFNs were delivered at 3.0E+05, and AAV2/6 hFVIII cDNA CRMSBS2 No Intron at 3.0E+04, 6.0E+04 and 1.2E+05for 1E+05 cells per well of a 24-well dish. The following day media was exchanged. Supernatants were analyzed for secreted hFVIII using the hFVIII ELISAs described below at time points t3, t5 and t7 days post-AAV2/6 virus addition. In Vitro Studies, HepG2 AAV F8 cDNA. Human HepG2 liver cells were maintained per manufacturer's guidelines (ATCC, Manassas Va.). On the day of the experiment, HepG2 cells were washed, trypsinized and counted. AAV2/6 hF8 cDNA (CRMSBS2 SBR Intron 3) was delivered at doses of 6.0E+06, 1.2E+06, 2.4E+06 and 4.8E+06 per 1E+05 cells in a well of a 24-well dish. Media was exchanged at time point t3 (t=day). Supernatants at time points t5 and t7 post-AAV 2/6 virus addition were analyzed for secreted hFVIII levels using the hFVIII ELISA from Affinity Biologics, and for hFVIII activity by the Chromogenic and Clotting Assays described below. Human Factor VIII ELISA. Affinity Biologics hFVIII ELISA (Mouse and HepG2 Cells). Secreted human Factor VIII levels were determined using Affinity Biologicals (Canada) ELISA kit (FVIII-AG) according to the manufacture's protocol with the exception of the human Factor VIII standard. The human Factor VIII standard used in the ELISA assay was a recombinant purified human Factor VIII (#F0016-06) from US Biologicals (Salem, Mass.). Briefly mouse plasma was added to the plate, incubated with rocking at room temperature for one and a half hours, followed by washing three times with wash buffer provided in the kit. Detecting antibody, provided with the kit, was added and incubated for forty five minutes at room temperature, followed by washing three times with wash buffer provided in the kit. TMB substrate provided with kit was added and allowed to develop for ten minutes. The reaction was stopped with stop solution and absorbance read at 450 nM using a plate reader. In-House hFVIII ELISA (Cynomolgus Monkey). Levels of hFVIII secreted into NHP plasma were determined using a custom ELISA. Polystyrene microplates (Corning, 96-well half-area high binding) were coated overnight at 4° C. with mouse monoclonal anti-hFVIII antibody (Green Mountain, Burlington, Vt.) in 0.2 M carbonate bicarbonate buffer pH 9.4 (Thermo Fisher Scientific, Waltham Mass.). The following day the plates were washed four times using 1×TBST (Thermo Fisher Scientific, Waltham Mass.). 96-well plates were then blocked two hours at room temperature using 3% BSA/TBS blocking buffer, followed by washing four times with 1×TBST. Plasma was added to the plate and incubated with rocking at room temperature for two hours, followed by washing four times with 1×TBST. Detection antibody, biotinylated monoclonal mouse anti-FVIII antibody (Green Mountain, Burlington, Vt.) was added and incubated for one hour at room temperature, followed by washing four times with 1×TBST. Streptavidin HRP (Jackson ImmunoResearch, West Grove Pa.) was added and incubated for one hour at room temperature followed by washing four times with 1×TBST. TMB Ultra (Thermo Fisher Scientific, Waltham Mass.) was added and allowed to develop for ten minutes, reaction was stopped with stop solution and absorbance read at 450 nM using a plate reader. Background absorbance readings were negligible (typically 0). Chromogenic Human Factor VIII Activity Assay. Activity of secreted human Factor VIII in plasma was determined using the Diapharma Chromogenic Coamatic Factor VIII assay (West Chester, Ohio) according to the manufacture's protocol with the exception of the human Factor VIII standard. The human Factor VIII standard used in the ELISA assay was a recombinant purified human Factor VIII (#F0016-06) from US Biologicals (Salem, Mass.). Clotting Activity Assay Activity of secreted human Factor VIII in HepG2 supernatant (or Cynomolgus monkey plasma) was determined using the activated partial thromboplastin time (aPTT) assay by Diagnostica Stago (Boston Mass.) according to the manufacture's protocol with the exception of the human Factor VIII standard and human Factor VIII-deficient plasma. The human Factor VIII standard was the same as used in the ELISA assay (recombinant purified human Factor VIII, #F0016-06 from US Biologicals, Salem, Mass.). The deficient FVIII reagent used in the clotting assay was FVIII-CD<1% FVIII Activity (frozen deficient FVIII) from Haematologic Technologies, Inc. (Essex Junction, Vt.). Briefly, standard or sample was added to cuvettes containing a steel ball. FVIII-CD<1% FVIII Activity and PTT Automate provided with the kit were added, incubated at 37° C. for one hundred eighty seconds. STA CaCl2 provided with the kit was added to reaction while the steel ball went into motion within the cuvette. Clotting time was measured from the addition for STA CaCl2 until the movement of the steel ball has stopped. Incubation and recording of time was done using the Stago Start Hemostasis Analyzer for this assay. Example 2: In Vivo Studies Wild Type Mice: Eight to ten week old C57BL/6 mice were used for the in vivo studies. The study complied with the animal welfare act for humane care and use of animals. Test articles (AAV virus containing constructs) were thawed at room temperature prior to dosing, and all animals received a single intravenous (IV) 2004, injection. Table 1 below shows the study design for the testing of the constructs studied in vivo in FIG. 8 (mapped in FIGS. 4, 6 and 7). Table 2 shows the study design for the testing of the constructs outlined in FIG. 15. Doses were 1.8E+11 vg per mouse which was approximately 7E+12 vg/kg. All animals received a follow-up 200 μL intraperitoneal injection of cyclophosphamide on Days 0 and 14. Non-terminal and terminal blood collections were done as outlined in Tables 1 and 2. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "TABLE 1\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Study design for constructs from FIGS. 4, 6 and 7 (results in FIG. 8)\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "N/Time point for\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Immune\n",
      "\n",
      "Total Volume/\n",
      "serial bleed (day)\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Group\n",
      "Test article Description\n",
      "Serotype\n",
      "Supp.\n",
      "Dose\n",
      "mouse (μL)\n",
      "7\n",
      "14\n",
      "21\n",
      "28\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "1\n",
      "Formulation\n",
      "NA\n",
      "50 mg/kg\n",
      "NA\n",
      "200\n",
      "6\n",
      "6\n",
      "6\n",
      "6\n",
      "6\n",
      "\n",
      "\n",
      "2\n",
      "Parent\n",
      "AAV2/6\n",
      "50 mg/kg\n",
      "1.80E+11\n",
      "200\n",
      "6\n",
      "6\n",
      "6\n",
      "6\n",
      "6\n",
      "\n",
      "\n",
      "3\n",
      "CRMSBS1\n",
      "AAV2/6\n",
      "50 mg/kg\n",
      "1.80E+11\n",
      "200\n",
      "6\n",
      "6\n",
      "6\n",
      "6\n",
      "6\n",
      "\n",
      "\n",
      "4\n",
      "CRMSBS1 No Intron\n",
      "AAV2/6\n",
      "50 mg/kg\n",
      "1.80E+11\n",
      "200\n",
      "6\n",
      "6\n",
      "6\n",
      "6\n",
      "6\n",
      "\n",
      "\n",
      "5\n",
      "CRMSBS1 T-Chimeric\n",
      "AAV2/6\n",
      "50 mg/kg\n",
      "1.80E+11\n",
      "200\n",
      "6\n",
      "6\n",
      "6\n",
      "6\n",
      "6\n",
      "\n",
      "\n",
      "\n",
      "Intron\n",
      "\n",
      "\n",
      "6\n",
      "CRMSBS2\n",
      "AAV2/6\n",
      "50 mg/kg\n",
      "1.80E+11\n",
      "200\n",
      "6\n",
      "6\n",
      "6\n",
      "6\n",
      "6\n",
      "\n",
      "\n",
      "7\n",
      "CRMSBS2 No Intron\n",
      "AAV2/6\n",
      "50 mg/kg\n",
      "1.80E+11\n",
      "200\n",
      "6\n",
      "6\n",
      "6\n",
      "6\n",
      "6\n",
      "\n",
      "\n",
      "8\n",
      "CRMSBS2 T-Chimeric\n",
      "AAV2/6\n",
      "50 mg/kg\n",
      "1.80E+11\n",
      "200\n",
      "6\n",
      "6\n",
      "6\n",
      "6\n",
      "6\n",
      "\n",
      "\n",
      "\n",
      "Intron\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "48\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "TABLE 2\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Study design for constructs from FIG. 15\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "N/Time point for\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Immune\n",
      "\n",
      "Total Volume/\n",
      "serial bleed (day)\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Group\n",
      "Test article Description\n",
      "Serotype\n",
      "Supp.\n",
      "Dose\n",
      "mouse (μL)\n",
      "7\n",
      "14\n",
      "21\n",
      "28\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "1\n",
      "Formulation\n",
      "NA\n",
      "50 mg/kg\n",
      "NA\n",
      "200\n",
      "4\n",
      "4\n",
      "4\n",
      "4\n",
      "4\n",
      "\n",
      "\n",
      "2\n",
      "Parent\n",
      "AAV2/6\n",
      "50 mg/kg\n",
      "1.80E+11\n",
      "200\n",
      "4\n",
      "4\n",
      "4\n",
      "4\n",
      "4\n",
      "\n",
      "\n",
      "3\n",
      "CRMSBS2\n",
      "AAV2/6\n",
      "50 mg/kg\n",
      "1.80E+11\n",
      "200\n",
      "4\n",
      "4\n",
      "4\n",
      "4\n",
      "4\n",
      "\n",
      "\n",
      "4\n",
      "CRMSBS2 SBR Intron 1\n",
      "AAV2/6\n",
      "50 mg/kg\n",
      "1.80E+11\n",
      "200\n",
      "4\n",
      "4\n",
      "4\n",
      "4\n",
      "4\n",
      "\n",
      "\n",
      "5\n",
      "CRMSBS2 SBR Intron 2\n",
      "AAV2/6\n",
      "50 mg/kg\n",
      "1.80E+11\n",
      "200\n",
      "4\n",
      "4\n",
      "4\n",
      "4\n",
      "4\n",
      "\n",
      "\n",
      "6\n",
      "CRMSBS2 SBR Intron 3\n",
      "AAV2/6\n",
      "50 mg/kg\n",
      "1.80E+11\n",
      "200\n",
      "4\n",
      "4\n",
      "4\n",
      "4\n",
      "4\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "24\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " Blood was collected from all mice on Days 7, 14, 21 (non-terminal) and Day 28 (terminal). All blood was collected into tubes containing sodium citrate and processed to plasma. Non-terminal blood collections were collected via the submandibular vein or the retro-orbital sinus. Blood collections at the time of sacrifice were collected via cardiac puncture or vena cava. The plasma was separated and stored at −60 to −80° C. until use in the ELISA assay described below. All animals were sacrificed at Day 28 and the liver, spleen, testes, brain, heart, lung and kidneys were collected and weighed. The left lateral lobe of the liver was separated and divided into 3 pieces and snap frozen in liquid nitrogen separately from the rest of the liver. The remaining liver lobes and other tissues (whole) were snap frozen in liquid nitrogen. Frozen specimens were stored at −60 to −80° C. until processing for RNA/DNA extraction. As shown in FIGS. 8 and 15, all constructs tested resulted in in vivo production of the transgene (human secreted Factor VIII B-domain deleted) in vivo at Day 7 (FIG. 8A and FIG. 15A) and Day 28 (FIG. 8B and FIG. 15B) after administration. Furthermore, as shown in FIGS. 9 and 16, the transgene was expressed only in liver and no other tissues (FIGS. 9A and 16A) and the AAV vector transduces primarily liver cells (vector genome biodistribution analysis as shown in FIGS. 9B and 16B). In these datasets, human factor VIII-BDD (hFVIII-BDD) mRNA was analyzed from tissues (brain, heart, kidney, lung, liver, spleen, testes) in the study represented in Table 1 by qRT-PCR as described above in Example 1. Additionally, vector genome distribution was analyzed in these same tissues by qPCR (see Example 1) and the results are shown in FIGS. 9B/16B. These data demonstrate that the AAV2/6 vector primarily transduce the liver. The constructs designed to examine the efficacy of intron modifications were tested in vivo as well in a study outlined in Table 2, and the data for days 7 and at peak levels are shown in FIG. 15. hFVIII-BDD mRNA was also analyzed (FIG. 16A) as was vector genome distribution (FIG. 16B) and showed that hF8 mRNA expression was liver specific, and AAV2/6 primarily transduces liver. Thus, the constructs described herein provide for robust transgene expression following hepatic delivery. An additional study was carried out to test if the levels of hFVIII-BDD observed in vivo were sensitive to the serotype of the AAV being used. Male C57BL/6 mice were intravenously injected with 6E+10 vg/mouse (˜2E+12 vg/kg) or 1.8E+11 vg/mouse (˜7E+12 vg/kg) of the AAV2/5, AAV2/6, AAV2/8 or AAV2/9 F8 parent cDNA. Transducing mice with serotype AAV2/6, known to be inefficient at transducing mouse liver, at 6E+10 vg/mouse (˜2E+12 vg/kg) mean peak value of 91.9%+/−15.5 SEM (n=6) of normal hFVIII plasma levels in humans was achieved. At a higher dose representing ˜7E+12 vg/kg mean peak value of hFVIII plasma over six independent in vivo mouse studies of 169.2%+/−10.1 SEM (n=36) was achieved. Mean peak levels for AAV2/8 at 2E+12 vg/kg were 320% and 323.6% at 6E+12 vg/kg. For AAV2/9 at 2E+12 vg/kg mean peak levels were 389.6% (see FIG. 23, also showing results using AAV2/5 and AAV2/6). Studies were also conducted to determine if the production method used to generate the AAV had an impact on the hFVIII-BDD expression achieved in vivo. Male C57BL/6 mice were administered parent F8 parent cDNA via IV injection (tail vein) with 1.8E+11 vg/mouse (˜7E+12 vg/kg) of the AAV2/6 F8 parent cDNA produced from either HEK293 cells or Sf9/rBV (recombinant baculovirus). Treatment with F8 parent cDNA from HEK293 cells achieved a mean peak value of 142.1%±8.3% SEM (n=8)(measured by hFVIII ELISA) of normal human FVIII plasma levels. A similar level of 132.8%±18.6% SEM (n=5) (measured by hFVIII ELISA) was achieved following administration of F8 parent cDNA (Sf9/rBV) to mice (FIG. 24). The studies were repeated for comparison purposes with the F8 CRMSBS2 SBR Intron 3 cDNA (see FIG. 10). Male C57BL/6 mice were intravenously injected with 1.8E+11 vg/mouse (˜6E+12 vg/kg) of AAV2/6 CRMSBS2 SBR Intron 3 cDNA (n=8). Shown are mean peak levels of hFVIII in the plasma of C57BL/6 mice as measured by hFVIII ELISA (FIG. 25). Hemophilia A Mice: The constructs were also tested in the R593A mouse model of Hemophilia A (Bril et al (2006) Thromb Haemost 95(2):341-7; Chavez et al., (2012) Hum Gen Ther 23(4):390). These mice carry a knock out of the endogenous murine F8 gene. In addition, they carry a mutant human FVIII-R593C transgene under the control of a murine albumin promoter such that they express undetectable amounts of the mutant human protein but are thought to be tolerant to human FVIII expression because of the trace amounts of mutant FVIII R593A protein produced. The original strain was FVB but has been back-crossed to C57BL/6 mice for at least 5 generations at Jackson Laboratory. The study complied with the animal welfare act for humane care and use of animals. Test articles were thawed at room temperature prior to dosing, and all animals received a single intravenous (IV) 200 μL injection. Doses were 1.8E+11 vg per mouse which was approximately 7E+12 vg/kg. The study design is shown below in Table 3: \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "TABLE 3\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "CRMSBS2 SBR Intron 3 in Hemophilia A mutant mice\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Test Article\n",
      "Immune\n",
      "\n",
      "Total Volume/\n",
      "Time point for serial bleed (days)\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Group\n",
      "Description\n",
      "Serotype\n",
      "Supp.\n",
      "Dose\n",
      "mouse (μL)\n",
      "8\n",
      "14\n",
      "21\n",
      "28\n",
      "35\n",
      "42\n",
      "Sac\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "1\n",
      "Formulation\n",
      "NA\n",
      "N/A\n",
      "N/A\n",
      "200\n",
      "6\n",
      "6\n",
      "6\n",
      "6\n",
      "6\n",
      "6\n",
      "6\n",
      "\n",
      "\n",
      "\n",
      "buffer\n",
      "\n",
      "\n",
      "2\n",
      "CRMSBS2 SBR\n",
      "AAV2/6\n",
      "N/A\n",
      "1.80E+11\n",
      "200\n",
      "6\n",
      "6\n",
      "6\n",
      "6\n",
      "6\n",
      "6\n",
      "6\n",
      "\n",
      "\n",
      "\n",
      "Intron 3\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "12\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " The study was carried out for three months, representative results of the three month study are shown, both a day 14 and at day 42 results (FIG. 17) show that the FVIII-BDD transgene was expressed at levels >300% of the levels of FVIII protein found in normal human plasma at both days 14 (FIG. 17A) and 42 (FIG. 17B). To test functionality and therapeutic efficacy of the hFVIII in the mouse Hemophilia A model, a tail vein transection (TVT) model was used. In brief, mice were initially anaesthetized with isoflurane, and anesthesia was maintained via an anesthesia mask for the study duration. Immediately following anesthesia induction, the mice were placed on a heating pad (set to 37° C.) with the temperature sensor between the stomach and the heating pad ensuring the head was positioned properly in the anesthesia mask. Using a marker block for measurement, the tail was marked with a marker pen at “12 o'clock” corresponding to exactly 2.5 mm in diameter where after the tail was submerged into a saline collection tube (37° C. saline). The tail was submerged in the temperature saline for a total of 10 minutes before induction of the bleed. The tail was then placed in the cutting block with the mark from “13” pointing at “15 o'clock” approximately ten seconds before the cut was made (to facilitate transection of the left lateral tail vein). At exactly t=0 minutes, the tail was cut with a one mm deep cut placed laterally on the left side of the mouse tail thereby transecting the lateral tail vein. Immediately following the tail was immersed in the pre-warmed saline collection tube. The primary bleeding episode was recorded for three minutes. If the primary bleed was greater than three minutes, the animal was euthanized and replaced. At three minutes post injury, the collection tube was exchanged with a new pre-warmed saline collection tube. All secondary bleeding episodes were recorded for an additional 57 minutes. If the bleeding stopped at 15, 30, or 45 min, the wound was challenged by gently wiping twice with a saline wetted gauze swab. Immediately following the challenge, the tail was re-submerged into the saline. At t=60 minutes the mice were euthanized while still under full anesthesia. Bleeding time was reported as the sum of primary and secondary bleeding times. Primary and secondary bleeds were lysed and stored for later hemoglobin measurements for blood loss. (Johansen et al., Haemophilia, (2016) doi: 10.1111/hae.12907). The results demonstrate a significant reduction in the amount of time to achieve hemostasis (p<0.0001) in the Hemophilia A R593C mice following tail vein transection (FIG. 18), demonstrating therapeutic efficacy in these mice. Non-Human Primates: Experiments were carried out in NHP using the hFVIII-BDD cDNA constructs where AAV2/6 and AAV2/8 serotypes were evaluated. Table 4 below and FIG. 26B show the identity of the dosing groups. The difference between the F8 transgene expression cassette designed “cDNA 1” (Groups 2-4 of Table 4 below) and “cDNA2” (Group 5 of Table 4 below) is that the “cDNA2” donor had a slightly different promoter module (hybrid liver promoter, see McIntosh et al (2013) Blood 121(17):3335), but the rest of the F8-BDD transgene expression cassette (including the coding region) was the same. For these experiments, the dosing regimen outlined in FIG. 26A was used (where the rituximab was administered pre-test article and the steroid (administered concurrently with the test article and daily thereafter). \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "TABLE 4\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "NHP groups with FVIII transgene cassette\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Component\n",
      "Total AAV\n",
      "\n",
      "\n",
      "Group\n",
      "No. of\n",
      "Test Article\n",
      "AAV Transgene\n",
      "\n",
      "Dose Level\n",
      "Vector Dose\n",
      "\n",
      "\n",
      "No.\n",
      "Malesa\n",
      "Identification\n",
      "Description\n",
      "Serotype\n",
      "(vg/kg)\n",
      "Level (vg/kg)\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "1\n",
      "2\n",
      "SGMO.01\n",
      "Formulation Buffer\n",
      "NA\n",
      "NA\n",
      "NA\n",
      "\n",
      "\n",
      "2\n",
      "3\n",
      "SGMO.02\n",
      "hF8-BDD cDNA 1\n",
      "AAV2/6\n",
      "2E+12\n",
      "2E+12\n",
      "\n",
      "\n",
      "3\n",
      "3\n",
      "SGMO.03\n",
      "hF8-BDD cDNA 1\n",
      "AAV2/6\n",
      "6E+12\n",
      "6E+12\n",
      "\n",
      "\n",
      "4\n",
      "3\n",
      "SGMO.04\n",
      "hF8-BDD cDNA 1\n",
      "AAV2/8\n",
      "6E+12\n",
      "6E+12\n",
      "\n",
      "\n",
      "5\n",
      "3\n",
      "SGMO.05\n",
      "hF8-BDD cDNA 2\n",
      "AAV2/8\n",
      "6E+12\n",
      "6E+12\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " Cynomolgus monkeys were administered formulation buffer or 6E+12 vg/kg of AAV2/6 hF8 cDNA (parent). At day 14 following test article addition, circulating levels and activity of hFVIII were analyzed by ELISA or clotting activity (see FIG. 27). Normal levels of Cynomolgus monkey FVIII are ˜1U/mL reflected in the clotting activity data for the formulation control group as the clotting activity assay is not specific for human FVIII. The ELISA is specific for human FVIII over Cynomolgus monkey FVIII thus, as expected there is no hFVIII levels as measured by ELISA in the formulation control group. Shown are individual animals for the formulation control group (Group 1, animal IDs 1101-1102), and the 6E+12 vg/kg dose group (Group 3, animal IDs 3101-3103). In the Group 3 animals there are supraphysiological levels and activity of circulating hFVIII, upwards of 8U/mL. As an indicator of liver condition following treatment, liver enzymes were measured for the formulation control group (Group 1, animal ID 1101), and the 6E+12 vg/kg dose group (Group 3, animal ID 3102). Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured. The acceptable upper limit reference values for Cynomlogus monkeys for ALT is 126 U/L and 120U/L for AST. For both the formulation control group and the 6E+12 vg/kg AAV hF8 cDNA (parent) group ALT/AST levels were elevated post-liver biopsy (liver biopsy was on day 41), denoted by an asterisk. Otherwise AAV hF8 cDNA was well-tolerated over the entirety of the study (247 days) (see FIGS. 28A and 28B). The data is presented in FIG. 29, were the data set for each monkey is depicted on the graphs. The data indicates that the higher doses (compare FIG. 29A with FIG. 29B) of test article in the AAV6 serotype background gave expression of FVIII-BDD at nearly 10× the level found in normal human plasma. The data for test article in the AAV2/8 serotype showed an increase in the FVIII activity, but not to the same extent as was observed for AAV2/6. Subsequent to the initial 14 day period described above, the experiment was continued up to 247 days post the single dose of the AAV-FVIII-BDD. The co-dosing of the steroid was stopped at day 103. Determination of the hFVIII-BDD levels in the plasma of the monkeys was determined using a custom ELISA as follows. 96-well half-area HB (high binding) polystyrene microplates (Corning) were coated overnight at 4° C. with mouse monoclonal anti-hFVIII antibody (Green Mountain, Burlington, Vt.) in 0.2 M carbonate bicarbonate buffer pH 9.4 (Thermo Fisher Scientific, Waltham Mass.). The following day the plates were washed four times using 1×TBST (Thermo Fisher Scientific, Waltham Mass.). 96-well plates were then blocked two hours at room temperature using 3% BSA/TBS blocking buffer, followed by washing four times with 1×TBST. Plasma was added to the plate and incubated with rocking at room temperature for two hours, followed by washing four times with 1×TBST. Detection antibody, biotinylated monoclonal mouse anti-FVIII antibody (Green Mountain, Burlington, Vt.) was added and incubated for one hour at room temperature, followed by washing four times with 1×TBST. Streptavidin HRP (Jackson ImmunoResearch, West Grove Pa.) was added and incubated for one hour at room temperature followed by washing four times with 1×TBST. TMB Ultra (Thermo Fisher Scientific, Waltham Mass.) was added and allowed to develop for ten minutes, reaction was stopped with stop solution and absorbance read at 450 nM using a plate reader. Background absorbance readings were negligible (typically 0). The presence of inhibitory anti-FVIII antibodies were determined using a Bethesda assay (for example, see Kasper et al (1975) Thromb Diath Haemorrh 34:869-72). The ELISA assay was used to evaluate peak human FVIII antigen levels over the study. At dose levels of 2E+12 vg/kg (n=3), peak values of 111.0%, 493.9% and 840.0% (overall mean 481.6% as measured by hFVIII ELISA) of normal hFVIII plasma levels in humans were achieved. At a higher dose representing 6E+12 vg/kg (n=3), peak values of 450.0%, 625.6% and 886.7% [overall mean 654.1%] of hFVIII plasma levels were achieved (FIG. 30). The study outlined in Table 4 was carried out and levels of FVIII-BDD and any inhibitory anti-FVIII antibodies were measured. For the low dose animals (n=3), comprising the FVIII-BDD cDNA in AAV2/6, dosed at 2E+12 vg/kg, following detection of robust hFVIII antigen levels (Ag), hFVIII-BDD levels decreased with a concomitant increase in Bethesda Units (BU). BU decreased over time and the hFVIII Ag increased (FIG. 31). The results demonstrated that following the cessation of the immunosuppressive therapy, the levels (as measured by ELISA) of human FVIII antigen dropped. For the high dose animals (n=3), comprising the FVIII-BDD cDNA in AAV2/6, dosed at 6E+12 vg/kg, a similar pattern was observed (see FIG. 32). However in one animal, 3101, following the removal of Solu-medrol, anti-FVIII antibodies were not detected despite a detectable and persistent level of FVIII antigen (representing 200% of normal hFVIII levels), which could be indicative of a tolerance of animal to the human FVIII antigen. When serotype AAV2/8 was used for the delivery of the high dose, similar results were observed except that the amount of hFVIII antigen detectable in the plasma was less that measured using the AAV2/6 vector (FIG. 33). Similarly, when a different FVIII-BDD cDNA promoter module was tested (Group 5, described above) in the AAV2/8 vector, hFVIII-BDD plasma levels were similar to those seen in Group 4 (FIG. 34). However, as above, there were two individuals that maintained a detectable amount of FVIII-BDD expression (5101 and 5102), and an individual in Group 4 (4103, FIG. 33D) without a marked antibody response following the removal of the Solu-medrol, again suggestive of tolerization to the antigen following the robust response levels seen in the initial days of the experiment. As shown in FIG. 34D, Animal No. 5101 appeared to be tolerized to hFVIII-BDD as after removal of methylprednisolone, hFVIII-BDD levels remained stable for 8 weeks at approximately 0.1U/mL (representing 10% of normal hFVIII levels). Also, as shown in FIG. 34E, Animal No. 5102 appeared to be tolerized to hFVIII-BDD as after removal of methylprednisolone, hFVIII-BDD levels remained stable for 8 weeks at approximately 0.6U/mL (representing 60% of normal hFVIII levels). It is worth noting that normal levels of hFVIII in human plasma is approximately 1U/mL or 200 ng/mL, and that expression of even 1%-5% of normal (>0.001 U/mL) can have therapeutic efficacy (Llung, RC (1999) Thromb Haemost 82(2):525-530). Experiments in NHP were also conducted as described above except that different immunosuppression regimes were investigated. For these experiments, the dosing regimen shown in FIG. 26B was followed were some groups (1-5) received the immunosuppressive treatment was administered prior to test article dosing, while other groups (6-8) received immunosuppression after test article dosing. As shown in FIG. 38, at dose levels of 6E+11 vg/kg (n=3, Group 3), the overall mean of peak values was 5.7% (measured by hFVIII ELISA) of normal hFVIII plasma levels in humans were achieved. At a higher dose representing 2E+12 vg/kg (n=3, Group 4), the overall mean of peak values was 56.5% and at 6E+12 vg/kg (n=3, Group 5) the overall mean of peak values was 229.0% (measured by hFVIII ELISA) of hFVIII plasma levels were achieved. At dose level 2E+12 vg/kg (n=3, Group 7) the overall mean of peak values was 87.9%, and for 6E+12 vg/kg (n=3, Group 8), 101.7%. Groups 1 and 6 were the formulation control groups, denoted as Formulation. In addition, as shown in FIG. 39, re-dosing using the same serotype resulted in detectable circulating human FVIII antigen levels. These results indicate that pretreatment of the animals with immunosuppression may be helpful for maximal therapeutic protein expression. Additionally, pretreatment allows re-dosing when no neutralizing antibodies were developed during the first dose. FIG. 39 also demonstrates a dose response in the treated animals of hFVIII expression in response to varying ranges of FVIII-BDD cDNA dosed. Since the presence of even 1 to 5% of FVIII protein in the plasma is thought to have significant therapeutic efficacy in humans, clinical doses in the Ell range (resulting in 5.7 to 12.0 percent of normal levels in this experiment) are likely to provide significant therapeutic benefit. Thus, the data demonstrate that the constructs described herein result in therapeutic levels of transgene production in vivo. Example 3: Nuclease-Mediated Targeted Integration The constructs described in Examples 1 and 2 were also evaluated for expression when used in combination with albumin-specific nucleases for targeted integration of the expression construct into an albumin locus. In particular, the constructs were administered to HepG2 cells with albumin-specific zinc finger nucleases. See, e.g., U.S. Pat. Nos. 9,150,847; 9,255,250 and U.S. Patent Publication Nos. 20130177983; 20150159172; 20150056705 and 20150166618. Human HepG2 liver cells were maintained per manufacturer's guidelines (ATCC, Manassas Va.). On the day of the experiment, HepG2 cells were washed, trypsinized and counted. ZFNs used were to the human albumin intron locus, together with the human Factor VIII-BDD (hFVIII) cDNA CRMSBS2 No Intron, were delivered as AAV2/6, denoted as time zero. AAV2/6 ZFNs were delivered at 3.0E+05 and AAV2/6 hFVIII cDNA CRMSBS2 No Intron at 3.0E+04, 6.0E+04 and 1.2E+05 for 1E+05 cells per well of a 24-well dish. Thus the expression constructs were administered at increasing doses from 3.0E+04, 6.0E+04 and 1.2E+05 together with ZFN 3.0E+05. Control samples included administration of the CRMSGS2 SBR Intron 3 transgene alone or with GFP, ZFN alone or GFP alone. The following day media was exchanged. Supernatants were analyzed for secreted hFVIII using the hFVIII ELISAs described below at 19 days post-AAV2/6 virus addition. Secreted human Factor VIII-BDD levels were determined using Affinity Biologicals (Canada) ELISA kit (FVIII-AG) according to the manufacture's protocol with the exception of the human Factor VIII standard. The human Factor VIII standard used in the ELISA assay is a recombinant purified human Factor VIII (#F0016-06) from US Biologicals (Salem, Mass.). Briefly, HepG2 supernatant was added to the plate, incubated with rocking at room temperature for one and a half hours, followed by washing three times with wash buffer provided in the kit. Detecting antibody, provided with the kit, was added and incubated for forty five minutes at room temperature, followed by washing three times with wash buffer provided in the kit. TMB substrate provided with kit was added and allowed to develop for ten minutes. The reaction was stopped with stop solution and absorbance read at 450 nM using a plate reader. The total level of hFVIII-BDD protein detected in HepG2 cellular supernatant over time (t=days) following administration of albumin-targeted ZFNs (SBS#47171/47898, see PCT Patent Publication WO 2015/089077) and the indicated construct was analyzed (FIG. 36). In the presence of both the FVIII BDD expression construct and the ZFN, secreted FVIII BDD was detected in the supernatant three days after treatment at the highest dose of FVIII BDD transgene, and then detectable at a lower dose on day five, and detectable at all levels on day seven. In the absence of ZFN, FVIII BDD in the supernatant was barely detectable above the background of the assay at day seven. Data shown are of n=3 biological replicates. Error bars represent the standard error of the mean of technical replicates. Dotted line represents the limit of detection of the hFVIII ELISA. Secreted hFVIII-BDD was only weakly detected in the absence of the ZFNs, as the episomal hFVIII-BDD is likely diluted or degraded prior to build up of sufficient amounts of detectable secreted hFVIII-BDD from that episome. Furthermore, as determined by quantitative PCR (using a 5′ primer is located within the endogenous human albumin locus and a probe is located within the ITR of the hFVIII-BDD cassette and the 3′ primer within the hFVIII-BDD), targeted integration (by NHEJ) of the indicated constructs was achieved only in the presence of the albumin-specific ZFNs (FIG. 37). Thus these data demonstrate successful integration of the hFVIII-BDD cassette and expression of the encoded F8 protein. These experiments were repeated testing another set of albumin-specific ZFNs (SBS#42906/43043, see PCT Patent Publication WO 2015/089046). The results (FIGS. 40A and 40B) show expression of FVIII protein in the supernatant of these cells and targeted integration of the transgene. Albumin-specific ZFNs and constructs are subsequently delivered in vivo to animals essentially as described in Examples 1 and 2. The constructs are integrated into the endogenous albumin locus and express the transgene. The experimental design for the in vivo studies are shown below in Table 5. In brief, F1 generation male C57BL/6 pups mice were used for the in vivo study (test article denoted in Table 5). The ZFNs used in the study were SBS#48641 and SBS#31523 (See U.S. Patent Publication 2014-0017212). The study complied with the animal welfare act for humane care and use of animals. Test articles were thawed at room temperature prior to dosing, and all animals received a single subcutaneous 1004, injection as outlined below. The ZFN dose was 1.5E+11 vg per mouse and the F8 cDNA dose was 1.5E+11 vg per mouse. Blood was collected following euthanasia from two or three pups per group on each of Days 7, 14, 21, and 28 and processed to plasma for analysis of circulating levels of hFVIII in plasma using the In house hFVIII ELISA for mouse. Tissues were collected from all mice for analysis of levels of gene modification by deep sequencing (indels, insertions and deletions), mRNA analysis by RT-PCR, vector genome analysis using qPCR and target integration analysis using qPCR. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "TABLE 5\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Experimental Design\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Total\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "F8 cDNA\n",
      "Total AAV\n",
      "AAV\n",
      "Number\n",
      "Dose\n",
      "\n",
      "\n",
      "Group\n",
      "Test Article\n",
      "Test\n",
      "ZFN Dose\n",
      "Dose\n",
      "Dose\n",
      "Dosea\n",
      "of Male\n",
      "Volume\n",
      "\n",
      "\n",
      "No.\n",
      "Description\n",
      "Material\n",
      "(vg/mouse)\n",
      "(vg/mouse)\n",
      "(vg/mouse)\n",
      "(vg/kg)\n",
      "Pups\n",
      "(μL)b\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "1\n",
      "Formulation\n",
      "SGMO.01\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "9\n",
      "100\n",
      "\n",
      "\n",
      "\n",
      "Buffer\n",
      "\n",
      "\n",
      "2\n",
      "ZFNs +\n",
      "SGMO.02\n",
      "1.5 × 1011\n",
      "1.5 × 1011\n",
      "4.5 × 1011\n",
      "3.75 × 1014\n",
      "12\n",
      "100\n",
      "\n",
      "\n",
      "\n",
      "F8 cDNA\n",
      "\n",
      "per ZFN\n",
      "\n",
      "\n",
      "3\n",
      "F8 cDNA\n",
      "SGMO.03\n",
      "0\n",
      "1.5 × 1011\n",
      "1.5 × 1011\n",
      "1.25 × 1014\n",
      "12\n",
      "100\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "aTotal AAV dose calculated using a 1.2 g body weight\n",
      "\n",
      "\n",
      "bAdministered once in one volume of 100 μL.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " Levels of F8 detected in the plasma are presented below in Table 6, as well as the amount of targeted integration of the FVIII-BDD transgene. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "TABLE 6\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "F8 expression and transgene integration\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "F8 Levels (ELISA)\n",
      "\n",
      "Target Integration\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Day\n",
      "Sample #\n",
      "Group #\n",
      "Description\n",
      "Animal #\n",
      "U/mL\n",
      "ng/mL\n",
      "Indels %\n",
      "Mean\n",
      "SEM\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "7\n",
      "1\n",
      "1\n",
      "Formulation\n",
      "101\n",
      "0.002\n",
      "0.4\n",
      "N.S.\n",
      "0\n",
      "\n",
      "\n",
      "\n",
      "7\n",
      "2\n",
      "1\n",
      "Formulation\n",
      "201\n",
      "0.006\n",
      "1.2\n",
      "N.S.\n",
      "0\n",
      "\n",
      "\n",
      "7\n",
      "3\n",
      "2\n",
      "ZFN/F8 cDNA\n",
      "401\n",
      "0\n",
      "0\n",
      " 7.8\n",
      "1.48\n",
      "0.00\n",
      "\n",
      "\n",
      "7\n",
      "4\n",
      "2\n",
      "ZFN/F8 cDNA\n",
      "501\n",
      "0.006\n",
      "1.2\n",
      " 8.4\n",
      "4.15\n",
      "1.13\n",
      "\n",
      "\n",
      "7\n",
      "5\n",
      "2\n",
      "ZFN/F8 cDNA\n",
      "601\n",
      "0.082\n",
      "16.4\n",
      "12.5\n",
      "11.38\n",
      "3.82\n",
      "\n",
      "\n",
      "7\n",
      "6\n",
      "3\n",
      "F8 cDNA\n",
      "901\n",
      "0.022\n",
      "4.4\n",
      "N.S.\n",
      "0\n",
      "\n",
      "\n",
      "7\n",
      "7\n",
      "3\n",
      "F8 cDNA\n",
      "1001\n",
      "0.012\n",
      "2.4\n",
      "N.S.\n",
      "0\n",
      "\n",
      "\n",
      "7\n",
      "8\n",
      "3\n",
      "F8 cDNA\n",
      "1101\n",
      "0.006\n",
      "1.2\n",
      "N.S.\n",
      "0\n",
      "\n",
      "\n",
      "14\n",
      "1\n",
      "1\n",
      "Formulation\n",
      "301\n",
      "0.006\n",
      "1.2\n",
      "N.S.\n",
      "0\n",
      "\n",
      "\n",
      "14\n",
      "2\n",
      "1\n",
      "Formulation\n",
      "102\n",
      "0.006\n",
      "1.2\n",
      "N.S.\n",
      "0\n",
      "\n",
      "\n",
      "14\n",
      "3\n",
      "2\n",
      "ZFN/F8 cDNA\n",
      "701\n",
      "0.124\n",
      "24.8\n",
      "14.4\n",
      "4.45\n",
      "1.76\n",
      "\n",
      "\n",
      "14\n",
      "4\n",
      "2\n",
      "ZFN/F8 cDNA\n",
      "402\n",
      "0.037\n",
      "7.4\n",
      "16.1\n",
      "3.02\n",
      "0.09\n",
      "\n",
      "\n",
      "14\n",
      "5\n",
      "2\n",
      "ZFN/F8 cDNA\n",
      "502\n",
      "0.169\n",
      "33.8\n",
      "11.7\n",
      "2.93\n",
      "0.71\n",
      "\n",
      "\n",
      "14\n",
      "6\n",
      "3\n",
      "F8 cDNA\n",
      "1201\n",
      "0.002\n",
      "0.4\n",
      "N.S.\n",
      "0\n",
      "\n",
      "\n",
      "14\n",
      "7\n",
      "3\n",
      "F8 cDNA\n",
      "902\n",
      "0.001\n",
      "0.2\n",
      "N.S.\n",
      "0\n",
      "\n",
      "\n",
      "14\n",
      "8\n",
      "3\n",
      "F8 cDNA\n",
      "1002\n",
      "0.015\n",
      "3\n",
      "N.S.\n",
      "0\n",
      "\n",
      "\n",
      "21\n",
      "1\n",
      "1\n",
      "Formulation\n",
      "202\n",
      "0\n",
      "0\n",
      "N.S.\n",
      "0\n",
      "\n",
      "\n",
      "21\n",
      "2\n",
      "1\n",
      "Formulation\n",
      "302\n",
      "0.006\n",
      "1.2\n",
      "N.S.\n",
      "0\n",
      "\n",
      "\n",
      "21\n",
      "3\n",
      "2\n",
      "ZFN/F8 cDNA\n",
      "602\n",
      "0.082\n",
      "16.4\n",
      "15.7\n",
      "21.11\n",
      "1.11\n",
      "\n",
      "\n",
      "21\n",
      "4\n",
      "2\n",
      "ZFN/F8 cDNA\n",
      "702\n",
      "*\n",
      "*\n",
      "18.6\n",
      "4.76\n",
      "1.36\n",
      "\n",
      "\n",
      "21\n",
      "5\n",
      "2\n",
      "ZFN/F8 cDNA\n",
      "403\n",
      "*\n",
      "*\n",
      "16.7\n",
      "5.72\n",
      "2.36\n",
      "\n",
      "\n",
      "21\n",
      "6\n",
      "3\n",
      "F8 cDNA\n",
      "1102\n",
      "0.012\n",
      "4.4\n",
      "N.S.\n",
      "0\n",
      "\n",
      "\n",
      "21\n",
      "7\n",
      "3\n",
      "F8 cDNA\n",
      "903\n",
      "0.022\n",
      "2.4\n",
      "N.S.\n",
      "0\n",
      "\n",
      "\n",
      "28\n",
      "1\n",
      "1\n",
      "Formulation\n",
      "103\n",
      "0.006\n",
      "1.2\n",
      "N.S.\n",
      "0\n",
      "\n",
      "\n",
      "28\n",
      "4\n",
      "1\n",
      "Formulation\n",
      "603\n",
      "0\n",
      "0\n",
      "N.S.\n",
      "0\n",
      "\n",
      "\n",
      "28\n",
      "2\n",
      "2\n",
      "ZFN/F8 cDNA\n",
      "303\n",
      "0.004\n",
      "0.8\n",
      " 9.4\n",
      "1.00\n",
      "0.68\n",
      "\n",
      "\n",
      "28\n",
      "3\n",
      "2\n",
      "ZFN/F8 cDNA\n",
      "503\n",
      "0.128\n",
      "25.6\n",
      "17.3\n",
      "5.96\n",
      "1.26\n",
      "\n",
      "\n",
      "28\n",
      "5\n",
      "2\n",
      "ZFN/F8 cDNA\n",
      "703\n",
      "0.001\n",
      "0.2\n",
      "15.0\n",
      "1.93\n",
      "0.49\n",
      "\n",
      "\n",
      "28\n",
      "6\n",
      "3\n",
      "F8 cDNA\n",
      "1003\n",
      "0.004\n",
      "0.8\n",
      "N.S.\n",
      "0\n",
      "\n",
      "\n",
      "28\n",
      "7\n",
      "3\n",
      "F8 cDNA\n",
      "1103\n",
      "0.002\n",
      "0.4\n",
      "N.S.\n",
      "0\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "* data not available\n",
      "\n",
      "\n",
      "NS: not significantly above background\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " Thus, FVIII was detectable in the mouse pups following administration of the albumin-specific nucleases and the FVIII-BDD transgene. Insertion of the transgene was also detectable at a higher amount in those mice treated with both the ZFNs and the transgene. Thus, nuclease-mediated targeted integration of the constructs described herein provides for transgene expression in hepatic cells. All patents, patent applications and publications mentioned herein are hereby incorporated by reference in their entirety. Although disclosure has been provided in some detail by way of illustration and example for the purposes of clarity of understanding, it will be apparent to those skilled in the art that various changes and modifications can be practiced without departing from the spirit or scope of the disclosure. Accordingly, the foregoing descriptions and examples should not be construed as limiting. \n"
     ]
    }
   ],
   "source": [
    "# Extract detailed description section\n",
    "desc_boundary_start = 0\n",
    "desc_boundary_end = 0\n",
    "desc_col = []\n",
    "\n",
    "for index, row in patents_df4.iterrows():\n",
    "    desc_boundary_start = re.search('([A-Z])*DETAILED DESCRIPTION(([A-Z])*(\\s))*', \\\n",
    "                                          str(row['description']), re.MULTILINE)\n",
    "    desc_boundary_end = len(str(row['description']))\n",
    "    \n",
    "    if desc_boundary_start:\n",
    "        desc_col.append(find_inbetween_text(str(row['description']), desc_boundary_start.end(), \\\n",
    "                                             desc_boundary_end))\n",
    "    else:\n",
    "        desc_col.append(' ')\n",
    "\n",
    "print(desc_col[0])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>detailed_description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Disclosed herein are expression cassettes for ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>The present invention includes a composition o...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Disclosed herein are compositions and methods ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Anti-aP2 monoclonal antibodies and antigen bin...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>method is provided for identifying an agent as...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Pharmaceutical Compositions The present disclo...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>In some embodiments, the present invention pro...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Reference will now be made in detail to certai...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>The present invention sets forth a novel metho...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>The invention is based at least in part on dev...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>Unless otherwise defined herein, scientific an...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>Various embodiments and aspects of the disclos...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>The following description and examples illustr...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>I. Terms Unless otherwise noted, technical ter...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>The present invention will be described with r...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>Stimulation of an immune response is dependent...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>Adeno-associated virus (AAV) is a small (26 nm...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>Disclosed herein are compositions and methods ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>According to various embodiments, the present ...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                 detailed_description\n",
       "0   Disclosed herein are expression cassettes for ...\n",
       "1                                                    \n",
       "2   The present invention includes a composition o...\n",
       "3   Disclosed herein are compositions and methods ...\n",
       "4   Anti-aP2 monoclonal antibodies and antigen bin...\n",
       "5   method is provided for identifying an agent as...\n",
       "6   Pharmaceutical Compositions The present disclo...\n",
       "7   In some embodiments, the present invention pro...\n",
       "8   Reference will now be made in detail to certai...\n",
       "9   The present invention sets forth a novel metho...\n",
       "10  The invention is based at least in part on dev...\n",
       "11  Unless otherwise defined herein, scientific an...\n",
       "12  Various embodiments and aspects of the disclos...\n",
       "13  The following description and examples illustr...\n",
       "14  I. Terms Unless otherwise noted, technical ter...\n",
       "15  The present invention will be described with r...\n",
       "16  Stimulation of an immune response is dependent...\n",
       "17  Adeno-associated virus (AAV) is a small (26 nm...\n",
       "18                                                   \n",
       "19  Disclosed herein are compositions and methods ...\n",
       "20  According to various embodiments, the present ..."
      ]
     },
     "execution_count": 16,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "detailed_desc_df = pd.DataFrame({'detailed_description': desc_col})\n",
    "detailed_desc_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id</th>\n",
       "      <th>invention_title</th>\n",
       "      <th>abstract</th>\n",
       "      <th>claims</th>\n",
       "      <th>description</th>\n",
       "      <th>drawings_description</th>\n",
       "      <th>drawings_file_paths</th>\n",
       "      <th>invention_background</th>\n",
       "      <th>cross_reference</th>\n",
       "      <th>summary</th>\n",
       "      <th>detailed_description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>20190151472</td>\n",
       "      <td>LIVER-SPECIFIC CONSTRUCTS, FACTOR VIII EXPRESS...</td>\n",
       "      <td>Described herein are constructs used for liver...</td>\n",
       "      <td>1-10. (canceled)  11. A method of providing a...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS The pr...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...</td>\n",
       "      <td>[US20190151472A1-20190523-D00001.TIF, US201901...</td>\n",
       "      <td>Gene therapy can be used to genetically engine...</td>\n",
       "      <td>The present application is a divisional of U.S...</td>\n",
       "      <td>The present invention describes compositions a...</td>\n",
       "      <td>Disclosed herein are expression cassettes for ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>20190135863</td>\n",
       "      <td>RETRO-INVERSO PEPTIDE INHIBITORS OF CELL MIGRA...</td>\n",
       "      <td>The present invention discloses retro-inverso ...</td>\n",
       "      <td>1. A compound of formula (I):   X1-(D)-Arg-X2...</td>\n",
       "      <td>The present invention concerns retro-inverso p...</td>\n",
       "      <td>DESCRIPTION OF THE FIGURES FIG. 1 High degree ...</td>\n",
       "      <td>[US20190135863A1-20190509-D00001.TIF, US201901...</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>20190133992</td>\n",
       "      <td>CANNABINOID COMPOSITION HAVING AN OPTIMIZED FA...</td>\n",
       "      <td>A composition of matter for enhancing delivery...</td>\n",
       "      <td>1. A cannabinoid composition comprising: at l...</td>\n",
       "      <td>FIELD OF THE INVENTION The present invention r...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...</td>\n",
       "      <td>[US20190133992A1-20190509-D00001.TIF, US201901...</td>\n",
       "      <td>Formulations of bioactive compounds have been ...</td>\n",
       "      <td></td>\n",
       "      <td>The present invention includes a cannabinoid c...</td>\n",
       "      <td>The present invention includes a composition o...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>20190136261</td>\n",
       "      <td>GENETIC MODIFICATION OF CYTOKINE INDUCIBLE SH2...</td>\n",
       "      <td>The present disclosure is in the field of geno...</td>\n",
       "      <td>1. A genetically modified cell comprising a g...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS The pr...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 shows...</td>\n",
       "      <td>[US20190136261A1-20190509-D00001.TIF, US201901...</td>\n",
       "      <td>Cells communicate with each other either by di...</td>\n",
       "      <td>The present application claims the benefit of ...</td>\n",
       "      <td>The present invention describes compositions a...</td>\n",
       "      <td>Disclosed herein are compositions and methods ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>20190161536</td>\n",
       "      <td>ANTI-AP2 ANTIBODIES AND ANTIGEN BINDING AGENTS...</td>\n",
       "      <td>This invention is in the area of improved anti...</td>\n",
       "      <td>1. A method of attenuating an aP2-mediated di...</td>\n",
       "      <td>RELATED APPLICATIONS This application is a con...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1-8 ar...</td>\n",
       "      <td>[US20190161536A1-20190530-D00001.TIF, US201901...</td>\n",
       "      <td>Human adipocyte lipid-binding protein (aP2) be...</td>\n",
       "      <td></td>\n",
       "      <td>Anti-aP2 monoclonal antibodies and antigen bin...</td>\n",
       "      <td>Anti-aP2 monoclonal antibodies and antigen bin...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>20190202865</td>\n",
       "      <td>TARGETING DIMERIZATION OF BAX TO MODULATE BAX ...</td>\n",
       "      <td>Methods are provided for identifying an agent ...</td>\n",
       "      <td>1-19. (canceled)  20. A method of inhibiting ...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS This a...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1A-1D. ...</td>\n",
       "      <td>[US20190202865A1-20190704-D00001.TIF, US201902...</td>\n",
       "      <td>Throughout this application various publicatio...</td>\n",
       "      <td>This application claims the benefit of U.S. Pr...</td>\n",
       "      <td>The present invention discloses assays for ide...</td>\n",
       "      <td>method is provided for identifying an agent as...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>20190201532</td>\n",
       "      <td>SENSITIZATION OF BACTERIAL CELLS TO QUINOLONE ...</td>\n",
       "      <td>Provided herein are pharmaceutical composition...</td>\n",
       "      <td>1. A pharmaceutical composition comprising a ...</td>\n",
       "      <td>RELATED APPLICATION The present application cl...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1F....</td>\n",
       "      <td>[US20190201532A1-20190704-D00001.TIF, US201902...</td>\n",
       "      <td>Antibiotics are the main tools to treat infect...</td>\n",
       "      <td></td>\n",
       "      <td>Density-dependent drug failure is a form of an...</td>\n",
       "      <td>Pharmaceutical Compositions The present disclo...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>20190201444</td>\n",
       "      <td>GLYCOENGINEERING OF E-SELECTIN LIGANDS</td>\n",
       "      <td>The present invention provides methods of enfo...</td>\n",
       "      <td>1. A method of enforcing expression of an E-s...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS The pr...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1A-FIG....</td>\n",
       "      <td>[US20190201444A1-20190704-D00000.TIF, US201902...</td>\n",
       "      <td>Mesenchymal stem cells (MSCs) hold much promis...</td>\n",
       "      <td></td>\n",
       "      <td>Despite the promise of these methods, there ex...</td>\n",
       "      <td>In some embodiments, the present invention pro...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>20190177429</td>\n",
       "      <td>Anti-HER2 Antibodies and Immunoconjugates</td>\n",
       "      <td>The invention provides anti-HER2 antibodies an...</td>\n",
       "      <td>1. An isolated antibody that binds to HER2, w...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS The pr...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE FIGURES FIG. 1 shows ...</td>\n",
       "      <td>[US20190177429A1-20190613-D00001.TIF, US201901...</td>\n",
       "      <td>Breast cancer is a highly significant cause of...</td>\n",
       "      <td>The present application is a divisional of U.S...</td>\n",
       "      <td>The invention provides anti-HER2 antibodies an...</td>\n",
       "      <td>Reference will now be made in detail to certai...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>20190184190</td>\n",
       "      <td>PHOSPHOR-CONTAINING DRUG ACTIVATOR ACTIVATABLE...</td>\n",
       "      <td>A phosphor-containing drug activator activatab...</td>\n",
       "      <td>1. A phosphor-containing drug activator activ...</td>\n",
       "      <td>CROSS REFERENCE TO RELATED APPLICATIONS This a...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE FIGURES A more comple...</td>\n",
       "      <td>[US20190184190A1-20190620-D00000.TIF, US201901...</td>\n",
       "      <td>Field of Invention The invention relates to me...</td>\n",
       "      <td></td>\n",
       "      <td>In one embodiment, the present invention provi...</td>\n",
       "      <td>The present invention sets forth a novel metho...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>20190192693</td>\n",
       "      <td>METHODS AND VECTORS FOR TREATING CNS DISORDERS</td>\n",
       "      <td>Methods and uses of treating a disease in a ma...</td>\n",
       "      <td>1. A method of delivering a therapeutic prote...</td>\n",
       "      <td>RELATED APPLICATIONS This application claims p...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE FIGURES A more comple...</td>\n",
       "      <td>[US20190184190A1-20190620-D00000.TIF, US201901...</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>In certain embodiments, the invention provides...</td>\n",
       "      <td>The invention is based at least in part on dev...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>20190159474</td>\n",
       "      <td>AMELIORATIVE EFFECTS OF A WHOLE COFFEE FRUIT E...</td>\n",
       "      <td>The invention provides a method of extracting ...</td>\n",
       "      <td>1. A method of producing a whole coffee fruit...</td>\n",
       "      <td>FIELD OF THE INVENTION The invention provides ...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A and...</td>\n",
       "      <td>[US20190159474A1-20190530-D00000.TIF, US201901...</td>\n",
       "      <td>Coffee fruits are mainly produced in Africa an...</td>\n",
       "      <td></td>\n",
       "      <td>It is found in the present invention that a wh...</td>\n",
       "      <td>Unless otherwise defined herein, scientific an...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>20190125691</td>\n",
       "      <td>ENCAPSULATION-FREE CONTROLLED PROTEIN RELEASE ...</td>\n",
       "      <td>The present disclosure provides a delivery sys...</td>\n",
       "      <td>1. A biocompatible polymer composite comprise...</td>\n",
       "      <td>FIELD The present disclosure relates to a bioc...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS Embodiments ...</td>\n",
       "      <td>[US20190125691A1-20190502-D00000.TIF, US201901...</td>\n",
       "      <td>Controlled protein release is a key strategy t...</td>\n",
       "      <td></td>\n",
       "      <td>The present invention provides a biocompatible...</td>\n",
       "      <td>Various embodiments and aspects of the disclos...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>20190169260</td>\n",
       "      <td>Human Leukocyte Antigen Restricted Gamma Delta...</td>\n",
       "      <td>Disclosed herein are compositions and methods ...</td>\n",
       "      <td>1. A composition comprising a polypeptide con...</td>\n",
       "      <td>SEQUENCE LISTING The instant application conta...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS The novel fe...</td>\n",
       "      <td>[US20190169260A1-20190606-D00001.TIF, US201901...</td>\n",
       "      <td>Cancer has a major impact on society across th...</td>\n",
       "      <td></td>\n",
       "      <td>There exists a pressing need for alternative a...</td>\n",
       "      <td>The following description and examples illustr...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>20190194282</td>\n",
       "      <td>CHIMERIC PROTEINS FOR TARGETING dsRNA</td>\n",
       "      <td>Described herein are recombinant chimeric prot...</td>\n",
       "      <td>1. A chimeric recombinant protein comprising:...</td>\n",
       "      <td>CROSS REFERENCE TO RELATED APPLICATIONS Benefi...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1D:...</td>\n",
       "      <td>[US20190194282A1-20190627-D00000.TIF, US201901...</td>\n",
       "      <td>Prostate cancer is the second most commonly di...</td>\n",
       "      <td></td>\n",
       "      <td>Described herein is an improved approach to th...</td>\n",
       "      <td>I. Terms Unless otherwise noted, technical ter...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>20190127440</td>\n",
       "      <td>NOVEL TSLP INHIBITORS</td>\n",
       "      <td>The present invention relates to monomeric fus...</td>\n",
       "      <td>1. A monomeric fusion protein comprising: a f...</td>\n",
       "      <td>FIELD OF THE INVENTION The present invention r...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE FIGURES FIG. 1 shows ...</td>\n",
       "      <td>[US20190127440A1-20190502-D00001.TIF, US201901...</td>\n",
       "      <td>Thymic stromal lymphopoietin (TSLP) is an inte...</td>\n",
       "      <td></td>\n",
       "      <td>It is surprisingly shown herein that a monomer...</td>\n",
       "      <td>The present invention will be described with r...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>20190177383</td>\n",
       "      <td>NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR...</td>\n",
       "      <td>The present invention relates to peptides, pro...</td>\n",
       "      <td>1. A method of treating a patient who has can...</td>\n",
       "      <td>CROSS REFERENCE TO RELATED APPLICATIONS This a...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS The patent o...</td>\n",
       "      <td>[US20190177383A1-20190613-D00001.TIF, US201901...</td>\n",
       "      <td>Ovarian Cancer With an estimated 239 000 new c...</td>\n",
       "      <td></td>\n",
       "      <td>In a first aspect of the present invention, th...</td>\n",
       "      <td>Stimulation of an immune response is dependent...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>20190194689</td>\n",
       "      <td>CNS TARGETING AAV VECTORS AND METHODS OF USE T...</td>\n",
       "      <td>The invention in some aspects relates to recom...</td>\n",
       "      <td>1-55. (canceled)  56. A method for delivering...</td>\n",
       "      <td>RELATED APPLICATIONS This application is a con...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1B ...</td>\n",
       "      <td>[US20190194689A1-20190627-D00001.TIF, US201901...</td>\n",
       "      <td>Gene therapy has been investigated for deliver...</td>\n",
       "      <td></td>\n",
       "      <td>Aspects of the invention, are based on the dis...</td>\n",
       "      <td>Adeno-associated virus (AAV) is a small (26 nm...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>20190144517</td>\n",
       "      <td>PROTEIN FOR NEUTRALIZING PROGRAMMED NECROCYTOS...</td>\n",
       "      <td>Provided is polypeptide which derives from wil...</td>\n",
       "      <td>1. A polypeptide that inhibits cell necrosis,...</td>\n",
       "      <td>TECHNICAL FIELD The present invention relates ...</td>\n",
       "      <td>DESCRIPTION OF DRAWINGS FIG. 1 shows the scree...</td>\n",
       "      <td>[US20190144517A1-20190516-D00001.TIF, US201901...</td>\n",
       "      <td>Tumor necrosis factor α (TNF) is a multifuncti...</td>\n",
       "      <td></td>\n",
       "      <td>It is an object of the present invention to pr...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>20190177709</td>\n",
       "      <td>REGULATION OF GENE EXPRESSION USING ENGINEERED...</td>\n",
       "      <td>The present disclosure is in the field of geno...</td>\n",
       "      <td>1. A zinc finger nuclease (ZFN) comprising le...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS This a...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A and...</td>\n",
       "      <td>[US20190177709A1-20190613-D00000.TIF, US201901...</td>\n",
       "      <td>When one considers that genome sequencing effo...</td>\n",
       "      <td>This application is filed pursuant to 35 U.S.C...</td>\n",
       "      <td>The present invention describes highly specifi...</td>\n",
       "      <td>Disclosed herein are compositions and methods ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>20190169583</td>\n",
       "      <td>STEP-Derived Peptide for Brain Injury Treatment</td>\n",
       "      <td>A novel peptide sequence that is a modified de...</td>\n",
       "      <td>1. An isolated peptide comprising a kinase in...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS The fo...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...</td>\n",
       "      <td>[US20190169583A1-20190606-D00001.TIF, US201901...</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>According to various embodiments, the present ...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "             id                                    invention_title  \\\n",
       "0   20190151472  LIVER-SPECIFIC CONSTRUCTS, FACTOR VIII EXPRESS...   \n",
       "1   20190135863  RETRO-INVERSO PEPTIDE INHIBITORS OF CELL MIGRA...   \n",
       "2   20190133992  CANNABINOID COMPOSITION HAVING AN OPTIMIZED FA...   \n",
       "3   20190136261  GENETIC MODIFICATION OF CYTOKINE INDUCIBLE SH2...   \n",
       "4   20190161536  ANTI-AP2 ANTIBODIES AND ANTIGEN BINDING AGENTS...   \n",
       "5   20190202865  TARGETING DIMERIZATION OF BAX TO MODULATE BAX ...   \n",
       "6   20190201532  SENSITIZATION OF BACTERIAL CELLS TO QUINOLONE ...   \n",
       "7   20190201444             GLYCOENGINEERING OF E-SELECTIN LIGANDS   \n",
       "8   20190177429          Anti-HER2 Antibodies and Immunoconjugates   \n",
       "9   20190184190  PHOSPHOR-CONTAINING DRUG ACTIVATOR ACTIVATABLE...   \n",
       "10  20190192693     METHODS AND VECTORS FOR TREATING CNS DISORDERS   \n",
       "11  20190159474  AMELIORATIVE EFFECTS OF A WHOLE COFFEE FRUIT E...   \n",
       "12  20190125691  ENCAPSULATION-FREE CONTROLLED PROTEIN RELEASE ...   \n",
       "13  20190169260  Human Leukocyte Antigen Restricted Gamma Delta...   \n",
       "14  20190194282              CHIMERIC PROTEINS FOR TARGETING dsRNA   \n",
       "15  20190127440                              NOVEL TSLP INHIBITORS   \n",
       "16  20190177383  NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR...   \n",
       "17  20190194689  CNS TARGETING AAV VECTORS AND METHODS OF USE T...   \n",
       "18  20190144517  PROTEIN FOR NEUTRALIZING PROGRAMMED NECROCYTOS...   \n",
       "19  20190177709  REGULATION OF GENE EXPRESSION USING ENGINEERED...   \n",
       "20  20190169583    STEP-Derived Peptide for Brain Injury Treatment   \n",
       "\n",
       "                                             abstract  \\\n",
       "0   Described herein are constructs used for liver...   \n",
       "1   The present invention discloses retro-inverso ...   \n",
       "2   A composition of matter for enhancing delivery...   \n",
       "3   The present disclosure is in the field of geno...   \n",
       "4   This invention is in the area of improved anti...   \n",
       "5   Methods are provided for identifying an agent ...   \n",
       "6   Provided herein are pharmaceutical composition...   \n",
       "7   The present invention provides methods of enfo...   \n",
       "8   The invention provides anti-HER2 antibodies an...   \n",
       "9   A phosphor-containing drug activator activatab...   \n",
       "10  Methods and uses of treating a disease in a ma...   \n",
       "11  The invention provides a method of extracting ...   \n",
       "12  The present disclosure provides a delivery sys...   \n",
       "13  Disclosed herein are compositions and methods ...   \n",
       "14  Described herein are recombinant chimeric prot...   \n",
       "15  The present invention relates to monomeric fus...   \n",
       "16  The present invention relates to peptides, pro...   \n",
       "17  The invention in some aspects relates to recom...   \n",
       "18  Provided is polypeptide which derives from wil...   \n",
       "19  The present disclosure is in the field of geno...   \n",
       "20  A novel peptide sequence that is a modified de...   \n",
       "\n",
       "                                               claims  \\\n",
       "0    1-10. (canceled)  11. A method of providing a...   \n",
       "1    1. A compound of formula (I):   X1-(D)-Arg-X2...   \n",
       "2    1. A cannabinoid composition comprising: at l...   \n",
       "3    1. A genetically modified cell comprising a g...   \n",
       "4    1. A method of attenuating an aP2-mediated di...   \n",
       "5    1-19. (canceled)  20. A method of inhibiting ...   \n",
       "6    1. A pharmaceutical composition comprising a ...   \n",
       "7    1. A method of enforcing expression of an E-s...   \n",
       "8    1. An isolated antibody that binds to HER2, w...   \n",
       "9    1. A phosphor-containing drug activator activ...   \n",
       "10   1. A method of delivering a therapeutic prote...   \n",
       "11   1. A method of producing a whole coffee fruit...   \n",
       "12   1. A biocompatible polymer composite comprise...   \n",
       "13   1. A composition comprising a polypeptide con...   \n",
       "14   1. A chimeric recombinant protein comprising:...   \n",
       "15   1. A monomeric fusion protein comprising: a f...   \n",
       "16   1. A method of treating a patient who has can...   \n",
       "17   1-55. (canceled)  56. A method for delivering...   \n",
       "18   1. A polypeptide that inhibits cell necrosis,...   \n",
       "19   1. A zinc finger nuclease (ZFN) comprising le...   \n",
       "20   1. An isolated peptide comprising a kinase in...   \n",
       "\n",
       "                                          description  \\\n",
       "0   CROSS-REFERENCE TO RELATED APPLICATIONS The pr...   \n",
       "1   The present invention concerns retro-inverso p...   \n",
       "2   FIELD OF THE INVENTION The present invention r...   \n",
       "3   CROSS-REFERENCE TO RELATED APPLICATIONS The pr...   \n",
       "4   RELATED APPLICATIONS This application is a con...   \n",
       "5   CROSS-REFERENCE TO RELATED APPLICATIONS This a...   \n",
       "6   RELATED APPLICATION The present application cl...   \n",
       "7   CROSS-REFERENCE TO RELATED APPLICATIONS The pr...   \n",
       "8   CROSS-REFERENCE TO RELATED APPLICATIONS The pr...   \n",
       "9   CROSS REFERENCE TO RELATED APPLICATIONS This a...   \n",
       "10  RELATED APPLICATIONS This application claims p...   \n",
       "11  FIELD OF THE INVENTION The invention provides ...   \n",
       "12  FIELD The present disclosure relates to a bioc...   \n",
       "13  SEQUENCE LISTING The instant application conta...   \n",
       "14  CROSS REFERENCE TO RELATED APPLICATIONS Benefi...   \n",
       "15  FIELD OF THE INVENTION The present invention r...   \n",
       "16  CROSS REFERENCE TO RELATED APPLICATIONS This a...   \n",
       "17  RELATED APPLICATIONS This application is a con...   \n",
       "18  TECHNICAL FIELD The present invention relates ...   \n",
       "19  CROSS-REFERENCE TO RELATED APPLICATIONS This a...   \n",
       "20  CROSS-REFERENCE TO RELATED APPLICATIONS The fo...   \n",
       "\n",
       "                                 drawings_description  \\\n",
       "0   BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...   \n",
       "1   DESCRIPTION OF THE FIGURES FIG. 1 High degree ...   \n",
       "2   BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...   \n",
       "3   BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 shows...   \n",
       "4   BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1-8 ar...   \n",
       "5   BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1A-1D. ...   \n",
       "6   BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1F....   \n",
       "7   BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1A-FIG....   \n",
       "8   BRIEF DESCRIPTION OF THE FIGURES FIG. 1 shows ...   \n",
       "9   BRIEF DESCRIPTION OF THE FIGURES A more comple...   \n",
       "10  BRIEF DESCRIPTION OF THE FIGURES A more comple...   \n",
       "11  BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A and...   \n",
       "12  BRIEF DESCRIPTION OF THE DRAWINGS Embodiments ...   \n",
       "13  BRIEF DESCRIPTION OF THE DRAWINGS The novel fe...   \n",
       "14  BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1D:...   \n",
       "15  BRIEF DESCRIPTION OF THE FIGURES FIG. 1 shows ...   \n",
       "16  BRIEF DESCRIPTION OF THE DRAWINGS The patent o...   \n",
       "17  BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1B ...   \n",
       "18  DESCRIPTION OF DRAWINGS FIG. 1 shows the scree...   \n",
       "19  BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A and...   \n",
       "20  BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...   \n",
       "\n",
       "                                  drawings_file_paths  \\\n",
       "0   [US20190151472A1-20190523-D00001.TIF, US201901...   \n",
       "1   [US20190135863A1-20190509-D00001.TIF, US201901...   \n",
       "2   [US20190133992A1-20190509-D00001.TIF, US201901...   \n",
       "3   [US20190136261A1-20190509-D00001.TIF, US201901...   \n",
       "4   [US20190161536A1-20190530-D00001.TIF, US201901...   \n",
       "5   [US20190202865A1-20190704-D00001.TIF, US201902...   \n",
       "6   [US20190201532A1-20190704-D00001.TIF, US201902...   \n",
       "7   [US20190201444A1-20190704-D00000.TIF, US201902...   \n",
       "8   [US20190177429A1-20190613-D00001.TIF, US201901...   \n",
       "9   [US20190184190A1-20190620-D00000.TIF, US201901...   \n",
       "10  [US20190184190A1-20190620-D00000.TIF, US201901...   \n",
       "11  [US20190159474A1-20190530-D00000.TIF, US201901...   \n",
       "12  [US20190125691A1-20190502-D00000.TIF, US201901...   \n",
       "13  [US20190169260A1-20190606-D00001.TIF, US201901...   \n",
       "14  [US20190194282A1-20190627-D00000.TIF, US201901...   \n",
       "15  [US20190127440A1-20190502-D00001.TIF, US201901...   \n",
       "16  [US20190177383A1-20190613-D00001.TIF, US201901...   \n",
       "17  [US20190194689A1-20190627-D00001.TIF, US201901...   \n",
       "18  [US20190144517A1-20190516-D00001.TIF, US201901...   \n",
       "19  [US20190177709A1-20190613-D00000.TIF, US201901...   \n",
       "20  [US20190169583A1-20190606-D00001.TIF, US201901...   \n",
       "\n",
       "                                 invention_background  \\\n",
       "0   Gene therapy can be used to genetically engine...   \n",
       "1                                                       \n",
       "2   Formulations of bioactive compounds have been ...   \n",
       "3   Cells communicate with each other either by di...   \n",
       "4   Human adipocyte lipid-binding protein (aP2) be...   \n",
       "5   Throughout this application various publicatio...   \n",
       "6   Antibiotics are the main tools to treat infect...   \n",
       "7   Mesenchymal stem cells (MSCs) hold much promis...   \n",
       "8   Breast cancer is a highly significant cause of...   \n",
       "9   Field of Invention The invention relates to me...   \n",
       "10                                                      \n",
       "11  Coffee fruits are mainly produced in Africa an...   \n",
       "12  Controlled protein release is a key strategy t...   \n",
       "13  Cancer has a major impact on society across th...   \n",
       "14  Prostate cancer is the second most commonly di...   \n",
       "15  Thymic stromal lymphopoietin (TSLP) is an inte...   \n",
       "16  Ovarian Cancer With an estimated 239 000 new c...   \n",
       "17  Gene therapy has been investigated for deliver...   \n",
       "18  Tumor necrosis factor α (TNF) is a multifuncti...   \n",
       "19  When one considers that genome sequencing effo...   \n",
       "20                                                      \n",
       "\n",
       "                                      cross_reference  \\\n",
       "0   The present application is a divisional of U.S...   \n",
       "1                                                       \n",
       "2                                                       \n",
       "3   The present application claims the benefit of ...   \n",
       "4                                                       \n",
       "5   This application claims the benefit of U.S. Pr...   \n",
       "6                                                       \n",
       "7                                                       \n",
       "8   The present application is a divisional of U.S...   \n",
       "9                                                       \n",
       "10                                                      \n",
       "11                                                      \n",
       "12                                                      \n",
       "13                                                      \n",
       "14                                                      \n",
       "15                                                      \n",
       "16                                                      \n",
       "17                                                      \n",
       "18                                                      \n",
       "19  This application is filed pursuant to 35 U.S.C...   \n",
       "20                                                      \n",
       "\n",
       "                                              summary  \\\n",
       "0   The present invention describes compositions a...   \n",
       "1                                                       \n",
       "2   The present invention includes a cannabinoid c...   \n",
       "3   The present invention describes compositions a...   \n",
       "4   Anti-aP2 monoclonal antibodies and antigen bin...   \n",
       "5   The present invention discloses assays for ide...   \n",
       "6   Density-dependent drug failure is a form of an...   \n",
       "7   Despite the promise of these methods, there ex...   \n",
       "8   The invention provides anti-HER2 antibodies an...   \n",
       "9   In one embodiment, the present invention provi...   \n",
       "10  In certain embodiments, the invention provides...   \n",
       "11  It is found in the present invention that a wh...   \n",
       "12  The present invention provides a biocompatible...   \n",
       "13  There exists a pressing need for alternative a...   \n",
       "14  Described herein is an improved approach to th...   \n",
       "15  It is surprisingly shown herein that a monomer...   \n",
       "16  In a first aspect of the present invention, th...   \n",
       "17  Aspects of the invention, are based on the dis...   \n",
       "18  It is an object of the present invention to pr...   \n",
       "19  The present invention describes highly specifi...   \n",
       "20                                                      \n",
       "\n",
       "                                 detailed_description  \n",
       "0   Disclosed herein are expression cassettes for ...  \n",
       "1                                                      \n",
       "2   The present invention includes a composition o...  \n",
       "3   Disclosed herein are compositions and methods ...  \n",
       "4   Anti-aP2 monoclonal antibodies and antigen bin...  \n",
       "5   method is provided for identifying an agent as...  \n",
       "6   Pharmaceutical Compositions The present disclo...  \n",
       "7   In some embodiments, the present invention pro...  \n",
       "8   Reference will now be made in detail to certai...  \n",
       "9   The present invention sets forth a novel metho...  \n",
       "10  The invention is based at least in part on dev...  \n",
       "11  Unless otherwise defined herein, scientific an...  \n",
       "12  Various embodiments and aspects of the disclos...  \n",
       "13  The following description and examples illustr...  \n",
       "14  I. Terms Unless otherwise noted, technical ter...  \n",
       "15  The present invention will be described with r...  \n",
       "16  Stimulation of an immune response is dependent...  \n",
       "17  Adeno-associated virus (AAV) is a small (26 nm...  \n",
       "18                                                     \n",
       "19  Disclosed herein are compositions and methods ...  \n",
       "20  According to various embodiments, the present ...  "
      ]
     },
     "execution_count": 17,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "patents_df5 = pd.concat([patents_df4, detailed_desc_df], axis=1)\n",
    "patents_df5"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<hr>\n",
    "<br>\n",
    "\n",
    "<a id='section-3'></a>\n",
    "\n",
    "### - Append information about Chemical Structures in the patents"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Loading dependencies\n",
    "import subprocess\n",
    "import glob\n",
    "import pandas as pd\n",
    "import os\n",
    "import numpy as np"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "scrolled": true
   },
   "outputs": [],
   "source": [
    "# Extract SMILES notation\n",
    "\n",
    "# Loop through all folders and grab .tif image files\n",
    "for index, row in patents_df.iterrows():\n",
    "    \n",
    "    print('Recognizing structures in file US{}'.format(str(row['id'])))\n",
    "\n",
    "    # Select only main tiff image file and ignore supplementary ones\n",
    "    for _file in glob.glob('../Dataset/US{}*/*.TIF'.format(row['id'])):\n",
    "\n",
    "        # Check if folder with the current document name exists\n",
    "        if not os.path.exists('../temp/chemical-names-smiles/' + _file[11:35]):\n",
    "\n",
    "            # If folder does not exist, create it\n",
    "            os.makedirs('../temp/chemical-names-smiles/' + _file[11:35])\n",
    "\n",
    "        subprocess.check_call(['osra', '-r', '300', _file, \\\n",
    "                               '-w', '../temp/chemical-names-smiles/{}/{}.txt'.format(str(_file[11:35]), \\\n",
    "                                                                                      str(_file[11:35]))])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id</th>\n",
       "      <th>invention_title</th>\n",
       "      <th>abstract</th>\n",
       "      <th>claims</th>\n",
       "      <th>description</th>\n",
       "      <th>drawings_description</th>\n",
       "      <th>drawings_file_paths</th>\n",
       "      <th>invention_background</th>\n",
       "      <th>cross_reference</th>\n",
       "      <th>summary</th>\n",
       "      <th>detailed_description</th>\n",
       "      <th>chemical_compounds_smiles</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>20190151472</td>\n",
       "      <td>LIVER-SPECIFIC CONSTRUCTS, FACTOR VIII EXPRESS...</td>\n",
       "      <td>Described herein are constructs used for liver...</td>\n",
       "      <td>1-10. (canceled)  11. A method of providing a...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS The pr...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...</td>\n",
       "      <td>[US20190151472A1-20190523-D00001.TIF, US201901...</td>\n",
       "      <td>Gene therapy can be used to genetically engine...</td>\n",
       "      <td>The present application is a divisional of U.S...</td>\n",
       "      <td>The present invention describes compositions a...</td>\n",
       "      <td>Disclosed herein are expression cassettes for ...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>20190135863</td>\n",
       "      <td>RETRO-INVERSO PEPTIDE INHIBITORS OF CELL MIGRA...</td>\n",
       "      <td>The present invention discloses retro-inverso ...</td>\n",
       "      <td>1. A compound of formula (I):   X1-(D)-Arg-X2...</td>\n",
       "      <td>The present invention concerns retro-inverso p...</td>\n",
       "      <td>DESCRIPTION OF THE FIGURES FIG. 1 High degree ...</td>\n",
       "      <td>[US20190135863A1-20190509-D00001.TIF, US201901...</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>20190133992</td>\n",
       "      <td>CANNABINOID COMPOSITION HAVING AN OPTIMIZED FA...</td>\n",
       "      <td>A composition of matter for enhancing delivery...</td>\n",
       "      <td>1. A cannabinoid composition comprising: at l...</td>\n",
       "      <td>FIELD OF THE INVENTION The present invention r...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...</td>\n",
       "      <td>[US20190133992A1-20190509-D00001.TIF, US201901...</td>\n",
       "      <td>Formulations of bioactive compounds have been ...</td>\n",
       "      <td></td>\n",
       "      <td>The present invention includes a cannabinoid c...</td>\n",
       "      <td>The present invention includes a composition o...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>20190136261</td>\n",
       "      <td>GENETIC MODIFICATION OF CYTOKINE INDUCIBLE SH2...</td>\n",
       "      <td>The present disclosure is in the field of geno...</td>\n",
       "      <td>1. A genetically modified cell comprising a g...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS The pr...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 shows...</td>\n",
       "      <td>[US20190136261A1-20190509-D00001.TIF, US201901...</td>\n",
       "      <td>Cells communicate with each other either by di...</td>\n",
       "      <td>The present application claims the benefit of ...</td>\n",
       "      <td>The present invention describes compositions a...</td>\n",
       "      <td>Disclosed herein are compositions and methods ...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>20190161536</td>\n",
       "      <td>ANTI-AP2 ANTIBODIES AND ANTIGEN BINDING AGENTS...</td>\n",
       "      <td>This invention is in the area of improved anti...</td>\n",
       "      <td>1. A method of attenuating an aP2-mediated di...</td>\n",
       "      <td>RELATED APPLICATIONS This application is a con...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1-8 ar...</td>\n",
       "      <td>[US20190161536A1-20190530-D00001.TIF, US201901...</td>\n",
       "      <td>Human adipocyte lipid-binding protein (aP2) be...</td>\n",
       "      <td></td>\n",
       "      <td>Anti-aP2 monoclonal antibodies and antigen bin...</td>\n",
       "      <td>Anti-aP2 monoclonal antibodies and antigen bin...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>20190202865</td>\n",
       "      <td>TARGETING DIMERIZATION OF BAX TO MODULATE BAX ...</td>\n",
       "      <td>Methods are provided for identifying an agent ...</td>\n",
       "      <td>1-19. (canceled)  20. A method of inhibiting ...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS This a...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1A-1D. ...</td>\n",
       "      <td>[US20190202865A1-20190704-D00001.TIF, US201902...</td>\n",
       "      <td>Throughout this application various publicatio...</td>\n",
       "      <td>This application claims the benefit of U.S. Pr...</td>\n",
       "      <td>The present invention discloses assays for ide...</td>\n",
       "      <td>method is provided for identifying an agent as...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>20190201532</td>\n",
       "      <td>SENSITIZATION OF BACTERIAL CELLS TO QUINOLONE ...</td>\n",
       "      <td>Provided herein are pharmaceutical composition...</td>\n",
       "      <td>1. A pharmaceutical composition comprising a ...</td>\n",
       "      <td>RELATED APPLICATION The present application cl...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1F....</td>\n",
       "      <td>[US20190201532A1-20190704-D00001.TIF, US201902...</td>\n",
       "      <td>Antibiotics are the main tools to treat infect...</td>\n",
       "      <td></td>\n",
       "      <td>Density-dependent drug failure is a form of an...</td>\n",
       "      <td>Pharmaceutical Compositions The present disclo...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>20190201444</td>\n",
       "      <td>GLYCOENGINEERING OF E-SELECTIN LIGANDS</td>\n",
       "      <td>The present invention provides methods of enfo...</td>\n",
       "      <td>1. A method of enforcing expression of an E-s...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS The pr...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1A-FIG....</td>\n",
       "      <td>[US20190201444A1-20190704-D00000.TIF, US201902...</td>\n",
       "      <td>Mesenchymal stem cells (MSCs) hold much promis...</td>\n",
       "      <td></td>\n",
       "      <td>Despite the promise of these methods, there ex...</td>\n",
       "      <td>In some embodiments, the present invention pro...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>20190177429</td>\n",
       "      <td>Anti-HER2 Antibodies and Immunoconjugates</td>\n",
       "      <td>The invention provides anti-HER2 antibodies an...</td>\n",
       "      <td>1. An isolated antibody that binds to HER2, w...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS The pr...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE FIGURES FIG. 1 shows ...</td>\n",
       "      <td>[US20190177429A1-20190613-D00001.TIF, US201901...</td>\n",
       "      <td>Breast cancer is a highly significant cause of...</td>\n",
       "      <td>The present application is a divisional of U.S...</td>\n",
       "      <td>The invention provides anti-HER2 antibodies an...</td>\n",
       "      <td>Reference will now be made in detail to certai...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>20190184190</td>\n",
       "      <td>PHOSPHOR-CONTAINING DRUG ACTIVATOR ACTIVATABLE...</td>\n",
       "      <td>A phosphor-containing drug activator activatab...</td>\n",
       "      <td>1. A phosphor-containing drug activator activ...</td>\n",
       "      <td>CROSS REFERENCE TO RELATED APPLICATIONS This a...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE FIGURES A more comple...</td>\n",
       "      <td>[US20190184190A1-20190620-D00000.TIF, US201901...</td>\n",
       "      <td>Field of Invention The invention relates to me...</td>\n",
       "      <td></td>\n",
       "      <td>In one embodiment, the present invention provi...</td>\n",
       "      <td>The present invention sets forth a novel metho...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>20190192693</td>\n",
       "      <td>METHODS AND VECTORS FOR TREATING CNS DISORDERS</td>\n",
       "      <td>Methods and uses of treating a disease in a ma...</td>\n",
       "      <td>1. A method of delivering a therapeutic prote...</td>\n",
       "      <td>RELATED APPLICATIONS This application claims p...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE FIGURES A more comple...</td>\n",
       "      <td>[US20190184190A1-20190620-D00000.TIF, US201901...</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>In certain embodiments, the invention provides...</td>\n",
       "      <td>The invention is based at least in part on dev...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>20190159474</td>\n",
       "      <td>AMELIORATIVE EFFECTS OF A WHOLE COFFEE FRUIT E...</td>\n",
       "      <td>The invention provides a method of extracting ...</td>\n",
       "      <td>1. A method of producing a whole coffee fruit...</td>\n",
       "      <td>FIELD OF THE INVENTION The invention provides ...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A and...</td>\n",
       "      <td>[US20190159474A1-20190530-D00000.TIF, US201901...</td>\n",
       "      <td>Coffee fruits are mainly produced in Africa an...</td>\n",
       "      <td></td>\n",
       "      <td>It is found in the present invention that a wh...</td>\n",
       "      <td>Unless otherwise defined herein, scientific an...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>20190125691</td>\n",
       "      <td>ENCAPSULATION-FREE CONTROLLED PROTEIN RELEASE ...</td>\n",
       "      <td>The present disclosure provides a delivery sys...</td>\n",
       "      <td>1. A biocompatible polymer composite comprise...</td>\n",
       "      <td>FIELD The present disclosure relates to a bioc...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS Embodiments ...</td>\n",
       "      <td>[US20190125691A1-20190502-D00000.TIF, US201901...</td>\n",
       "      <td>Controlled protein release is a key strategy t...</td>\n",
       "      <td></td>\n",
       "      <td>The present invention provides a biocompatible...</td>\n",
       "      <td>Various embodiments and aspects of the disclos...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>20190169260</td>\n",
       "      <td>Human Leukocyte Antigen Restricted Gamma Delta...</td>\n",
       "      <td>Disclosed herein are compositions and methods ...</td>\n",
       "      <td>1. A composition comprising a polypeptide con...</td>\n",
       "      <td>SEQUENCE LISTING The instant application conta...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS The novel fe...</td>\n",
       "      <td>[US20190169260A1-20190606-D00001.TIF, US201901...</td>\n",
       "      <td>Cancer has a major impact on society across th...</td>\n",
       "      <td></td>\n",
       "      <td>There exists a pressing need for alternative a...</td>\n",
       "      <td>The following description and examples illustr...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>20190194282</td>\n",
       "      <td>CHIMERIC PROTEINS FOR TARGETING dsRNA</td>\n",
       "      <td>Described herein are recombinant chimeric prot...</td>\n",
       "      <td>1. A chimeric recombinant protein comprising:...</td>\n",
       "      <td>CROSS REFERENCE TO RELATED APPLICATIONS Benefi...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1D:...</td>\n",
       "      <td>[US20190194282A1-20190627-D00000.TIF, US201901...</td>\n",
       "      <td>Prostate cancer is the second most commonly di...</td>\n",
       "      <td></td>\n",
       "      <td>Described herein is an improved approach to th...</td>\n",
       "      <td>I. Terms Unless otherwise noted, technical ter...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>20190127440</td>\n",
       "      <td>NOVEL TSLP INHIBITORS</td>\n",
       "      <td>The present invention relates to monomeric fus...</td>\n",
       "      <td>1. A monomeric fusion protein comprising: a f...</td>\n",
       "      <td>FIELD OF THE INVENTION The present invention r...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE FIGURES FIG. 1 shows ...</td>\n",
       "      <td>[US20190127440A1-20190502-D00001.TIF, US201901...</td>\n",
       "      <td>Thymic stromal lymphopoietin (TSLP) is an inte...</td>\n",
       "      <td></td>\n",
       "      <td>It is surprisingly shown herein that a monomer...</td>\n",
       "      <td>The present invention will be described with r...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>20190177383</td>\n",
       "      <td>NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR...</td>\n",
       "      <td>The present invention relates to peptides, pro...</td>\n",
       "      <td>1. A method of treating a patient who has can...</td>\n",
       "      <td>CROSS REFERENCE TO RELATED APPLICATIONS This a...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS The patent o...</td>\n",
       "      <td>[US20190177383A1-20190613-D00001.TIF, US201901...</td>\n",
       "      <td>Ovarian Cancer With an estimated 239 000 new c...</td>\n",
       "      <td></td>\n",
       "      <td>In a first aspect of the present invention, th...</td>\n",
       "      <td>Stimulation of an immune response is dependent...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>20190194689</td>\n",
       "      <td>CNS TARGETING AAV VECTORS AND METHODS OF USE T...</td>\n",
       "      <td>The invention in some aspects relates to recom...</td>\n",
       "      <td>1-55. (canceled)  56. A method for delivering...</td>\n",
       "      <td>RELATED APPLICATIONS This application is a con...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1B ...</td>\n",
       "      <td>[US20190194689A1-20190627-D00001.TIF, US201901...</td>\n",
       "      <td>Gene therapy has been investigated for deliver...</td>\n",
       "      <td></td>\n",
       "      <td>Aspects of the invention, are based on the dis...</td>\n",
       "      <td>Adeno-associated virus (AAV) is a small (26 nm...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>20190144517</td>\n",
       "      <td>PROTEIN FOR NEUTRALIZING PROGRAMMED NECROCYTOS...</td>\n",
       "      <td>Provided is polypeptide which derives from wil...</td>\n",
       "      <td>1. A polypeptide that inhibits cell necrosis,...</td>\n",
       "      <td>TECHNICAL FIELD The present invention relates ...</td>\n",
       "      <td>DESCRIPTION OF DRAWINGS FIG. 1 shows the scree...</td>\n",
       "      <td>[US20190144517A1-20190516-D00001.TIF, US201901...</td>\n",
       "      <td>Tumor necrosis factor α (TNF) is a multifuncti...</td>\n",
       "      <td></td>\n",
       "      <td>It is an object of the present invention to pr...</td>\n",
       "      <td></td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>20190177709</td>\n",
       "      <td>REGULATION OF GENE EXPRESSION USING ENGINEERED...</td>\n",
       "      <td>The present disclosure is in the field of geno...</td>\n",
       "      <td>1. A zinc finger nuclease (ZFN) comprising le...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS This a...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A and...</td>\n",
       "      <td>[US20190177709A1-20190613-D00000.TIF, US201901...</td>\n",
       "      <td>When one considers that genome sequencing effo...</td>\n",
       "      <td>This application is filed pursuant to 35 U.S.C...</td>\n",
       "      <td>The present invention describes highly specifi...</td>\n",
       "      <td>Disclosed herein are compositions and methods ...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>20190169583</td>\n",
       "      <td>STEP-Derived Peptide for Brain Injury Treatment</td>\n",
       "      <td>A novel peptide sequence that is a modified de...</td>\n",
       "      <td>1. An isolated peptide comprising a kinase in...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS The fo...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...</td>\n",
       "      <td>[US20190169583A1-20190606-D00001.TIF, US201901...</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>According to various embodiments, the present ...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "             id                                    invention_title  \\\n",
       "0   20190151472  LIVER-SPECIFIC CONSTRUCTS, FACTOR VIII EXPRESS...   \n",
       "1   20190135863  RETRO-INVERSO PEPTIDE INHIBITORS OF CELL MIGRA...   \n",
       "2   20190133992  CANNABINOID COMPOSITION HAVING AN OPTIMIZED FA...   \n",
       "3   20190136261  GENETIC MODIFICATION OF CYTOKINE INDUCIBLE SH2...   \n",
       "4   20190161536  ANTI-AP2 ANTIBODIES AND ANTIGEN BINDING AGENTS...   \n",
       "5   20190202865  TARGETING DIMERIZATION OF BAX TO MODULATE BAX ...   \n",
       "6   20190201532  SENSITIZATION OF BACTERIAL CELLS TO QUINOLONE ...   \n",
       "7   20190201444             GLYCOENGINEERING OF E-SELECTIN LIGANDS   \n",
       "8   20190177429          Anti-HER2 Antibodies and Immunoconjugates   \n",
       "9   20190184190  PHOSPHOR-CONTAINING DRUG ACTIVATOR ACTIVATABLE...   \n",
       "10  20190192693     METHODS AND VECTORS FOR TREATING CNS DISORDERS   \n",
       "11  20190159474  AMELIORATIVE EFFECTS OF A WHOLE COFFEE FRUIT E...   \n",
       "12  20190125691  ENCAPSULATION-FREE CONTROLLED PROTEIN RELEASE ...   \n",
       "13  20190169260  Human Leukocyte Antigen Restricted Gamma Delta...   \n",
       "14  20190194282              CHIMERIC PROTEINS FOR TARGETING dsRNA   \n",
       "15  20190127440                              NOVEL TSLP INHIBITORS   \n",
       "16  20190177383  NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR...   \n",
       "17  20190194689  CNS TARGETING AAV VECTORS AND METHODS OF USE T...   \n",
       "18  20190144517  PROTEIN FOR NEUTRALIZING PROGRAMMED NECROCYTOS...   \n",
       "19  20190177709  REGULATION OF GENE EXPRESSION USING ENGINEERED...   \n",
       "20  20190169583    STEP-Derived Peptide for Brain Injury Treatment   \n",
       "\n",
       "                                             abstract  \\\n",
       "0   Described herein are constructs used for liver...   \n",
       "1   The present invention discloses retro-inverso ...   \n",
       "2   A composition of matter for enhancing delivery...   \n",
       "3   The present disclosure is in the field of geno...   \n",
       "4   This invention is in the area of improved anti...   \n",
       "5   Methods are provided for identifying an agent ...   \n",
       "6   Provided herein are pharmaceutical composition...   \n",
       "7   The present invention provides methods of enfo...   \n",
       "8   The invention provides anti-HER2 antibodies an...   \n",
       "9   A phosphor-containing drug activator activatab...   \n",
       "10  Methods and uses of treating a disease in a ma...   \n",
       "11  The invention provides a method of extracting ...   \n",
       "12  The present disclosure provides a delivery sys...   \n",
       "13  Disclosed herein are compositions and methods ...   \n",
       "14  Described herein are recombinant chimeric prot...   \n",
       "15  The present invention relates to monomeric fus...   \n",
       "16  The present invention relates to peptides, pro...   \n",
       "17  The invention in some aspects relates to recom...   \n",
       "18  Provided is polypeptide which derives from wil...   \n",
       "19  The present disclosure is in the field of geno...   \n",
       "20  A novel peptide sequence that is a modified de...   \n",
       "\n",
       "                                               claims  \\\n",
       "0    1-10. (canceled)  11. A method of providing a...   \n",
       "1    1. A compound of formula (I):   X1-(D)-Arg-X2...   \n",
       "2    1. A cannabinoid composition comprising: at l...   \n",
       "3    1. A genetically modified cell comprising a g...   \n",
       "4    1. A method of attenuating an aP2-mediated di...   \n",
       "5    1-19. (canceled)  20. A method of inhibiting ...   \n",
       "6    1. A pharmaceutical composition comprising a ...   \n",
       "7    1. A method of enforcing expression of an E-s...   \n",
       "8    1. An isolated antibody that binds to HER2, w...   \n",
       "9    1. A phosphor-containing drug activator activ...   \n",
       "10   1. A method of delivering a therapeutic prote...   \n",
       "11   1. A method of producing a whole coffee fruit...   \n",
       "12   1. A biocompatible polymer composite comprise...   \n",
       "13   1. A composition comprising a polypeptide con...   \n",
       "14   1. A chimeric recombinant protein comprising:...   \n",
       "15   1. A monomeric fusion protein comprising: a f...   \n",
       "16   1. A method of treating a patient who has can...   \n",
       "17   1-55. (canceled)  56. A method for delivering...   \n",
       "18   1. A polypeptide that inhibits cell necrosis,...   \n",
       "19   1. A zinc finger nuclease (ZFN) comprising le...   \n",
       "20   1. An isolated peptide comprising a kinase in...   \n",
       "\n",
       "                                          description  \\\n",
       "0   CROSS-REFERENCE TO RELATED APPLICATIONS The pr...   \n",
       "1   The present invention concerns retro-inverso p...   \n",
       "2   FIELD OF THE INVENTION The present invention r...   \n",
       "3   CROSS-REFERENCE TO RELATED APPLICATIONS The pr...   \n",
       "4   RELATED APPLICATIONS This application is a con...   \n",
       "5   CROSS-REFERENCE TO RELATED APPLICATIONS This a...   \n",
       "6   RELATED APPLICATION The present application cl...   \n",
       "7   CROSS-REFERENCE TO RELATED APPLICATIONS The pr...   \n",
       "8   CROSS-REFERENCE TO RELATED APPLICATIONS The pr...   \n",
       "9   CROSS REFERENCE TO RELATED APPLICATIONS This a...   \n",
       "10  RELATED APPLICATIONS This application claims p...   \n",
       "11  FIELD OF THE INVENTION The invention provides ...   \n",
       "12  FIELD The present disclosure relates to a bioc...   \n",
       "13  SEQUENCE LISTING The instant application conta...   \n",
       "14  CROSS REFERENCE TO RELATED APPLICATIONS Benefi...   \n",
       "15  FIELD OF THE INVENTION The present invention r...   \n",
       "16  CROSS REFERENCE TO RELATED APPLICATIONS This a...   \n",
       "17  RELATED APPLICATIONS This application is a con...   \n",
       "18  TECHNICAL FIELD The present invention relates ...   \n",
       "19  CROSS-REFERENCE TO RELATED APPLICATIONS This a...   \n",
       "20  CROSS-REFERENCE TO RELATED APPLICATIONS The fo...   \n",
       "\n",
       "                                 drawings_description  \\\n",
       "0   BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...   \n",
       "1   DESCRIPTION OF THE FIGURES FIG. 1 High degree ...   \n",
       "2   BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...   \n",
       "3   BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 shows...   \n",
       "4   BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1-8 ar...   \n",
       "5   BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1A-1D. ...   \n",
       "6   BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1F....   \n",
       "7   BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1A-FIG....   \n",
       "8   BRIEF DESCRIPTION OF THE FIGURES FIG. 1 shows ...   \n",
       "9   BRIEF DESCRIPTION OF THE FIGURES A more comple...   \n",
       "10  BRIEF DESCRIPTION OF THE FIGURES A more comple...   \n",
       "11  BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A and...   \n",
       "12  BRIEF DESCRIPTION OF THE DRAWINGS Embodiments ...   \n",
       "13  BRIEF DESCRIPTION OF THE DRAWINGS The novel fe...   \n",
       "14  BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1D:...   \n",
       "15  BRIEF DESCRIPTION OF THE FIGURES FIG. 1 shows ...   \n",
       "16  BRIEF DESCRIPTION OF THE DRAWINGS The patent o...   \n",
       "17  BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1B ...   \n",
       "18  DESCRIPTION OF DRAWINGS FIG. 1 shows the scree...   \n",
       "19  BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A and...   \n",
       "20  BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...   \n",
       "\n",
       "                                  drawings_file_paths  \\\n",
       "0   [US20190151472A1-20190523-D00001.TIF, US201901...   \n",
       "1   [US20190135863A1-20190509-D00001.TIF, US201901...   \n",
       "2   [US20190133992A1-20190509-D00001.TIF, US201901...   \n",
       "3   [US20190136261A1-20190509-D00001.TIF, US201901...   \n",
       "4   [US20190161536A1-20190530-D00001.TIF, US201901...   \n",
       "5   [US20190202865A1-20190704-D00001.TIF, US201902...   \n",
       "6   [US20190201532A1-20190704-D00001.TIF, US201902...   \n",
       "7   [US20190201444A1-20190704-D00000.TIF, US201902...   \n",
       "8   [US20190177429A1-20190613-D00001.TIF, US201901...   \n",
       "9   [US20190184190A1-20190620-D00000.TIF, US201901...   \n",
       "10  [US20190184190A1-20190620-D00000.TIF, US201901...   \n",
       "11  [US20190159474A1-20190530-D00000.TIF, US201901...   \n",
       "12  [US20190125691A1-20190502-D00000.TIF, US201901...   \n",
       "13  [US20190169260A1-20190606-D00001.TIF, US201901...   \n",
       "14  [US20190194282A1-20190627-D00000.TIF, US201901...   \n",
       "15  [US20190127440A1-20190502-D00001.TIF, US201901...   \n",
       "16  [US20190177383A1-20190613-D00001.TIF, US201901...   \n",
       "17  [US20190194689A1-20190627-D00001.TIF, US201901...   \n",
       "18  [US20190144517A1-20190516-D00001.TIF, US201901...   \n",
       "19  [US20190177709A1-20190613-D00000.TIF, US201901...   \n",
       "20  [US20190169583A1-20190606-D00001.TIF, US201901...   \n",
       "\n",
       "                                 invention_background  \\\n",
       "0   Gene therapy can be used to genetically engine...   \n",
       "1                                                       \n",
       "2   Formulations of bioactive compounds have been ...   \n",
       "3   Cells communicate with each other either by di...   \n",
       "4   Human adipocyte lipid-binding protein (aP2) be...   \n",
       "5   Throughout this application various publicatio...   \n",
       "6   Antibiotics are the main tools to treat infect...   \n",
       "7   Mesenchymal stem cells (MSCs) hold much promis...   \n",
       "8   Breast cancer is a highly significant cause of...   \n",
       "9   Field of Invention The invention relates to me...   \n",
       "10                                                      \n",
       "11  Coffee fruits are mainly produced in Africa an...   \n",
       "12  Controlled protein release is a key strategy t...   \n",
       "13  Cancer has a major impact on society across th...   \n",
       "14  Prostate cancer is the second most commonly di...   \n",
       "15  Thymic stromal lymphopoietin (TSLP) is an inte...   \n",
       "16  Ovarian Cancer With an estimated 239 000 new c...   \n",
       "17  Gene therapy has been investigated for deliver...   \n",
       "18  Tumor necrosis factor α (TNF) is a multifuncti...   \n",
       "19  When one considers that genome sequencing effo...   \n",
       "20                                                      \n",
       "\n",
       "                                      cross_reference  \\\n",
       "0   The present application is a divisional of U.S...   \n",
       "1                                                       \n",
       "2                                                       \n",
       "3   The present application claims the benefit of ...   \n",
       "4                                                       \n",
       "5   This application claims the benefit of U.S. Pr...   \n",
       "6                                                       \n",
       "7                                                       \n",
       "8   The present application is a divisional of U.S...   \n",
       "9                                                       \n",
       "10                                                      \n",
       "11                                                      \n",
       "12                                                      \n",
       "13                                                      \n",
       "14                                                      \n",
       "15                                                      \n",
       "16                                                      \n",
       "17                                                      \n",
       "18                                                      \n",
       "19  This application is filed pursuant to 35 U.S.C...   \n",
       "20                                                      \n",
       "\n",
       "                                              summary  \\\n",
       "0   The present invention describes compositions a...   \n",
       "1                                                       \n",
       "2   The present invention includes a cannabinoid c...   \n",
       "3   The present invention describes compositions a...   \n",
       "4   Anti-aP2 monoclonal antibodies and antigen bin...   \n",
       "5   The present invention discloses assays for ide...   \n",
       "6   Density-dependent drug failure is a form of an...   \n",
       "7   Despite the promise of these methods, there ex...   \n",
       "8   The invention provides anti-HER2 antibodies an...   \n",
       "9   In one embodiment, the present invention provi...   \n",
       "10  In certain embodiments, the invention provides...   \n",
       "11  It is found in the present invention that a wh...   \n",
       "12  The present invention provides a biocompatible...   \n",
       "13  There exists a pressing need for alternative a...   \n",
       "14  Described herein is an improved approach to th...   \n",
       "15  It is surprisingly shown herein that a monomer...   \n",
       "16  In a first aspect of the present invention, th...   \n",
       "17  Aspects of the invention, are based on the dis...   \n",
       "18  It is an object of the present invention to pr...   \n",
       "19  The present invention describes highly specifi...   \n",
       "20                                                      \n",
       "\n",
       "                                 detailed_description  \\\n",
       "0   Disclosed herein are expression cassettes for ...   \n",
       "1                                                       \n",
       "2   The present invention includes a composition o...   \n",
       "3   Disclosed herein are compositions and methods ...   \n",
       "4   Anti-aP2 monoclonal antibodies and antigen bin...   \n",
       "5   method is provided for identifying an agent as...   \n",
       "6   Pharmaceutical Compositions The present disclo...   \n",
       "7   In some embodiments, the present invention pro...   \n",
       "8   Reference will now be made in detail to certai...   \n",
       "9   The present invention sets forth a novel metho...   \n",
       "10  The invention is based at least in part on dev...   \n",
       "11  Unless otherwise defined herein, scientific an...   \n",
       "12  Various embodiments and aspects of the disclos...   \n",
       "13  The following description and examples illustr...   \n",
       "14  I. Terms Unless otherwise noted, technical ter...   \n",
       "15  The present invention will be described with r...   \n",
       "16  Stimulation of an immune response is dependent...   \n",
       "17  Adeno-associated virus (AAV) is a small (26 nm...   \n",
       "18                                                      \n",
       "19  Disclosed herein are compositions and methods ...   \n",
       "20  According to various embodiments, the present ...   \n",
       "\n",
       "    chemical_compounds_smiles  \n",
       "0                         NaN  \n",
       "1                         NaN  \n",
       "2                         NaN  \n",
       "3                         NaN  \n",
       "4                         NaN  \n",
       "5                         NaN  \n",
       "6                         NaN  \n",
       "7                         NaN  \n",
       "8                         NaN  \n",
       "9                         NaN  \n",
       "10                        NaN  \n",
       "11                        NaN  \n",
       "12                        NaN  \n",
       "13                        NaN  \n",
       "14                        NaN  \n",
       "15                        NaN  \n",
       "16                        NaN  \n",
       "17                        NaN  \n",
       "18                        NaN  \n",
       "19                        NaN  \n",
       "20                        NaN  "
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "patents_df5['chemical_compounds_smiles'] = np.nan\n",
    "patents_df5"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Reading SMILES in file US20190151472\n",
      "Reading SMILES in file US20190135863\n",
      "Reading SMILES in file US20190133992\n",
      "Reading SMILES in file US20190136261\n",
      "Reading SMILES in file US20190161536\n",
      "Reading SMILES in file US20190202865\n",
      "Reading SMILES in file US20190201532\n",
      "Reading SMILES in file US20190201444\n",
      "Reading SMILES in file US20190177429\n",
      "Reading SMILES in file US20190184190\n",
      "Reading SMILES in file US20190159474\n",
      "Reading SMILES in file US20190125691\n",
      "Reading SMILES in file US20190169260\n",
      "Reading SMILES in file US20190194282\n",
      "Reading SMILES in file US20190127440\n",
      "Reading SMILES in file US20190177383\n",
      "Reading SMILES in file US20190194689\n",
      "Reading SMILES in file US20190144517\n",
      "Reading SMILES in file US20190177709\n",
      "Reading SMILES in file US20190169583\n",
      "Reading SMILES in file US20190202879\n",
      "Reading SMILES in file US20190167778\n",
      "Reading SMILES in file US20190125672\n",
      "Reading SMILES in file US20190153497\n",
      "Reading SMILES in file US20190161548\n",
      "Reading SMILES in file US20190167567\n",
      "Reading SMILES in file US20190191675\n",
      "Reading SMILES in file US20190203282\n",
      "Reading SMILES in file US20190153054\n",
      "Reading SMILES in file US20190169640\n",
      "Reading SMILES in file US20190125799\n",
      "Reading SMILES in file US20190153063\n",
      "Reading SMILES in file US20190144569\n",
      "Reading SMILES in file US20190209619\n",
      "Reading SMILES in file US20190153036\n",
      "Reading SMILES in file US20190211088\n",
      "Reading SMILES in file US20190201390\n",
      "Reading SMILES in file US20190203228\n",
      "Reading SMILES in file US20190142960\n",
      "Reading SMILES in file US20190183927\n",
      "Reading SMILES in file US20190216685\n",
      "Reading SMILES in file US20190169615\n",
      "Reading SMILES in file US20190134147\n",
      "Reading SMILES in file US20190160188\n",
      "Reading SMILES in file US20190192625\n",
      "Reading SMILES in file US20190202886\n",
      "Reading SMILES in file US20190169701\n",
      "Reading SMILES in file US20190153115\n",
      "Reading SMILES in file US20190135741\n",
      "Reading SMILES in file US20190153104\n",
      "Reading SMILES in file US20190216780\n",
      "Reading SMILES in file US20190183936\n",
      "Reading SMILES in file US20190134156\n",
      "Reading SMILES in file US20190135891\n",
      "Reading SMILES in file US20190127724\n",
      "Reading SMILES in file US20190209608\n",
      "Reading SMILES in file US20190216926\n",
      "Reading SMILES in file US20190127713\n",
      "Reading SMILES in file US20190192508\n",
      "Reading SMILES in file US20190185551\n",
      "Reading SMILES in file US20190133935\n",
      "Reading SMILES in file US20190151380\n",
      "Reading SMILES in file US20190153045\n"
     ]
    }
   ],
   "source": [
    "# Loop through all text files\n",
    "for folder in glob.glob('../temp/chemical-names-smiles/*'): \n",
    "    \n",
    "    print('Reading SMILES in file {}'.format(str(folder[30:-11])))\n",
    "    smiles_for_one = ''\n",
    "    \n",
    "    # Checking integrity, writing to same file\n",
    "    if ([folder[32:-11] == item[1]['id'] for item in patents_df.iterrows()]):\n",
    "        \n",
    "        for _file in glob.glob('{}/*.txt'.format(folder)):\n",
    "            \n",
    "            # Read each file and append each line that represents a compound\n",
    "            # to an array\n",
    "            one = ''\n",
    "\n",
    "            with open(_file, 'r') as smiles_file:\n",
    "                one = smiles_file.read()\n",
    "\n",
    "            if one != '':\n",
    "                smiles_for_one += str(one.split())\n",
    "        \n",
    "        # Append to dataframe row-by-row to ensure alignment\n",
    "        patents_df5.loc[patents_df5['id'] == folder[32:-11], ['chemical_compounds_smiles']] = \\\n",
    "        smiles_for_one\n",
    "\n",
    "    else:\n",
    "        print('No structures recognized in this file..')\n",
    "        patents_df5.loc[patents_df5['id'] == folder[32:-11], ['chemical_compounds_smiles']] = \\\n",
    "        ' '"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['C1*CCCC1', 'C1CCCCC1', 'C*CCCC1*CC*21CCCCC2']\n"
     ]
    }
   ],
   "source": [
    "print(patents_df5['chemical_compounds_smiles'][17])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id</th>\n",
       "      <th>invention_title</th>\n",
       "      <th>abstract</th>\n",
       "      <th>claims</th>\n",
       "      <th>description</th>\n",
       "      <th>drawings_description</th>\n",
       "      <th>drawings_file_paths</th>\n",
       "      <th>invention_background</th>\n",
       "      <th>cross_reference</th>\n",
       "      <th>summary</th>\n",
       "      <th>detailed_description</th>\n",
       "      <th>chemical_compounds_smiles</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>20190151472</td>\n",
       "      <td>LIVER-SPECIFIC CONSTRUCTS, FACTOR VIII EXPRESS...</td>\n",
       "      <td>Described herein are constructs used for liver...</td>\n",
       "      <td>1-10. (canceled)  11. A method of providing a...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS The pr...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...</td>\n",
       "      <td>[US20190151472A1-20190523-D00001.TIF, US201901...</td>\n",
       "      <td>Gene therapy can be used to genetically engine...</td>\n",
       "      <td>The present application is a divisional of U.S...</td>\n",
       "      <td>The present invention describes compositions a...</td>\n",
       "      <td>Disclosed herein are expression cassettes for ...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>20190135863</td>\n",
       "      <td>RETRO-INVERSO PEPTIDE INHIBITORS OF CELL MIGRA...</td>\n",
       "      <td>The present invention discloses retro-inverso ...</td>\n",
       "      <td>1. A compound of formula (I):   X1-(D)-Arg-X2...</td>\n",
       "      <td>The present invention concerns retro-inverso p...</td>\n",
       "      <td>DESCRIPTION OF THE FIGURES FIG. 1 High degree ...</td>\n",
       "      <td>[US20190135863A1-20190509-D00001.TIF, US201901...</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>20190133992</td>\n",
       "      <td>CANNABINOID COMPOSITION HAVING AN OPTIMIZED FA...</td>\n",
       "      <td>A composition of matter for enhancing delivery...</td>\n",
       "      <td>1. A cannabinoid composition comprising: at l...</td>\n",
       "      <td>FIELD OF THE INVENTION The present invention r...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...</td>\n",
       "      <td>[US20190133992A1-20190509-D00001.TIF, US201901...</td>\n",
       "      <td>Formulations of bioactive compounds have been ...</td>\n",
       "      <td></td>\n",
       "      <td>The present invention includes a cannabinoid c...</td>\n",
       "      <td>The present invention includes a composition o...</td>\n",
       "      <td>['CCCCCC/C=C\\\\CCCCCCCC(=*1CCCCC1)C1*C*(C1)*']</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>20190136261</td>\n",
       "      <td>GENETIC MODIFICATION OF CYTOKINE INDUCIBLE SH2...</td>\n",
       "      <td>The present disclosure is in the field of geno...</td>\n",
       "      <td>1. A genetically modified cell comprising a g...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS The pr...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 shows...</td>\n",
       "      <td>[US20190136261A1-20190509-D00001.TIF, US201901...</td>\n",
       "      <td>Cells communicate with each other either by di...</td>\n",
       "      <td>The present application claims the benefit of ...</td>\n",
       "      <td>The present invention describes compositions a...</td>\n",
       "      <td>Disclosed herein are compositions and methods ...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>20190161536</td>\n",
       "      <td>ANTI-AP2 ANTIBODIES AND ANTIGEN BINDING AGENTS...</td>\n",
       "      <td>This invention is in the area of improved anti...</td>\n",
       "      <td>1. A method of attenuating an aP2-mediated di...</td>\n",
       "      <td>RELATED APPLICATIONS This application is a con...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1-8 ar...</td>\n",
       "      <td>[US20190161536A1-20190530-D00001.TIF, US201901...</td>\n",
       "      <td>Human adipocyte lipid-binding protein (aP2) be...</td>\n",
       "      <td></td>\n",
       "      <td>Anti-aP2 monoclonal antibodies and antigen bin...</td>\n",
       "      <td>Anti-aP2 monoclonal antibodies and antigen bin...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>20190202865</td>\n",
       "      <td>TARGETING DIMERIZATION OF BAX TO MODULATE BAX ...</td>\n",
       "      <td>Methods are provided for identifying an agent ...</td>\n",
       "      <td>1-19. (canceled)  20. A method of inhibiting ...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS This a...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1A-1D. ...</td>\n",
       "      <td>[US20190202865A1-20190704-D00001.TIF, US201902...</td>\n",
       "      <td>Throughout this application various publicatio...</td>\n",
       "      <td>This application claims the benefit of U.S. Pr...</td>\n",
       "      <td>The present invention discloses assays for ide...</td>\n",
       "      <td>method is provided for identifying an agent as...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>20190201532</td>\n",
       "      <td>SENSITIZATION OF BACTERIAL CELLS TO QUINOLONE ...</td>\n",
       "      <td>Provided herein are pharmaceutical composition...</td>\n",
       "      <td>1. A pharmaceutical composition comprising a ...</td>\n",
       "      <td>RELATED APPLICATION The present application cl...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1F....</td>\n",
       "      <td>[US20190201532A1-20190704-D00001.TIF, US201902...</td>\n",
       "      <td>Antibiotics are the main tools to treat infect...</td>\n",
       "      <td></td>\n",
       "      <td>Density-dependent drug failure is a form of an...</td>\n",
       "      <td>Pharmaceutical Compositions The present disclo...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>20190201444</td>\n",
       "      <td>GLYCOENGINEERING OF E-SELECTIN LIGANDS</td>\n",
       "      <td>The present invention provides methods of enfo...</td>\n",
       "      <td>1. A method of enforcing expression of an E-s...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS The pr...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1A-FIG....</td>\n",
       "      <td>[US20190201444A1-20190704-D00000.TIF, US201902...</td>\n",
       "      <td>Mesenchymal stem cells (MSCs) hold much promis...</td>\n",
       "      <td></td>\n",
       "      <td>Despite the promise of these methods, there ex...</td>\n",
       "      <td>In some embodiments, the present invention pro...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>20190177429</td>\n",
       "      <td>Anti-HER2 Antibodies and Immunoconjugates</td>\n",
       "      <td>The invention provides anti-HER2 antibodies an...</td>\n",
       "      <td>1. An isolated antibody that binds to HER2, w...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS The pr...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE FIGURES FIG. 1 shows ...</td>\n",
       "      <td>[US20190177429A1-20190613-D00001.TIF, US201901...</td>\n",
       "      <td>Breast cancer is a highly significant cause of...</td>\n",
       "      <td>The present application is a divisional of U.S...</td>\n",
       "      <td>The invention provides anti-HER2 antibodies an...</td>\n",
       "      <td>Reference will now be made in detail to certai...</td>\n",
       "      <td>['CC[C@@H]([C@H](N(C(=O)[C@H](C(C)C)NC(=O)[C@@...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>20190184190</td>\n",
       "      <td>PHOSPHOR-CONTAINING DRUG ACTIVATOR ACTIVATABLE...</td>\n",
       "      <td>A phosphor-containing drug activator activatab...</td>\n",
       "      <td>1. A phosphor-containing drug activator activ...</td>\n",
       "      <td>CROSS REFERENCE TO RELATED APPLICATIONS This a...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE FIGURES A more comple...</td>\n",
       "      <td>[US20190184190A1-20190620-D00000.TIF, US201901...</td>\n",
       "      <td>Field of Invention The invention relates to me...</td>\n",
       "      <td></td>\n",
       "      <td>In one embodiment, the present invention provi...</td>\n",
       "      <td>The present invention sets forth a novel metho...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>20190192693</td>\n",
       "      <td>METHODS AND VECTORS FOR TREATING CNS DISORDERS</td>\n",
       "      <td>Methods and uses of treating a disease in a ma...</td>\n",
       "      <td>1. A method of delivering a therapeutic prote...</td>\n",
       "      <td>RELATED APPLICATIONS This application claims p...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE FIGURES A more comple...</td>\n",
       "      <td>[US20190184190A1-20190620-D00000.TIF, US201901...</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>In certain embodiments, the invention provides...</td>\n",
       "      <td>The invention is based at least in part on dev...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>20190159474</td>\n",
       "      <td>AMELIORATIVE EFFECTS OF A WHOLE COFFEE FRUIT E...</td>\n",
       "      <td>The invention provides a method of extracting ...</td>\n",
       "      <td>1. A method of producing a whole coffee fruit...</td>\n",
       "      <td>FIELD OF THE INVENTION The invention provides ...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A and...</td>\n",
       "      <td>[US20190159474A1-20190530-D00000.TIF, US201901...</td>\n",
       "      <td>Coffee fruits are mainly produced in Africa an...</td>\n",
       "      <td></td>\n",
       "      <td>It is found in the present invention that a wh...</td>\n",
       "      <td>Unless otherwise defined herein, scientific an...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>20190125691</td>\n",
       "      <td>ENCAPSULATION-FREE CONTROLLED PROTEIN RELEASE ...</td>\n",
       "      <td>The present disclosure provides a delivery sys...</td>\n",
       "      <td>1. A biocompatible polymer composite comprise...</td>\n",
       "      <td>FIELD The present disclosure relates to a bioc...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS Embodiments ...</td>\n",
       "      <td>[US20190125691A1-20190502-D00000.TIF, US201901...</td>\n",
       "      <td>Controlled protein release is a key strategy t...</td>\n",
       "      <td></td>\n",
       "      <td>The present invention provides a biocompatible...</td>\n",
       "      <td>Various embodiments and aspects of the disclos...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>20190169260</td>\n",
       "      <td>Human Leukocyte Antigen Restricted Gamma Delta...</td>\n",
       "      <td>Disclosed herein are compositions and methods ...</td>\n",
       "      <td>1. A composition comprising a polypeptide con...</td>\n",
       "      <td>SEQUENCE LISTING The instant application conta...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS The novel fe...</td>\n",
       "      <td>[US20190169260A1-20190606-D00001.TIF, US201901...</td>\n",
       "      <td>Cancer has a major impact on society across th...</td>\n",
       "      <td></td>\n",
       "      <td>There exists a pressing need for alternative a...</td>\n",
       "      <td>The following description and examples illustr...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>20190194282</td>\n",
       "      <td>CHIMERIC PROTEINS FOR TARGETING dsRNA</td>\n",
       "      <td>Described herein are recombinant chimeric prot...</td>\n",
       "      <td>1. A chimeric recombinant protein comprising:...</td>\n",
       "      <td>CROSS REFERENCE TO RELATED APPLICATIONS Benefi...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1D:...</td>\n",
       "      <td>[US20190194282A1-20190627-D00000.TIF, US201901...</td>\n",
       "      <td>Prostate cancer is the second most commonly di...</td>\n",
       "      <td></td>\n",
       "      <td>Described herein is an improved approach to th...</td>\n",
       "      <td>I. Terms Unless otherwise noted, technical ter...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>20190127440</td>\n",
       "      <td>NOVEL TSLP INHIBITORS</td>\n",
       "      <td>The present invention relates to monomeric fus...</td>\n",
       "      <td>1. A monomeric fusion protein comprising: a f...</td>\n",
       "      <td>FIELD OF THE INVENTION The present invention r...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE FIGURES FIG. 1 shows ...</td>\n",
       "      <td>[US20190127440A1-20190502-D00001.TIF, US201901...</td>\n",
       "      <td>Thymic stromal lymphopoietin (TSLP) is an inte...</td>\n",
       "      <td></td>\n",
       "      <td>It is surprisingly shown herein that a monomer...</td>\n",
       "      <td>The present invention will be described with r...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>20190177383</td>\n",
       "      <td>NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR...</td>\n",
       "      <td>The present invention relates to peptides, pro...</td>\n",
       "      <td>1. A method of treating a patient who has can...</td>\n",
       "      <td>CROSS REFERENCE TO RELATED APPLICATIONS This a...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS The patent o...</td>\n",
       "      <td>[US20190177383A1-20190613-D00001.TIF, US201901...</td>\n",
       "      <td>Ovarian Cancer With an estimated 239 000 new c...</td>\n",
       "      <td></td>\n",
       "      <td>In a first aspect of the present invention, th...</td>\n",
       "      <td>Stimulation of an immune response is dependent...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>20190194689</td>\n",
       "      <td>CNS TARGETING AAV VECTORS AND METHODS OF USE T...</td>\n",
       "      <td>The invention in some aspects relates to recom...</td>\n",
       "      <td>1-55. (canceled)  56. A method for delivering...</td>\n",
       "      <td>RELATED APPLICATIONS This application is a con...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1B ...</td>\n",
       "      <td>[US20190194689A1-20190627-D00001.TIF, US201901...</td>\n",
       "      <td>Gene therapy has been investigated for deliver...</td>\n",
       "      <td></td>\n",
       "      <td>Aspects of the invention, are based on the dis...</td>\n",
       "      <td>Adeno-associated virus (AAV) is a small (26 nm...</td>\n",
       "      <td>['C1*CCCC1', 'C1CCCCC1', 'C*CCCC1*CC*21CCCCC2']</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>20190144517</td>\n",
       "      <td>PROTEIN FOR NEUTRALIZING PROGRAMMED NECROCYTOS...</td>\n",
       "      <td>Provided is polypeptide which derives from wil...</td>\n",
       "      <td>1. A polypeptide that inhibits cell necrosis,...</td>\n",
       "      <td>TECHNICAL FIELD The present invention relates ...</td>\n",
       "      <td>DESCRIPTION OF DRAWINGS FIG. 1 shows the scree...</td>\n",
       "      <td>[US20190144517A1-20190516-D00001.TIF, US201901...</td>\n",
       "      <td>Tumor necrosis factor α (TNF) is a multifuncti...</td>\n",
       "      <td></td>\n",
       "      <td>It is an object of the present invention to pr...</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>20190177709</td>\n",
       "      <td>REGULATION OF GENE EXPRESSION USING ENGINEERED...</td>\n",
       "      <td>The present disclosure is in the field of geno...</td>\n",
       "      <td>1. A zinc finger nuclease (ZFN) comprising le...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS This a...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A and...</td>\n",
       "      <td>[US20190177709A1-20190613-D00000.TIF, US201901...</td>\n",
       "      <td>When one considers that genome sequencing effo...</td>\n",
       "      <td>This application is filed pursuant to 35 U.S.C...</td>\n",
       "      <td>The present invention describes highly specifi...</td>\n",
       "      <td>Disclosed herein are compositions and methods ...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>20190169583</td>\n",
       "      <td>STEP-Derived Peptide for Brain Injury Treatment</td>\n",
       "      <td>A novel peptide sequence that is a modified de...</td>\n",
       "      <td>1. An isolated peptide comprising a kinase in...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS The fo...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...</td>\n",
       "      <td>[US20190169583A1-20190606-D00001.TIF, US201901...</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>According to various embodiments, the present ...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "             id                                    invention_title  \\\n",
       "0   20190151472  LIVER-SPECIFIC CONSTRUCTS, FACTOR VIII EXPRESS...   \n",
       "1   20190135863  RETRO-INVERSO PEPTIDE INHIBITORS OF CELL MIGRA...   \n",
       "2   20190133992  CANNABINOID COMPOSITION HAVING AN OPTIMIZED FA...   \n",
       "3   20190136261  GENETIC MODIFICATION OF CYTOKINE INDUCIBLE SH2...   \n",
       "4   20190161536  ANTI-AP2 ANTIBODIES AND ANTIGEN BINDING AGENTS...   \n",
       "5   20190202865  TARGETING DIMERIZATION OF BAX TO MODULATE BAX ...   \n",
       "6   20190201532  SENSITIZATION OF BACTERIAL CELLS TO QUINOLONE ...   \n",
       "7   20190201444             GLYCOENGINEERING OF E-SELECTIN LIGANDS   \n",
       "8   20190177429          Anti-HER2 Antibodies and Immunoconjugates   \n",
       "9   20190184190  PHOSPHOR-CONTAINING DRUG ACTIVATOR ACTIVATABLE...   \n",
       "10  20190192693     METHODS AND VECTORS FOR TREATING CNS DISORDERS   \n",
       "11  20190159474  AMELIORATIVE EFFECTS OF A WHOLE COFFEE FRUIT E...   \n",
       "12  20190125691  ENCAPSULATION-FREE CONTROLLED PROTEIN RELEASE ...   \n",
       "13  20190169260  Human Leukocyte Antigen Restricted Gamma Delta...   \n",
       "14  20190194282              CHIMERIC PROTEINS FOR TARGETING dsRNA   \n",
       "15  20190127440                              NOVEL TSLP INHIBITORS   \n",
       "16  20190177383  NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR...   \n",
       "17  20190194689  CNS TARGETING AAV VECTORS AND METHODS OF USE T...   \n",
       "18  20190144517  PROTEIN FOR NEUTRALIZING PROGRAMMED NECROCYTOS...   \n",
       "19  20190177709  REGULATION OF GENE EXPRESSION USING ENGINEERED...   \n",
       "20  20190169583    STEP-Derived Peptide for Brain Injury Treatment   \n",
       "\n",
       "                                             abstract  \\\n",
       "0   Described herein are constructs used for liver...   \n",
       "1   The present invention discloses retro-inverso ...   \n",
       "2   A composition of matter for enhancing delivery...   \n",
       "3   The present disclosure is in the field of geno...   \n",
       "4   This invention is in the area of improved anti...   \n",
       "5   Methods are provided for identifying an agent ...   \n",
       "6   Provided herein are pharmaceutical composition...   \n",
       "7   The present invention provides methods of enfo...   \n",
       "8   The invention provides anti-HER2 antibodies an...   \n",
       "9   A phosphor-containing drug activator activatab...   \n",
       "10  Methods and uses of treating a disease in a ma...   \n",
       "11  The invention provides a method of extracting ...   \n",
       "12  The present disclosure provides a delivery sys...   \n",
       "13  Disclosed herein are compositions and methods ...   \n",
       "14  Described herein are recombinant chimeric prot...   \n",
       "15  The present invention relates to monomeric fus...   \n",
       "16  The present invention relates to peptides, pro...   \n",
       "17  The invention in some aspects relates to recom...   \n",
       "18  Provided is polypeptide which derives from wil...   \n",
       "19  The present disclosure is in the field of geno...   \n",
       "20  A novel peptide sequence that is a modified de...   \n",
       "\n",
       "                                               claims  \\\n",
       "0    1-10. (canceled)  11. A method of providing a...   \n",
       "1    1. A compound of formula (I):   X1-(D)-Arg-X2...   \n",
       "2    1. A cannabinoid composition comprising: at l...   \n",
       "3    1. A genetically modified cell comprising a g...   \n",
       "4    1. A method of attenuating an aP2-mediated di...   \n",
       "5    1-19. (canceled)  20. A method of inhibiting ...   \n",
       "6    1. A pharmaceutical composition comprising a ...   \n",
       "7    1. A method of enforcing expression of an E-s...   \n",
       "8    1. An isolated antibody that binds to HER2, w...   \n",
       "9    1. A phosphor-containing drug activator activ...   \n",
       "10   1. A method of delivering a therapeutic prote...   \n",
       "11   1. A method of producing a whole coffee fruit...   \n",
       "12   1. A biocompatible polymer composite comprise...   \n",
       "13   1. A composition comprising a polypeptide con...   \n",
       "14   1. A chimeric recombinant protein comprising:...   \n",
       "15   1. A monomeric fusion protein comprising: a f...   \n",
       "16   1. A method of treating a patient who has can...   \n",
       "17   1-55. (canceled)  56. A method for delivering...   \n",
       "18   1. A polypeptide that inhibits cell necrosis,...   \n",
       "19   1. A zinc finger nuclease (ZFN) comprising le...   \n",
       "20   1. An isolated peptide comprising a kinase in...   \n",
       "\n",
       "                                          description  \\\n",
       "0   CROSS-REFERENCE TO RELATED APPLICATIONS The pr...   \n",
       "1   The present invention concerns retro-inverso p...   \n",
       "2   FIELD OF THE INVENTION The present invention r...   \n",
       "3   CROSS-REFERENCE TO RELATED APPLICATIONS The pr...   \n",
       "4   RELATED APPLICATIONS This application is a con...   \n",
       "5   CROSS-REFERENCE TO RELATED APPLICATIONS This a...   \n",
       "6   RELATED APPLICATION The present application cl...   \n",
       "7   CROSS-REFERENCE TO RELATED APPLICATIONS The pr...   \n",
       "8   CROSS-REFERENCE TO RELATED APPLICATIONS The pr...   \n",
       "9   CROSS REFERENCE TO RELATED APPLICATIONS This a...   \n",
       "10  RELATED APPLICATIONS This application claims p...   \n",
       "11  FIELD OF THE INVENTION The invention provides ...   \n",
       "12  FIELD The present disclosure relates to a bioc...   \n",
       "13  SEQUENCE LISTING The instant application conta...   \n",
       "14  CROSS REFERENCE TO RELATED APPLICATIONS Benefi...   \n",
       "15  FIELD OF THE INVENTION The present invention r...   \n",
       "16  CROSS REFERENCE TO RELATED APPLICATIONS This a...   \n",
       "17  RELATED APPLICATIONS This application is a con...   \n",
       "18  TECHNICAL FIELD The present invention relates ...   \n",
       "19  CROSS-REFERENCE TO RELATED APPLICATIONS This a...   \n",
       "20  CROSS-REFERENCE TO RELATED APPLICATIONS The fo...   \n",
       "\n",
       "                                 drawings_description  \\\n",
       "0   BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...   \n",
       "1   DESCRIPTION OF THE FIGURES FIG. 1 High degree ...   \n",
       "2   BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...   \n",
       "3   BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 shows...   \n",
       "4   BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1-8 ar...   \n",
       "5   BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1A-1D. ...   \n",
       "6   BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1F....   \n",
       "7   BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1A-FIG....   \n",
       "8   BRIEF DESCRIPTION OF THE FIGURES FIG. 1 shows ...   \n",
       "9   BRIEF DESCRIPTION OF THE FIGURES A more comple...   \n",
       "10  BRIEF DESCRIPTION OF THE FIGURES A more comple...   \n",
       "11  BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A and...   \n",
       "12  BRIEF DESCRIPTION OF THE DRAWINGS Embodiments ...   \n",
       "13  BRIEF DESCRIPTION OF THE DRAWINGS The novel fe...   \n",
       "14  BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1D:...   \n",
       "15  BRIEF DESCRIPTION OF THE FIGURES FIG. 1 shows ...   \n",
       "16  BRIEF DESCRIPTION OF THE DRAWINGS The patent o...   \n",
       "17  BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1B ...   \n",
       "18  DESCRIPTION OF DRAWINGS FIG. 1 shows the scree...   \n",
       "19  BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A and...   \n",
       "20  BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...   \n",
       "\n",
       "                                  drawings_file_paths  \\\n",
       "0   [US20190151472A1-20190523-D00001.TIF, US201901...   \n",
       "1   [US20190135863A1-20190509-D00001.TIF, US201901...   \n",
       "2   [US20190133992A1-20190509-D00001.TIF, US201901...   \n",
       "3   [US20190136261A1-20190509-D00001.TIF, US201901...   \n",
       "4   [US20190161536A1-20190530-D00001.TIF, US201901...   \n",
       "5   [US20190202865A1-20190704-D00001.TIF, US201902...   \n",
       "6   [US20190201532A1-20190704-D00001.TIF, US201902...   \n",
       "7   [US20190201444A1-20190704-D00000.TIF, US201902...   \n",
       "8   [US20190177429A1-20190613-D00001.TIF, US201901...   \n",
       "9   [US20190184190A1-20190620-D00000.TIF, US201901...   \n",
       "10  [US20190184190A1-20190620-D00000.TIF, US201901...   \n",
       "11  [US20190159474A1-20190530-D00000.TIF, US201901...   \n",
       "12  [US20190125691A1-20190502-D00000.TIF, US201901...   \n",
       "13  [US20190169260A1-20190606-D00001.TIF, US201901...   \n",
       "14  [US20190194282A1-20190627-D00000.TIF, US201901...   \n",
       "15  [US20190127440A1-20190502-D00001.TIF, US201901...   \n",
       "16  [US20190177383A1-20190613-D00001.TIF, US201901...   \n",
       "17  [US20190194689A1-20190627-D00001.TIF, US201901...   \n",
       "18  [US20190144517A1-20190516-D00001.TIF, US201901...   \n",
       "19  [US20190177709A1-20190613-D00000.TIF, US201901...   \n",
       "20  [US20190169583A1-20190606-D00001.TIF, US201901...   \n",
       "\n",
       "                                 invention_background  \\\n",
       "0   Gene therapy can be used to genetically engine...   \n",
       "1                                                       \n",
       "2   Formulations of bioactive compounds have been ...   \n",
       "3   Cells communicate with each other either by di...   \n",
       "4   Human adipocyte lipid-binding protein (aP2) be...   \n",
       "5   Throughout this application various publicatio...   \n",
       "6   Antibiotics are the main tools to treat infect...   \n",
       "7   Mesenchymal stem cells (MSCs) hold much promis...   \n",
       "8   Breast cancer is a highly significant cause of...   \n",
       "9   Field of Invention The invention relates to me...   \n",
       "10                                                      \n",
       "11  Coffee fruits are mainly produced in Africa an...   \n",
       "12  Controlled protein release is a key strategy t...   \n",
       "13  Cancer has a major impact on society across th...   \n",
       "14  Prostate cancer is the second most commonly di...   \n",
       "15  Thymic stromal lymphopoietin (TSLP) is an inte...   \n",
       "16  Ovarian Cancer With an estimated 239 000 new c...   \n",
       "17  Gene therapy has been investigated for deliver...   \n",
       "18  Tumor necrosis factor α (TNF) is a multifuncti...   \n",
       "19  When one considers that genome sequencing effo...   \n",
       "20                                                      \n",
       "\n",
       "                                      cross_reference  \\\n",
       "0   The present application is a divisional of U.S...   \n",
       "1                                                       \n",
       "2                                                       \n",
       "3   The present application claims the benefit of ...   \n",
       "4                                                       \n",
       "5   This application claims the benefit of U.S. Pr...   \n",
       "6                                                       \n",
       "7                                                       \n",
       "8   The present application is a divisional of U.S...   \n",
       "9                                                       \n",
       "10                                                      \n",
       "11                                                      \n",
       "12                                                      \n",
       "13                                                      \n",
       "14                                                      \n",
       "15                                                      \n",
       "16                                                      \n",
       "17                                                      \n",
       "18                                                      \n",
       "19  This application is filed pursuant to 35 U.S.C...   \n",
       "20                                                      \n",
       "\n",
       "                                              summary  \\\n",
       "0   The present invention describes compositions a...   \n",
       "1                                                       \n",
       "2   The present invention includes a cannabinoid c...   \n",
       "3   The present invention describes compositions a...   \n",
       "4   Anti-aP2 monoclonal antibodies and antigen bin...   \n",
       "5   The present invention discloses assays for ide...   \n",
       "6   Density-dependent drug failure is a form of an...   \n",
       "7   Despite the promise of these methods, there ex...   \n",
       "8   The invention provides anti-HER2 antibodies an...   \n",
       "9   In one embodiment, the present invention provi...   \n",
       "10  In certain embodiments, the invention provides...   \n",
       "11  It is found in the present invention that a wh...   \n",
       "12  The present invention provides a biocompatible...   \n",
       "13  There exists a pressing need for alternative a...   \n",
       "14  Described herein is an improved approach to th...   \n",
       "15  It is surprisingly shown herein that a monomer...   \n",
       "16  In a first aspect of the present invention, th...   \n",
       "17  Aspects of the invention, are based on the dis...   \n",
       "18  It is an object of the present invention to pr...   \n",
       "19  The present invention describes highly specifi...   \n",
       "20                                                      \n",
       "\n",
       "                                 detailed_description  \\\n",
       "0   Disclosed herein are expression cassettes for ...   \n",
       "1                                                       \n",
       "2   The present invention includes a composition o...   \n",
       "3   Disclosed herein are compositions and methods ...   \n",
       "4   Anti-aP2 monoclonal antibodies and antigen bin...   \n",
       "5   method is provided for identifying an agent as...   \n",
       "6   Pharmaceutical Compositions The present disclo...   \n",
       "7   In some embodiments, the present invention pro...   \n",
       "8   Reference will now be made in detail to certai...   \n",
       "9   The present invention sets forth a novel metho...   \n",
       "10  The invention is based at least in part on dev...   \n",
       "11  Unless otherwise defined herein, scientific an...   \n",
       "12  Various embodiments and aspects of the disclos...   \n",
       "13  The following description and examples illustr...   \n",
       "14  I. Terms Unless otherwise noted, technical ter...   \n",
       "15  The present invention will be described with r...   \n",
       "16  Stimulation of an immune response is dependent...   \n",
       "17  Adeno-associated virus (AAV) is a small (26 nm...   \n",
       "18                                                      \n",
       "19  Disclosed herein are compositions and methods ...   \n",
       "20  According to various embodiments, the present ...   \n",
       "\n",
       "                            chemical_compounds_smiles  \n",
       "0                                                      \n",
       "1                                                      \n",
       "2       ['CCCCCC/C=C\\\\CCCCCCCC(=*1CCCCC1)C1*C*(C1)*']  \n",
       "3                                                      \n",
       "4                                                      \n",
       "5                                                      \n",
       "6                                                      \n",
       "7                                                      \n",
       "8   ['CC[C@@H]([C@H](N(C(=O)[C@H](C(C)C)NC(=O)[C@@...  \n",
       "9                                                      \n",
       "10                                                NaN  \n",
       "11                                                     \n",
       "12                                                     \n",
       "13                                                     \n",
       "14                                                     \n",
       "15                                                     \n",
       "16                                                     \n",
       "17    ['C1*CCCC1', 'C1CCCCC1', 'C*CCCC1*CC*21CCCCC2']  \n",
       "18                                                     \n",
       "19                                                     \n",
       "20                                                     "
      ]
     },
     "execution_count": 22,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "patents_df5"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<hr>\n",
    "<br>\n",
    "\n",
    "<a id='section-4'></a>\n",
    "\n",
    "### - Extract chemical names from text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Loading dependencies\n",
    "import subprocess\n",
    "import glob\n",
    "import re"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Chemspot accepts only text files as input, so we write the description\n",
    "# extracted previously to file\n",
    "for index, row in patents_df.iterrows():\n",
    "    with open('../temp/patent_text/US{}.txt'.format(row['id']), 'w') as description_file:\n",
    "        description_file.write(row['description'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Extract from full patent description\n",
    "print('Chemical NER extraction')\n",
    "\n",
    "for _file in glob.glob('../temp/patent_text/US*.txt'):\n",
    "    \n",
    "    # Run ChemSpot, the Chemical named entity recognition library (in shell)\n",
    "    subprocess.check_call(['java', '-Xmx4G', '-jar', '../chemspot-2.0/chemspot.jar', \\\n",
    "        '-t', _file, '-o', '../temp/chemical-names-inchi/{}.txt'.format(_file[20:-4])]) "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id</th>\n",
       "      <th>invention_title</th>\n",
       "      <th>abstract</th>\n",
       "      <th>claims</th>\n",
       "      <th>description</th>\n",
       "      <th>drawings_description</th>\n",
       "      <th>drawings_file_paths</th>\n",
       "      <th>invention_background</th>\n",
       "      <th>cross_reference</th>\n",
       "      <th>summary</th>\n",
       "      <th>detailed_description</th>\n",
       "      <th>chemical_compounds_smiles</th>\n",
       "      <th>chemical_compounds_inchi</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>20190151472</td>\n",
       "      <td>LIVER-SPECIFIC CONSTRUCTS, FACTOR VIII EXPRESS...</td>\n",
       "      <td>Described herein are constructs used for liver...</td>\n",
       "      <td>1-10. (canceled)  11. A method of providing a...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS The pr...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...</td>\n",
       "      <td>[US20190151472A1-20190523-D00001.TIF, US201901...</td>\n",
       "      <td>Gene therapy can be used to genetically engine...</td>\n",
       "      <td>The present application is a divisional of U.S...</td>\n",
       "      <td>The present invention describes compositions a...</td>\n",
       "      <td>Disclosed herein are expression cassettes for ...</td>\n",
       "      <td></td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>20190135863</td>\n",
       "      <td>RETRO-INVERSO PEPTIDE INHIBITORS OF CELL MIGRA...</td>\n",
       "      <td>The present invention discloses retro-inverso ...</td>\n",
       "      <td>1. A compound of formula (I):   X1-(D)-Arg-X2...</td>\n",
       "      <td>The present invention concerns retro-inverso p...</td>\n",
       "      <td>DESCRIPTION OF THE FIGURES FIG. 1 High degree ...</td>\n",
       "      <td>[US20190135863A1-20190509-D00001.TIF, US201901...</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>20190133992</td>\n",
       "      <td>CANNABINOID COMPOSITION HAVING AN OPTIMIZED FA...</td>\n",
       "      <td>A composition of matter for enhancing delivery...</td>\n",
       "      <td>1. A cannabinoid composition comprising: at l...</td>\n",
       "      <td>FIELD OF THE INVENTION The present invention r...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...</td>\n",
       "      <td>[US20190133992A1-20190509-D00001.TIF, US201901...</td>\n",
       "      <td>Formulations of bioactive compounds have been ...</td>\n",
       "      <td></td>\n",
       "      <td>The present invention includes a cannabinoid c...</td>\n",
       "      <td>The present invention includes a composition o...</td>\n",
       "      <td>['CCCCCC/C=C\\\\CCCCCCCC(=*1CCCCC1)C1*C*(C1)*']</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>20190136261</td>\n",
       "      <td>GENETIC MODIFICATION OF CYTOKINE INDUCIBLE SH2...</td>\n",
       "      <td>The present disclosure is in the field of geno...</td>\n",
       "      <td>1. A genetically modified cell comprising a g...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS The pr...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 shows...</td>\n",
       "      <td>[US20190136261A1-20190509-D00001.TIF, US201901...</td>\n",
       "      <td>Cells communicate with each other either by di...</td>\n",
       "      <td>The present application claims the benefit of ...</td>\n",
       "      <td>The present invention describes compositions a...</td>\n",
       "      <td>Disclosed herein are compositions and methods ...</td>\n",
       "      <td></td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>20190161536</td>\n",
       "      <td>ANTI-AP2 ANTIBODIES AND ANTIGEN BINDING AGENTS...</td>\n",
       "      <td>This invention is in the area of improved anti...</td>\n",
       "      <td>1. A method of attenuating an aP2-mediated di...</td>\n",
       "      <td>RELATED APPLICATIONS This application is a con...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1-8 ar...</td>\n",
       "      <td>[US20190161536A1-20190530-D00001.TIF, US201901...</td>\n",
       "      <td>Human adipocyte lipid-binding protein (aP2) be...</td>\n",
       "      <td></td>\n",
       "      <td>Anti-aP2 monoclonal antibodies and antigen bin...</td>\n",
       "      <td>Anti-aP2 monoclonal antibodies and antigen bin...</td>\n",
       "      <td></td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>20190202865</td>\n",
       "      <td>TARGETING DIMERIZATION OF BAX TO MODULATE BAX ...</td>\n",
       "      <td>Methods are provided for identifying an agent ...</td>\n",
       "      <td>1-19. (canceled)  20. A method of inhibiting ...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS This a...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1A-1D. ...</td>\n",
       "      <td>[US20190202865A1-20190704-D00001.TIF, US201902...</td>\n",
       "      <td>Throughout this application various publicatio...</td>\n",
       "      <td>This application claims the benefit of U.S. Pr...</td>\n",
       "      <td>The present invention discloses assays for ide...</td>\n",
       "      <td>method is provided for identifying an agent as...</td>\n",
       "      <td></td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>20190201532</td>\n",
       "      <td>SENSITIZATION OF BACTERIAL CELLS TO QUINOLONE ...</td>\n",
       "      <td>Provided herein are pharmaceutical composition...</td>\n",
       "      <td>1. A pharmaceutical composition comprising a ...</td>\n",
       "      <td>RELATED APPLICATION The present application cl...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1F....</td>\n",
       "      <td>[US20190201532A1-20190704-D00001.TIF, US201902...</td>\n",
       "      <td>Antibiotics are the main tools to treat infect...</td>\n",
       "      <td></td>\n",
       "      <td>Density-dependent drug failure is a form of an...</td>\n",
       "      <td>Pharmaceutical Compositions The present disclo...</td>\n",
       "      <td></td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>20190201444</td>\n",
       "      <td>GLYCOENGINEERING OF E-SELECTIN LIGANDS</td>\n",
       "      <td>The present invention provides methods of enfo...</td>\n",
       "      <td>1. A method of enforcing expression of an E-s...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS The pr...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1A-FIG....</td>\n",
       "      <td>[US20190201444A1-20190704-D00000.TIF, US201902...</td>\n",
       "      <td>Mesenchymal stem cells (MSCs) hold much promis...</td>\n",
       "      <td></td>\n",
       "      <td>Despite the promise of these methods, there ex...</td>\n",
       "      <td>In some embodiments, the present invention pro...</td>\n",
       "      <td></td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>20190177429</td>\n",
       "      <td>Anti-HER2 Antibodies and Immunoconjugates</td>\n",
       "      <td>The invention provides anti-HER2 antibodies an...</td>\n",
       "      <td>1. An isolated antibody that binds to HER2, w...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS The pr...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE FIGURES FIG. 1 shows ...</td>\n",
       "      <td>[US20190177429A1-20190613-D00001.TIF, US201901...</td>\n",
       "      <td>Breast cancer is a highly significant cause of...</td>\n",
       "      <td>The present application is a divisional of U.S...</td>\n",
       "      <td>The invention provides anti-HER2 antibodies an...</td>\n",
       "      <td>Reference will now be made in detail to certai...</td>\n",
       "      <td>['CC[C@@H]([C@H](N(C(=O)[C@H](C(C)C)NC(=O)[C@@...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>20190184190</td>\n",
       "      <td>PHOSPHOR-CONTAINING DRUG ACTIVATOR ACTIVATABLE...</td>\n",
       "      <td>A phosphor-containing drug activator activatab...</td>\n",
       "      <td>1. A phosphor-containing drug activator activ...</td>\n",
       "      <td>CROSS REFERENCE TO RELATED APPLICATIONS This a...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE FIGURES A more comple...</td>\n",
       "      <td>[US20190184190A1-20190620-D00000.TIF, US201901...</td>\n",
       "      <td>Field of Invention The invention relates to me...</td>\n",
       "      <td></td>\n",
       "      <td>In one embodiment, the present invention provi...</td>\n",
       "      <td>The present invention sets forth a novel metho...</td>\n",
       "      <td></td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>20190192693</td>\n",
       "      <td>METHODS AND VECTORS FOR TREATING CNS DISORDERS</td>\n",
       "      <td>Methods and uses of treating a disease in a ma...</td>\n",
       "      <td>1. A method of delivering a therapeutic prote...</td>\n",
       "      <td>RELATED APPLICATIONS This application claims p...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE FIGURES A more comple...</td>\n",
       "      <td>[US20190184190A1-20190620-D00000.TIF, US201901...</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>In certain embodiments, the invention provides...</td>\n",
       "      <td>The invention is based at least in part on dev...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>20190159474</td>\n",
       "      <td>AMELIORATIVE EFFECTS OF A WHOLE COFFEE FRUIT E...</td>\n",
       "      <td>The invention provides a method of extracting ...</td>\n",
       "      <td>1. A method of producing a whole coffee fruit...</td>\n",
       "      <td>FIELD OF THE INVENTION The invention provides ...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A and...</td>\n",
       "      <td>[US20190159474A1-20190530-D00000.TIF, US201901...</td>\n",
       "      <td>Coffee fruits are mainly produced in Africa an...</td>\n",
       "      <td></td>\n",
       "      <td>It is found in the present invention that a wh...</td>\n",
       "      <td>Unless otherwise defined herein, scientific an...</td>\n",
       "      <td></td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>20190125691</td>\n",
       "      <td>ENCAPSULATION-FREE CONTROLLED PROTEIN RELEASE ...</td>\n",
       "      <td>The present disclosure provides a delivery sys...</td>\n",
       "      <td>1. A biocompatible polymer composite comprise...</td>\n",
       "      <td>FIELD The present disclosure relates to a bioc...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS Embodiments ...</td>\n",
       "      <td>[US20190125691A1-20190502-D00000.TIF, US201901...</td>\n",
       "      <td>Controlled protein release is a key strategy t...</td>\n",
       "      <td></td>\n",
       "      <td>The present invention provides a biocompatible...</td>\n",
       "      <td>Various embodiments and aspects of the disclos...</td>\n",
       "      <td></td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>20190169260</td>\n",
       "      <td>Human Leukocyte Antigen Restricted Gamma Delta...</td>\n",
       "      <td>Disclosed herein are compositions and methods ...</td>\n",
       "      <td>1. A composition comprising a polypeptide con...</td>\n",
       "      <td>SEQUENCE LISTING The instant application conta...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS The novel fe...</td>\n",
       "      <td>[US20190169260A1-20190606-D00001.TIF, US201901...</td>\n",
       "      <td>Cancer has a major impact on society across th...</td>\n",
       "      <td></td>\n",
       "      <td>There exists a pressing need for alternative a...</td>\n",
       "      <td>The following description and examples illustr...</td>\n",
       "      <td></td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>20190194282</td>\n",
       "      <td>CHIMERIC PROTEINS FOR TARGETING dsRNA</td>\n",
       "      <td>Described herein are recombinant chimeric prot...</td>\n",
       "      <td>1. A chimeric recombinant protein comprising:...</td>\n",
       "      <td>CROSS REFERENCE TO RELATED APPLICATIONS Benefi...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1D:...</td>\n",
       "      <td>[US20190194282A1-20190627-D00000.TIF, US201901...</td>\n",
       "      <td>Prostate cancer is the second most commonly di...</td>\n",
       "      <td></td>\n",
       "      <td>Described herein is an improved approach to th...</td>\n",
       "      <td>I. Terms Unless otherwise noted, technical ter...</td>\n",
       "      <td></td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>20190127440</td>\n",
       "      <td>NOVEL TSLP INHIBITORS</td>\n",
       "      <td>The present invention relates to monomeric fus...</td>\n",
       "      <td>1. A monomeric fusion protein comprising: a f...</td>\n",
       "      <td>FIELD OF THE INVENTION The present invention r...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE FIGURES FIG. 1 shows ...</td>\n",
       "      <td>[US20190127440A1-20190502-D00001.TIF, US201901...</td>\n",
       "      <td>Thymic stromal lymphopoietin (TSLP) is an inte...</td>\n",
       "      <td></td>\n",
       "      <td>It is surprisingly shown herein that a monomer...</td>\n",
       "      <td>The present invention will be described with r...</td>\n",
       "      <td></td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>20190177383</td>\n",
       "      <td>NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR...</td>\n",
       "      <td>The present invention relates to peptides, pro...</td>\n",
       "      <td>1. A method of treating a patient who has can...</td>\n",
       "      <td>CROSS REFERENCE TO RELATED APPLICATIONS This a...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS The patent o...</td>\n",
       "      <td>[US20190177383A1-20190613-D00001.TIF, US201901...</td>\n",
       "      <td>Ovarian Cancer With an estimated 239 000 new c...</td>\n",
       "      <td></td>\n",
       "      <td>In a first aspect of the present invention, th...</td>\n",
       "      <td>Stimulation of an immune response is dependent...</td>\n",
       "      <td></td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>20190194689</td>\n",
       "      <td>CNS TARGETING AAV VECTORS AND METHODS OF USE T...</td>\n",
       "      <td>The invention in some aspects relates to recom...</td>\n",
       "      <td>1-55. (canceled)  56. A method for delivering...</td>\n",
       "      <td>RELATED APPLICATIONS This application is a con...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1B ...</td>\n",
       "      <td>[US20190194689A1-20190627-D00001.TIF, US201901...</td>\n",
       "      <td>Gene therapy has been investigated for deliver...</td>\n",
       "      <td></td>\n",
       "      <td>Aspects of the invention, are based on the dis...</td>\n",
       "      <td>Adeno-associated virus (AAV) is a small (26 nm...</td>\n",
       "      <td>['C1*CCCC1', 'C1CCCCC1', 'C*CCCC1*CC*21CCCCC2']</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>20190144517</td>\n",
       "      <td>PROTEIN FOR NEUTRALIZING PROGRAMMED NECROCYTOS...</td>\n",
       "      <td>Provided is polypeptide which derives from wil...</td>\n",
       "      <td>1. A polypeptide that inhibits cell necrosis,...</td>\n",
       "      <td>TECHNICAL FIELD The present invention relates ...</td>\n",
       "      <td>DESCRIPTION OF DRAWINGS FIG. 1 shows the scree...</td>\n",
       "      <td>[US20190144517A1-20190516-D00001.TIF, US201901...</td>\n",
       "      <td>Tumor necrosis factor α (TNF) is a multifuncti...</td>\n",
       "      <td></td>\n",
       "      <td>It is an object of the present invention to pr...</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>20190177709</td>\n",
       "      <td>REGULATION OF GENE EXPRESSION USING ENGINEERED...</td>\n",
       "      <td>The present disclosure is in the field of geno...</td>\n",
       "      <td>1. A zinc finger nuclease (ZFN) comprising le...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS This a...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A and...</td>\n",
       "      <td>[US20190177709A1-20190613-D00000.TIF, US201901...</td>\n",
       "      <td>When one considers that genome sequencing effo...</td>\n",
       "      <td>This application is filed pursuant to 35 U.S.C...</td>\n",
       "      <td>The present invention describes highly specifi...</td>\n",
       "      <td>Disclosed herein are compositions and methods ...</td>\n",
       "      <td></td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>20190169583</td>\n",
       "      <td>STEP-Derived Peptide for Brain Injury Treatment</td>\n",
       "      <td>A novel peptide sequence that is a modified de...</td>\n",
       "      <td>1. An isolated peptide comprising a kinase in...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS The fo...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...</td>\n",
       "      <td>[US20190169583A1-20190606-D00001.TIF, US201901...</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>According to various embodiments, the present ...</td>\n",
       "      <td></td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "             id                                    invention_title  \\\n",
       "0   20190151472  LIVER-SPECIFIC CONSTRUCTS, FACTOR VIII EXPRESS...   \n",
       "1   20190135863  RETRO-INVERSO PEPTIDE INHIBITORS OF CELL MIGRA...   \n",
       "2   20190133992  CANNABINOID COMPOSITION HAVING AN OPTIMIZED FA...   \n",
       "3   20190136261  GENETIC MODIFICATION OF CYTOKINE INDUCIBLE SH2...   \n",
       "4   20190161536  ANTI-AP2 ANTIBODIES AND ANTIGEN BINDING AGENTS...   \n",
       "5   20190202865  TARGETING DIMERIZATION OF BAX TO MODULATE BAX ...   \n",
       "6   20190201532  SENSITIZATION OF BACTERIAL CELLS TO QUINOLONE ...   \n",
       "7   20190201444             GLYCOENGINEERING OF E-SELECTIN LIGANDS   \n",
       "8   20190177429          Anti-HER2 Antibodies and Immunoconjugates   \n",
       "9   20190184190  PHOSPHOR-CONTAINING DRUG ACTIVATOR ACTIVATABLE...   \n",
       "10  20190192693     METHODS AND VECTORS FOR TREATING CNS DISORDERS   \n",
       "11  20190159474  AMELIORATIVE EFFECTS OF A WHOLE COFFEE FRUIT E...   \n",
       "12  20190125691  ENCAPSULATION-FREE CONTROLLED PROTEIN RELEASE ...   \n",
       "13  20190169260  Human Leukocyte Antigen Restricted Gamma Delta...   \n",
       "14  20190194282              CHIMERIC PROTEINS FOR TARGETING dsRNA   \n",
       "15  20190127440                              NOVEL TSLP INHIBITORS   \n",
       "16  20190177383  NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR...   \n",
       "17  20190194689  CNS TARGETING AAV VECTORS AND METHODS OF USE T...   \n",
       "18  20190144517  PROTEIN FOR NEUTRALIZING PROGRAMMED NECROCYTOS...   \n",
       "19  20190177709  REGULATION OF GENE EXPRESSION USING ENGINEERED...   \n",
       "20  20190169583    STEP-Derived Peptide for Brain Injury Treatment   \n",
       "\n",
       "                                             abstract  \\\n",
       "0   Described herein are constructs used for liver...   \n",
       "1   The present invention discloses retro-inverso ...   \n",
       "2   A composition of matter for enhancing delivery...   \n",
       "3   The present disclosure is in the field of geno...   \n",
       "4   This invention is in the area of improved anti...   \n",
       "5   Methods are provided for identifying an agent ...   \n",
       "6   Provided herein are pharmaceutical composition...   \n",
       "7   The present invention provides methods of enfo...   \n",
       "8   The invention provides anti-HER2 antibodies an...   \n",
       "9   A phosphor-containing drug activator activatab...   \n",
       "10  Methods and uses of treating a disease in a ma...   \n",
       "11  The invention provides a method of extracting ...   \n",
       "12  The present disclosure provides a delivery sys...   \n",
       "13  Disclosed herein are compositions and methods ...   \n",
       "14  Described herein are recombinant chimeric prot...   \n",
       "15  The present invention relates to monomeric fus...   \n",
       "16  The present invention relates to peptides, pro...   \n",
       "17  The invention in some aspects relates to recom...   \n",
       "18  Provided is polypeptide which derives from wil...   \n",
       "19  The present disclosure is in the field of geno...   \n",
       "20  A novel peptide sequence that is a modified de...   \n",
       "\n",
       "                                               claims  \\\n",
       "0    1-10. (canceled)  11. A method of providing a...   \n",
       "1    1. A compound of formula (I):   X1-(D)-Arg-X2...   \n",
       "2    1. A cannabinoid composition comprising: at l...   \n",
       "3    1. A genetically modified cell comprising a g...   \n",
       "4    1. A method of attenuating an aP2-mediated di...   \n",
       "5    1-19. (canceled)  20. A method of inhibiting ...   \n",
       "6    1. A pharmaceutical composition comprising a ...   \n",
       "7    1. A method of enforcing expression of an E-s...   \n",
       "8    1. An isolated antibody that binds to HER2, w...   \n",
       "9    1. A phosphor-containing drug activator activ...   \n",
       "10   1. A method of delivering a therapeutic prote...   \n",
       "11   1. A method of producing a whole coffee fruit...   \n",
       "12   1. A biocompatible polymer composite comprise...   \n",
       "13   1. A composition comprising a polypeptide con...   \n",
       "14   1. A chimeric recombinant protein comprising:...   \n",
       "15   1. A monomeric fusion protein comprising: a f...   \n",
       "16   1. A method of treating a patient who has can...   \n",
       "17   1-55. (canceled)  56. A method for delivering...   \n",
       "18   1. A polypeptide that inhibits cell necrosis,...   \n",
       "19   1. A zinc finger nuclease (ZFN) comprising le...   \n",
       "20   1. An isolated peptide comprising a kinase in...   \n",
       "\n",
       "                                          description  \\\n",
       "0   CROSS-REFERENCE TO RELATED APPLICATIONS The pr...   \n",
       "1   The present invention concerns retro-inverso p...   \n",
       "2   FIELD OF THE INVENTION The present invention r...   \n",
       "3   CROSS-REFERENCE TO RELATED APPLICATIONS The pr...   \n",
       "4   RELATED APPLICATIONS This application is a con...   \n",
       "5   CROSS-REFERENCE TO RELATED APPLICATIONS This a...   \n",
       "6   RELATED APPLICATION The present application cl...   \n",
       "7   CROSS-REFERENCE TO RELATED APPLICATIONS The pr...   \n",
       "8   CROSS-REFERENCE TO RELATED APPLICATIONS The pr...   \n",
       "9   CROSS REFERENCE TO RELATED APPLICATIONS This a...   \n",
       "10  RELATED APPLICATIONS This application claims p...   \n",
       "11  FIELD OF THE INVENTION The invention provides ...   \n",
       "12  FIELD The present disclosure relates to a bioc...   \n",
       "13  SEQUENCE LISTING The instant application conta...   \n",
       "14  CROSS REFERENCE TO RELATED APPLICATIONS Benefi...   \n",
       "15  FIELD OF THE INVENTION The present invention r...   \n",
       "16  CROSS REFERENCE TO RELATED APPLICATIONS This a...   \n",
       "17  RELATED APPLICATIONS This application is a con...   \n",
       "18  TECHNICAL FIELD The present invention relates ...   \n",
       "19  CROSS-REFERENCE TO RELATED APPLICATIONS This a...   \n",
       "20  CROSS-REFERENCE TO RELATED APPLICATIONS The fo...   \n",
       "\n",
       "                                 drawings_description  \\\n",
       "0   BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...   \n",
       "1   DESCRIPTION OF THE FIGURES FIG. 1 High degree ...   \n",
       "2   BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...   \n",
       "3   BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 shows...   \n",
       "4   BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1-8 ar...   \n",
       "5   BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1A-1D. ...   \n",
       "6   BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1F....   \n",
       "7   BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1A-FIG....   \n",
       "8   BRIEF DESCRIPTION OF THE FIGURES FIG. 1 shows ...   \n",
       "9   BRIEF DESCRIPTION OF THE FIGURES A more comple...   \n",
       "10  BRIEF DESCRIPTION OF THE FIGURES A more comple...   \n",
       "11  BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A and...   \n",
       "12  BRIEF DESCRIPTION OF THE DRAWINGS Embodiments ...   \n",
       "13  BRIEF DESCRIPTION OF THE DRAWINGS The novel fe...   \n",
       "14  BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1D:...   \n",
       "15  BRIEF DESCRIPTION OF THE FIGURES FIG. 1 shows ...   \n",
       "16  BRIEF DESCRIPTION OF THE DRAWINGS The patent o...   \n",
       "17  BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1B ...   \n",
       "18  DESCRIPTION OF DRAWINGS FIG. 1 shows the scree...   \n",
       "19  BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A and...   \n",
       "20  BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...   \n",
       "\n",
       "                                  drawings_file_paths  \\\n",
       "0   [US20190151472A1-20190523-D00001.TIF, US201901...   \n",
       "1   [US20190135863A1-20190509-D00001.TIF, US201901...   \n",
       "2   [US20190133992A1-20190509-D00001.TIF, US201901...   \n",
       "3   [US20190136261A1-20190509-D00001.TIF, US201901...   \n",
       "4   [US20190161536A1-20190530-D00001.TIF, US201901...   \n",
       "5   [US20190202865A1-20190704-D00001.TIF, US201902...   \n",
       "6   [US20190201532A1-20190704-D00001.TIF, US201902...   \n",
       "7   [US20190201444A1-20190704-D00000.TIF, US201902...   \n",
       "8   [US20190177429A1-20190613-D00001.TIF, US201901...   \n",
       "9   [US20190184190A1-20190620-D00000.TIF, US201901...   \n",
       "10  [US20190184190A1-20190620-D00000.TIF, US201901...   \n",
       "11  [US20190159474A1-20190530-D00000.TIF, US201901...   \n",
       "12  [US20190125691A1-20190502-D00000.TIF, US201901...   \n",
       "13  [US20190169260A1-20190606-D00001.TIF, US201901...   \n",
       "14  [US20190194282A1-20190627-D00000.TIF, US201901...   \n",
       "15  [US20190127440A1-20190502-D00001.TIF, US201901...   \n",
       "16  [US20190177383A1-20190613-D00001.TIF, US201901...   \n",
       "17  [US20190194689A1-20190627-D00001.TIF, US201901...   \n",
       "18  [US20190144517A1-20190516-D00001.TIF, US201901...   \n",
       "19  [US20190177709A1-20190613-D00000.TIF, US201901...   \n",
       "20  [US20190169583A1-20190606-D00001.TIF, US201901...   \n",
       "\n",
       "                                 invention_background  \\\n",
       "0   Gene therapy can be used to genetically engine...   \n",
       "1                                                       \n",
       "2   Formulations of bioactive compounds have been ...   \n",
       "3   Cells communicate with each other either by di...   \n",
       "4   Human adipocyte lipid-binding protein (aP2) be...   \n",
       "5   Throughout this application various publicatio...   \n",
       "6   Antibiotics are the main tools to treat infect...   \n",
       "7   Mesenchymal stem cells (MSCs) hold much promis...   \n",
       "8   Breast cancer is a highly significant cause of...   \n",
       "9   Field of Invention The invention relates to me...   \n",
       "10                                                      \n",
       "11  Coffee fruits are mainly produced in Africa an...   \n",
       "12  Controlled protein release is a key strategy t...   \n",
       "13  Cancer has a major impact on society across th...   \n",
       "14  Prostate cancer is the second most commonly di...   \n",
       "15  Thymic stromal lymphopoietin (TSLP) is an inte...   \n",
       "16  Ovarian Cancer With an estimated 239 000 new c...   \n",
       "17  Gene therapy has been investigated for deliver...   \n",
       "18  Tumor necrosis factor α (TNF) is a multifuncti...   \n",
       "19  When one considers that genome sequencing effo...   \n",
       "20                                                      \n",
       "\n",
       "                                      cross_reference  \\\n",
       "0   The present application is a divisional of U.S...   \n",
       "1                                                       \n",
       "2                                                       \n",
       "3   The present application claims the benefit of ...   \n",
       "4                                                       \n",
       "5   This application claims the benefit of U.S. Pr...   \n",
       "6                                                       \n",
       "7                                                       \n",
       "8   The present application is a divisional of U.S...   \n",
       "9                                                       \n",
       "10                                                      \n",
       "11                                                      \n",
       "12                                                      \n",
       "13                                                      \n",
       "14                                                      \n",
       "15                                                      \n",
       "16                                                      \n",
       "17                                                      \n",
       "18                                                      \n",
       "19  This application is filed pursuant to 35 U.S.C...   \n",
       "20                                                      \n",
       "\n",
       "                                              summary  \\\n",
       "0   The present invention describes compositions a...   \n",
       "1                                                       \n",
       "2   The present invention includes a cannabinoid c...   \n",
       "3   The present invention describes compositions a...   \n",
       "4   Anti-aP2 monoclonal antibodies and antigen bin...   \n",
       "5   The present invention discloses assays for ide...   \n",
       "6   Density-dependent drug failure is a form of an...   \n",
       "7   Despite the promise of these methods, there ex...   \n",
       "8   The invention provides anti-HER2 antibodies an...   \n",
       "9   In one embodiment, the present invention provi...   \n",
       "10  In certain embodiments, the invention provides...   \n",
       "11  It is found in the present invention that a wh...   \n",
       "12  The present invention provides a biocompatible...   \n",
       "13  There exists a pressing need for alternative a...   \n",
       "14  Described herein is an improved approach to th...   \n",
       "15  It is surprisingly shown herein that a monomer...   \n",
       "16  In a first aspect of the present invention, th...   \n",
       "17  Aspects of the invention, are based on the dis...   \n",
       "18  It is an object of the present invention to pr...   \n",
       "19  The present invention describes highly specifi...   \n",
       "20                                                      \n",
       "\n",
       "                                 detailed_description  \\\n",
       "0   Disclosed herein are expression cassettes for ...   \n",
       "1                                                       \n",
       "2   The present invention includes a composition o...   \n",
       "3   Disclosed herein are compositions and methods ...   \n",
       "4   Anti-aP2 monoclonal antibodies and antigen bin...   \n",
       "5   method is provided for identifying an agent as...   \n",
       "6   Pharmaceutical Compositions The present disclo...   \n",
       "7   In some embodiments, the present invention pro...   \n",
       "8   Reference will now be made in detail to certai...   \n",
       "9   The present invention sets forth a novel metho...   \n",
       "10  The invention is based at least in part on dev...   \n",
       "11  Unless otherwise defined herein, scientific an...   \n",
       "12  Various embodiments and aspects of the disclos...   \n",
       "13  The following description and examples illustr...   \n",
       "14  I. Terms Unless otherwise noted, technical ter...   \n",
       "15  The present invention will be described with r...   \n",
       "16  Stimulation of an immune response is dependent...   \n",
       "17  Adeno-associated virus (AAV) is a small (26 nm...   \n",
       "18                                                      \n",
       "19  Disclosed herein are compositions and methods ...   \n",
       "20  According to various embodiments, the present ...   \n",
       "\n",
       "                            chemical_compounds_smiles  \\\n",
       "0                                                       \n",
       "1                                                       \n",
       "2       ['CCCCCC/C=C\\\\CCCCCCCC(=*1CCCCC1)C1*C*(C1)*']   \n",
       "3                                                       \n",
       "4                                                       \n",
       "5                                                       \n",
       "6                                                       \n",
       "7                                                       \n",
       "8   ['CC[C@@H]([C@H](N(C(=O)[C@H](C(C)C)NC(=O)[C@@...   \n",
       "9                                                       \n",
       "10                                                NaN   \n",
       "11                                                      \n",
       "12                                                      \n",
       "13                                                      \n",
       "14                                                      \n",
       "15                                                      \n",
       "16                                                      \n",
       "17    ['C1*CCCC1', 'C1CCCCC1', 'C*CCCC1*CC*21CCCCC2']   \n",
       "18                                                      \n",
       "19                                                      \n",
       "20                                                      \n",
       "\n",
       "    chemical_compounds_inchi  \n",
       "0                        NaN  \n",
       "1                        NaN  \n",
       "2                        NaN  \n",
       "3                        NaN  \n",
       "4                        NaN  \n",
       "5                        NaN  \n",
       "6                        NaN  \n",
       "7                        NaN  \n",
       "8                        NaN  \n",
       "9                        NaN  \n",
       "10                       NaN  \n",
       "11                       NaN  \n",
       "12                       NaN  \n",
       "13                       NaN  \n",
       "14                       NaN  \n",
       "15                       NaN  \n",
       "16                       NaN  \n",
       "17                       NaN  \n",
       "18                       NaN  \n",
       "19                       NaN  \n",
       "20                       NaN  "
      ]
     },
     "execution_count": 24,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "patents_df5['chemical_compounds_inchi'] = np.nan\n",
    "patents_df5"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Reading InCHhI structures for file US20190177383\n",
      "Reading InCHhI structures for file US20190161536\n",
      "Reading InCHhI structures for file US20190192693\n",
      "Reading InCHhI structures for file US20190201532\n",
      "Reading InCHhI structures for file US20190169583\n",
      "Reading InCHhI structures for file US20190184190\n",
      "Reading InCHhI structures for file US20190201444\n",
      "Reading InCHhI structures for file US20190133992\n",
      "Reading InCHhI structures for file US20190144517\n",
      "Reading InCHhI structures for file US20190177709\n",
      "Reading InCHhI structures for file US20190194282\n",
      "Reading InCHhI structures for file US20190127440\n",
      "Reading InCHhI structures for file US20190125691\n",
      "Reading InCHhI structures for file US20190169260\n",
      "Reading InCHhI structures for file US20190194689\n",
      "Reading InCHhI structures for file US20190202865\n",
      "Reading InCHhI structures for file US20190135863\n",
      "Reading InCHhI structures for file US20190151472\n",
      "Reading InCHhI structures for file US20190136261\n",
      "Reading InCHhI structures for file US20190159474\n",
      "Reading InCHhI structures for file US20190177429\n"
     ]
    }
   ],
   "source": [
    "# Loop through all files and grab text files\n",
    "for _file in glob.glob('../temp/chemical-names-inchi/US*.txt'):\n",
    "    \n",
    "    print('Reading InCHhI structures for file {}'.format(str(_file[29:-4])))\n",
    "    \n",
    "    # Checking integrity, writing to same document\n",
    "    if ([_file[31:-4] == item for item in patents_df['id']]):\n",
    "        \n",
    "        inchi_for_one = ''\n",
    "\n",
    "        # Read each file \n",
    "        with open(_file, 'r') as f:\n",
    "            for line in f:\n",
    "                inchi_for_one += line.replace('\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t', '')\n",
    "\n",
    "        # Append to dataframe row-by-row to ensure alignment\n",
    "        patents_df5.loc[patents_df5['id'] == _file[31:-4], ['chemical_compounds_inchi']] = \\\n",
    "        inchi_for_one\n",
    "\n",
    "    else:\n",
    "        print('No structures recognized in this file..')\n",
    "        patents_df5.loc[patents_df5['id'] == folder[31:-4], ['chemical_compounds_inchi']] = \\\n",
    "        ' '"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id</th>\n",
       "      <th>invention_title</th>\n",
       "      <th>abstract</th>\n",
       "      <th>claims</th>\n",
       "      <th>description</th>\n",
       "      <th>drawings_description</th>\n",
       "      <th>drawings_file_paths</th>\n",
       "      <th>invention_background</th>\n",
       "      <th>cross_reference</th>\n",
       "      <th>summary</th>\n",
       "      <th>detailed_description</th>\n",
       "      <th>chemical_compounds_smiles</th>\n",
       "      <th>chemical_compounds_inchi</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>20190151472</td>\n",
       "      <td>LIVER-SPECIFIC CONSTRUCTS, FACTOR VIII EXPRESS...</td>\n",
       "      <td>Described herein are constructs used for liver...</td>\n",
       "      <td>1-10. (canceled)  11. A method of providing a...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS The pr...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...</td>\n",
       "      <td>[US20190151472A1-20190523-D00001.TIF, US201901...</td>\n",
       "      <td>Gene therapy can be used to genetically engine...</td>\n",
       "      <td>The present application is a divisional of U.S...</td>\n",
       "      <td>The present invention describes compositions a...</td>\n",
       "      <td>Disclosed herein are expression cassettes for ...</td>\n",
       "      <td></td>\n",
       "      <td>\\t19571\\t19601\\tglucose-6-phosphate transporte...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>20190135863</td>\n",
       "      <td>RETRO-INVERSO PEPTIDE INHIBITORS OF CELL MIGRA...</td>\n",
       "      <td>The present invention discloses retro-inverso ...</td>\n",
       "      <td>1. A compound of formula (I):   X1-(D)-Arg-X2...</td>\n",
       "      <td>The present invention concerns retro-inverso p...</td>\n",
       "      <td>DESCRIPTION OF THE FIGURES FIG. 1 High degree ...</td>\n",
       "      <td>[US20190135863A1-20190509-D00001.TIF, US201901...</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>\\t2711\\t2740\\tglycosyl-phosphatidyl-inositol\\t...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>20190133992</td>\n",
       "      <td>CANNABINOID COMPOSITION HAVING AN OPTIMIZED FA...</td>\n",
       "      <td>A composition of matter for enhancing delivery...</td>\n",
       "      <td>1. A cannabinoid composition comprising: at l...</td>\n",
       "      <td>FIELD OF THE INVENTION The present invention r...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...</td>\n",
       "      <td>[US20190133992A1-20190509-D00001.TIF, US201901...</td>\n",
       "      <td>Formulations of bioactive compounds have been ...</td>\n",
       "      <td></td>\n",
       "      <td>The present invention includes a cannabinoid c...</td>\n",
       "      <td>The present invention includes a composition o...</td>\n",
       "      <td>['CCCCCC/C=C\\\\CCCCCCCC(=*1CCCCC1)C1*C*(C1)*']</td>\n",
       "      <td>\\t12506\\t12524\\t1,5-diarylpyrazoles\\tSYSTEMATI...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>20190136261</td>\n",
       "      <td>GENETIC MODIFICATION OF CYTOKINE INDUCIBLE SH2...</td>\n",
       "      <td>The present disclosure is in the field of geno...</td>\n",
       "      <td>1. A genetically modified cell comprising a g...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS The pr...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 shows...</td>\n",
       "      <td>[US20190136261A1-20190509-D00001.TIF, US201901...</td>\n",
       "      <td>Cells communicate with each other either by di...</td>\n",
       "      <td>The present application claims the benefit of ...</td>\n",
       "      <td>The present invention describes compositions a...</td>\n",
       "      <td>Disclosed herein are compositions and methods ...</td>\n",
       "      <td></td>\n",
       "      <td>\\t15305\\t15313\\tB2M-HLA-E\\tABBREVIATION\\thuman...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>20190161536</td>\n",
       "      <td>ANTI-AP2 ANTIBODIES AND ANTIGEN BINDING AGENTS...</td>\n",
       "      <td>This invention is in the area of improved anti...</td>\n",
       "      <td>1. A method of attenuating an aP2-mediated di...</td>\n",
       "      <td>RELATED APPLICATIONS This application is a con...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1-8 ar...</td>\n",
       "      <td>[US20190161536A1-20190530-D00001.TIF, US201901...</td>\n",
       "      <td>Human adipocyte lipid-binding protein (aP2) be...</td>\n",
       "      <td></td>\n",
       "      <td>Anti-aP2 monoclonal antibodies and antigen bin...</td>\n",
       "      <td>Anti-aP2 monoclonal antibodies and antigen bin...</td>\n",
       "      <td></td>\n",
       "      <td>\\t31413\\t31415\\t10K\\tFORMULA\\t\\t\\n\\t31423\\t314...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>20190202865</td>\n",
       "      <td>TARGETING DIMERIZATION OF BAX TO MODULATE BAX ...</td>\n",
       "      <td>Methods are provided for identifying an agent ...</td>\n",
       "      <td>1-19. (canceled)  20. A method of inhibiting ...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS This a...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1A-1D. ...</td>\n",
       "      <td>[US20190202865A1-20190704-D00001.TIF, US201902...</td>\n",
       "      <td>Throughout this application various publicatio...</td>\n",
       "      <td>This application claims the benefit of U.S. Pr...</td>\n",
       "      <td>The present invention discloses assays for ide...</td>\n",
       "      <td>method is provided for identifying an agent as...</td>\n",
       "      <td></td>\n",
       "      <td>\\t15825\\t15844\\tco-immunoprecipitate\\tSYSTEMAT...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>20190201532</td>\n",
       "      <td>SENSITIZATION OF BACTERIAL CELLS TO QUINOLONE ...</td>\n",
       "      <td>Provided herein are pharmaceutical composition...</td>\n",
       "      <td>1. A pharmaceutical composition comprising a ...</td>\n",
       "      <td>RELATED APPLICATION The present application cl...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1F....</td>\n",
       "      <td>[US20190201532A1-20190704-D00001.TIF, US201902...</td>\n",
       "      <td>Antibiotics are the main tools to treat infect...</td>\n",
       "      <td></td>\n",
       "      <td>Density-dependent drug failure is a form of an...</td>\n",
       "      <td>Pharmaceutical Compositions The present disclo...</td>\n",
       "      <td></td>\n",
       "      <td>\\t16983\\t16998\\tGlucose-fumarate\\tSYSTEMATIC\\t...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>20190201444</td>\n",
       "      <td>GLYCOENGINEERING OF E-SELECTIN LIGANDS</td>\n",
       "      <td>The present invention provides methods of enfo...</td>\n",
       "      <td>1. A method of enforcing expression of an E-s...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS The pr...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1A-FIG....</td>\n",
       "      <td>[US20190201444A1-20190704-D00000.TIF, US201902...</td>\n",
       "      <td>Mesenchymal stem cells (MSCs) hold much promis...</td>\n",
       "      <td></td>\n",
       "      <td>Despite the promise of these methods, there ex...</td>\n",
       "      <td>In some embodiments, the present invention pro...</td>\n",
       "      <td></td>\n",
       "      <td>\\t2697\\t2714\\talpha-(1,3)-fucose\\tSYSTEMATIC\\t...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>20190177429</td>\n",
       "      <td>Anti-HER2 Antibodies and Immunoconjugates</td>\n",
       "      <td>The invention provides anti-HER2 antibodies an...</td>\n",
       "      <td>1. An isolated antibody that binds to HER2, w...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS The pr...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE FIGURES FIG. 1 shows ...</td>\n",
       "      <td>[US20190177429A1-20190613-D00001.TIF, US201901...</td>\n",
       "      <td>Breast cancer is a highly significant cause of...</td>\n",
       "      <td>The present application is a divisional of U.S...</td>\n",
       "      <td>The invention provides anti-HER2 antibodies an...</td>\n",
       "      <td>Reference will now be made in detail to certai...</td>\n",
       "      <td>['CC[C@@H]([C@H](N(C(=O)[C@H](C(C)C)NC(=O)[C@@...</td>\n",
       "      <td>\\t4914\\t4916\\t2C4\\tFORMULA\\t\\t\\n\\t4926\\t4928\\t...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>20190184190</td>\n",
       "      <td>PHOSPHOR-CONTAINING DRUG ACTIVATOR ACTIVATABLE...</td>\n",
       "      <td>A phosphor-containing drug activator activatab...</td>\n",
       "      <td>1. A phosphor-containing drug activator activ...</td>\n",
       "      <td>CROSS REFERENCE TO RELATED APPLICATIONS This a...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE FIGURES A more comple...</td>\n",
       "      <td>[US20190184190A1-20190620-D00000.TIF, US201901...</td>\n",
       "      <td>Field of Invention The invention relates to me...</td>\n",
       "      <td></td>\n",
       "      <td>In one embodiment, the present invention provi...</td>\n",
       "      <td>The present invention sets forth a novel metho...</td>\n",
       "      <td></td>\n",
       "      <td>\\t10807\\t10818\\tZn2SiO4:Mn2+\\tFORMULA\\t\\t\\n\\t1...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>20190192693</td>\n",
       "      <td>METHODS AND VECTORS FOR TREATING CNS DISORDERS</td>\n",
       "      <td>Methods and uses of treating a disease in a ma...</td>\n",
       "      <td>1. A method of delivering a therapeutic prote...</td>\n",
       "      <td>RELATED APPLICATIONS This application claims p...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE FIGURES A more comple...</td>\n",
       "      <td>[US20190184190A1-20190620-D00000.TIF, US201901...</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>In certain embodiments, the invention provides...</td>\n",
       "      <td>The invention is based at least in part on dev...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>\\t11756\\t11784\\tcytosine-guanine dinucleotide\\...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>20190159474</td>\n",
       "      <td>AMELIORATIVE EFFECTS OF A WHOLE COFFEE FRUIT E...</td>\n",
       "      <td>The invention provides a method of extracting ...</td>\n",
       "      <td>1. A method of producing a whole coffee fruit...</td>\n",
       "      <td>FIELD OF THE INVENTION The invention provides ...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A and...</td>\n",
       "      <td>[US20190159474A1-20190530-D00000.TIF, US201901...</td>\n",
       "      <td>Coffee fruits are mainly produced in Africa an...</td>\n",
       "      <td></td>\n",
       "      <td>It is found in the present invention that a wh...</td>\n",
       "      <td>Unless otherwise defined herein, scientific an...</td>\n",
       "      <td></td>\n",
       "      <td>\\t7599\\t7621\\t5-O-caffeoylquinic acid\\tSYSTEMA...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>20190125691</td>\n",
       "      <td>ENCAPSULATION-FREE CONTROLLED PROTEIN RELEASE ...</td>\n",
       "      <td>The present disclosure provides a delivery sys...</td>\n",
       "      <td>1. A biocompatible polymer composite comprise...</td>\n",
       "      <td>FIELD The present disclosure relates to a bioc...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS Embodiments ...</td>\n",
       "      <td>[US20190125691A1-20190502-D00000.TIF, US201901...</td>\n",
       "      <td>Controlled protein release is a key strategy t...</td>\n",
       "      <td></td>\n",
       "      <td>The present invention provides a biocompatible...</td>\n",
       "      <td>Various embodiments and aspects of the disclos...</td>\n",
       "      <td></td>\n",
       "      <td>\\t816\\t863\\tpoly(alkyl-cyanoacrylate), poly(et...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>20190169260</td>\n",
       "      <td>Human Leukocyte Antigen Restricted Gamma Delta...</td>\n",
       "      <td>Disclosed herein are compositions and methods ...</td>\n",
       "      <td>1. A composition comprising a polypeptide con...</td>\n",
       "      <td>SEQUENCE LISTING The instant application conta...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS The novel fe...</td>\n",
       "      <td>[US20190169260A1-20190606-D00001.TIF, US201901...</td>\n",
       "      <td>Cancer has a major impact on society across th...</td>\n",
       "      <td></td>\n",
       "      <td>There exists a pressing need for alternative a...</td>\n",
       "      <td>The following description and examples illustr...</td>\n",
       "      <td></td>\n",
       "      <td>\\t21203\\t21205\\t10B\\tFORMULA\\t\\t\\n\\t21316\\t213...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>20190194282</td>\n",
       "      <td>CHIMERIC PROTEINS FOR TARGETING dsRNA</td>\n",
       "      <td>Described herein are recombinant chimeric prot...</td>\n",
       "      <td>1. A chimeric recombinant protein comprising:...</td>\n",
       "      <td>CROSS REFERENCE TO RELATED APPLICATIONS Benefi...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1D:...</td>\n",
       "      <td>[US20190194282A1-20190627-D00000.TIF, US201901...</td>\n",
       "      <td>Prostate cancer is the second most commonly di...</td>\n",
       "      <td></td>\n",
       "      <td>Described herein is an improved approach to th...</td>\n",
       "      <td>I. Terms Unless otherwise noted, technical ter...</td>\n",
       "      <td></td>\n",
       "      <td>\\t3814\\t3842\\t4, 6-diamidino-2-phenylindole\\tS...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>20190127440</td>\n",
       "      <td>NOVEL TSLP INHIBITORS</td>\n",
       "      <td>The present invention relates to monomeric fus...</td>\n",
       "      <td>1. A monomeric fusion protein comprising: a f...</td>\n",
       "      <td>FIELD OF THE INVENTION The present invention r...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE FIGURES FIG. 1 shows ...</td>\n",
       "      <td>[US20190127440A1-20190502-D00001.TIF, US201901...</td>\n",
       "      <td>Thymic stromal lymphopoietin (TSLP) is an inte...</td>\n",
       "      <td></td>\n",
       "      <td>It is surprisingly shown herein that a monomer...</td>\n",
       "      <td>The present invention will be described with r...</td>\n",
       "      <td></td>\n",
       "      <td>\\t24717\\t24730\\tto—haloacetyls\\tSYSTEMATIC\\t\\t...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>20190177383</td>\n",
       "      <td>NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR...</td>\n",
       "      <td>The present invention relates to peptides, pro...</td>\n",
       "      <td>1. A method of treating a patient who has can...</td>\n",
       "      <td>CROSS REFERENCE TO RELATED APPLICATIONS This a...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS The patent o...</td>\n",
       "      <td>[US20190177383A1-20190613-D00001.TIF, US201901...</td>\n",
       "      <td>Ovarian Cancer With an estimated 239 000 new c...</td>\n",
       "      <td></td>\n",
       "      <td>In a first aspect of the present invention, th...</td>\n",
       "      <td>Stimulation of an immune response is dependent...</td>\n",
       "      <td></td>\n",
       "      <td>\\t12904\\t12923\\tbeta-2-microglobulin\\tSYSTEMAT...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>20190194689</td>\n",
       "      <td>CNS TARGETING AAV VECTORS AND METHODS OF USE T...</td>\n",
       "      <td>The invention in some aspects relates to recom...</td>\n",
       "      <td>1-55. (canceled)  56. A method for delivering...</td>\n",
       "      <td>RELATED APPLICATIONS This application is a con...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1B ...</td>\n",
       "      <td>[US20190194689A1-20190627-D00001.TIF, US201901...</td>\n",
       "      <td>Gene therapy has been investigated for deliver...</td>\n",
       "      <td></td>\n",
       "      <td>Aspects of the invention, are based on the dis...</td>\n",
       "      <td>Adeno-associated virus (AAV) is a small (26 nm...</td>\n",
       "      <td>['C1*CCCC1', 'C1CCCCC1', 'C*CCCC1*CC*21CCCCC2']</td>\n",
       "      <td>\\t8512\\t8530\\tN-acetyl-tranferase\\tSYSTEMATIC\\...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>20190144517</td>\n",
       "      <td>PROTEIN FOR NEUTRALIZING PROGRAMMED NECROCYTOS...</td>\n",
       "      <td>Provided is polypeptide which derives from wil...</td>\n",
       "      <td>1. A polypeptide that inhibits cell necrosis,...</td>\n",
       "      <td>TECHNICAL FIELD The present invention relates ...</td>\n",
       "      <td>DESCRIPTION OF DRAWINGS FIG. 1 shows the scree...</td>\n",
       "      <td>[US20190144517A1-20190516-D00001.TIF, US201901...</td>\n",
       "      <td>Tumor necrosis factor α (TNF) is a multifuncti...</td>\n",
       "      <td></td>\n",
       "      <td>It is an object of the present invention to pr...</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>\\t-1\\t-1\\t\\N\\t\\N\\t\\N\\t\\t\\n</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>20190177709</td>\n",
       "      <td>REGULATION OF GENE EXPRESSION USING ENGINEERED...</td>\n",
       "      <td>The present disclosure is in the field of geno...</td>\n",
       "      <td>1. A zinc finger nuclease (ZFN) comprising le...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS This a...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A and...</td>\n",
       "      <td>[US20190177709A1-20190613-D00000.TIF, US201901...</td>\n",
       "      <td>When one considers that genome sequencing effo...</td>\n",
       "      <td>This application is filed pursuant to 35 U.S.C...</td>\n",
       "      <td>The present invention describes highly specifi...</td>\n",
       "      <td>Disclosed herein are compositions and methods ...</td>\n",
       "      <td></td>\n",
       "      <td>\\t11961\\t11973\\t5-azacytidine\\tSYSTEMATIC\\t\\t\\...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>20190169583</td>\n",
       "      <td>STEP-Derived Peptide for Brain Injury Treatment</td>\n",
       "      <td>A novel peptide sequence that is a modified de...</td>\n",
       "      <td>1. An isolated peptide comprising a kinase in...</td>\n",
       "      <td>CROSS-REFERENCE TO RELATED APPLICATIONS The fo...</td>\n",
       "      <td>BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...</td>\n",
       "      <td>[US20190169583A1-20190606-D00001.TIF, US201901...</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>According to various embodiments, the present ...</td>\n",
       "      <td></td>\n",
       "      <td>\\t313\\t316\\tUS11\\tFORMULA\\t\\t\\n\\t1810\\t1821\\tN...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "             id                                    invention_title  \\\n",
       "0   20190151472  LIVER-SPECIFIC CONSTRUCTS, FACTOR VIII EXPRESS...   \n",
       "1   20190135863  RETRO-INVERSO PEPTIDE INHIBITORS OF CELL MIGRA...   \n",
       "2   20190133992  CANNABINOID COMPOSITION HAVING AN OPTIMIZED FA...   \n",
       "3   20190136261  GENETIC MODIFICATION OF CYTOKINE INDUCIBLE SH2...   \n",
       "4   20190161536  ANTI-AP2 ANTIBODIES AND ANTIGEN BINDING AGENTS...   \n",
       "5   20190202865  TARGETING DIMERIZATION OF BAX TO MODULATE BAX ...   \n",
       "6   20190201532  SENSITIZATION OF BACTERIAL CELLS TO QUINOLONE ...   \n",
       "7   20190201444             GLYCOENGINEERING OF E-SELECTIN LIGANDS   \n",
       "8   20190177429          Anti-HER2 Antibodies and Immunoconjugates   \n",
       "9   20190184190  PHOSPHOR-CONTAINING DRUG ACTIVATOR ACTIVATABLE...   \n",
       "10  20190192693     METHODS AND VECTORS FOR TREATING CNS DISORDERS   \n",
       "11  20190159474  AMELIORATIVE EFFECTS OF A WHOLE COFFEE FRUIT E...   \n",
       "12  20190125691  ENCAPSULATION-FREE CONTROLLED PROTEIN RELEASE ...   \n",
       "13  20190169260  Human Leukocyte Antigen Restricted Gamma Delta...   \n",
       "14  20190194282              CHIMERIC PROTEINS FOR TARGETING dsRNA   \n",
       "15  20190127440                              NOVEL TSLP INHIBITORS   \n",
       "16  20190177383  NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR...   \n",
       "17  20190194689  CNS TARGETING AAV VECTORS AND METHODS OF USE T...   \n",
       "18  20190144517  PROTEIN FOR NEUTRALIZING PROGRAMMED NECROCYTOS...   \n",
       "19  20190177709  REGULATION OF GENE EXPRESSION USING ENGINEERED...   \n",
       "20  20190169583    STEP-Derived Peptide for Brain Injury Treatment   \n",
       "\n",
       "                                             abstract  \\\n",
       "0   Described herein are constructs used for liver...   \n",
       "1   The present invention discloses retro-inverso ...   \n",
       "2   A composition of matter for enhancing delivery...   \n",
       "3   The present disclosure is in the field of geno...   \n",
       "4   This invention is in the area of improved anti...   \n",
       "5   Methods are provided for identifying an agent ...   \n",
       "6   Provided herein are pharmaceutical composition...   \n",
       "7   The present invention provides methods of enfo...   \n",
       "8   The invention provides anti-HER2 antibodies an...   \n",
       "9   A phosphor-containing drug activator activatab...   \n",
       "10  Methods and uses of treating a disease in a ma...   \n",
       "11  The invention provides a method of extracting ...   \n",
       "12  The present disclosure provides a delivery sys...   \n",
       "13  Disclosed herein are compositions and methods ...   \n",
       "14  Described herein are recombinant chimeric prot...   \n",
       "15  The present invention relates to monomeric fus...   \n",
       "16  The present invention relates to peptides, pro...   \n",
       "17  The invention in some aspects relates to recom...   \n",
       "18  Provided is polypeptide which derives from wil...   \n",
       "19  The present disclosure is in the field of geno...   \n",
       "20  A novel peptide sequence that is a modified de...   \n",
       "\n",
       "                                               claims  \\\n",
       "0    1-10. (canceled)  11. A method of providing a...   \n",
       "1    1. A compound of formula (I):   X1-(D)-Arg-X2...   \n",
       "2    1. A cannabinoid composition comprising: at l...   \n",
       "3    1. A genetically modified cell comprising a g...   \n",
       "4    1. A method of attenuating an aP2-mediated di...   \n",
       "5    1-19. (canceled)  20. A method of inhibiting ...   \n",
       "6    1. A pharmaceutical composition comprising a ...   \n",
       "7    1. A method of enforcing expression of an E-s...   \n",
       "8    1. An isolated antibody that binds to HER2, w...   \n",
       "9    1. A phosphor-containing drug activator activ...   \n",
       "10   1. A method of delivering a therapeutic prote...   \n",
       "11   1. A method of producing a whole coffee fruit...   \n",
       "12   1. A biocompatible polymer composite comprise...   \n",
       "13   1. A composition comprising a polypeptide con...   \n",
       "14   1. A chimeric recombinant protein comprising:...   \n",
       "15   1. A monomeric fusion protein comprising: a f...   \n",
       "16   1. A method of treating a patient who has can...   \n",
       "17   1-55. (canceled)  56. A method for delivering...   \n",
       "18   1. A polypeptide that inhibits cell necrosis,...   \n",
       "19   1. A zinc finger nuclease (ZFN) comprising le...   \n",
       "20   1. An isolated peptide comprising a kinase in...   \n",
       "\n",
       "                                          description  \\\n",
       "0   CROSS-REFERENCE TO RELATED APPLICATIONS The pr...   \n",
       "1   The present invention concerns retro-inverso p...   \n",
       "2   FIELD OF THE INVENTION The present invention r...   \n",
       "3   CROSS-REFERENCE TO RELATED APPLICATIONS The pr...   \n",
       "4   RELATED APPLICATIONS This application is a con...   \n",
       "5   CROSS-REFERENCE TO RELATED APPLICATIONS This a...   \n",
       "6   RELATED APPLICATION The present application cl...   \n",
       "7   CROSS-REFERENCE TO RELATED APPLICATIONS The pr...   \n",
       "8   CROSS-REFERENCE TO RELATED APPLICATIONS The pr...   \n",
       "9   CROSS REFERENCE TO RELATED APPLICATIONS This a...   \n",
       "10  RELATED APPLICATIONS This application claims p...   \n",
       "11  FIELD OF THE INVENTION The invention provides ...   \n",
       "12  FIELD The present disclosure relates to a bioc...   \n",
       "13  SEQUENCE LISTING The instant application conta...   \n",
       "14  CROSS REFERENCE TO RELATED APPLICATIONS Benefi...   \n",
       "15  FIELD OF THE INVENTION The present invention r...   \n",
       "16  CROSS REFERENCE TO RELATED APPLICATIONS This a...   \n",
       "17  RELATED APPLICATIONS This application is a con...   \n",
       "18  TECHNICAL FIELD The present invention relates ...   \n",
       "19  CROSS-REFERENCE TO RELATED APPLICATIONS This a...   \n",
       "20  CROSS-REFERENCE TO RELATED APPLICATIONS The fo...   \n",
       "\n",
       "                                 drawings_description  \\\n",
       "0   BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...   \n",
       "1   DESCRIPTION OF THE FIGURES FIG. 1 High degree ...   \n",
       "2   BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...   \n",
       "3   BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 shows...   \n",
       "4   BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1-8 ar...   \n",
       "5   BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1A-1D. ...   \n",
       "6   BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1F....   \n",
       "7   BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1A-FIG....   \n",
       "8   BRIEF DESCRIPTION OF THE FIGURES FIG. 1 shows ...   \n",
       "9   BRIEF DESCRIPTION OF THE FIGURES A more comple...   \n",
       "10  BRIEF DESCRIPTION OF THE FIGURES A more comple...   \n",
       "11  BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A and...   \n",
       "12  BRIEF DESCRIPTION OF THE DRAWINGS Embodiments ...   \n",
       "13  BRIEF DESCRIPTION OF THE DRAWINGS The novel fe...   \n",
       "14  BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1D:...   \n",
       "15  BRIEF DESCRIPTION OF THE FIGURES FIG. 1 shows ...   \n",
       "16  BRIEF DESCRIPTION OF THE DRAWINGS The patent o...   \n",
       "17  BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-1B ...   \n",
       "18  DESCRIPTION OF DRAWINGS FIG. 1 shows the scree...   \n",
       "19  BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A and...   \n",
       "20  BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a ...   \n",
       "\n",
       "                                  drawings_file_paths  \\\n",
       "0   [US20190151472A1-20190523-D00001.TIF, US201901...   \n",
       "1   [US20190135863A1-20190509-D00001.TIF, US201901...   \n",
       "2   [US20190133992A1-20190509-D00001.TIF, US201901...   \n",
       "3   [US20190136261A1-20190509-D00001.TIF, US201901...   \n",
       "4   [US20190161536A1-20190530-D00001.TIF, US201901...   \n",
       "5   [US20190202865A1-20190704-D00001.TIF, US201902...   \n",
       "6   [US20190201532A1-20190704-D00001.TIF, US201902...   \n",
       "7   [US20190201444A1-20190704-D00000.TIF, US201902...   \n",
       "8   [US20190177429A1-20190613-D00001.TIF, US201901...   \n",
       "9   [US20190184190A1-20190620-D00000.TIF, US201901...   \n",
       "10  [US20190184190A1-20190620-D00000.TIF, US201901...   \n",
       "11  [US20190159474A1-20190530-D00000.TIF, US201901...   \n",
       "12  [US20190125691A1-20190502-D00000.TIF, US201901...   \n",
       "13  [US20190169260A1-20190606-D00001.TIF, US201901...   \n",
       "14  [US20190194282A1-20190627-D00000.TIF, US201901...   \n",
       "15  [US20190127440A1-20190502-D00001.TIF, US201901...   \n",
       "16  [US20190177383A1-20190613-D00001.TIF, US201901...   \n",
       "17  [US20190194689A1-20190627-D00001.TIF, US201901...   \n",
       "18  [US20190144517A1-20190516-D00001.TIF, US201901...   \n",
       "19  [US20190177709A1-20190613-D00000.TIF, US201901...   \n",
       "20  [US20190169583A1-20190606-D00001.TIF, US201901...   \n",
       "\n",
       "                                 invention_background  \\\n",
       "0   Gene therapy can be used to genetically engine...   \n",
       "1                                                       \n",
       "2   Formulations of bioactive compounds have been ...   \n",
       "3   Cells communicate with each other either by di...   \n",
       "4   Human adipocyte lipid-binding protein (aP2) be...   \n",
       "5   Throughout this application various publicatio...   \n",
       "6   Antibiotics are the main tools to treat infect...   \n",
       "7   Mesenchymal stem cells (MSCs) hold much promis...   \n",
       "8   Breast cancer is a highly significant cause of...   \n",
       "9   Field of Invention The invention relates to me...   \n",
       "10                                                      \n",
       "11  Coffee fruits are mainly produced in Africa an...   \n",
       "12  Controlled protein release is a key strategy t...   \n",
       "13  Cancer has a major impact on society across th...   \n",
       "14  Prostate cancer is the second most commonly di...   \n",
       "15  Thymic stromal lymphopoietin (TSLP) is an inte...   \n",
       "16  Ovarian Cancer With an estimated 239 000 new c...   \n",
       "17  Gene therapy has been investigated for deliver...   \n",
       "18  Tumor necrosis factor α (TNF) is a multifuncti...   \n",
       "19  When one considers that genome sequencing effo...   \n",
       "20                                                      \n",
       "\n",
       "                                      cross_reference  \\\n",
       "0   The present application is a divisional of U.S...   \n",
       "1                                                       \n",
       "2                                                       \n",
       "3   The present application claims the benefit of ...   \n",
       "4                                                       \n",
       "5   This application claims the benefit of U.S. Pr...   \n",
       "6                                                       \n",
       "7                                                       \n",
       "8   The present application is a divisional of U.S...   \n",
       "9                                                       \n",
       "10                                                      \n",
       "11                                                      \n",
       "12                                                      \n",
       "13                                                      \n",
       "14                                                      \n",
       "15                                                      \n",
       "16                                                      \n",
       "17                                                      \n",
       "18                                                      \n",
       "19  This application is filed pursuant to 35 U.S.C...   \n",
       "20                                                      \n",
       "\n",
       "                                              summary  \\\n",
       "0   The present invention describes compositions a...   \n",
       "1                                                       \n",
       "2   The present invention includes a cannabinoid c...   \n",
       "3   The present invention describes compositions a...   \n",
       "4   Anti-aP2 monoclonal antibodies and antigen bin...   \n",
       "5   The present invention discloses assays for ide...   \n",
       "6   Density-dependent drug failure is a form of an...   \n",
       "7   Despite the promise of these methods, there ex...   \n",
       "8   The invention provides anti-HER2 antibodies an...   \n",
       "9   In one embodiment, the present invention provi...   \n",
       "10  In certain embodiments, the invention provides...   \n",
       "11  It is found in the present invention that a wh...   \n",
       "12  The present invention provides a biocompatible...   \n",
       "13  There exists a pressing need for alternative a...   \n",
       "14  Described herein is an improved approach to th...   \n",
       "15  It is surprisingly shown herein that a monomer...   \n",
       "16  In a first aspect of the present invention, th...   \n",
       "17  Aspects of the invention, are based on the dis...   \n",
       "18  It is an object of the present invention to pr...   \n",
       "19  The present invention describes highly specifi...   \n",
       "20                                                      \n",
       "\n",
       "                                 detailed_description  \\\n",
       "0   Disclosed herein are expression cassettes for ...   \n",
       "1                                                       \n",
       "2   The present invention includes a composition o...   \n",
       "3   Disclosed herein are compositions and methods ...   \n",
       "4   Anti-aP2 monoclonal antibodies and antigen bin...   \n",
       "5   method is provided for identifying an agent as...   \n",
       "6   Pharmaceutical Compositions The present disclo...   \n",
       "7   In some embodiments, the present invention pro...   \n",
       "8   Reference will now be made in detail to certai...   \n",
       "9   The present invention sets forth a novel metho...   \n",
       "10  The invention is based at least in part on dev...   \n",
       "11  Unless otherwise defined herein, scientific an...   \n",
       "12  Various embodiments and aspects of the disclos...   \n",
       "13  The following description and examples illustr...   \n",
       "14  I. Terms Unless otherwise noted, technical ter...   \n",
       "15  The present invention will be described with r...   \n",
       "16  Stimulation of an immune response is dependent...   \n",
       "17  Adeno-associated virus (AAV) is a small (26 nm...   \n",
       "18                                                      \n",
       "19  Disclosed herein are compositions and methods ...   \n",
       "20  According to various embodiments, the present ...   \n",
       "\n",
       "                            chemical_compounds_smiles  \\\n",
       "0                                                       \n",
       "1                                                       \n",
       "2       ['CCCCCC/C=C\\\\CCCCCCCC(=*1CCCCC1)C1*C*(C1)*']   \n",
       "3                                                       \n",
       "4                                                       \n",
       "5                                                       \n",
       "6                                                       \n",
       "7                                                       \n",
       "8   ['CC[C@@H]([C@H](N(C(=O)[C@H](C(C)C)NC(=O)[C@@...   \n",
       "9                                                       \n",
       "10                                                NaN   \n",
       "11                                                      \n",
       "12                                                      \n",
       "13                                                      \n",
       "14                                                      \n",
       "15                                                      \n",
       "16                                                      \n",
       "17    ['C1*CCCC1', 'C1CCCCC1', 'C*CCCC1*CC*21CCCCC2']   \n",
       "18                                                      \n",
       "19                                                      \n",
       "20                                                      \n",
       "\n",
       "                             chemical_compounds_inchi  \n",
       "0   \\t19571\\t19601\\tglucose-6-phosphate transporte...  \n",
       "1   \\t2711\\t2740\\tglycosyl-phosphatidyl-inositol\\t...  \n",
       "2   \\t12506\\t12524\\t1,5-diarylpyrazoles\\tSYSTEMATI...  \n",
       "3   \\t15305\\t15313\\tB2M-HLA-E\\tABBREVIATION\\thuman...  \n",
       "4   \\t31413\\t31415\\t10K\\tFORMULA\\t\\t\\n\\t31423\\t314...  \n",
       "5   \\t15825\\t15844\\tco-immunoprecipitate\\tSYSTEMAT...  \n",
       "6   \\t16983\\t16998\\tGlucose-fumarate\\tSYSTEMATIC\\t...  \n",
       "7   \\t2697\\t2714\\talpha-(1,3)-fucose\\tSYSTEMATIC\\t...  \n",
       "8   \\t4914\\t4916\\t2C4\\tFORMULA\\t\\t\\n\\t4926\\t4928\\t...  \n",
       "9   \\t10807\\t10818\\tZn2SiO4:Mn2+\\tFORMULA\\t\\t\\n\\t1...  \n",
       "10  \\t11756\\t11784\\tcytosine-guanine dinucleotide\\...  \n",
       "11  \\t7599\\t7621\\t5-O-caffeoylquinic acid\\tSYSTEMA...  \n",
       "12  \\t816\\t863\\tpoly(alkyl-cyanoacrylate), poly(et...  \n",
       "13  \\t21203\\t21205\\t10B\\tFORMULA\\t\\t\\n\\t21316\\t213...  \n",
       "14  \\t3814\\t3842\\t4, 6-diamidino-2-phenylindole\\tS...  \n",
       "15  \\t24717\\t24730\\tto—haloacetyls\\tSYSTEMATIC\\t\\t...  \n",
       "16  \\t12904\\t12923\\tbeta-2-microglobulin\\tSYSTEMAT...  \n",
       "17  \\t8512\\t8530\\tN-acetyl-tranferase\\tSYSTEMATIC\\...  \n",
       "18                         \\t-1\\t-1\\t\\N\\t\\N\\t\\N\\t\\t\\n  \n",
       "19  \\t11961\\t11973\\t5-azacytidine\\tSYSTEMATIC\\t\\t\\...  \n",
       "20  \\t313\\t316\\tUS11\\tFORMULA\\t\\t\\n\\t1810\\t1821\\tN...  "
      ]
     },
     "execution_count": 26,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "patents_df5"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<hr>\n",
    "<br>\n",
    "\n",
    "<a id='section-5'></a>\n",
    "\n",
    "### - Text Preprocessing and Tokenization"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Loading dependencies\n",
    "import numpy as np\n",
    "from gensim.models.doc2vec import Doc2Vec, TaggedDocument\n",
    "from gensim.models.fasttext import FastText\n",
    "import multiprocessing\n",
    "from tqdm import tqdm\n",
    "from gensim.utils import simple_preprocess\n",
    "from sklearn.model_selection import train_test_split"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id</th>\n",
       "      <th>invention_title</th>\n",
       "      <th>abstract</th>\n",
       "      <th>claims</th>\n",
       "      <th>description</th>\n",
       "      <th>drawings_description</th>\n",
       "      <th>invention_background</th>\n",
       "      <th>cross_reference</th>\n",
       "      <th>summary</th>\n",
       "      <th>detailed_description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>20190151472</td>\n",
       "      <td>[liver, specific, constructs, factor, viii, ex...</td>\n",
       "      <td>[described, herein, are, constructs, used, for...</td>\n",
       "      <td>[canceled, method, of, providing, protein, to,...</td>\n",
       "      <td>[cross, reference, to, related, applications, ...</td>\n",
       "      <td>[brief, description, of, the, drawings, fig, i...</td>\n",
       "      <td>[gene, therapy, can, be, used, to, genetically...</td>\n",
       "      <td>[the, present, application, is, divisional, of...</td>\n",
       "      <td>[the, present, invention, describes, compositi...</td>\n",
       "      <td>[disclosed, herein, are, expression, cassettes...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>20190135863</td>\n",
       "      <td>[retro, inverso, peptide, inhibitors, of, cell...</td>\n",
       "      <td>[the, present, invention, discloses, retro, in...</td>\n",
       "      <td>[compound, of, formula, arg, arg, nh, wherein,...</td>\n",
       "      <td>[the, present, invention, concerns, retro, inv...</td>\n",
       "      <td>[description, of, the, figures, fig, high, deg...</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>20190133992</td>\n",
       "      <td>[cannabinoid, composition, having, an, optimiz...</td>\n",
       "      <td>[composition, of, matter, for, enhancing, deli...</td>\n",
       "      <td>[cannabinoid, composition, comprising, at, lea...</td>\n",
       "      <td>[field, of, the, invention, the, present, inve...</td>\n",
       "      <td>[brief, description, of, the, drawings, fig, i...</td>\n",
       "      <td>[formulations, of, bioactive, compounds, have,...</td>\n",
       "      <td>[]</td>\n",
       "      <td>[the, present, invention, includes, cannabinoi...</td>\n",
       "      <td>[the, present, invention, includes, compositio...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>20190136261</td>\n",
       "      <td>[genetic, modification, of, cytokine, inducibl...</td>\n",
       "      <td>[the, present, disclosure, is, in, the, field,...</td>\n",
       "      <td>[genetically, modified, cell, comprising, geno...</td>\n",
       "      <td>[cross, reference, to, related, applications, ...</td>\n",
       "      <td>[brief, description, of, the, drawings, fig, s...</td>\n",
       "      <td>[cells, communicate, with, each, other, either...</td>\n",
       "      <td>[the, present, application, claims, the, benef...</td>\n",
       "      <td>[the, present, invention, describes, compositi...</td>\n",
       "      <td>[disclosed, herein, are, compositions, and, me...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>20190161536</td>\n",
       "      <td>[anti, ap, antibodies, and, antigen, binding, ...</td>\n",
       "      <td>[this, invention, is, in, the, area, of, impro...</td>\n",
       "      <td>[method, of, attenuating, an, ap, mediated, di...</td>\n",
       "      <td>[related, applications, this, application, is,...</td>\n",
       "      <td>[brief, description, of, the, drawings, figs, ...</td>\n",
       "      <td>[human, adipocyte, lipid, binding, protein, ap...</td>\n",
       "      <td>[]</td>\n",
       "      <td>[anti, ap, monoclonal, antibodies, and, antige...</td>\n",
       "      <td>[anti, ap, monoclonal, antibodies, and, antige...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>20190202865</td>\n",
       "      <td>[targeting, dimerization, of, bax, to, modulat...</td>\n",
       "      <td>[methods, are, provided, for, identifying, an,...</td>\n",
       "      <td>[canceled, method, of, inhibiting, bcl, associ...</td>\n",
       "      <td>[cross, reference, to, related, applications, ...</td>\n",
       "      <td>[brief, description, of, the, drawings, fig, b...</td>\n",
       "      <td>[throughout, this, application, various, publi...</td>\n",
       "      <td>[this, application, claims, the, benefit, of, ...</td>\n",
       "      <td>[the, present, invention, discloses, assays, f...</td>\n",
       "      <td>[method, is, provided, for, identifying, an, a...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>20190201532</td>\n",
       "      <td>[sensitization, of, bacterial, cells, to, quin...</td>\n",
       "      <td>[provided, herein, are, pharmaceutical, compos...</td>\n",
       "      <td>[pharmaceutical, composition, comprising, carb...</td>\n",
       "      <td>[related, application, the, present, applicati...</td>\n",
       "      <td>[brief, description, of, the, drawings, figs, ...</td>\n",
       "      <td>[antibiotics, are, the, main, tools, to, treat...</td>\n",
       "      <td>[]</td>\n",
       "      <td>[density, dependent, drug, failure, is, form, ...</td>\n",
       "      <td>[pharmaceutical, compositions, the, present, d...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>20190201444</td>\n",
       "      <td>[of, selectin, ligands]</td>\n",
       "      <td>[the, present, invention, provides, methods, o...</td>\n",
       "      <td>[method, of, enforcing, expression, of, an, se...</td>\n",
       "      <td>[cross, reference, to, related, applications, ...</td>\n",
       "      <td>[brief, description, of, the, drawings, fig, f...</td>\n",
       "      <td>[mesenchymal, stem, cells, mscs, hold, much, p...</td>\n",
       "      <td>[]</td>\n",
       "      <td>[despite, the, promise, of, these, methods, th...</td>\n",
       "      <td>[in, some, embodiments, the, present, inventio...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>20190177429</td>\n",
       "      <td>[anti, her, antibodies, and]</td>\n",
       "      <td>[the, invention, provides, anti, her, antibodi...</td>\n",
       "      <td>[an, isolated, antibody, that, binds, to, her,...</td>\n",
       "      <td>[cross, reference, to, related, applications, ...</td>\n",
       "      <td>[brief, description, of, the, figures, fig, sh...</td>\n",
       "      <td>[breast, cancer, is, highly, significant, caus...</td>\n",
       "      <td>[the, present, application, is, divisional, of...</td>\n",
       "      <td>[the, invention, provides, anti, her, antibodi...</td>\n",
       "      <td>[reference, will, now, be, made, in, detail, t...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>20190184190</td>\n",
       "      <td>[phosphor, containing, drug, activator, activa...</td>\n",
       "      <td>[phosphor, containing, drug, activator, activa...</td>\n",
       "      <td>[phosphor, containing, drug, activator, activa...</td>\n",
       "      <td>[cross, reference, to, related, applications, ...</td>\n",
       "      <td>[brief, description, of, the, figures, more, c...</td>\n",
       "      <td>[field, of, invention, the, invention, relates...</td>\n",
       "      <td>[]</td>\n",
       "      <td>[in, one, embodiment, the, present, invention,...</td>\n",
       "      <td>[the, present, invention, sets, forth, novel, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>20190192693</td>\n",
       "      <td>[methods, and, vectors, for, treating, cns, di...</td>\n",
       "      <td>[methods, and, uses, of, treating, disease, in...</td>\n",
       "      <td>[method, of, delivering, therapeutic, protein,...</td>\n",
       "      <td>[related, applications, this, application, cla...</td>\n",
       "      <td>[brief, description, of, the, figures, more, c...</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[in, certain, embodiments, the, invention, pro...</td>\n",
       "      <td>[the, invention, is, based, at, least, in, par...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>20190159474</td>\n",
       "      <td>[ameliorative, effects, of, whole, coffee, fru...</td>\n",
       "      <td>[the, invention, provides, method, of, extract...</td>\n",
       "      <td>[method, of, producing, whole, coffee, fruit, ...</td>\n",
       "      <td>[field, of, the, invention, the, invention, pr...</td>\n",
       "      <td>[brief, description, of, the, drawings, figs, ...</td>\n",
       "      <td>[coffee, fruits, are, mainly, produced, in, af...</td>\n",
       "      <td>[]</td>\n",
       "      <td>[it, is, found, in, the, present, invention, t...</td>\n",
       "      <td>[unless, otherwise, defined, herein, scientifi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>20190125691</td>\n",
       "      <td>[encapsulation, free, controlled, protein, rel...</td>\n",
       "      <td>[the, present, disclosure, provides, delivery,...</td>\n",
       "      <td>[biocompatible, polymer, composite, comprised,...</td>\n",
       "      <td>[field, the, present, disclosure, relates, to,...</td>\n",
       "      <td>[brief, description, of, the, drawings, embodi...</td>\n",
       "      <td>[controlled, protein, release, is, key, strate...</td>\n",
       "      <td>[]</td>\n",
       "      <td>[the, present, invention, provides, biocompati...</td>\n",
       "      <td>[various, embodiments, and, aspects, of, the, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>20190169260</td>\n",
       "      <td>[human, leukocyte, antigen, restricted, gamma,...</td>\n",
       "      <td>[disclosed, herein, are, compositions, and, me...</td>\n",
       "      <td>[composition, comprising, polypeptide, constru...</td>\n",
       "      <td>[sequence, listing, the, instant, application,...</td>\n",
       "      <td>[brief, description, of, the, drawings, the, n...</td>\n",
       "      <td>[cancer, has, major, impact, on, society, acro...</td>\n",
       "      <td>[]</td>\n",
       "      <td>[there, exists, pressing, need, for, alternati...</td>\n",
       "      <td>[the, following, description, and, examples, i...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>20190194282</td>\n",
       "      <td>[chimeric, proteins, for, targeting, dsrna]</td>\n",
       "      <td>[described, herein, are, recombinant, chimeric...</td>\n",
       "      <td>[chimeric, recombinant, protein, comprising, d...</td>\n",
       "      <td>[cross, reference, to, related, applications, ...</td>\n",
       "      <td>[brief, description, of, the, drawings, figs, ...</td>\n",
       "      <td>[prostate, cancer, is, the, second, most, comm...</td>\n",
       "      <td>[]</td>\n",
       "      <td>[described, herein, is, an, improved, approach...</td>\n",
       "      <td>[terms, unless, otherwise, noted, technical, t...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>20190127440</td>\n",
       "      <td>[novel, tslp, inhibitors]</td>\n",
       "      <td>[the, present, invention, relates, to, monomer...</td>\n",
       "      <td>[monomeric, fusion, protein, comprising, funct...</td>\n",
       "      <td>[field, of, the, invention, the, present, inve...</td>\n",
       "      <td>[brief, description, of, the, figures, fig, sh...</td>\n",
       "      <td>[thymic, stromal, lymphopoietin, tslp, is, an,...</td>\n",
       "      <td>[]</td>\n",
       "      <td>[it, is, surprisingly, shown, herein, that, mo...</td>\n",
       "      <td>[the, present, invention, will, be, described,...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>20190177383</td>\n",
       "      <td>[novel, peptides, and, combination, of, peptid...</td>\n",
       "      <td>[the, present, invention, relates, to, peptide...</td>\n",
       "      <td>[method, of, treating, patient, who, has, canc...</td>\n",
       "      <td>[cross, reference, to, related, applications, ...</td>\n",
       "      <td>[brief, description, of, the, drawings, the, p...</td>\n",
       "      <td>[ovarian, cancer, with, an, estimated, new, ca...</td>\n",
       "      <td>[]</td>\n",
       "      <td>[in, first, aspect, of, the, present, inventio...</td>\n",
       "      <td>[stimulation, of, an, immune, response, is, de...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>20190194689</td>\n",
       "      <td>[cns, targeting, aav, vectors, and, methods, o...</td>\n",
       "      <td>[the, invention, in, some, aspects, relates, t...</td>\n",
       "      <td>[canceled, method, for, delivering, transgene,...</td>\n",
       "      <td>[related, applications, this, application, is,...</td>\n",
       "      <td>[brief, description, of, the, drawings, figs, ...</td>\n",
       "      <td>[gene, therapy, has, been, investigated, for, ...</td>\n",
       "      <td>[]</td>\n",
       "      <td>[aspects, of, the, invention, are, based, on, ...</td>\n",
       "      <td>[adeno, associated, virus, aav, is, small, nm,...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>20190144517</td>\n",
       "      <td>[protein, for, neutralizing, programmed, necro...</td>\n",
       "      <td>[provided, is, polypeptide, which, derives, fr...</td>\n",
       "      <td>[polypeptide, that, inhibits, cell, necrosis, ...</td>\n",
       "      <td>[technical, field, the, present, invention, re...</td>\n",
       "      <td>[description, of, drawings, fig, shows, the, s...</td>\n",
       "      <td>[tumor, necrosis, factor, tnf, is, multifuncti...</td>\n",
       "      <td>[]</td>\n",
       "      <td>[it, is, an, object, of, the, present, inventi...</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>20190177709</td>\n",
       "      <td>[regulation, of, gene, expression, using, engi...</td>\n",
       "      <td>[the, present, disclosure, is, in, the, field,...</td>\n",
       "      <td>[zinc, finger, nuclease, zfn, comprising, left...</td>\n",
       "      <td>[cross, reference, to, related, applications, ...</td>\n",
       "      <td>[brief, description, of, the, drawings, figs, ...</td>\n",
       "      <td>[when, one, considers, that, genome, sequencin...</td>\n",
       "      <td>[this, application, is, filed, pursuant, to, a...</td>\n",
       "      <td>[the, present, invention, describes, highly, s...</td>\n",
       "      <td>[disclosed, herein, are, compositions, and, me...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>20190169583</td>\n",
       "      <td>[step, derived, peptide, for, brain, injury, t...</td>\n",
       "      <td>[novel, peptide, sequence, that, is, modified,...</td>\n",
       "      <td>[an, isolated, peptide, comprising, kinase, in...</td>\n",
       "      <td>[cross, reference, to, related, applications, ...</td>\n",
       "      <td>[brief, description, of, the, drawings, fig, i...</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[according, to, various, embodiments, the, pre...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "             id                                    invention_title  \\\n",
       "0   20190151472  [liver, specific, constructs, factor, viii, ex...   \n",
       "1   20190135863  [retro, inverso, peptide, inhibitors, of, cell...   \n",
       "2   20190133992  [cannabinoid, composition, having, an, optimiz...   \n",
       "3   20190136261  [genetic, modification, of, cytokine, inducibl...   \n",
       "4   20190161536  [anti, ap, antibodies, and, antigen, binding, ...   \n",
       "5   20190202865  [targeting, dimerization, of, bax, to, modulat...   \n",
       "6   20190201532  [sensitization, of, bacterial, cells, to, quin...   \n",
       "7   20190201444                            [of, selectin, ligands]   \n",
       "8   20190177429                       [anti, her, antibodies, and]   \n",
       "9   20190184190  [phosphor, containing, drug, activator, activa...   \n",
       "10  20190192693  [methods, and, vectors, for, treating, cns, di...   \n",
       "11  20190159474  [ameliorative, effects, of, whole, coffee, fru...   \n",
       "12  20190125691  [encapsulation, free, controlled, protein, rel...   \n",
       "13  20190169260  [human, leukocyte, antigen, restricted, gamma,...   \n",
       "14  20190194282        [chimeric, proteins, for, targeting, dsrna]   \n",
       "15  20190127440                          [novel, tslp, inhibitors]   \n",
       "16  20190177383  [novel, peptides, and, combination, of, peptid...   \n",
       "17  20190194689  [cns, targeting, aav, vectors, and, methods, o...   \n",
       "18  20190144517  [protein, for, neutralizing, programmed, necro...   \n",
       "19  20190177709  [regulation, of, gene, expression, using, engi...   \n",
       "20  20190169583  [step, derived, peptide, for, brain, injury, t...   \n",
       "\n",
       "                                             abstract  \\\n",
       "0   [described, herein, are, constructs, used, for...   \n",
       "1   [the, present, invention, discloses, retro, in...   \n",
       "2   [composition, of, matter, for, enhancing, deli...   \n",
       "3   [the, present, disclosure, is, in, the, field,...   \n",
       "4   [this, invention, is, in, the, area, of, impro...   \n",
       "5   [methods, are, provided, for, identifying, an,...   \n",
       "6   [provided, herein, are, pharmaceutical, compos...   \n",
       "7   [the, present, invention, provides, methods, o...   \n",
       "8   [the, invention, provides, anti, her, antibodi...   \n",
       "9   [phosphor, containing, drug, activator, activa...   \n",
       "10  [methods, and, uses, of, treating, disease, in...   \n",
       "11  [the, invention, provides, method, of, extract...   \n",
       "12  [the, present, disclosure, provides, delivery,...   \n",
       "13  [disclosed, herein, are, compositions, and, me...   \n",
       "14  [described, herein, are, recombinant, chimeric...   \n",
       "15  [the, present, invention, relates, to, monomer...   \n",
       "16  [the, present, invention, relates, to, peptide...   \n",
       "17  [the, invention, in, some, aspects, relates, t...   \n",
       "18  [provided, is, polypeptide, which, derives, fr...   \n",
       "19  [the, present, disclosure, is, in, the, field,...   \n",
       "20  [novel, peptide, sequence, that, is, modified,...   \n",
       "\n",
       "                                               claims  \\\n",
       "0   [canceled, method, of, providing, protein, to,...   \n",
       "1   [compound, of, formula, arg, arg, nh, wherein,...   \n",
       "2   [cannabinoid, composition, comprising, at, lea...   \n",
       "3   [genetically, modified, cell, comprising, geno...   \n",
       "4   [method, of, attenuating, an, ap, mediated, di...   \n",
       "5   [canceled, method, of, inhibiting, bcl, associ...   \n",
       "6   [pharmaceutical, composition, comprising, carb...   \n",
       "7   [method, of, enforcing, expression, of, an, se...   \n",
       "8   [an, isolated, antibody, that, binds, to, her,...   \n",
       "9   [phosphor, containing, drug, activator, activa...   \n",
       "10  [method, of, delivering, therapeutic, protein,...   \n",
       "11  [method, of, producing, whole, coffee, fruit, ...   \n",
       "12  [biocompatible, polymer, composite, comprised,...   \n",
       "13  [composition, comprising, polypeptide, constru...   \n",
       "14  [chimeric, recombinant, protein, comprising, d...   \n",
       "15  [monomeric, fusion, protein, comprising, funct...   \n",
       "16  [method, of, treating, patient, who, has, canc...   \n",
       "17  [canceled, method, for, delivering, transgene,...   \n",
       "18  [polypeptide, that, inhibits, cell, necrosis, ...   \n",
       "19  [zinc, finger, nuclease, zfn, comprising, left...   \n",
       "20  [an, isolated, peptide, comprising, kinase, in...   \n",
       "\n",
       "                                          description  \\\n",
       "0   [cross, reference, to, related, applications, ...   \n",
       "1   [the, present, invention, concerns, retro, inv...   \n",
       "2   [field, of, the, invention, the, present, inve...   \n",
       "3   [cross, reference, to, related, applications, ...   \n",
       "4   [related, applications, this, application, is,...   \n",
       "5   [cross, reference, to, related, applications, ...   \n",
       "6   [related, application, the, present, applicati...   \n",
       "7   [cross, reference, to, related, applications, ...   \n",
       "8   [cross, reference, to, related, applications, ...   \n",
       "9   [cross, reference, to, related, applications, ...   \n",
       "10  [related, applications, this, application, cla...   \n",
       "11  [field, of, the, invention, the, invention, pr...   \n",
       "12  [field, the, present, disclosure, relates, to,...   \n",
       "13  [sequence, listing, the, instant, application,...   \n",
       "14  [cross, reference, to, related, applications, ...   \n",
       "15  [field, of, the, invention, the, present, inve...   \n",
       "16  [cross, reference, to, related, applications, ...   \n",
       "17  [related, applications, this, application, is,...   \n",
       "18  [technical, field, the, present, invention, re...   \n",
       "19  [cross, reference, to, related, applications, ...   \n",
       "20  [cross, reference, to, related, applications, ...   \n",
       "\n",
       "                                 drawings_description  \\\n",
       "0   [brief, description, of, the, drawings, fig, i...   \n",
       "1   [description, of, the, figures, fig, high, deg...   \n",
       "2   [brief, description, of, the, drawings, fig, i...   \n",
       "3   [brief, description, of, the, drawings, fig, s...   \n",
       "4   [brief, description, of, the, drawings, figs, ...   \n",
       "5   [brief, description, of, the, drawings, fig, b...   \n",
       "6   [brief, description, of, the, drawings, figs, ...   \n",
       "7   [brief, description, of, the, drawings, fig, f...   \n",
       "8   [brief, description, of, the, figures, fig, sh...   \n",
       "9   [brief, description, of, the, figures, more, c...   \n",
       "10  [brief, description, of, the, figures, more, c...   \n",
       "11  [brief, description, of, the, drawings, figs, ...   \n",
       "12  [brief, description, of, the, drawings, embodi...   \n",
       "13  [brief, description, of, the, drawings, the, n...   \n",
       "14  [brief, description, of, the, drawings, figs, ...   \n",
       "15  [brief, description, of, the, figures, fig, sh...   \n",
       "16  [brief, description, of, the, drawings, the, p...   \n",
       "17  [brief, description, of, the, drawings, figs, ...   \n",
       "18  [description, of, drawings, fig, shows, the, s...   \n",
       "19  [brief, description, of, the, drawings, figs, ...   \n",
       "20  [brief, description, of, the, drawings, fig, i...   \n",
       "\n",
       "                                 invention_background  \\\n",
       "0   [gene, therapy, can, be, used, to, genetically...   \n",
       "1                                                  []   \n",
       "2   [formulations, of, bioactive, compounds, have,...   \n",
       "3   [cells, communicate, with, each, other, either...   \n",
       "4   [human, adipocyte, lipid, binding, protein, ap...   \n",
       "5   [throughout, this, application, various, publi...   \n",
       "6   [antibiotics, are, the, main, tools, to, treat...   \n",
       "7   [mesenchymal, stem, cells, mscs, hold, much, p...   \n",
       "8   [breast, cancer, is, highly, significant, caus...   \n",
       "9   [field, of, invention, the, invention, relates...   \n",
       "10                                                 []   \n",
       "11  [coffee, fruits, are, mainly, produced, in, af...   \n",
       "12  [controlled, protein, release, is, key, strate...   \n",
       "13  [cancer, has, major, impact, on, society, acro...   \n",
       "14  [prostate, cancer, is, the, second, most, comm...   \n",
       "15  [thymic, stromal, lymphopoietin, tslp, is, an,...   \n",
       "16  [ovarian, cancer, with, an, estimated, new, ca...   \n",
       "17  [gene, therapy, has, been, investigated, for, ...   \n",
       "18  [tumor, necrosis, factor, tnf, is, multifuncti...   \n",
       "19  [when, one, considers, that, genome, sequencin...   \n",
       "20                                                 []   \n",
       "\n",
       "                                      cross_reference  \\\n",
       "0   [the, present, application, is, divisional, of...   \n",
       "1                                                  []   \n",
       "2                                                  []   \n",
       "3   [the, present, application, claims, the, benef...   \n",
       "4                                                  []   \n",
       "5   [this, application, claims, the, benefit, of, ...   \n",
       "6                                                  []   \n",
       "7                                                  []   \n",
       "8   [the, present, application, is, divisional, of...   \n",
       "9                                                  []   \n",
       "10                                                 []   \n",
       "11                                                 []   \n",
       "12                                                 []   \n",
       "13                                                 []   \n",
       "14                                                 []   \n",
       "15                                                 []   \n",
       "16                                                 []   \n",
       "17                                                 []   \n",
       "18                                                 []   \n",
       "19  [this, application, is, filed, pursuant, to, a...   \n",
       "20                                                 []   \n",
       "\n",
       "                                              summary  \\\n",
       "0   [the, present, invention, describes, compositi...   \n",
       "1                                                  []   \n",
       "2   [the, present, invention, includes, cannabinoi...   \n",
       "3   [the, present, invention, describes, compositi...   \n",
       "4   [anti, ap, monoclonal, antibodies, and, antige...   \n",
       "5   [the, present, invention, discloses, assays, f...   \n",
       "6   [density, dependent, drug, failure, is, form, ...   \n",
       "7   [despite, the, promise, of, these, methods, th...   \n",
       "8   [the, invention, provides, anti, her, antibodi...   \n",
       "9   [in, one, embodiment, the, present, invention,...   \n",
       "10  [in, certain, embodiments, the, invention, pro...   \n",
       "11  [it, is, found, in, the, present, invention, t...   \n",
       "12  [the, present, invention, provides, biocompati...   \n",
       "13  [there, exists, pressing, need, for, alternati...   \n",
       "14  [described, herein, is, an, improved, approach...   \n",
       "15  [it, is, surprisingly, shown, herein, that, mo...   \n",
       "16  [in, first, aspect, of, the, present, inventio...   \n",
       "17  [aspects, of, the, invention, are, based, on, ...   \n",
       "18  [it, is, an, object, of, the, present, inventi...   \n",
       "19  [the, present, invention, describes, highly, s...   \n",
       "20                                                 []   \n",
       "\n",
       "                                 detailed_description  \n",
       "0   [disclosed, herein, are, expression, cassettes...  \n",
       "1                                                  []  \n",
       "2   [the, present, invention, includes, compositio...  \n",
       "3   [disclosed, herein, are, compositions, and, me...  \n",
       "4   [anti, ap, monoclonal, antibodies, and, antige...  \n",
       "5   [method, is, provided, for, identifying, an, a...  \n",
       "6   [pharmaceutical, compositions, the, present, d...  \n",
       "7   [in, some, embodiments, the, present, inventio...  \n",
       "8   [reference, will, now, be, made, in, detail, t...  \n",
       "9   [the, present, invention, sets, forth, novel, ...  \n",
       "10  [the, invention, is, based, at, least, in, par...  \n",
       "11  [unless, otherwise, defined, herein, scientifi...  \n",
       "12  [various, embodiments, and, aspects, of, the, ...  \n",
       "13  [the, following, description, and, examples, i...  \n",
       "14  [terms, unless, otherwise, noted, technical, t...  \n",
       "15  [the, present, invention, will, be, described,...  \n",
       "16  [stimulation, of, an, immune, response, is, de...  \n",
       "17  [adeno, associated, virus, aav, is, small, nm,...  \n",
       "18                                                 []  \n",
       "19  [disclosed, herein, are, compositions, and, me...  \n",
       "20  [according, to, various, embodiments, the, pre...  "
      ]
     },
     "execution_count": 28,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Tokenize text into sentences using nltk\n",
    "patents_df_tokenized = pd.concat([patents_df5.iloc[:, 0], patents_df5.iloc[:, 1:6].applymap(lambda x: simple_preprocess(x)), \\\n",
    "patents_df5.iloc[:, 7:11].applymap(lambda x: simple_preprocess(x))], axis=1)\n",
    "patents_df_tokenized"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [],
   "source": [
    "class TaggedPatentDocument(object):\n",
    "    \"\"\"\n",
    "    This class tags documents to convert them into a suitable\n",
    "    format for Doc2Vec\n",
    "    \"\"\"\n",
    "\n",
    "    def __init__(self, training_df, col):\n",
    "        self.training_df = training_df\n",
    "        self.col = col\n",
    "        self.section = []\n",
    "\n",
    "    def __iter__(self):\n",
    "        for idx, row in self.training_df.iterrows():\n",
    "            self.section += row[self.col]\n",
    "            yield TaggedDocument(self.section, [self.training_df['id'][idx]])"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<hr>\n",
    "<br>\n",
    "\n",
    "<a id='section-6'></a>\n",
    "\n",
    "### - Train word/document embeddings model"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Apply tokenization by sentences to selected fields in the dataframe\n",
    "# as some features will be used as is in other comparison methods\n",
    "# and construct a new dataframe for lstm (without the full description column)\n",
    "tagged_title = TaggedPatentDocument(patents_df_tokenized, 'invention_title')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "TaggedDocument(['liver', 'specific', 'constructs', 'factor', 'viii', 'expression', 'cassettes', 'and', 'methods', 'of', 'use', 'thereof'], ['20190151472'])\n",
      "TaggedDocument(['liver', 'specific', 'constructs', 'factor', 'viii', 'expression', 'cassettes', 'and', 'methods', 'of', 'use', 'thereof', 'retro', 'inverso', 'peptide', 'inhibitors', 'of', 'cell', 'migration', 'extracellular', 'matrix', 'and', 'endothelial', 'invasion', 'by', 'tumor', 'cells'], ['20190135863'])\n",
      "TaggedDocument(['liver', 'specific', 'constructs', 'factor', 'viii', 'expression', 'cassettes', 'and', 'methods', 'of', 'use', 'thereof', 'retro', 'inverso', 'peptide', 'inhibitors', 'of', 'cell', 'migration', 'extracellular', 'matrix', 'and', 'endothelial', 'invasion', 'by', 'tumor', 'cells', 'cannabinoid', 'composition', 'having', 'an', 'optimized', 'fatty', 'acid', 'excipient', 'profile'], ['20190133992'])\n",
      "TaggedDocument(['liver', 'specific', 'constructs', 'factor', 'viii', 'expression', 'cassettes', 'and', 'methods', 'of', 'use', 'thereof', 'retro', 'inverso', 'peptide', 'inhibitors', 'of', 'cell', 'migration', 'extracellular', 'matrix', 'and', 'endothelial', 'invasion', 'by', 'tumor', 'cells', 'cannabinoid', 'composition', 'having', 'an', 'optimized', 'fatty', 'acid', 'excipient', 'profile', 'genetic', 'modification', 'of', 'cytokine', 'inducible', 'sh', 'containing', 'protein', 'cish', 'gene'], ['20190136261'])\n",
      "TaggedDocument(['liver', 'specific', 'constructs', 'factor', 'viii', 'expression', 'cassettes', 'and', 'methods', 'of', 'use', 'thereof', 'retro', 'inverso', 'peptide', 'inhibitors', 'of', 'cell', 'migration', 'extracellular', 'matrix', 'and', 'endothelial', 'invasion', 'by', 'tumor', 'cells', 'cannabinoid', 'composition', 'having', 'an', 'optimized', 'fatty', 'acid', 'excipient', 'profile', 'genetic', 'modification', 'of', 'cytokine', 'inducible', 'sh', 'containing', 'protein', 'cish', 'gene', 'anti', 'ap', 'antibodies', 'and', 'antigen', 'binding', 'agents', 'to', 'treat', 'metabolic', 'disorders'], ['20190161536'])\n",
      "TaggedDocument(['liver', 'specific', 'constructs', 'factor', 'viii', 'expression', 'cassettes', 'and', 'methods', 'of', 'use', 'thereof', 'retro', 'inverso', 'peptide', 'inhibitors', 'of', 'cell', 'migration', 'extracellular', 'matrix', 'and', 'endothelial', 'invasion', 'by', 'tumor', 'cells', 'cannabinoid', 'composition', 'having', 'an', 'optimized', 'fatty', 'acid', 'excipient', 'profile', 'genetic', 'modification', 'of', 'cytokine', 'inducible', 'sh', 'containing', 'protein', 'cish', 'gene', 'anti', 'ap', 'antibodies', 'and', 'antigen', 'binding', 'agents', 'to', 'treat', 'metabolic', 'disorders', 'targeting', 'dimerization', 'of', 'bax', 'to', 'modulate', 'bax', 'activity'], ['20190202865'])\n",
      "TaggedDocument(['liver', 'specific', 'constructs', 'factor', 'viii', 'expression', 'cassettes', 'and', 'methods', 'of', 'use', 'thereof', 'retro', 'inverso', 'peptide', 'inhibitors', 'of', 'cell', 'migration', 'extracellular', 'matrix', 'and', 'endothelial', 'invasion', 'by', 'tumor', 'cells', 'cannabinoid', 'composition', 'having', 'an', 'optimized', 'fatty', 'acid', 'excipient', 'profile', 'genetic', 'modification', 'of', 'cytokine', 'inducible', 'sh', 'containing', 'protein', 'cish', 'gene', 'anti', 'ap', 'antibodies', 'and', 'antigen', 'binding', 'agents', 'to', 'treat', 'metabolic', 'disorders', 'targeting', 'dimerization', 'of', 'bax', 'to', 'modulate', 'bax', 'activity', 'sensitization', 'of', 'bacterial', 'cells', 'to', 'quinolone', 'antibiotics'], ['20190201532'])\n",
      "TaggedDocument(['liver', 'specific', 'constructs', 'factor', 'viii', 'expression', 'cassettes', 'and', 'methods', 'of', 'use', 'thereof', 'retro', 'inverso', 'peptide', 'inhibitors', 'of', 'cell', 'migration', 'extracellular', 'matrix', 'and', 'endothelial', 'invasion', 'by', 'tumor', 'cells', 'cannabinoid', 'composition', 'having', 'an', 'optimized', 'fatty', 'acid', 'excipient', 'profile', 'genetic', 'modification', 'of', 'cytokine', 'inducible', 'sh', 'containing', 'protein', 'cish', 'gene', 'anti', 'ap', 'antibodies', 'and', 'antigen', 'binding', 'agents', 'to', 'treat', 'metabolic', 'disorders', 'targeting', 'dimerization', 'of', 'bax', 'to', 'modulate', 'bax', 'activity', 'sensitization', 'of', 'bacterial', 'cells', 'to', 'quinolone', 'antibiotics', 'of', 'selectin', 'ligands'], ['20190201444'])\n",
      "TaggedDocument(['liver', 'specific', 'constructs', 'factor', 'viii', 'expression', 'cassettes', 'and', 'methods', 'of', 'use', 'thereof', 'retro', 'inverso', 'peptide', 'inhibitors', 'of', 'cell', 'migration', 'extracellular', 'matrix', 'and', 'endothelial', 'invasion', 'by', 'tumor', 'cells', 'cannabinoid', 'composition', 'having', 'an', 'optimized', 'fatty', 'acid', 'excipient', 'profile', 'genetic', 'modification', 'of', 'cytokine', 'inducible', 'sh', 'containing', 'protein', 'cish', 'gene', 'anti', 'ap', 'antibodies', 'and', 'antigen', 'binding', 'agents', 'to', 'treat', 'metabolic', 'disorders', 'targeting', 'dimerization', 'of', 'bax', 'to', 'modulate', 'bax', 'activity', 'sensitization', 'of', 'bacterial', 'cells', 'to', 'quinolone', 'antibiotics', 'of', 'selectin', 'ligands', 'anti', 'her', 'antibodies', 'and'], ['20190177429'])\n",
      "TaggedDocument(['liver', 'specific', 'constructs', 'factor', 'viii', 'expression', 'cassettes', 'and', 'methods', 'of', 'use', 'thereof', 'retro', 'inverso', 'peptide', 'inhibitors', 'of', 'cell', 'migration', 'extracellular', 'matrix', 'and', 'endothelial', 'invasion', 'by', 'tumor', 'cells', 'cannabinoid', 'composition', 'having', 'an', 'optimized', 'fatty', 'acid', 'excipient', 'profile', 'genetic', 'modification', 'of', 'cytokine', 'inducible', 'sh', 'containing', 'protein', 'cish', 'gene', 'anti', 'ap', 'antibodies', 'and', 'antigen', 'binding', 'agents', 'to', 'treat', 'metabolic', 'disorders', 'targeting', 'dimerization', 'of', 'bax', 'to', 'modulate', 'bax', 'activity', 'sensitization', 'of', 'bacterial', 'cells', 'to', 'quinolone', 'antibiotics', 'of', 'selectin', 'ligands', 'anti', 'her', 'antibodies', 'and', 'phosphor', 'containing', 'drug', 'activator', 'activatable', 'by', 'monte', 'carlo', 'derived', 'ray', 'exposure', 'system', 'containing', 'the', 'activator', 'and', 'methods', 'for', 'use'], ['20190184190'])\n",
      "TaggedDocument(['liver', 'specific', 'constructs', 'factor', 'viii', 'expression', 'cassettes', 'and', 'methods', 'of', 'use', 'thereof', 'retro', 'inverso', 'peptide', 'inhibitors', 'of', 'cell', 'migration', 'extracellular', 'matrix', 'and', 'endothelial', 'invasion', 'by', 'tumor', 'cells', 'cannabinoid', 'composition', 'having', 'an', 'optimized', 'fatty', 'acid', 'excipient', 'profile', 'genetic', 'modification', 'of', 'cytokine', 'inducible', 'sh', 'containing', 'protein', 'cish', 'gene', 'anti', 'ap', 'antibodies', 'and', 'antigen', 'binding', 'agents', 'to', 'treat', 'metabolic', 'disorders', 'targeting', 'dimerization', 'of', 'bax', 'to', 'modulate', 'bax', 'activity', 'sensitization', 'of', 'bacterial', 'cells', 'to', 'quinolone', 'antibiotics', 'of', 'selectin', 'ligands', 'anti', 'her', 'antibodies', 'and', 'phosphor', 'containing', 'drug', 'activator', 'activatable', 'by', 'monte', 'carlo', 'derived', 'ray', 'exposure', 'system', 'containing', 'the', 'activator', 'and', 'methods', 'for', 'use', 'methods', 'and', 'vectors', 'for', 'treating', 'cns', 'disorders'], ['20190192693'])\n",
      "TaggedDocument(['liver', 'specific', 'constructs', 'factor', 'viii', 'expression', 'cassettes', 'and', 'methods', 'of', 'use', 'thereof', 'retro', 'inverso', 'peptide', 'inhibitors', 'of', 'cell', 'migration', 'extracellular', 'matrix', 'and', 'endothelial', 'invasion', 'by', 'tumor', 'cells', 'cannabinoid', 'composition', 'having', 'an', 'optimized', 'fatty', 'acid', 'excipient', 'profile', 'genetic', 'modification', 'of', 'cytokine', 'inducible', 'sh', 'containing', 'protein', 'cish', 'gene', 'anti', 'ap', 'antibodies', 'and', 'antigen', 'binding', 'agents', 'to', 'treat', 'metabolic', 'disorders', 'targeting', 'dimerization', 'of', 'bax', 'to', 'modulate', 'bax', 'activity', 'sensitization', 'of', 'bacterial', 'cells', 'to', 'quinolone', 'antibiotics', 'of', 'selectin', 'ligands', 'anti', 'her', 'antibodies', 'and', 'phosphor', 'containing', 'drug', 'activator', 'activatable', 'by', 'monte', 'carlo', 'derived', 'ray', 'exposure', 'system', 'containing', 'the', 'activator', 'and', 'methods', 'for', 'use', 'methods', 'and', 'vectors', 'for', 'treating', 'cns', 'disorders', 'ameliorative', 'effects', 'of', 'whole', 'coffee', 'fruit', 'extract', 'on', 'age', 'related', 'disease'], ['20190159474'])\n",
      "TaggedDocument(['liver', 'specific', 'constructs', 'factor', 'viii', 'expression', 'cassettes', 'and', 'methods', 'of', 'use', 'thereof', 'retro', 'inverso', 'peptide', 'inhibitors', 'of', 'cell', 'migration', 'extracellular', 'matrix', 'and', 'endothelial', 'invasion', 'by', 'tumor', 'cells', 'cannabinoid', 'composition', 'having', 'an', 'optimized', 'fatty', 'acid', 'excipient', 'profile', 'genetic', 'modification', 'of', 'cytokine', 'inducible', 'sh', 'containing', 'protein', 'cish', 'gene', 'anti', 'ap', 'antibodies', 'and', 'antigen', 'binding', 'agents', 'to', 'treat', 'metabolic', 'disorders', 'targeting', 'dimerization', 'of', 'bax', 'to', 'modulate', 'bax', 'activity', 'sensitization', 'of', 'bacterial', 'cells', 'to', 'quinolone', 'antibiotics', 'of', 'selectin', 'ligands', 'anti', 'her', 'antibodies', 'and', 'phosphor', 'containing', 'drug', 'activator', 'activatable', 'by', 'monte', 'carlo', 'derived', 'ray', 'exposure', 'system', 'containing', 'the', 'activator', 'and', 'methods', 'for', 'use', 'methods', 'and', 'vectors', 'for', 'treating', 'cns', 'disorders', 'ameliorative', 'effects', 'of', 'whole', 'coffee', 'fruit', 'extract', 'on', 'age', 'related', 'disease', 'encapsulation', 'free', 'controlled', 'protein', 'release', 'system'], ['20190125691'])\n",
      "TaggedDocument(['liver', 'specific', 'constructs', 'factor', 'viii', 'expression', 'cassettes', 'and', 'methods', 'of', 'use', 'thereof', 'retro', 'inverso', 'peptide', 'inhibitors', 'of', 'cell', 'migration', 'extracellular', 'matrix', 'and', 'endothelial', 'invasion', 'by', 'tumor', 'cells', 'cannabinoid', 'composition', 'having', 'an', 'optimized', 'fatty', 'acid', 'excipient', 'profile', 'genetic', 'modification', 'of', 'cytokine', 'inducible', 'sh', 'containing', 'protein', 'cish', 'gene', 'anti', 'ap', 'antibodies', 'and', 'antigen', 'binding', 'agents', 'to', 'treat', 'metabolic', 'disorders', 'targeting', 'dimerization', 'of', 'bax', 'to', 'modulate', 'bax', 'activity', 'sensitization', 'of', 'bacterial', 'cells', 'to', 'quinolone', 'antibiotics', 'of', 'selectin', 'ligands', 'anti', 'her', 'antibodies', 'and', 'phosphor', 'containing', 'drug', 'activator', 'activatable', 'by', 'monte', 'carlo', 'derived', 'ray', 'exposure', 'system', 'containing', 'the', 'activator', 'and', 'methods', 'for', 'use', 'methods', 'and', 'vectors', 'for', 'treating', 'cns', 'disorders', 'ameliorative', 'effects', 'of', 'whole', 'coffee', 'fruit', 'extract', 'on', 'age', 'related', 'disease', 'encapsulation', 'free', 'controlled', 'protein', 'release', 'system', 'human', 'leukocyte', 'antigen', 'restricted', 'gamma', 'delta', 'cell', 'receptors', 'and', 'methods', 'of', 'use', 'thereof'], ['20190169260'])\n",
      "TaggedDocument(['liver', 'specific', 'constructs', 'factor', 'viii', 'expression', 'cassettes', 'and', 'methods', 'of', 'use', 'thereof', 'retro', 'inverso', 'peptide', 'inhibitors', 'of', 'cell', 'migration', 'extracellular', 'matrix', 'and', 'endothelial', 'invasion', 'by', 'tumor', 'cells', 'cannabinoid', 'composition', 'having', 'an', 'optimized', 'fatty', 'acid', 'excipient', 'profile', 'genetic', 'modification', 'of', 'cytokine', 'inducible', 'sh', 'containing', 'protein', 'cish', 'gene', 'anti', 'ap', 'antibodies', 'and', 'antigen', 'binding', 'agents', 'to', 'treat', 'metabolic', 'disorders', 'targeting', 'dimerization', 'of', 'bax', 'to', 'modulate', 'bax', 'activity', 'sensitization', 'of', 'bacterial', 'cells', 'to', 'quinolone', 'antibiotics', 'of', 'selectin', 'ligands', 'anti', 'her', 'antibodies', 'and', 'phosphor', 'containing', 'drug', 'activator', 'activatable', 'by', 'monte', 'carlo', 'derived', 'ray', 'exposure', 'system', 'containing', 'the', 'activator', 'and', 'methods', 'for', 'use', 'methods', 'and', 'vectors', 'for', 'treating', 'cns', 'disorders', 'ameliorative', 'effects', 'of', 'whole', 'coffee', 'fruit', 'extract', 'on', 'age', 'related', 'disease', 'encapsulation', 'free', 'controlled', 'protein', 'release', 'system', 'human', 'leukocyte', 'antigen', 'restricted', 'gamma', 'delta', 'cell', 'receptors', 'and', 'methods', 'of', 'use', 'thereof', 'chimeric', 'proteins', 'for', 'targeting', 'dsrna'], ['20190194282'])\n",
      "TaggedDocument(['liver', 'specific', 'constructs', 'factor', 'viii', 'expression', 'cassettes', 'and', 'methods', 'of', 'use', 'thereof', 'retro', 'inverso', 'peptide', 'inhibitors', 'of', 'cell', 'migration', 'extracellular', 'matrix', 'and', 'endothelial', 'invasion', 'by', 'tumor', 'cells', 'cannabinoid', 'composition', 'having', 'an', 'optimized', 'fatty', 'acid', 'excipient', 'profile', 'genetic', 'modification', 'of', 'cytokine', 'inducible', 'sh', 'containing', 'protein', 'cish', 'gene', 'anti', 'ap', 'antibodies', 'and', 'antigen', 'binding', 'agents', 'to', 'treat', 'metabolic', 'disorders', 'targeting', 'dimerization', 'of', 'bax', 'to', 'modulate', 'bax', 'activity', 'sensitization', 'of', 'bacterial', 'cells', 'to', 'quinolone', 'antibiotics', 'of', 'selectin', 'ligands', 'anti', 'her', 'antibodies', 'and', 'phosphor', 'containing', 'drug', 'activator', 'activatable', 'by', 'monte', 'carlo', 'derived', 'ray', 'exposure', 'system', 'containing', 'the', 'activator', 'and', 'methods', 'for', 'use', 'methods', 'and', 'vectors', 'for', 'treating', 'cns', 'disorders', 'ameliorative', 'effects', 'of', 'whole', 'coffee', 'fruit', 'extract', 'on', 'age', 'related', 'disease', 'encapsulation', 'free', 'controlled', 'protein', 'release', 'system', 'human', 'leukocyte', 'antigen', 'restricted', 'gamma', 'delta', 'cell', 'receptors', 'and', 'methods', 'of', 'use', 'thereof', 'chimeric', 'proteins', 'for', 'targeting', 'dsrna', 'novel', 'tslp', 'inhibitors'], ['20190127440'])\n",
      "TaggedDocument(['liver', 'specific', 'constructs', 'factor', 'viii', 'expression', 'cassettes', 'and', 'methods', 'of', 'use', 'thereof', 'retro', 'inverso', 'peptide', 'inhibitors', 'of', 'cell', 'migration', 'extracellular', 'matrix', 'and', 'endothelial', 'invasion', 'by', 'tumor', 'cells', 'cannabinoid', 'composition', 'having', 'an', 'optimized', 'fatty', 'acid', 'excipient', 'profile', 'genetic', 'modification', 'of', 'cytokine', 'inducible', 'sh', 'containing', 'protein', 'cish', 'gene', 'anti', 'ap', 'antibodies', 'and', 'antigen', 'binding', 'agents', 'to', 'treat', 'metabolic', 'disorders', 'targeting', 'dimerization', 'of', 'bax', 'to', 'modulate', 'bax', 'activity', 'sensitization', 'of', 'bacterial', 'cells', 'to', 'quinolone', 'antibiotics', 'of', 'selectin', 'ligands', 'anti', 'her', 'antibodies', 'and', 'phosphor', 'containing', 'drug', 'activator', 'activatable', 'by', 'monte', 'carlo', 'derived', 'ray', 'exposure', 'system', 'containing', 'the', 'activator', 'and', 'methods', 'for', 'use', 'methods', 'and', 'vectors', 'for', 'treating', 'cns', 'disorders', 'ameliorative', 'effects', 'of', 'whole', 'coffee', 'fruit', 'extract', 'on', 'age', 'related', 'disease', 'encapsulation', 'free', 'controlled', 'protein', 'release', 'system', 'human', 'leukocyte', 'antigen', 'restricted', 'gamma', 'delta', 'cell', 'receptors', 'and', 'methods', 'of', 'use', 'thereof', 'chimeric', 'proteins', 'for', 'targeting', 'dsrna', 'novel', 'tslp', 'inhibitors', 'novel', 'peptides', 'and', 'combination', 'of', 'peptides', 'for', 'use', 'in', 'immunotherapy', 'against', 'ovarian', 'cancer', 'and', 'other', 'cancers'], ['20190177383'])\n",
      "TaggedDocument(['liver', 'specific', 'constructs', 'factor', 'viii', 'expression', 'cassettes', 'and', 'methods', 'of', 'use', 'thereof', 'retro', 'inverso', 'peptide', 'inhibitors', 'of', 'cell', 'migration', 'extracellular', 'matrix', 'and', 'endothelial', 'invasion', 'by', 'tumor', 'cells', 'cannabinoid', 'composition', 'having', 'an', 'optimized', 'fatty', 'acid', 'excipient', 'profile', 'genetic', 'modification', 'of', 'cytokine', 'inducible', 'sh', 'containing', 'protein', 'cish', 'gene', 'anti', 'ap', 'antibodies', 'and', 'antigen', 'binding', 'agents', 'to', 'treat', 'metabolic', 'disorders', 'targeting', 'dimerization', 'of', 'bax', 'to', 'modulate', 'bax', 'activity', 'sensitization', 'of', 'bacterial', 'cells', 'to', 'quinolone', 'antibiotics', 'of', 'selectin', 'ligands', 'anti', 'her', 'antibodies', 'and', 'phosphor', 'containing', 'drug', 'activator', 'activatable', 'by', 'monte', 'carlo', 'derived', 'ray', 'exposure', 'system', 'containing', 'the', 'activator', 'and', 'methods', 'for', 'use', 'methods', 'and', 'vectors', 'for', 'treating', 'cns', 'disorders', 'ameliorative', 'effects', 'of', 'whole', 'coffee', 'fruit', 'extract', 'on', 'age', 'related', 'disease', 'encapsulation', 'free', 'controlled', 'protein', 'release', 'system', 'human', 'leukocyte', 'antigen', 'restricted', 'gamma', 'delta', 'cell', 'receptors', 'and', 'methods', 'of', 'use', 'thereof', 'chimeric', 'proteins', 'for', 'targeting', 'dsrna', 'novel', 'tslp', 'inhibitors', 'novel', 'peptides', 'and', 'combination', 'of', 'peptides', 'for', 'use', 'in', 'immunotherapy', 'against', 'ovarian', 'cancer', 'and', 'other', 'cancers', 'cns', 'targeting', 'aav', 'vectors', 'and', 'methods', 'of', 'use', 'thereof'], ['20190194689'])\n",
      "TaggedDocument(['liver', 'specific', 'constructs', 'factor', 'viii', 'expression', 'cassettes', 'and', 'methods', 'of', 'use', 'thereof', 'retro', 'inverso', 'peptide', 'inhibitors', 'of', 'cell', 'migration', 'extracellular', 'matrix', 'and', 'endothelial', 'invasion', 'by', 'tumor', 'cells', 'cannabinoid', 'composition', 'having', 'an', 'optimized', 'fatty', 'acid', 'excipient', 'profile', 'genetic', 'modification', 'of', 'cytokine', 'inducible', 'sh', 'containing', 'protein', 'cish', 'gene', 'anti', 'ap', 'antibodies', 'and', 'antigen', 'binding', 'agents', 'to', 'treat', 'metabolic', 'disorders', 'targeting', 'dimerization', 'of', 'bax', 'to', 'modulate', 'bax', 'activity', 'sensitization', 'of', 'bacterial', 'cells', 'to', 'quinolone', 'antibiotics', 'of', 'selectin', 'ligands', 'anti', 'her', 'antibodies', 'and', 'phosphor', 'containing', 'drug', 'activator', 'activatable', 'by', 'monte', 'carlo', 'derived', 'ray', 'exposure', 'system', 'containing', 'the', 'activator', 'and', 'methods', 'for', 'use', 'methods', 'and', 'vectors', 'for', 'treating', 'cns', 'disorders', 'ameliorative', 'effects', 'of', 'whole', 'coffee', 'fruit', 'extract', 'on', 'age', 'related', 'disease', 'encapsulation', 'free', 'controlled', 'protein', 'release', 'system', 'human', 'leukocyte', 'antigen', 'restricted', 'gamma', 'delta', 'cell', 'receptors', 'and', 'methods', 'of', 'use', 'thereof', 'chimeric', 'proteins', 'for', 'targeting', 'dsrna', 'novel', 'tslp', 'inhibitors', 'novel', 'peptides', 'and', 'combination', 'of', 'peptides', 'for', 'use', 'in', 'immunotherapy', 'against', 'ovarian', 'cancer', 'and', 'other', 'cancers', 'cns', 'targeting', 'aav', 'vectors', 'and', 'methods', 'of', 'use', 'thereof', 'protein', 'for', 'neutralizing', 'programmed', 'necrocytosis', 'promotion', 'antibody', 'and', 'application', 'of', 'protein'], ['20190144517'])\n",
      "TaggedDocument(['liver', 'specific', 'constructs', 'factor', 'viii', 'expression', 'cassettes', 'and', 'methods', 'of', 'use', 'thereof', 'retro', 'inverso', 'peptide', 'inhibitors', 'of', 'cell', 'migration', 'extracellular', 'matrix', 'and', 'endothelial', 'invasion', 'by', 'tumor', 'cells', 'cannabinoid', 'composition', 'having', 'an', 'optimized', 'fatty', 'acid', 'excipient', 'profile', 'genetic', 'modification', 'of', 'cytokine', 'inducible', 'sh', 'containing', 'protein', 'cish', 'gene', 'anti', 'ap', 'antibodies', 'and', 'antigen', 'binding', 'agents', 'to', 'treat', 'metabolic', 'disorders', 'targeting', 'dimerization', 'of', 'bax', 'to', 'modulate', 'bax', 'activity', 'sensitization', 'of', 'bacterial', 'cells', 'to', 'quinolone', 'antibiotics', 'of', 'selectin', 'ligands', 'anti', 'her', 'antibodies', 'and', 'phosphor', 'containing', 'drug', 'activator', 'activatable', 'by', 'monte', 'carlo', 'derived', 'ray', 'exposure', 'system', 'containing', 'the', 'activator', 'and', 'methods', 'for', 'use', 'methods', 'and', 'vectors', 'for', 'treating', 'cns', 'disorders', 'ameliorative', 'effects', 'of', 'whole', 'coffee', 'fruit', 'extract', 'on', 'age', 'related', 'disease', 'encapsulation', 'free', 'controlled', 'protein', 'release', 'system', 'human', 'leukocyte', 'antigen', 'restricted', 'gamma', 'delta', 'cell', 'receptors', 'and', 'methods', 'of', 'use', 'thereof', 'chimeric', 'proteins', 'for', 'targeting', 'dsrna', 'novel', 'tslp', 'inhibitors', 'novel', 'peptides', 'and', 'combination', 'of', 'peptides', 'for', 'use', 'in', 'immunotherapy', 'against', 'ovarian', 'cancer', 'and', 'other', 'cancers', 'cns', 'targeting', 'aav', 'vectors', 'and', 'methods', 'of', 'use', 'thereof', 'protein', 'for', 'neutralizing', 'programmed', 'necrocytosis', 'promotion', 'antibody', 'and', 'application', 'of', 'protein', 'regulation', 'of', 'gene', 'expression', 'using', 'engineered', 'nucleases'], ['20190177709'])\n",
      "TaggedDocument(['liver', 'specific', 'constructs', 'factor', 'viii', 'expression', 'cassettes', 'and', 'methods', 'of', 'use', 'thereof', 'retro', 'inverso', 'peptide', 'inhibitors', 'of', 'cell', 'migration', 'extracellular', 'matrix', 'and', 'endothelial', 'invasion', 'by', 'tumor', 'cells', 'cannabinoid', 'composition', 'having', 'an', 'optimized', 'fatty', 'acid', 'excipient', 'profile', 'genetic', 'modification', 'of', 'cytokine', 'inducible', 'sh', 'containing', 'protein', 'cish', 'gene', 'anti', 'ap', 'antibodies', 'and', 'antigen', 'binding', 'agents', 'to', 'treat', 'metabolic', 'disorders', 'targeting', 'dimerization', 'of', 'bax', 'to', 'modulate', 'bax', 'activity', 'sensitization', 'of', 'bacterial', 'cells', 'to', 'quinolone', 'antibiotics', 'of', 'selectin', 'ligands', 'anti', 'her', 'antibodies', 'and', 'phosphor', 'containing', 'drug', 'activator', 'activatable', 'by', 'monte', 'carlo', 'derived', 'ray', 'exposure', 'system', 'containing', 'the', 'activator', 'and', 'methods', 'for', 'use', 'methods', 'and', 'vectors', 'for', 'treating', 'cns', 'disorders', 'ameliorative', 'effects', 'of', 'whole', 'coffee', 'fruit', 'extract', 'on', 'age', 'related', 'disease', 'encapsulation', 'free', 'controlled', 'protein', 'release', 'system', 'human', 'leukocyte', 'antigen', 'restricted', 'gamma', 'delta', 'cell', 'receptors', 'and', 'methods', 'of', 'use', 'thereof', 'chimeric', 'proteins', 'for', 'targeting', 'dsrna', 'novel', 'tslp', 'inhibitors', 'novel', 'peptides', 'and', 'combination', 'of', 'peptides', 'for', 'use', 'in', 'immunotherapy', 'against', 'ovarian', 'cancer', 'and', 'other', 'cancers', 'cns', 'targeting', 'aav', 'vectors', 'and', 'methods', 'of', 'use', 'thereof', 'protein', 'for', 'neutralizing', 'programmed', 'necrocytosis', 'promotion', 'antibody', 'and', 'application', 'of', 'protein', 'regulation', 'of', 'gene', 'expression', 'using', 'engineered', 'nucleases', 'step', 'derived', 'peptide', 'for', 'brain', 'injury', 'treatment'], ['20190169583'])\n"
     ]
    }
   ],
   "source": [
    "for p in tagged_title:\n",
    "    print(p)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Training epoch 1\n",
      "Training epoch 2\n",
      "Training epoch 3\n",
      "Training epoch 4\n",
      "Training epoch 5\n",
      "Training epoch 6\n",
      "Training epoch 7\n",
      "Training epoch 8\n",
      "Training epoch 9\n",
      "Training epoch 10\n",
      "Training epoch 11\n",
      "Training epoch 12\n",
      "Training epoch 13\n",
      "Training epoch 14\n",
      "Training epoch 15\n",
      "Training epoch 16\n",
      "Training epoch 17\n",
      "Training epoch 18\n",
      "Training epoch 19\n",
      "Training epoch 20\n",
      "Training epoch 21\n",
      "Training epoch 22\n",
      "Training epoch 23\n",
      "Training epoch 24\n",
      "Training epoch 25\n",
      "Training epoch 26\n",
      "Training epoch 27\n",
      "Training epoch 28\n",
      "Training epoch 29\n",
      "Training epoch 30\n",
      "Training epoch 31\n",
      "Training epoch 32\n",
      "Training epoch 33\n",
      "Training epoch 34\n",
      "Training epoch 35\n",
      "Training epoch 36\n",
      "Training epoch 37\n",
      "Training epoch 38\n",
      "Training epoch 39\n",
      "Training epoch 40\n",
      "Training epoch 41\n",
      "Training epoch 42\n",
      "Training epoch 43\n",
      "Training epoch 44\n",
      "Training epoch 45\n",
      "Training epoch 46\n",
      "Training epoch 47\n",
      "Training epoch 48\n",
      "Training epoch 49\n",
      "Training epoch 50\n"
     ]
    }
   ],
   "source": [
    "# Create model definition\n",
    "epochs = 50\n",
    "patent_title_model = Doc2Vec(dm=0, hs=1, vector_size=500, min_count=3, \\\n",
    "                workers=4, epochs=epochs)\n",
    "\n",
    "# Build vocabulary from documents\n",
    "patent_title_model.build_vocab(tagged_title)\n",
    "\n",
    "# Start training the model\n",
    "for epoch in range(epochs):\n",
    "    print(\"Training epoch {}\".format(epoch + 1))\n",
    "    patent_title_model.train(tagged_title,\n",
    "                total_examples=len(patents_df_tokenized['id']), epochs=patent_title_model.epochs)\n",
    "    patent_title_model.alpha = patent_title_model.alpha - 0.002\n",
    "    patent_title_model.min_alpha = patent_title_model.alpha"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[('aav', 0.15866905450820923), ('by', 0.10744364559650421), ('regulation', 0.10386599600315094), ('and', 0.08959125727415085), ('monte', 0.0835028812289238), ('gamma', 0.08255290985107422), ('exposure', 0.08163495361804962), ('cassettes', 0.08007222414016724), ('fruit', 0.07726302742958069), ('agents', 0.07491530478000641)]\n"
     ]
    }
   ],
   "source": [
    "# Simple test for the model to get the most similar words\n",
    "# to a given term\n",
    "print(patent_title_model.wv.most_similar(\"drug\"))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Model saved..\n"
     ]
    }
   ],
   "source": [
    "# Save model to use later\n",
    "patent_title_model.save('../models/patent_title_model.w2v')\n",
    "print('Model saved..')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Load already saved model - in case the notebook kernel dies and restarts\n",
    "# to save model training time\n",
    "patent_title_model = Doc2Vec.load('../models/patent_title_model.w2v')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Repeat the process for all other columns\n",
    "tagged_abstract = TaggedPatentDocument(patents_df_tokenized, 'abstract')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Training epoch 1\n",
      "Training epoch 2\n",
      "Training epoch 3\n",
      "Training epoch 4\n",
      "Training epoch 5\n",
      "Training epoch 6\n",
      "Training epoch 7\n",
      "Training epoch 8\n",
      "Training epoch 9\n",
      "Training epoch 10\n",
      "Training epoch 11\n",
      "Training epoch 12\n",
      "Training epoch 13\n",
      "Training epoch 14\n",
      "Training epoch 15\n",
      "Training epoch 16\n",
      "Training epoch 17\n",
      "Training epoch 18\n",
      "Training epoch 19\n",
      "Training epoch 20\n",
      "Training epoch 21\n",
      "Training epoch 22\n",
      "Training epoch 23\n",
      "Training epoch 24\n",
      "Training epoch 25\n",
      "Training epoch 26\n",
      "Training epoch 27\n",
      "Training epoch 28\n",
      "Training epoch 29\n",
      "Training epoch 30\n",
      "Training epoch 31\n",
      "Training epoch 32\n",
      "Training epoch 33\n",
      "Training epoch 34\n",
      "Training epoch 35\n",
      "Training epoch 36\n",
      "Training epoch 37\n",
      "Training epoch 38\n",
      "Training epoch 39\n",
      "Training epoch 40\n",
      "Training epoch 41\n",
      "Training epoch 42\n",
      "Training epoch 43\n",
      "Training epoch 44\n",
      "Training epoch 45\n",
      "Training epoch 46\n",
      "Training epoch 47\n",
      "Training epoch 48\n",
      "Training epoch 49\n",
      "Training epoch 50\n"
     ]
    }
   ],
   "source": [
    "# Create model definition\n",
    "epochs = 50\n",
    "patent_abstract_model = Doc2Vec(dm=0, hs=1, vector_size=500, min_count=3, \\\n",
    "                workers=4, epochs=epochs)\n",
    "\n",
    "# Build vocabulary from documents\n",
    "patent_abstract_model.build_vocab(tagged_abstract)\n",
    "\n",
    "# Start training the model\n",
    "for epoch in range(epochs):\n",
    "    print(\"Training epoch {}\".format(epoch + 1))\n",
    "    patent_abstract_model.train(tagged_abstract,\n",
    "                total_examples=len(patents_df_tokenized['id']), epochs=patent_abstract_model.epochs)\n",
    "    patent_abstract_model.alpha = patent_abstract_model.alpha - 0.002\n",
    "    patent_abstract_model.min_alpha = patent_abstract_model.alpha"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Model saved..\n"
     ]
    }
   ],
   "source": [
    "# Save model to use later\n",
    "patent_abstract_model.save('../models/patent_abstract_model.w2v')\n",
    "print('Model saved..')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Load already saved model - in case the notebook kernel dies and restarts\n",
    "# to save model training time\n",
    "patent_abstract_model = Doc2Vec.load('../models/patent_abstract_model.w2v')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Repeat the process for all other columns\n",
    "tagged_claims = TaggedPatentDocument(patents_df_tokenized, 'claims')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Training epoch 1\n",
      "Training epoch 2\n",
      "Training epoch 3\n",
      "Training epoch 4\n",
      "Training epoch 5\n",
      "Training epoch 6\n",
      "Training epoch 7\n",
      "Training epoch 8\n",
      "Training epoch 9\n",
      "Training epoch 10\n",
      "Training epoch 11\n",
      "Training epoch 12\n",
      "Training epoch 13\n",
      "Training epoch 14\n",
      "Training epoch 15\n"
     ]
    }
   ],
   "source": [
    "# Create model definition\n",
    "epochs = 50\n",
    "patent_claims_model = Doc2Vec(dm=0, hs=1, vector_size=500, min_count=3, \\\n",
    "                workers=4, epochs=epochs)\n",
    "\n",
    "# Build vocabulary from documents\n",
    "patent_claims_model.build_vocab(tagged_claims)\n",
    "\n",
    "# Start training the model\n",
    "for epoch in range(epochs):\n",
    "    print(\"Training epoch {}\".format(epoch + 1))\n",
    "    patent_claims_model.train(tagged_claims,\n",
    "                total_examples=len(patents_df_tokenized['id']), epochs=patent_claims_model.epochs)\n",
    "    patent_claims_model.alpha = patent_claims_model.alpha - 0.002\n",
    "    patent_claims_model.min_alpha = patent_claims_model.alpha"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Model saved..\n"
     ]
    }
   ],
   "source": [
    "# Save model to use later\n",
    "patent_claims_model.save('../models/patent_claims_model.w2v')\n",
    "print('Model saved..')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Load already saved model - in case the notebook kernel dies and restarts\n",
    "# to save model training time\n",
    "patent_claims_model = Doc2Vec.load('../models/patent_claims_model.w2v')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Repeat the process for all other columns\n",
    "tagged_description = TaggedPatentDocument(patents_df_tokenized, 'description')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Training epoch 1\n",
      "Training epoch 2\n",
      "Training epoch 3\n",
      "Training epoch 4\n",
      "Training epoch 5\n",
      "Training epoch 6\n",
      "Training epoch 7\n",
      "Training epoch 8\n",
      "Training epoch 9\n",
      "Training epoch 10\n",
      "Training epoch 11\n",
      "Training epoch 12\n",
      "Training epoch 13\n",
      "Training epoch 14\n",
      "Training epoch 15\n",
      "Training epoch 16\n",
      "Training epoch 17\n",
      "Training epoch 18\n",
      "Training epoch 19\n",
      "Training epoch 20\n",
      "Training epoch 21\n",
      "Training epoch 22\n",
      "Training epoch 23\n",
      "Training epoch 24\n",
      "Training epoch 25\n",
      "Training epoch 26\n",
      "Training epoch 27\n",
      "Training epoch 28\n",
      "Training epoch 29\n",
      "Training epoch 30\n",
      "Training epoch 31\n",
      "Training epoch 32\n",
      "Training epoch 33\n",
      "Training epoch 34\n",
      "Training epoch 35\n",
      "Training epoch 36\n",
      "Training epoch 37\n",
      "Training epoch 38\n",
      "Training epoch 39\n",
      "Training epoch 40\n",
      "Training epoch 41\n",
      "Training epoch 42\n",
      "Training epoch 43\n",
      "Training epoch 44\n",
      "Training epoch 45\n",
      "Training epoch 46\n",
      "Training epoch 47\n",
      "Training epoch 48\n",
      "Training epoch 49\n",
      "Training epoch 50\n"
     ]
    }
   ],
   "source": [
    "# Create model definition\n",
    "epochs = 50\n",
    "patent_description_model = Doc2Vec(dm=0, hs=1, vector_size=500, min_count=3, \\\n",
    "                workers=4, epochs=epochs)\n",
    "\n",
    "# Build vocabulary from documents\n",
    "patent_description_model.build_vocab(tagged_description)\n",
    "\n",
    "# Start training the model\n",
    "for epoch in range(epochs):\n",
    "    print(\"Training epoch {}\".format(epoch + 1))\n",
    "    patent_description_model.train(tagged_description,\n",
    "                total_examples=len(patents_df_tokenized['id']), epochs=patent_description_model.epochs)\n",
    "    patent_description_model.alpha = patent_description_model.alpha - 0.002\n",
    "    patent_description_model.min_alpha = patent_description_model.alpha"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Model saved..\n"
     ]
    }
   ],
   "source": [
    "# Save model to use later\n",
    "patent_description_model.save('../models/patent_description_model.w2v')\n",
    "print('Model saved..')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 73,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Load already saved model - in case the notebook kernel dies and restarts\n",
    "# to save model training time\n",
    "patent_description_model = Doc2Vec.load('../models/patent_description_model.w2v')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Repeat the process for all other columns\n",
    "tagged_drawings_description = TaggedPatentDocument(patents_df_tokenized, 'drawings_description')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Training epoch 1\n",
      "Training epoch 2\n",
      "Training epoch 3\n",
      "Training epoch 4\n",
      "Training epoch 5\n",
      "Training epoch 6\n",
      "Training epoch 7\n",
      "Training epoch 8\n",
      "Training epoch 9\n",
      "Training epoch 10\n",
      "Training epoch 11\n",
      "Training epoch 12\n",
      "Training epoch 13\n",
      "Training epoch 14\n",
      "Training epoch 15\n",
      "Training epoch 16\n",
      "Training epoch 17\n",
      "Training epoch 18\n",
      "Training epoch 19\n",
      "Training epoch 20\n",
      "Training epoch 21\n",
      "Training epoch 22\n",
      "Training epoch 23\n",
      "Training epoch 24\n",
      "Training epoch 25\n",
      "Training epoch 26\n",
      "Training epoch 27\n",
      "Training epoch 28\n",
      "Training epoch 29\n",
      "Training epoch 30\n",
      "Training epoch 31\n",
      "Training epoch 32\n",
      "Training epoch 33\n",
      "Training epoch 34\n",
      "Training epoch 35\n",
      "Training epoch 36\n",
      "Training epoch 37\n",
      "Training epoch 38\n",
      "Training epoch 39\n",
      "Training epoch 40\n",
      "Training epoch 41\n",
      "Training epoch 42\n",
      "Training epoch 43\n",
      "Training epoch 44\n",
      "Training epoch 45\n",
      "Training epoch 46\n",
      "Training epoch 47\n",
      "Training epoch 48\n",
      "Training epoch 49\n",
      "Training epoch 50\n"
     ]
    }
   ],
   "source": [
    "# Create model definition\n",
    "epochs = 50\n",
    "patent_drawings_description_model = Doc2Vec(dm=0, hs=1, vector_size=500, min_count=3, \\\n",
    "                workers=3, epochs=epochs)\n",
    "\n",
    "# Build vocabulary from documents\n",
    "patent_drawings_description_model.build_vocab(tagged_drawings_description)\n",
    "\n",
    "# Start training the model\n",
    "for epoch in range(epochs):\n",
    "    print(\"Training epoch {}\".format(epoch + 1))\n",
    "    patent_drawings_description_model.train(tagged_drawings_description,\n",
    "                total_examples=len(patents_df_tokenized['id']), epochs=patent_drawings_description_model.epochs)\n",
    "    patent_drawings_description_model.alpha = patent_drawings_description_model.alpha - 0.002\n",
    "    patent_drawings_description_model.min_alpha = patent_drawings_description_model.alpha"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Model saved..\n"
     ]
    }
   ],
   "source": [
    "# Save model to use later\n",
    "patent_drawings_description_model.save('../models/patent_drawings_description_model.w2v')\n",
    "print('Model saved..')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Load already saved model - in case the notebook kernel dies and restarts\n",
    "# to save model training time\n",
    "patent_drawings_description_model = Doc2Vec.load('../models/patent_drawings_description_model.w2v')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Repeat the process for all other columns\n",
    "tagged_invention_background = TaggedPatentDocument(patents_df_tokenized, 'invention_background')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Training epoch 1\n",
      "Training epoch 2\n",
      "Training epoch 3\n",
      "Training epoch 4\n",
      "Training epoch 5\n",
      "Training epoch 6\n",
      "Training epoch 7\n",
      "Training epoch 8\n",
      "Training epoch 9\n",
      "Training epoch 10\n",
      "Training epoch 11\n",
      "Training epoch 12\n",
      "Training epoch 13\n",
      "Training epoch 14\n",
      "Training epoch 15\n",
      "Training epoch 16\n",
      "Training epoch 17\n",
      "Training epoch 18\n",
      "Training epoch 19\n",
      "Training epoch 20\n",
      "Training epoch 21\n",
      "Training epoch 22\n",
      "Training epoch 23\n",
      "Training epoch 24\n",
      "Training epoch 25\n",
      "Training epoch 26\n",
      "Training epoch 27\n",
      "Training epoch 28\n",
      "Training epoch 29\n",
      "Training epoch 30\n",
      "Training epoch 31\n",
      "Training epoch 32\n",
      "Training epoch 33\n",
      "Training epoch 34\n",
      "Training epoch 35\n",
      "Training epoch 36\n",
      "Training epoch 37\n",
      "Training epoch 38\n",
      "Training epoch 39\n",
      "Training epoch 40\n",
      "Training epoch 41\n",
      "Training epoch 42\n",
      "Training epoch 43\n",
      "Training epoch 44\n",
      "Training epoch 45\n",
      "Training epoch 46\n",
      "Training epoch 47\n",
      "Training epoch 48\n",
      "Training epoch 49\n",
      "Training epoch 50\n"
     ]
    }
   ],
   "source": [
    "# Create model definition\n",
    "epochs = 50\n",
    "patent_invention_background_model = Doc2Vec(dm=0, hs=1, vector_size=500, min_count=3, \\\n",
    "                workers=3, epochs=epochs)\n",
    "\n",
    "# Build vocabulary from documents\n",
    "patent_invention_background_model.build_vocab(tagged_invention_background)\n",
    "\n",
    "# Start training the model\n",
    "for epoch in range(epochs):\n",
    "    print(\"Training epoch {}\".format(epoch + 1))\n",
    "    patent_invention_background_model.train(tagged_invention_background,\n",
    "                total_examples=len(patents_df_tokenized['id']), epochs=patent_invention_background_model.epochs)\n",
    "    patent_invention_background_model.alpha = patent_invention_background_model.alpha - 0.002\n",
    "    patent_invention_background_model.min_alpha = patent_invention_background_model.alpha"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Model saved..\n"
     ]
    }
   ],
   "source": [
    "# Save model to use later\n",
    "patent_invention_background_model.save('../models/patent_invention_background_model.w2v')\n",
    "print('Model saved..')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Load already saved model - in case the notebook kernel dies and restarts\n",
    "# to save model training time\n",
    "patent_invention_background_model = Doc2Vec.load('../models/patent_invention_background_model.w2v')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Repeat the process for all other columns\n",
    "tagged_cross_reference = TaggedPatentDocument(patents_df_tokenized, 'cross_reference')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Training epoch 1\n",
      "Training epoch 2\n",
      "Training epoch 3\n",
      "Training epoch 4\n",
      "Training epoch 5\n",
      "Training epoch 6\n",
      "Training epoch 7\n",
      "Training epoch 8\n",
      "Training epoch 9\n",
      "Training epoch 10\n",
      "Training epoch 11\n",
      "Training epoch 12\n",
      "Training epoch 13\n",
      "Training epoch 14\n",
      "Training epoch 15\n",
      "Training epoch 16\n",
      "Training epoch 17\n",
      "Training epoch 18\n",
      "Training epoch 19\n",
      "Training epoch 20\n",
      "Training epoch 21\n",
      "Training epoch 22\n",
      "Training epoch 23\n",
      "Training epoch 24\n",
      "Training epoch 25\n",
      "Training epoch 26\n",
      "Training epoch 27\n",
      "Training epoch 28\n",
      "Training epoch 29\n",
      "Training epoch 30\n",
      "Training epoch 31\n",
      "Training epoch 32\n",
      "Training epoch 33\n",
      "Training epoch 34\n",
      "Training epoch 35\n",
      "Training epoch 36\n",
      "Training epoch 37\n",
      "Training epoch 38\n",
      "Training epoch 39\n",
      "Training epoch 40\n",
      "Training epoch 41\n",
      "Training epoch 42\n",
      "Training epoch 43\n",
      "Training epoch 44\n",
      "Training epoch 45\n",
      "Training epoch 46\n",
      "Training epoch 47\n",
      "Training epoch 48\n",
      "Training epoch 49\n",
      "Training epoch 50\n"
     ]
    }
   ],
   "source": [
    "# Create model definition\n",
    "epochs = 50\n",
    "patent_cross_reference_model = Doc2Vec(dm=0, hs=1, vector_size=500, min_count=3, \\\n",
    "                workers=3, epochs=epochs)\n",
    "\n",
    "# Build vocabulary from documents\n",
    "patent_cross_reference_model.build_vocab(tagged_cross_reference)\n",
    "\n",
    "# Start training the model\n",
    "for epoch in range(epochs):\n",
    "    print(\"Training epoch {}\".format(epoch + 1))\n",
    "    patent_cross_reference_model.train(tagged_cross_reference,\n",
    "                total_examples=len(patents_df_tokenized['id']), epochs=patent_cross_reference_model.epochs)\n",
    "    patent_cross_reference_model.alpha = patent_cross_reference_model.alpha - 0.002\n",
    "    patent_cross_reference_model.min_alpha = patent_cross_reference_model.alpha"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Model saved..\n"
     ]
    }
   ],
   "source": [
    "# Save model to use later\n",
    "patent_cross_reference_model.save('../models/patent_cross_reference_model.w2v')\n",
    "print('Model saved..')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Load already saved model - in case the notebook kernel dies and restarts\n",
    "# to save model training time\n",
    "patent_cross_reference_model = Doc2Vec.load('../models/patent_cross_reference_model.w2v')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Repeat the process for all other columns\n",
    "tagged_summary = TaggedPatentDocument(patents_df_tokenized, 'summary')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Training epoch 1\n",
      "Training epoch 2\n",
      "Training epoch 3\n",
      "Training epoch 4\n",
      "Training epoch 5\n",
      "Training epoch 6\n",
      "Training epoch 7\n",
      "Training epoch 8\n",
      "Training epoch 9\n",
      "Training epoch 10\n",
      "Training epoch 11\n",
      "Training epoch 12\n",
      "Training epoch 13\n",
      "Training epoch 14\n",
      "Training epoch 15\n",
      "Training epoch 16\n",
      "Training epoch 17\n",
      "Training epoch 18\n",
      "Training epoch 19\n",
      "Training epoch 20\n",
      "Training epoch 21\n",
      "Training epoch 22\n",
      "Training epoch 23\n",
      "Training epoch 24\n",
      "Training epoch 25\n",
      "Training epoch 26\n",
      "Training epoch 27\n",
      "Training epoch 28\n",
      "Training epoch 29\n",
      "Training epoch 30\n",
      "Training epoch 31\n",
      "Training epoch 32\n",
      "Training epoch 33\n",
      "Training epoch 34\n",
      "Training epoch 35\n",
      "Training epoch 36\n",
      "Training epoch 37\n",
      "Training epoch 38\n",
      "Training epoch 39\n",
      "Training epoch 40\n",
      "Training epoch 41\n",
      "Training epoch 42\n",
      "Training epoch 43\n",
      "Training epoch 44\n",
      "Training epoch 45\n",
      "Training epoch 46\n",
      "Training epoch 47\n",
      "Training epoch 48\n",
      "Training epoch 49\n",
      "Training epoch 50\n"
     ]
    }
   ],
   "source": [
    "# Create model definition\n",
    "epochs = 50\n",
    "patent_summary_model = Doc2Vec(dm=0, hs=1, vector_size=500, min_count=3, \\\n",
    "                workers=3, epochs=epochs)\n",
    "\n",
    "# Build vocabulary from documents\n",
    "patent_summary_model.build_vocab(tagged_summary)\n",
    "\n",
    "# Start training the model\n",
    "for epoch in range(epochs):\n",
    "    print(\"Training epoch {}\".format(epoch + 1))\n",
    "    patent_summary_model.train(tagged_summary,\n",
    "                total_examples=len(patents_df_tokenized['id']), epochs=patent_summary_model.epochs)\n",
    "    patent_summary_model.alpha = patent_summary_model.alpha - 0.002\n",
    "    patent_summary_model.min_alpha = patent_summary_model.alpha"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Model saved..\n"
     ]
    }
   ],
   "source": [
    "# Save model to use later\n",
    "patent_summary_model.save('../models/patent_summary_model.w2v')\n",
    "print('Model saved..')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Load already saved model - in case the notebook kernel dies and restarts\n",
    "# to save model training time\n",
    "patent_summary_model = Doc2Vec.load('../models/patent_summary_model.w2v')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Repeat the process for all other columns\n",
    "tagged_detailed_description = TaggedPatentDocument(patents_df_tokenized, 'detailed_description')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Training epoch 1\n",
      "Training epoch 2\n",
      "Training epoch 3\n",
      "Training epoch 4\n",
      "Training epoch 5\n",
      "Training epoch 6\n",
      "Training epoch 7\n",
      "Training epoch 8\n",
      "Training epoch 9\n",
      "Training epoch 10\n",
      "Training epoch 11\n",
      "Training epoch 12\n",
      "Training epoch 13\n",
      "Training epoch 14\n",
      "Training epoch 15\n",
      "Training epoch 16\n",
      "Training epoch 17\n",
      "Training epoch 18\n",
      "Training epoch 19\n",
      "Training epoch 20\n",
      "Training epoch 21\n",
      "Training epoch 22\n",
      "Training epoch 23\n",
      "Training epoch 24\n",
      "Training epoch 25\n",
      "Training epoch 26\n",
      "Training epoch 27\n",
      "Training epoch 28\n",
      "Training epoch 29\n",
      "Training epoch 30\n",
      "Training epoch 31\n",
      "Training epoch 32\n",
      "Training epoch 33\n",
      "Training epoch 34\n",
      "Training epoch 35\n",
      "Training epoch 36\n",
      "Training epoch 37\n",
      "Training epoch 38\n",
      "Training epoch 39\n",
      "Training epoch 40\n",
      "Training epoch 41\n",
      "Training epoch 42\n",
      "Training epoch 43\n",
      "Training epoch 44\n",
      "Training epoch 45\n",
      "Training epoch 46\n",
      "Training epoch 47\n",
      "Training epoch 48\n",
      "Training epoch 49\n",
      "Training epoch 50\n"
     ]
    }
   ],
   "source": [
    "# Create model definition\n",
    "epochs = 50\n",
    "patent_detailed_description_model = Doc2Vec(dm=0, hs=1, vector_size=500, min_count=3, \\\n",
    "                workers=2, epochs=epochs)\n",
    "\n",
    "# Build vocabulary from documents\n",
    "patent_detailed_description_model.build_vocab(tagged_detailed_description)\n",
    "\n",
    "# Start training the model\n",
    "for epoch in range(epochs):\n",
    "    print(\"Training epoch {}\".format(epoch + 1))\n",
    "    patent_detailed_description_model.train(tagged_detailed_description,\n",
    "                total_examples=len(patents_df_tokenized['id']), epochs=patent_detailed_description_model.epochs)\n",
    "    patent_detailed_description_model.alpha = patent_detailed_description_model.alpha - 0.002\n",
    "    patent_detailed_description_model.min_alpha = patent_detailed_description_model.alpha"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Model saved..\n"
     ]
    }
   ],
   "source": [
    "# Save model to use later\n",
    "patent_detailed_description_model.save('../models/patent_detailed_description_model.w2v')\n",
    "print('Model saved..')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Load already saved model - in case the notebook kernel dies and restarts\n",
    "# to save model training time\n",
    "patent_detailed_description_model = Doc2Vec.load('../models/patent_detailed_description_model.w2v')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 74,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Create dataframe of document vectors so that can be the input for LSTM and CNN\n",
    "patents_vectors = pd.DataFrame({'invention_title_vectors': list(patent_title_model.docvecs.vectors_docs), \\\n",
    "            'invention_abstract_vectors': list(patent_abstract_model.docvecs.vectors_docs), \\\n",
    "            'invention_claims_vectors': list(patent_claims_model.docvecs.vectors_docs), \\\n",
    "            'invention_description_vectors': list(patent_description_model.docvecs.vectors_docs), \\\n",
    "            'invention_drawings_description_vectors': list(patent_drawings_description_model.docvecs.vectors_docs), \\\n",
    "            'invention_invention_background_vectors': list(patent_invention_background_model.docvecs.vectors_docs), \\\n",
    "            'invention_cross_reference_vectors': list(patent_cross_reference_model.docvecs.vectors_docs), \\\n",
    "            'invention_summary_vectors': list(patent_summary_model.docvecs.vectors_docs), \\\n",
    "            'invention_detailed_description_vectors': list(patent_detailed_description_model.docvecs.vectors_docs)})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 75,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>invention_title_vectors</th>\n",
       "      <th>invention_abstract_vectors</th>\n",
       "      <th>invention_claims_vectors</th>\n",
       "      <th>invention_description_vectors</th>\n",
       "      <th>invention_drawings_description_vectors</th>\n",
       "      <th>invention_invention_background_vectors</th>\n",
       "      <th>invention_cross_reference_vectors</th>\n",
       "      <th>invention_summary_vectors</th>\n",
       "      <th>invention_detailed_description_vectors</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>[0.79648715, 0.49905267, 0.1990846, -0.6958045...</td>\n",
       "      <td>[-0.40922263, 0.7555281, -0.2939332, -0.824812...</td>\n",
       "      <td>[-0.32757396, -0.72097844, -0.6184255, 0.16919...</td>\n",
       "      <td>[-0.0877834, 0.14760958, 0.25188735, 0.2655999...</td>\n",
       "      <td>[0.18880707, 0.038463693, -0.090229504, -0.566...</td>\n",
       "      <td>[-1.0521476, -0.4201015, -0.49964833, 1.33142,...</td>\n",
       "      <td>[-0.8975088, 0.18549693, -0.9888742, 1.5618571...</td>\n",
       "      <td>[-0.25849417, -1.1690854, -0.036479406, -0.210...</td>\n",
       "      <td>[0.08795054, -0.6987753, -0.37846655, -1.37994...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>[-0.7099177, -0.45519656, -0.16896322, 0.63520...</td>\n",
       "      <td>[-0.42359048, 0.77543813, -0.3168563, -0.81115...</td>\n",
       "      <td>[-0.33781555, -0.74758077, -0.65743595, 0.1657...</td>\n",
       "      <td>[-0.10550693, 0.15406513, 0.26139632, 0.290942...</td>\n",
       "      <td>[0.21356149, 0.012393088, -0.111655094, -0.707...</td>\n",
       "      <td>[-1.077294, -0.44164196, -0.5072208, 1.3556875...</td>\n",
       "      <td>[-0.83632326, 0.1730581, -0.923424, 1.4212142,...</td>\n",
       "      <td>[-0.18138191, -1.0368152, -0.064771295, -0.301...</td>\n",
       "      <td>[0.08152865, -0.7884193, -0.36260352, -1.41967...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>[-0.7235869, -0.46847942, -0.1725856, 0.647002...</td>\n",
       "      <td>[-0.41187352, 0.73172605, -0.29745263, -0.7805...</td>\n",
       "      <td>[-0.33308947, -0.7066641, -0.62118995, 0.14689...</td>\n",
       "      <td>[-0.102144755, 0.14728326, 0.27713192, 0.29220...</td>\n",
       "      <td>[0.22136478, 0.01893254, -0.12228994, -0.76449...</td>\n",
       "      <td>[-1.0811398, -0.44532654, -0.5067718, 1.358797...</td>\n",
       "      <td>[-0.8759457, 0.17999512, -0.95992583, 1.477594...</td>\n",
       "      <td>[-0.17508577, -1.0230386, -0.06634464, -0.3075...</td>\n",
       "      <td>[0.07402404, -0.8209438, -0.3304778, -1.377606...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>[-0.69865316, -0.4536933, -0.1615031, 0.633394...</td>\n",
       "      <td>[-0.30996147, 0.6678213, -0.22810836, -0.70015...</td>\n",
       "      <td>[-0.34275448, -0.7370787, -0.63825417, 0.16050...</td>\n",
       "      <td>[-0.09711998, 0.13907178, 0.2622618, 0.2733011...</td>\n",
       "      <td>[0.22860701, 0.038189214, -0.13485856, -0.8222...</td>\n",
       "      <td>[-1.0559562, -0.37349042, -0.49916127, 1.36386...</td>\n",
       "      <td>[-0.80676436, 0.16835235, -0.8846372, 1.334677...</td>\n",
       "      <td>[-0.16409132, -1.004466, -0.08327, -0.32637736...</td>\n",
       "      <td>[0.072413385, -0.82365495, -0.3156028, -1.3700...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>[-0.69984543, -0.4555733, -0.16490342, 0.62932...</td>\n",
       "      <td>[-0.28795904, 0.6245526, -0.21497698, -0.64426...</td>\n",
       "      <td>[-0.33816746, -0.70621485, -0.603847, 0.160634...</td>\n",
       "      <td>[-0.10777167, 0.15237792, 0.33398283, 0.323142...</td>\n",
       "      <td>[0.23186213, 0.038659163, -0.13768524, -0.8303...</td>\n",
       "      <td>[-1.0407743, -0.36915192, -0.49463847, 1.34683...</td>\n",
       "      <td>[-0.8001403, 0.16775666, -0.8744451, 1.3131502...</td>\n",
       "      <td>[-0.14968641, -0.98594, -0.0915328, -0.3462096...</td>\n",
       "      <td>[0.071079336, -0.8088835, -0.30082428, -1.3383...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>[-0.5821559, -0.37541214, -0.13808706, 0.52178...</td>\n",
       "      <td>[-0.30232346, 0.63609827, -0.2249654, -0.65665...</td>\n",
       "      <td>[-0.34404105, -0.6670663, -0.563262, 0.1617206...</td>\n",
       "      <td>[-0.11638489, 0.16753761, 0.29881465, 0.317200...</td>\n",
       "      <td>[0.23166063, 0.038750764, -0.1396112, -0.84613...</td>\n",
       "      <td>[-1.0331254, -0.35680932, -0.48794186, 1.34843...</td>\n",
       "      <td>[-0.740817, 0.1635279, -0.79812187, 1.2022171,...</td>\n",
       "      <td>[-0.09514956, -0.8742499, -0.087382704, -0.389...</td>\n",
       "      <td>[0.07032651, -0.7992063, -0.28869677, -1.32294...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>[-0.59079534, -0.38521087, -0.1373858, 0.53435...</td>\n",
       "      <td>[-0.2382821, 0.5303434, -0.1864873, -0.5217362...</td>\n",
       "      <td>[-0.37029237, -0.60657454, -0.53663075, 0.1365...</td>\n",
       "      <td>[-0.11095362, 0.16591549, 0.29979724, 0.311120...</td>\n",
       "      <td>[0.2330211, 0.04080629, -0.13827029, -0.852073...</td>\n",
       "      <td>[-1.0231079, -0.3377742, -0.48051396, 1.367493...</td>\n",
       "      <td>[-0.733089, 0.15869096, -0.79562837, 1.1841578...</td>\n",
       "      <td>[-0.12985912, -0.934526, -0.0986678, -0.355308...</td>\n",
       "      <td>[0.06815048, -0.7940266, -0.28151748, -1.30173...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>[-0.50633824, -0.32620156, -0.11922513, 0.4552...</td>\n",
       "      <td>[-0.2784767, 0.59579116, -0.20884693, -0.60822...</td>\n",
       "      <td>[-0.3634243, -0.620504, -0.55767995, 0.1276821...</td>\n",
       "      <td>[-0.11473989, 0.16910565, 0.3037188, 0.3184888...</td>\n",
       "      <td>[0.23343514, 0.031101035, -0.14220843, -0.8663...</td>\n",
       "      <td>[-1.0195814, -0.33844554, -0.48286924, 1.35123...</td>\n",
       "      <td>[-0.73059857, 0.15637653, -0.79444903, 1.17351...</td>\n",
       "      <td>[-0.10586243, -0.87620986, -0.100350425, -0.37...</td>\n",
       "      <td>[0.06589129, -0.7960281, -0.27838722, -1.30570...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>[-0.5171465, -0.33310094, -0.12491555, 0.45968...</td>\n",
       "      <td>[-0.26925802, 0.5799887, -0.20516671, -0.58111...</td>\n",
       "      <td>[-0.33830756, -0.6813884, -0.614299, 0.1198018...</td>\n",
       "      <td>[-0.11506818, 0.17000505, 0.29748264, 0.313941...</td>\n",
       "      <td>[0.23067635, 0.04269409, -0.1396422, -0.855726...</td>\n",
       "      <td>[-1.0036359, -0.31219706, -0.4730591, 1.346242...</td>\n",
       "      <td>[-0.71547306, 0.16046862, -0.7717041, 1.147818...</td>\n",
       "      <td>[-0.08917042, -0.85957724, -0.097008586, -0.39...</td>\n",
       "      <td>[0.06310678, -0.78631765, -0.26396194, -1.2766...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>[-0.5227302, -0.33839604, -0.12566571, 0.46570...</td>\n",
       "      <td>[-0.25106287, 0.5484887, -0.19419573, -0.54430...</td>\n",
       "      <td>[-0.35075808, -0.65480304, -0.5921591, 0.11914...</td>\n",
       "      <td>[-0.10932141, 0.16534041, 0.2918858, 0.3062248...</td>\n",
       "      <td>[0.22992158, 0.032765526, -0.13919176, -0.8622...</td>\n",
       "      <td>[-1.005509, -0.3160468, -0.47284564, 1.3554734...</td>\n",
       "      <td>[-0.7016552, 0.1551208, -0.7547043, 1.1171947,...</td>\n",
       "      <td>[-0.07706193, -0.8197851, -0.09828377, -0.3953...</td>\n",
       "      <td>[0.06280867, -0.79217076, -0.27129033, -1.2867...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>[-0.47061554, -0.307625, -0.109487034, 0.42567...</td>\n",
       "      <td>[-0.19749379, 0.46645093, -0.14356388, -0.4823...</td>\n",
       "      <td>[-0.38725734, -0.6415169, -0.58372194, 0.11167...</td>\n",
       "      <td>[-0.11052402, 0.17022067, 0.29260236, 0.308002...</td>\n",
       "      <td>[0.22739454, 0.036577947, -0.1387988, -0.86019...</td>\n",
       "      <td>[-0.99944943, -0.3041484, -0.47157004, 1.35869...</td>\n",
       "      <td>[-0.6850978, 0.15374646, -0.73882926, 1.083988...</td>\n",
       "      <td>[-0.073009945, -0.8256452, -0.0923578, -0.4065...</td>\n",
       "      <td>[0.066403136, -0.7812938, -0.26460114, -1.2659...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>[-0.4901273, -0.3214211, -0.11738616, 0.437689...</td>\n",
       "      <td>[-0.24173442, 0.52941763, -0.18976764, -0.5156...</td>\n",
       "      <td>[-0.38080224, -0.62277603, -0.55334663, 0.1247...</td>\n",
       "      <td>[-0.110058986, 0.16596158, 0.28937757, 0.30527...</td>\n",
       "      <td>[0.22995177, 0.035887, -0.13832381, -0.8699819...</td>\n",
       "      <td>[-0.9936355, -0.28560787, -0.4715667, 1.367029...</td>\n",
       "      <td>[-0.6795256, 0.15174623, -0.73328966, 1.075036...</td>\n",
       "      <td>[-0.069649376, -0.8086956, -0.09974727, -0.405...</td>\n",
       "      <td>[0.065388195, -0.7792875, -0.25511208, -1.2556...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>[-0.46290845, -0.29670456, -0.10750166, 0.4185...</td>\n",
       "      <td>[-0.22208536, 0.5028574, -0.17484678, -0.48854...</td>\n",
       "      <td>[-0.38492045, -0.6147663, -0.54843, 0.12468389...</td>\n",
       "      <td>[-0.1082572, 0.17016186, 0.28585872, 0.3043103...</td>\n",
       "      <td>[0.22474298, 0.04533433, -0.13729292, -0.85224...</td>\n",
       "      <td>[-0.9966364, -0.29873344, -0.4709553, 1.359822...</td>\n",
       "      <td>[-0.679355, 0.15306266, -0.72654206, 1.0677699...</td>\n",
       "      <td>[-0.054633725, -0.77908933, -0.09287224, -0.41...</td>\n",
       "      <td>[0.06432982, -0.77723664, -0.25696844, -1.2537...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>[-0.45892102, -0.28994983, -0.11027811, 0.4085...</td>\n",
       "      <td>[-0.19160995, 0.44793442, -0.13720548, -0.4605...</td>\n",
       "      <td>[-0.38335565, -0.6703099, -0.60736144, 0.12329...</td>\n",
       "      <td>[-0.11123238, 0.16883205, 0.2882092, 0.3058267...</td>\n",
       "      <td>[0.22528628, 0.036967978, -0.13628073, -0.8551...</td>\n",
       "      <td>[-0.99297196, -0.28742987, -0.46957287, 1.3610...</td>\n",
       "      <td>[-0.6671168, 0.15053363, -0.7123045, 1.047582,...</td>\n",
       "      <td>[-0.052599773, -0.7801824, -0.0901256, -0.4224...</td>\n",
       "      <td>[0.061946783, -0.78059655, -0.25684628, -1.249...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>[-0.44748148, -0.29150218, -0.104292795, 0.404...</td>\n",
       "      <td>[-0.18811965, 0.43838164, -0.13728385, -0.4435...</td>\n",
       "      <td>[-0.37342605, -0.6104158, -0.54688597, 0.11797...</td>\n",
       "      <td>[-0.11084989, 0.16909991, 0.28805155, 0.305387...</td>\n",
       "      <td>[0.22827913, 0.05400539, -0.13642499, -0.85751...</td>\n",
       "      <td>[-0.9869354, -0.28668222, -0.4671708, 1.357901...</td>\n",
       "      <td>[-0.65737206, 0.1480869, -0.6963575, 1.0248624...</td>\n",
       "      <td>[-0.04842226, -0.75920665, -0.09735238, -0.418...</td>\n",
       "      <td>[0.06394965, -0.777868, -0.25607276, -1.251369...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>[-0.44263843, -0.28358045, -0.104260296, 0.397...</td>\n",
       "      <td>[-0.17686072, 0.41828358, -0.1277353, -0.42444...</td>\n",
       "      <td>[-0.37656358, -0.58599, -0.5254219, 0.11348722...</td>\n",
       "      <td>[-0.10664429, 0.16743109, 0.2854254, 0.2997889...</td>\n",
       "      <td>[0.22568499, 0.037875053, -0.13568015, -0.8596...</td>\n",
       "      <td>[-0.98225474, -0.2786164, -0.4645872, 1.355667...</td>\n",
       "      <td>[-0.6569261, 0.14980218, -0.70118004, 1.027852...</td>\n",
       "      <td>[-0.026772417, -0.79261565, -0.09080482, -0.48...</td>\n",
       "      <td>[0.06609155, -0.7733157, -0.2572213, -1.243367...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>[-0.42584246, -0.27854246, -0.098633565, 0.385...</td>\n",
       "      <td>[-0.17904149, 0.42401695, -0.12989186, -0.4297...</td>\n",
       "      <td>[-0.38713172, -0.5741414, -0.5123074, 0.117146...</td>\n",
       "      <td>[-0.10987463, 0.16779271, 0.28352064, 0.301310...</td>\n",
       "      <td>[0.22497615, 0.037248928, -0.13899787, -0.8615...</td>\n",
       "      <td>[-0.98293066, -0.27032343, -0.4664722, 1.36012...</td>\n",
       "      <td>[-0.65694547, 0.15053055, -0.6978702, 1.024970...</td>\n",
       "      <td>[-0.036777437, -0.7382452, -0.09562161, -0.428...</td>\n",
       "      <td>[0.06484093, -0.76782763, -0.24740863, -1.2305...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>[-0.4282952, -0.27730122, -0.10118428, 0.38462...</td>\n",
       "      <td>[-0.17065503, 0.40773362, -0.12179403, -0.4148...</td>\n",
       "      <td>[-0.37980783, -0.5554216, -0.4949705, 0.114138...</td>\n",
       "      <td>[-0.11127515, 0.1672081, 0.28349617, 0.3032644...</td>\n",
       "      <td>[0.22565006, 0.035720512, -0.13670567, -0.8651...</td>\n",
       "      <td>[-0.98246855, -0.2752491, -0.46853015, 1.35980...</td>\n",
       "      <td>[-0.6448657, 0.1475359, -0.686251, 1.0019553, ...</td>\n",
       "      <td>[-0.043432225, -0.7626878, -0.09744142, -0.435...</td>\n",
       "      <td>[0.066383995, -0.7588156, -0.24658193, -1.2260...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>[-0.4109341, -0.26545715, -0.09448171, 0.37333...</td>\n",
       "      <td>[-0.1655395, 0.3969213, -0.12129325, -0.398668...</td>\n",
       "      <td>[-0.3914858, -0.55836743, -0.49744543, 0.11205...</td>\n",
       "      <td>[-0.11106175, 0.16923137, 0.28288922, 0.30271,...</td>\n",
       "      <td>[0.22225837, 0.041459184, -0.13252345, -0.8464...</td>\n",
       "      <td>[-0.97711134, -0.26543346, -0.46634376, 1.3563...</td>\n",
       "      <td>[-0.64518166, 0.14648381, -0.684667, 1.0021563...</td>\n",
       "      <td>[-0.039409257, -0.74751884, -0.10413137, -0.43...</td>\n",
       "      <td>[0.067895606, -0.7545572, -0.24051224, -1.2192...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>[-0.40646362, -0.26347408, -0.094850145, 0.366...</td>\n",
       "      <td>[-0.16208214, 0.39491352, -0.11982638, -0.3961...</td>\n",
       "      <td>[-0.390498, -0.5628275, -0.49016607, 0.1259323...</td>\n",
       "      <td>[-0.11100735, 0.16926791, 0.28595096, 0.303550...</td>\n",
       "      <td>[0.2229863, 0.03952254, -0.13629602, -0.853800...</td>\n",
       "      <td>[-0.9690993, -0.26896876, -0.45996755, 1.34022...</td>\n",
       "      <td>[-0.6388113, 0.14651671, -0.6784392, 0.9858142...</td>\n",
       "      <td>[-0.036320124, -0.74209964, -0.09765476, -0.43...</td>\n",
       "      <td>[0.0635991, -0.7619611, -0.24275148, -1.215680...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>[-0.3991969, -0.25873992, -0.09327971, 0.36022...</td>\n",
       "      <td>[-0.15966617, 0.39516246, -0.120108955, -0.394...</td>\n",
       "      <td>[-0.39585358, -0.5644321, -0.4875565, 0.130028...</td>\n",
       "      <td>[-0.11249764, 0.16708381, 0.2872893, 0.3046351...</td>\n",
       "      <td>[0.22655013, 0.03985292, -0.13601395, -0.86271...</td>\n",
       "      <td>[-0.9636858, -0.2652513, -0.45959622, 1.331358...</td>\n",
       "      <td>[-0.67098993, 0.1561157, -0.7154773, 1.0347854...</td>\n",
       "      <td>[-0.03590548, -0.72597986, -0.10138552, -0.430...</td>\n",
       "      <td>[0.061812613, -0.7626716, -0.23310764, -1.2086...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                              invention_title_vectors  \\\n",
       "0   [0.79648715, 0.49905267, 0.1990846, -0.6958045...   \n",
       "1   [-0.7099177, -0.45519656, -0.16896322, 0.63520...   \n",
       "2   [-0.7235869, -0.46847942, -0.1725856, 0.647002...   \n",
       "3   [-0.69865316, -0.4536933, -0.1615031, 0.633394...   \n",
       "4   [-0.69984543, -0.4555733, -0.16490342, 0.62932...   \n",
       "5   [-0.5821559, -0.37541214, -0.13808706, 0.52178...   \n",
       "6   [-0.59079534, -0.38521087, -0.1373858, 0.53435...   \n",
       "7   [-0.50633824, -0.32620156, -0.11922513, 0.4552...   \n",
       "8   [-0.5171465, -0.33310094, -0.12491555, 0.45968...   \n",
       "9   [-0.5227302, -0.33839604, -0.12566571, 0.46570...   \n",
       "10  [-0.47061554, -0.307625, -0.109487034, 0.42567...   \n",
       "11  [-0.4901273, -0.3214211, -0.11738616, 0.437689...   \n",
       "12  [-0.46290845, -0.29670456, -0.10750166, 0.4185...   \n",
       "13  [-0.45892102, -0.28994983, -0.11027811, 0.4085...   \n",
       "14  [-0.44748148, -0.29150218, -0.104292795, 0.404...   \n",
       "15  [-0.44263843, -0.28358045, -0.104260296, 0.397...   \n",
       "16  [-0.42584246, -0.27854246, -0.098633565, 0.385...   \n",
       "17  [-0.4282952, -0.27730122, -0.10118428, 0.38462...   \n",
       "18  [-0.4109341, -0.26545715, -0.09448171, 0.37333...   \n",
       "19  [-0.40646362, -0.26347408, -0.094850145, 0.366...   \n",
       "20  [-0.3991969, -0.25873992, -0.09327971, 0.36022...   \n",
       "\n",
       "                           invention_abstract_vectors  \\\n",
       "0   [-0.40922263, 0.7555281, -0.2939332, -0.824812...   \n",
       "1   [-0.42359048, 0.77543813, -0.3168563, -0.81115...   \n",
       "2   [-0.41187352, 0.73172605, -0.29745263, -0.7805...   \n",
       "3   [-0.30996147, 0.6678213, -0.22810836, -0.70015...   \n",
       "4   [-0.28795904, 0.6245526, -0.21497698, -0.64426...   \n",
       "5   [-0.30232346, 0.63609827, -0.2249654, -0.65665...   \n",
       "6   [-0.2382821, 0.5303434, -0.1864873, -0.5217362...   \n",
       "7   [-0.2784767, 0.59579116, -0.20884693, -0.60822...   \n",
       "8   [-0.26925802, 0.5799887, -0.20516671, -0.58111...   \n",
       "9   [-0.25106287, 0.5484887, -0.19419573, -0.54430...   \n",
       "10  [-0.19749379, 0.46645093, -0.14356388, -0.4823...   \n",
       "11  [-0.24173442, 0.52941763, -0.18976764, -0.5156...   \n",
       "12  [-0.22208536, 0.5028574, -0.17484678, -0.48854...   \n",
       "13  [-0.19160995, 0.44793442, -0.13720548, -0.4605...   \n",
       "14  [-0.18811965, 0.43838164, -0.13728385, -0.4435...   \n",
       "15  [-0.17686072, 0.41828358, -0.1277353, -0.42444...   \n",
       "16  [-0.17904149, 0.42401695, -0.12989186, -0.4297...   \n",
       "17  [-0.17065503, 0.40773362, -0.12179403, -0.4148...   \n",
       "18  [-0.1655395, 0.3969213, -0.12129325, -0.398668...   \n",
       "19  [-0.16208214, 0.39491352, -0.11982638, -0.3961...   \n",
       "20  [-0.15966617, 0.39516246, -0.120108955, -0.394...   \n",
       "\n",
       "                             invention_claims_vectors  \\\n",
       "0   [-0.32757396, -0.72097844, -0.6184255, 0.16919...   \n",
       "1   [-0.33781555, -0.74758077, -0.65743595, 0.1657...   \n",
       "2   [-0.33308947, -0.7066641, -0.62118995, 0.14689...   \n",
       "3   [-0.34275448, -0.7370787, -0.63825417, 0.16050...   \n",
       "4   [-0.33816746, -0.70621485, -0.603847, 0.160634...   \n",
       "5   [-0.34404105, -0.6670663, -0.563262, 0.1617206...   \n",
       "6   [-0.37029237, -0.60657454, -0.53663075, 0.1365...   \n",
       "7   [-0.3634243, -0.620504, -0.55767995, 0.1276821...   \n",
       "8   [-0.33830756, -0.6813884, -0.614299, 0.1198018...   \n",
       "9   [-0.35075808, -0.65480304, -0.5921591, 0.11914...   \n",
       "10  [-0.38725734, -0.6415169, -0.58372194, 0.11167...   \n",
       "11  [-0.38080224, -0.62277603, -0.55334663, 0.1247...   \n",
       "12  [-0.38492045, -0.6147663, -0.54843, 0.12468389...   \n",
       "13  [-0.38335565, -0.6703099, -0.60736144, 0.12329...   \n",
       "14  [-0.37342605, -0.6104158, -0.54688597, 0.11797...   \n",
       "15  [-0.37656358, -0.58599, -0.5254219, 0.11348722...   \n",
       "16  [-0.38713172, -0.5741414, -0.5123074, 0.117146...   \n",
       "17  [-0.37980783, -0.5554216, -0.4949705, 0.114138...   \n",
       "18  [-0.3914858, -0.55836743, -0.49744543, 0.11205...   \n",
       "19  [-0.390498, -0.5628275, -0.49016607, 0.1259323...   \n",
       "20  [-0.39585358, -0.5644321, -0.4875565, 0.130028...   \n",
       "\n",
       "                        invention_description_vectors  \\\n",
       "0   [-0.0877834, 0.14760958, 0.25188735, 0.2655999...   \n",
       "1   [-0.10550693, 0.15406513, 0.26139632, 0.290942...   \n",
       "2   [-0.102144755, 0.14728326, 0.27713192, 0.29220...   \n",
       "3   [-0.09711998, 0.13907178, 0.2622618, 0.2733011...   \n",
       "4   [-0.10777167, 0.15237792, 0.33398283, 0.323142...   \n",
       "5   [-0.11638489, 0.16753761, 0.29881465, 0.317200...   \n",
       "6   [-0.11095362, 0.16591549, 0.29979724, 0.311120...   \n",
       "7   [-0.11473989, 0.16910565, 0.3037188, 0.3184888...   \n",
       "8   [-0.11506818, 0.17000505, 0.29748264, 0.313941...   \n",
       "9   [-0.10932141, 0.16534041, 0.2918858, 0.3062248...   \n",
       "10  [-0.11052402, 0.17022067, 0.29260236, 0.308002...   \n",
       "11  [-0.110058986, 0.16596158, 0.28937757, 0.30527...   \n",
       "12  [-0.1082572, 0.17016186, 0.28585872, 0.3043103...   \n",
       "13  [-0.11123238, 0.16883205, 0.2882092, 0.3058267...   \n",
       "14  [-0.11084989, 0.16909991, 0.28805155, 0.305387...   \n",
       "15  [-0.10664429, 0.16743109, 0.2854254, 0.2997889...   \n",
       "16  [-0.10987463, 0.16779271, 0.28352064, 0.301310...   \n",
       "17  [-0.11127515, 0.1672081, 0.28349617, 0.3032644...   \n",
       "18  [-0.11106175, 0.16923137, 0.28288922, 0.30271,...   \n",
       "19  [-0.11100735, 0.16926791, 0.28595096, 0.303550...   \n",
       "20  [-0.11249764, 0.16708381, 0.2872893, 0.3046351...   \n",
       "\n",
       "               invention_drawings_description_vectors  \\\n",
       "0   [0.18880707, 0.038463693, -0.090229504, -0.566...   \n",
       "1   [0.21356149, 0.012393088, -0.111655094, -0.707...   \n",
       "2   [0.22136478, 0.01893254, -0.12228994, -0.76449...   \n",
       "3   [0.22860701, 0.038189214, -0.13485856, -0.8222...   \n",
       "4   [0.23186213, 0.038659163, -0.13768524, -0.8303...   \n",
       "5   [0.23166063, 0.038750764, -0.1396112, -0.84613...   \n",
       "6   [0.2330211, 0.04080629, -0.13827029, -0.852073...   \n",
       "7   [0.23343514, 0.031101035, -0.14220843, -0.8663...   \n",
       "8   [0.23067635, 0.04269409, -0.1396422, -0.855726...   \n",
       "9   [0.22992158, 0.032765526, -0.13919176, -0.8622...   \n",
       "10  [0.22739454, 0.036577947, -0.1387988, -0.86019...   \n",
       "11  [0.22995177, 0.035887, -0.13832381, -0.8699819...   \n",
       "12  [0.22474298, 0.04533433, -0.13729292, -0.85224...   \n",
       "13  [0.22528628, 0.036967978, -0.13628073, -0.8551...   \n",
       "14  [0.22827913, 0.05400539, -0.13642499, -0.85751...   \n",
       "15  [0.22568499, 0.037875053, -0.13568015, -0.8596...   \n",
       "16  [0.22497615, 0.037248928, -0.13899787, -0.8615...   \n",
       "17  [0.22565006, 0.035720512, -0.13670567, -0.8651...   \n",
       "18  [0.22225837, 0.041459184, -0.13252345, -0.8464...   \n",
       "19  [0.2229863, 0.03952254, -0.13629602, -0.853800...   \n",
       "20  [0.22655013, 0.03985292, -0.13601395, -0.86271...   \n",
       "\n",
       "               invention_invention_background_vectors  \\\n",
       "0   [-1.0521476, -0.4201015, -0.49964833, 1.33142,...   \n",
       "1   [-1.077294, -0.44164196, -0.5072208, 1.3556875...   \n",
       "2   [-1.0811398, -0.44532654, -0.5067718, 1.358797...   \n",
       "3   [-1.0559562, -0.37349042, -0.49916127, 1.36386...   \n",
       "4   [-1.0407743, -0.36915192, -0.49463847, 1.34683...   \n",
       "5   [-1.0331254, -0.35680932, -0.48794186, 1.34843...   \n",
       "6   [-1.0231079, -0.3377742, -0.48051396, 1.367493...   \n",
       "7   [-1.0195814, -0.33844554, -0.48286924, 1.35123...   \n",
       "8   [-1.0036359, -0.31219706, -0.4730591, 1.346242...   \n",
       "9   [-1.005509, -0.3160468, -0.47284564, 1.3554734...   \n",
       "10  [-0.99944943, -0.3041484, -0.47157004, 1.35869...   \n",
       "11  [-0.9936355, -0.28560787, -0.4715667, 1.367029...   \n",
       "12  [-0.9966364, -0.29873344, -0.4709553, 1.359822...   \n",
       "13  [-0.99297196, -0.28742987, -0.46957287, 1.3610...   \n",
       "14  [-0.9869354, -0.28668222, -0.4671708, 1.357901...   \n",
       "15  [-0.98225474, -0.2786164, -0.4645872, 1.355667...   \n",
       "16  [-0.98293066, -0.27032343, -0.4664722, 1.36012...   \n",
       "17  [-0.98246855, -0.2752491, -0.46853015, 1.35980...   \n",
       "18  [-0.97711134, -0.26543346, -0.46634376, 1.3563...   \n",
       "19  [-0.9690993, -0.26896876, -0.45996755, 1.34022...   \n",
       "20  [-0.9636858, -0.2652513, -0.45959622, 1.331358...   \n",
       "\n",
       "                    invention_cross_reference_vectors  \\\n",
       "0   [-0.8975088, 0.18549693, -0.9888742, 1.5618571...   \n",
       "1   [-0.83632326, 0.1730581, -0.923424, 1.4212142,...   \n",
       "2   [-0.8759457, 0.17999512, -0.95992583, 1.477594...   \n",
       "3   [-0.80676436, 0.16835235, -0.8846372, 1.334677...   \n",
       "4   [-0.8001403, 0.16775666, -0.8744451, 1.3131502...   \n",
       "5   [-0.740817, 0.1635279, -0.79812187, 1.2022171,...   \n",
       "6   [-0.733089, 0.15869096, -0.79562837, 1.1841578...   \n",
       "7   [-0.73059857, 0.15637653, -0.79444903, 1.17351...   \n",
       "8   [-0.71547306, 0.16046862, -0.7717041, 1.147818...   \n",
       "9   [-0.7016552, 0.1551208, -0.7547043, 1.1171947,...   \n",
       "10  [-0.6850978, 0.15374646, -0.73882926, 1.083988...   \n",
       "11  [-0.6795256, 0.15174623, -0.73328966, 1.075036...   \n",
       "12  [-0.679355, 0.15306266, -0.72654206, 1.0677699...   \n",
       "13  [-0.6671168, 0.15053363, -0.7123045, 1.047582,...   \n",
       "14  [-0.65737206, 0.1480869, -0.6963575, 1.0248624...   \n",
       "15  [-0.6569261, 0.14980218, -0.70118004, 1.027852...   \n",
       "16  [-0.65694547, 0.15053055, -0.6978702, 1.024970...   \n",
       "17  [-0.6448657, 0.1475359, -0.686251, 1.0019553, ...   \n",
       "18  [-0.64518166, 0.14648381, -0.684667, 1.0021563...   \n",
       "19  [-0.6388113, 0.14651671, -0.6784392, 0.9858142...   \n",
       "20  [-0.67098993, 0.1561157, -0.7154773, 1.0347854...   \n",
       "\n",
       "                            invention_summary_vectors  \\\n",
       "0   [-0.25849417, -1.1690854, -0.036479406, -0.210...   \n",
       "1   [-0.18138191, -1.0368152, -0.064771295, -0.301...   \n",
       "2   [-0.17508577, -1.0230386, -0.06634464, -0.3075...   \n",
       "3   [-0.16409132, -1.004466, -0.08327, -0.32637736...   \n",
       "4   [-0.14968641, -0.98594, -0.0915328, -0.3462096...   \n",
       "5   [-0.09514956, -0.8742499, -0.087382704, -0.389...   \n",
       "6   [-0.12985912, -0.934526, -0.0986678, -0.355308...   \n",
       "7   [-0.10586243, -0.87620986, -0.100350425, -0.37...   \n",
       "8   [-0.08917042, -0.85957724, -0.097008586, -0.39...   \n",
       "9   [-0.07706193, -0.8197851, -0.09828377, -0.3953...   \n",
       "10  [-0.073009945, -0.8256452, -0.0923578, -0.4065...   \n",
       "11  [-0.069649376, -0.8086956, -0.09974727, -0.405...   \n",
       "12  [-0.054633725, -0.77908933, -0.09287224, -0.41...   \n",
       "13  [-0.052599773, -0.7801824, -0.0901256, -0.4224...   \n",
       "14  [-0.04842226, -0.75920665, -0.09735238, -0.418...   \n",
       "15  [-0.026772417, -0.79261565, -0.09080482, -0.48...   \n",
       "16  [-0.036777437, -0.7382452, -0.09562161, -0.428...   \n",
       "17  [-0.043432225, -0.7626878, -0.09744142, -0.435...   \n",
       "18  [-0.039409257, -0.74751884, -0.10413137, -0.43...   \n",
       "19  [-0.036320124, -0.74209964, -0.09765476, -0.43...   \n",
       "20  [-0.03590548, -0.72597986, -0.10138552, -0.430...   \n",
       "\n",
       "               invention_detailed_description_vectors  \n",
       "0   [0.08795054, -0.6987753, -0.37846655, -1.37994...  \n",
       "1   [0.08152865, -0.7884193, -0.36260352, -1.41967...  \n",
       "2   [0.07402404, -0.8209438, -0.3304778, -1.377606...  \n",
       "3   [0.072413385, -0.82365495, -0.3156028, -1.3700...  \n",
       "4   [0.071079336, -0.8088835, -0.30082428, -1.3383...  \n",
       "5   [0.07032651, -0.7992063, -0.28869677, -1.32294...  \n",
       "6   [0.06815048, -0.7940266, -0.28151748, -1.30173...  \n",
       "7   [0.06589129, -0.7960281, -0.27838722, -1.30570...  \n",
       "8   [0.06310678, -0.78631765, -0.26396194, -1.2766...  \n",
       "9   [0.06280867, -0.79217076, -0.27129033, -1.2867...  \n",
       "10  [0.066403136, -0.7812938, -0.26460114, -1.2659...  \n",
       "11  [0.065388195, -0.7792875, -0.25511208, -1.2556...  \n",
       "12  [0.06432982, -0.77723664, -0.25696844, -1.2537...  \n",
       "13  [0.061946783, -0.78059655, -0.25684628, -1.249...  \n",
       "14  [0.06394965, -0.777868, -0.25607276, -1.251369...  \n",
       "15  [0.06609155, -0.7733157, -0.2572213, -1.243367...  \n",
       "16  [0.06484093, -0.76782763, -0.24740863, -1.2305...  \n",
       "17  [0.066383995, -0.7588156, -0.24658193, -1.2260...  \n",
       "18  [0.067895606, -0.7545572, -0.24051224, -1.2192...  \n",
       "19  [0.0635991, -0.7619611, -0.24275148, -1.215680...  \n",
       "20  [0.061812613, -0.7626716, -0.23310764, -1.2086...  "
      ]
     },
     "execution_count": 75,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "patents_vectors"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 76,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Write file to csv for easy loading if notebook kernel dies\n",
    "patents_vectors.to_csv('../Dataset/patents_vectors.csv')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<hr>\n",
    "<br>\n",
    "\n",
    "<a id='section-7'></a>\n",
    "\n",
    "### - Train LSTM using document embeddings"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.6.8"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
